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Abstract	
This study was an exploration of numerous factors that influence patient outcome following 
hip and knee arthroplasty surgery. Total hip and knee arthroplasty are two of the most 
commonly performed orthopaedic procedures to relieve pain and improve joint function the 
most commonly indication being osteoarthritis. Surprisingly, understanding which patients 
will achieve optimal benefit is important but remains difficult and controversial.  This is 
confounded by an increasing active and ageing population, with high inherent expectations.  
Furthermore, young patients present for hip and knee replacement surgery hoping to restore 
their quality of life, which typically includes physically demanding activities.  
 
Advances in bioengineering technology have driven prosthesis development but universal 
economic constraints in healthcare services dictate that further developments will be 
governed by their cost-effectiveness.  It is with this background that necessitates every facet 
of patient care being evaluated to optimise outcome. 
 
The narrative of this study reflects the patient clinical pathway: 
• Pre-operative care and optimization 
• Intraoperative interventions 
§ Biomechanical prosthesis stability 
§ Pharmaceutical adjuncts 
§ Infection eradication 
• Post-operative complications  
• Analysis of patient outcomes 
 
This study incorporates 24 peer-reviewed journal articles published since 2006 representing a 
portion of my entire research portfolio.  The published work spans my surgical career to date 
from junior doctor, Masters student, higher surgical trainee, clinical fellow, consultant 
surgeon and senior clinical lecturer.  The data and development related to these articles 
originates from a spectrum of clinical and academic institutions, namely local district general 
hospital, UK teaching hospital, specialist orthopaedic hospitals and world renowned 
academic centres. 
 
The conclusions drawn from this study highlight only some of the facets of the patient 
clinical pathway and demonstrate the need for ongoing research into this topic.  	
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Preface	
 
Hip and knee replacement surgery is increasing common in an aging population and this 
thesis is divided into chapters that analyse separate aspects of care at each step on the patient 
pathway, namely: pre-operative care, intra-operative care, post-operative complication and 
assessment of surgical outcomes. This thesis does not, and cannot, afford a complete 
discourse surgical care. 
 
The thesis provides a narrative that combines 24 published peer reviewed articles that I have 
authored or co-authored over ten years.  The table in subsequent pages sets out the complete 
collection of articles, including title, study design and size, along with futures areas of 
research.  
 
In the appendices of this thesis, all articles are included in their full text format in addition to 
their citation metrics and as such this body of published work on Optimising the Outcome of 
Lower Limb Arthroplasty contributes to knowledge in this field. 
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Chapter	1	-	Introduction	
 
Knee and hip replacement surgery are frequently performed and highly successful for pain 
relief and functional improvement in people with advanced arthritis. The most common 
indication for the procedure is osteoarthritis (1).  The goals of hip and knee replacement 
surgery include pain relief, functional improvement and satisfaction (2). Such surgeries are 
now increasingly considered for patients younger than 55 years, making improved decision 
making about whether a patient should undergo the procedure and subsequent optimisation of 
outcomes important (3).  This thesis cites, in the addition to others, twenty-four scientific 
peer-reviewed papers that I have authored that consider pre-operative (4–8), intra-operative 
(9–17) and post-operative (18–27) factors that influence patient outcomes.  The full text 
manuscripts of these twenty-four papers are included in the appendices. 
 
There are significant clinical and fiscal implications of sub-optimal outcomes and 
complication associated with these operations. This impacts on the patient, clinicians, 
hospital resources and wider society especially in the UK with an aging demographic with 
increasing expectations. As such the demand for hip and knee replacement surgery has been 
predicted to increase, in conjunction with patient expectations (28,29).  In addition to an 
ageing population there is a well-documented increase in co-morbidities, with obesity being 
highlighted as of particular concern by the recent report of the UK Chief Medical Officer, 
which has received wide media coverage (30,31). 
 
Patients undergoing lower limb joint replacement surgery transition through a common 
clinical pathway from pre-operative status, the hospital admission and surgical procedure, the 
post-operative clinical outcome with the concurrent risk of complications.  This clinical 
timeline provides the framework for this dissertation, considering the optimisation of various 
aspects of each phase of the patient pathway. 
 
Numerous factors influence the clinical outcomes, some of which are not fully understood 
and this thesis is not an exhaustive discourse, rather an examination of a selection of some 
key factors. However, the optimisation of these common operations will undoubtedly afford 
benefits for patients and carers, hospitals, clinicians and the wider society. 
 
Pre-operative care commences with the appropriate and timely referral from primary care and 
novel models have now evolved (8).  The pre-emptive identification and treatment of 
anaemia in patients awaiting hip replacement is a simple but effective way of optimising one 
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common peri-operative problem (6).  With an ageing demographic, patients with multiple co-
morbidities and a high surgical risk is common and delivering safe surgical care of this cohort 
is increasingly important (4,5). 
 
Specific surgical technique planning is required for all surgical procedures, but particularly in 
complex cases. Developmental dysplasia of the hip (DDH) presents as hip in-congruence 
secondary to low or high dislocation (32).  Pathological changes include flattening or 
inversion of the labrum and capsular structures (limbus) in association with hypoplasia of the 
capital femoral ossific nucleus and abnormal acetabular development with a high inclination 
and reduced femoral head coverage. When considering a total hip replacement for DDH, 
these anatomical features require specific surgical techniques and implants that highlights the 
need for optimal pre-operative planning. This is expanded upon with a current concepts 
review that I was the lead author for (7). 
 
Three facets of intra-operative optimisation are evaluated in this thesis. Firstly, methods to 
achieve biomechanical stability of the knee and hip prostheses, using a variety of techniques 
including structural allograft and porous metal implants (16,13,10,17). Secondly, techniques 
used to optimise the eradication of periarticular infection, including antibiotic elution from 
cements spacers in both the hip (15) and the knee (14,33). Finally, the use of pharmaceutical 
adjunct to minimise post-operative complications and enhance recovery are reviewed, 
considering both the use of tranexamic acid in hip hemiarthroplasty surgery (11) and high 
volume multimodal wound infiltration in total knee arthroplasty (9). 
 
There are two serious post-operative complications that have been focused upon, namely 
venous thromboembolism (VTE) and heparin-induced thrombocytopenia. Various overall 
aspects of VTE following orthopaedic surgery are reviewed (24) in addition to an analysis of 
whether adequate VTE prophylaxis is being achieved (21).  A more detailed study of patient 
compliance with oral factor Xa inhibitor (Rivaroxaban), a modern therapeutic adjunct, 
following hip and knee replacements is included (18). Finally, a recent systemic review 
analyses the use of aspirin for VTE prophylaxis in the context of modern surgical practice 
(27).  
 
Heparin-induced thrombocytopenia is a potentially fatal complication following the use of 
low molecular weight heparins are commonly used after lower limb arthroplasty surgery.  
This was evaluated as an initial overview (25) and subsequently as an audit and international 
review (23). 
 
 
3 
 
The evaluation of surgical outcomes remains a topic of much ongoing research. This thesis 
includes two aspects of the measure of surgical outcomes. Firstly, outcomes that are non-
patient reported including the radiological methods of patellar height measurement after knee 
replacements (26,34) and the outcome of total hip replacement for hip fracture in 
octogenarians by dislocation rate, 30-day and one year mortality, revision surgery and 
periprosthetic fracture (19). Secondly, the use of patient reported outcome measures to assess 
healthcare quality in general (20) and then a specific analysis of patient satisfaction following 
THA and its association with pre-operative Western Ontario and McMaster score (22). 	
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Chapter	2	-	Pre-Operative	Optimisation	
 
The increasing incidence of lower limb degenerative joint pathology and the increasing 
demand for surgical intervention has led to initiatives in the UK to streamline the initial 
patient referral and avoid unnecessary hospital out-patient appointments. The NHS Plan 
formalised the concept of General Practitioners with Special Interests with the aim of 
providing ‘over one million out-patient appointments in the community rather than hospital’ 
(35,36). The evidence base for the effectiveness for triaging patients for surgical procedures 
by non-surgeons remains unclear as highlighted in a prospective study I conducted (8). We 
demonstrated that time delays, patient confusion regarding professional roles and diagnostic 
indecision are significant problems for patients subsequently referred to hospital orthopaedic 
clinics, risking sub-optimal patient care and medicolegal implications. 
 
It is estimated that high-risk surgical patients account for nearly 10% of the total inpatient 
surgical caseload, whilst account for 80% of deaths after any surgical procedure.  The 
hospital mortality for these patients is 10-15% and is clearly influenced by the efficacy of 
perioperative care. The difficulties of perioperative management of high risk surgical patients 
was highlighted by the National Confidential Enquiry into Patient Outcome & Death 
(NCEPOD) report ‘Knowing the risk – A review of perioperative care of surgical patients’ in 
December 2011 (37).  In response to this, we published a review of the relevance, 
management principles and key recommendations that came about as a consequence of the 
2011 NCEPOD report (4).  In particular, with the high caseload of such patients and the 
widespread implementation of protocol-driven clinical care, we highlighted the need for 
intensive care clinicians and surgeons to provide a combined care approach. The limitations 
of the NCEPOD reports were also highlighted.   
 
To date, there is no agreement amongst anaesthetists, surgeons or researchers as to the 
definition of a ‘high risk’ surgical patient. The NCEPOD have used a clinical anaesthetic 
assessment with no defined parameters to determine whether a case is considered high or low 
risk. The Royal College of Surgeons of England published a report on ‘Perioperative care of 
the higher risk general surgical patient’, within which a pre-operative estimated mortality rate 
of greater than or equal to 5% to define high surgical risk (38).  
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Using a predictive model, Bhattacharyya et al. identified five critical risk factors for acute 
postoperative mortality after orthopaedic surgery (39): 
• Chronic renal failure 
• Congestive heart failure 
• Chronic obstructive pulmonary disease 
• Hip fracture 
• Age greater than 70 years 
 
In a subsequent paper, I outline the key areas for reducing mortality in high risk surgical 
patients (5).  These areas include: 
• Identification of high risk patients (as highlight above) 
• Pre-operative assessment, triage and preparation 
• Consent and informed patient mortality risk 
• Improved intra-operative care 
• Improved post-operative resource use 
 
Several detailed reports provide evidence-based guidelines for the perioperative care of high 
risk surgical patients: 
1. Royal College of Surgeons of England/Department of Health 2011 
The higher risk general surgical patient: Towards improved care for a Forgotten 
Group (38) 
 
2. The Association of Anaesthetists of Great Britain and Ireland 
Recommendations for standards of monitoring during anaesthesia and recovery (40) 
 
3. National Institute of for Health & Clinical Excellence 
Acutely ill patients in hospital. Recognition of and response to acute illness in adults 
in hospital (CG50) (41) 
 
Pre-operative optimisation of anaemia is one facet of reducing perioperative mortality I 
investigated with a prospective study of 322 patients undergoing total hip replacement.  This 
study highlighted the benefit of quantifying serum haemoglobin levels early to afford prompt, 
effective and cheap treatment prior to surgery (6).  
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Thorough pre-operative planning optimises surgical procedures and the importance of this 
was highlighted in the Current Concepts Review paper I was the lead author on concerning 
total hip arthroplasty for adult hip dysplasia (7). 
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Chapter	3	-	Intra-operative	optimisation	
 
There are numerous facets of intra-operative clinical and surgical care that can be optimised.  
This thesis will consider three aspects: structural stability of prostheses, pharmaceutical 
adjuncts and local antibiotic delivery. 
 3.1	Structural	stability	
 3.1.1	Hip	
Implant stability in hip replacements may be anatomically sub-divided into femoral and 
acetabular component stability.  As the need for total hip replacements increases, the 
incidence of extensive bone loss will increase as a consequence of massive osteolysis, stress 
shielding and multiple revisions (42–45). 
	
3.1.1.1Femoral	stability	
Proximal femoral bone stock deficiency resulting from massive osteolysis, stress shielding, 
and multiple revisions provides a major challenge for revision hip arthroplasty and is likely to 
account for a significant future caseload.  Various surgical techniques have been advocated 
for treatment of proximal femoral bone loss including impaction allografting techniques, 
distal press-fit fixation and massive endoprosthetic reconstruction (megaprostheses) (46–52). 
 
A series of articles co-authored by myself have examined the use of allograft to reconstruct 
massive proximal femoral bone loss (13,17,12). This series of articles incorporates a 
systematic review (12), a meta-analysis (13) and the use in developmental dysplasia of the 
hip (17). 
The systematic review had three principal aims: 
i) to document variations in the surgical techniques used, 
ii) to assess the clinical outcome of allograft prosthesis composites (APC) for 
massive proximal femoral bone loss, 
iii) to quantify complication rates in relation to the surgical technique used. 
 
Sixteen studies reported on outcomes of proximal femoral composite allograft used to 
reconstruct major bone defects (see Table 1). All studies were retrospective case series and 
provided level IV evidence. All studies were published within the last fifteen years. The total 
number of allograft reconstructions reported in all the studies was 498. 
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Four studies described the complete resection of the proximal femur as the approach 
employed; however, the trans-trochanteric approach was the most common reported. The 
management of the proximal host femur varied. In 9 studies the proximal host femur was 
fully resected, with 5 studies using the split host proximal femur as an onlay graft after the 
allograft prosthesis composite had been inserted. Two studies did not detail this aspect of the 
surgical technique. Four studies reported the use of cortical strut allografts to reinforce the 
allograft- host junction, with one study reporting use in every case (12) (see Table 1). 
 
 Study n= Primary Diagnosis Mean follow up (yrs) 
1 Chandler et al (53) 30 Aseptic 2 
2 Langlais et al (54) 21 Tumour 6 
3 Haddad et al (55) 55 Tumour, Aseptic, Septic revision 8.8 
4 Zehr et al (46) 14 Tumour 10 
5 Zmolek et al (56) 15 Aseptic failure 2 
6 Safir et al (57) 50 Septic, Aseptic 16.2 
7 Vastel et al (58) 44 Aseptic failure 7.1 
8 Babis et al (59) 72 Aseptic 12 
9 Lee et al (60) 15 Aseptic, Septic Loosening 4.2 
10 Roque et al (61) 73 Tumour 6.7 
11 Biau et al (62) 32 Tumour 5.6 
12 Donati et al (63) 22 Tumour 4.8 
13 Farid et al (64) 20 Tumour 6.3 
14 Graham et al (65) 25 Aseptic, Septic loosening 4.5 
15 Muscolo et al (66) 37 Tumour 7.5 
16 Wang et al (67) 15 Aseptic, Septic loosening 7.6 
 
Table 1.  
List of papers articles incorporated in a systematic review (12), a meta-analysis (13) 
regarding the use of proximal femoral allografts. 
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The success rate was defined as the reported survivorship of the allograft prosthesis 
composites. The total cohort included 498 patients with a mean follow up of 8.1 years (range 
2 to 16 years). The pooled success rate was 81% (95% CI, 77%–86%). This suggests that this 
technique is valid and durable when performed by suitable trained and experienced surgeons, 
in institutions with the facilities to support such complex surgery. The infection rate ranged 
from 0% to over 21%, with a pooled mean of 8%. The two studies with a reported infection 
rate of over 20% had only 14 and 15 patients, respectively (46,67).  Conversely, the four 
studies reporting the lowest infection rates (0 to 4%) had a mean patient cohort of 40 patients 
(53–55,58). Dislocation is a significant postoperative complication, however five out of the 
sixteen studies did not report the incidence of dislocation (46,62,63,65,66).  For the eleven 
studies that did report dislocation rate the mean was 12.8% with a range 0% to 40%. The 
mean reported dislocation rate in studies that used a technique of splitting the host proximal 
femur to use as an onlay graft was 9.8%, compared to 14.9% in studies that resected the 
entire proximal femur.  
 
From the surgical approaches detailed in these studies, the risk of dislocation may be 
minimized by: 
i) preservation of the host posterior capsular structures if possible, 
ii) good biomechanical reconstruction of length, version and offset of the prosthesis-
allograft construct, 
iii) maintaining the bone-soft tissue attachment to the host femur, to provide both 
mechanical stability and to act as a vascularised graft. 
 
The systematic review concluded that, whilst a range of surgical techniques have been 
described, the following a key points: 
i) high caseload is associated with a lower infection rate, 
ii) uncemented distal fixation is associated with a reduced the risk of aseptic 
loosening or fracture, 
iii) if available, using the host femur as an onlay graft enhances hip stability whilst 
acting as a vascularised graft. 
 
A subsequent paper reported a meta-analysis of the proximal femoral allograft (13). The 
reported success rates ranged from 66% to 95%. The fixed effect and random effects pooled 
estimates of success were both 81%. The 95% CI was slightly wider for the random effects 
analysis (0.77-0.86) compared with that of the fixed effect (0.78-0.86). There was no 
significant data heterogeneity within the pooled success rate analysis (P = 0.0635). 
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The quantifiable reported structural failures of PFA reconstructions included fracture and 
aseptic loosening. The range of reported structural failures was from 0% to 55%. 
 
The pooled estimated of structural failure rate was 15% with both fixed (95% CI, 0.12-0.18) 
and random (95% CI, 0.10-0.19) effects model analysis. There was a significant level of data 
heterogeneity regarding pooled failure as an outcome (P = 0.0171), principally the result of a 
single outlying study. 
 
The reported infection rates ranged from 0% to 20%. The fixed and random effect pooled 
estimates of infection were 8% (95% CI, 0.06-0.11) and there was no significant data 
heterogeneity (P = 0.6892) regarding infection as an outcome. 
 
The data relating to structural failure of PFA reconstructions have the highest degree (I2) and 
magnitude (τ2) of heterogeneity and are the only outcome with statistically significant 
heterogeneity (P < 0.05).  Due to confounding factors, the three commonly reported 
outcomes were not amenable to meta-analysis; non-union, revision surgery of the PFA, and 
dislocation.  
 
The implications of the systematic review and meta-analysis on proximal femoral allograft 
are that logistic and ethical issues make it unlikely that future studies on this surgical 
technique will provide level III evidence or higher.  
 
Furthermore, although qualitative heterogeneity may exist between the studies, all the studies 
were conducted at academic orthopaedic units and had been accepted by international peer-
reviewed orthopaedic journals. Thus, although continued follow-up and critical analysis of 
this technique should be encouraged, this systematic review and meta-analysis support the 
use of PFAs for the reconstruction of massive femoral bone loss.  
 
Developmental dysplasia of the hip is a specific patient cohort where proximal femoral bone 
loss may present a significant challenge and this was evaluated in a co-authored 2012 JBJS 
(Br) paper (17). The outcome of 28 patients (30 hips) with developmental dysplasia of the hip 
who underwent revision total hip replacement in the presence of a deficient proximal femur, 
which was reconstructed with an allograft prosthetic composite, was evaluated. The mean 
number of previous total hip replacements was three (1 to 8) and the mean age at primary 
total hip replacement and at the index reconstruction was 41 years (18 to 61) and 58.1 years 
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(32 to 72), respectively. The indication for revision surgery included mechanical loosening in 
24 hips, infection in three and peri-prosthetic fracture in three. Six patients required removal 
and replacement of the allograft prosthetic composite, five for mechanical loosening and one 
for infection. The survivorship at 10, 15 and 20 years was 93% (95% confidence interval (CI) 
91 to 100), 75.5% (95% CI 60 to 95) and 75.5% (95% CI 60 to 95), respectively, with 25, 
eight, and four patients at risk, respectively. Additionally, two junctional non-unions between 
the allograft and host femur required bone grafting and plating.  
 
This study, in conjunction with the systematic review and meta-analysis of proximal femoral 
allograft composites, demonstrates that allograft prosthetic composite affords a good long-
term outcome in the management of proximal femoral bone loss in revision total hip 
replacement in patients with or without developmental dysplasia of the hip, while preserving 
distal femoral host bone.  
3.1.1.2	Acetabular	stability	
 
Massive acetabular bone loss provides a further challenge for the reconstructive surgeon. 
Periprosthetic pelvic discontinuity exists when there is loss of structural bone between the 
superior and inferior aspects of the pelvis, resulting from bone loss or fracture through the 
acetabulum. I co-authored a paper detailing the management of both acute and chronic cases 
of pelvic discontinuity (16).  
 
This two-centre international study identified 71 cases of pelvic discontinuity that were 
classified into acute, less than 12 weeks from primary surgery, or chronic, greater than 12 
weeks from primary surgery. All cases were treated at academic tertiary referral units, and all 
surgeries were performed by senior surgeons.  There were 9 acute cases and 62 chronic cases.  
Of the acute cases, over half were the results of iatrogenic acetabular fractures during the 
insertion of uncemented acetabular cups. 
 
Diagnosis of pelvic discontinuity was made using the criteria described by Berry (68):  
 
i) a visible trans- verse pelvic fracture on anteroposterior pelvic or Judet 
radiographs,  
ii) medial offset of the inferior part of the pelvis in relation to the superior part of the 
pelvis as seen by a break in the ilioischial line, 
iii) rotation of the hemipelvis as indicated by asymmetry of the obturator ring on the 
true anteroposterior pelvic radiograph.  
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In addition, the senior operating surgeon confirmed the definitive diagnosis of pelvic 
discontinuity once the entire acetabulum was directly visualized intraoperatively.  For chronic 
cases, porous tantalum components afford bone ingrowth to be achieved with a low 
percentage of bleeding. A large porous tantalum revision shell provides distraction that 
stabilizes the pelvic discontinuity while forming a bridging construct between the ilium and 
the ischium. A revision shell used in this manner is usually too vertical and retroverted to 
safely accommodate an acetabular liner. In addition, because of the inherent instability of 
pelvic discontinuity, additional protection is required to allow bone ingrowth, and this is 
achieved with a cup-cage reconstruction. By supplementing the construct with an ilioischial 
cage, a polyethylene liner can, thus, be cemented at the correct inclination and version, 
independent of the position and version of the acetabular shell. 
 
Regarding the acute cases, the results demonstrate that acute periprosthetic pelvic 
discontinuity can be successfully treated with compression of the posterior column, 
principally using a plate supplementing a trabecular metal acetabular revision shell. This 
clinical evidence suggests that cases of acute periprosthetic pelvic discontinuity possess bone 
healing potential if compression is achieved, assuming normal bone metabolism, in particular 
no concurrent infective or neoplastic conditions.  
 
Both the results of both the acute and chronic pelvic discontinuity series highlight the clinical 
application of porous metal. The work of Bobyn and others has highlighted the beneficial 
biomechanical properties of porous tantalum metal, including high porosity, high coefficient 
of friction, and a Young modulus similar to bone (69). These properties have made this 
biomaterial increasingly popular in revision hip arthroplasty (70–75). The use of porous 
tantalum in the reconstruction of pelvic discontinuity is attractive because bone ingrowth can 
be achieved with less than 50% of bleeding host bone contact. 
 3.1.2	Knee	
 
Similarly, loss of bone stock around the knee can lead to structural instability. Previous 
infections, tumour, and trauma can all result in bone loss that makes a standard primary total 
knee arthroplasty impossible without restoration of bone stock. More commonly, bone loss in 
revision knee arthroplasty is a frequent problem and may occur for any of the aforementioned 
reasons, osteolysis, periprosthetic fracture, or iatrogenic when components are being removed 
from host bone.  The extent of bone loss will determine whether it may be dealt with by 
simple autogenous bone grafting, cement, metal augments, porous metal supplementation, or 
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allograft of various sizes. Large uncontained defects of the knee may be treated with use of a 
large or massive allograft in conjunction with the total knee. 
 
I co-authored a clinical case series and literature review of structural allograft for treating this 
such bone loss published as both a book chapter (76) and journal article (10). The primary 
indications for using structural allografts in the setting of knee arthroplasty are:  
 
i) large uncontained defects that are outside the range of metal augments or thicker 
polyethylene inserts, 
ii) patients that are active and require bone-stock restoration for potential future 
operations, 
iii) patients who are physically well enough to tolerate both the surgical procedure 
and rehabilitation required for successful outcomes.  
 
A relative contraindication is a patient actively smoking, and cessation programs must be 
implemented prior to surgery. Lastly, presence of active infection is an absolute 
contraindication for allograft in the arthroplasty patient. 
 
The review paper highlights the preoperative planning and preparation including the 
consideration of segmental allografts or allograft-prosthetic composites. Allograft-prosthetic 
composites being considered for bone defects that are uncontained, often circumferential and 
involving > 25 mm of femur or > 45 mm of the tibia.  A critical principle is avoiding 
cementing the stems to the host bone. Conversely the allograft side of the stem and implant-
allograft interface must be cemented to provide stability to construct. No cement should be 
present between the allograft-host bone junction as it would potentially interfere with graft 
incorporation. 
 
The review summarises the outcome data to date. 
 
In one of the earliest papers, Stockley et al. reported 20 knees that had undergone a 
combination of structural allograft and morselized allograft with 85% survivorship at 4.2 
years (77). The lowest reported survivorship is that from Ghazavi et al. with only 67% 
survivorship at 5 years in their 30 patients (78). 
 
A recent publication by Richards et al. compared cohorts with severe bone loss of bone 
around total knee arthroplasty using femoral allograft compared with metal augments (79). 
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Despite the presence of more significant bone loss in the allograft group, these had better 
clinical outcome scores than the control cohort. This strengthens the argument for allograft 
use in patients with severe bone loss. 
 
Backstein et al. have one of the largest cohorts to date with 61 patients. The survival rate at 
5.4 years was 85.2% (80). Of note in this series, the infection rate was 6.5% (4/61); however, 
a high union rate of 98.4% (60/61) was seen radiographically. 
 
Structural allograft is a viable method for restoring peri-genicular bone stock. These complex 
procedures should be performed by surgeons with expertise in revision arthroplasty and with 
access to a dedicated bone bank. Allograft reconstruction is not indicated in the low demand 
or elderly patients who would benefit from implantation of an endoprosthesis, which allows 
rapid mobilization and recovery. Rather, the optimal allograft candidate is a young, higher 
demand and relatively healthy patient who is likely to require further revisions and can 
adhere to the rehabilitation protocol. The restoration of bone stock is a key component in 
choosing allograft in the reconstruction (10,76). 	3.2	Therapeutic	adjuncts	
 3.2.1	Tranexamic	acid	
 
Minimising blood loss and improving post-operative pain and function can both be enhanced 
by the use of various chemotherapeutic agents. Tranexamic acid (TXA) is an anti-fibrinolytic 
agent that binds with plasminogen to competitively block lysine binding sites. This prevents 
plasminogen interaction with fibrin, thus inhibiting plasmin induced fibrinolysis and clot 
breakdown. The use of TXA has been advocated in both elective and trauma surgery.  
However, a thorough literature search showed limited studies investigating the specific use of 
TXA for hip hemiarthroplasty surgery, despite this patient cohort being particularly 
susceptible to the effects of blood loss (81–83). 
 
The aim of our study was to evaluate the effect of TXA use on postoperative transfusion rates 
and haemoglobin (Hb) levels following hemiarthroplasty surgery for hip fractures (11).  This 
was a retrospective cohort study conducted for consecutive hip hemiarthroplasties for 
fractures between June 2013 and October 2014 comparing patients with or without 
prophylactic TXA before incision. During the study, 305 hemiarthroplasties were performed 
with 271 cases eligible. TXA was given in 84 (31%) cases, and both patient groups were 
matched for known confounding factors. Patients given TXA had a lower transfusion rate 
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(6% versus. 19%. P = 0.005) and less blood loss (Hb drop > 20 g/L) on day 1 post-surgery 
(26% versus42%; P = 0.014). One transfusion was prevented with every 8 patients given 
prophylactic TXA. There were no differences in the 30 and 90-day mortality rates with TXA 
use.  
 
The study demonstrated that TXA is cost-effective, reduces the need for blood transfusions 
and is safe for all patients undergoing hip hemiarthroplasty for fractures. 	3.2.2	Wound	infiltration	
 
High volume multimodal wound infiltration is now considered an aspect of enhanced 
recovery regimes for hip and knee replacement surgery with a variety of therapeutic mixtures 
advocated.   
 
There are potential benefits of infiltrating high volumes of local anaesthetics around the soft 
tissues of replaced hip and knee joints. The risk of systemic toxicity is minimized with 
diluted local anaesthetic solution, affording a high volume to be used. One of the principal 
advantages is that analgesia agents are administered intraoperatively by the surgeon, thereby 
minimizing the need for additional invasive procedures. 
 
I co-authored a systematic review, limited to randomised controlled studies, to evaluate if 
such wound infiltration during knee replacements results in reduced pain and opiates 
requirement, with early rehabilitation and discharge (9). 
 
Although better pain relief in the immediate postoperative period with wound infiltration is 
gained after TKA, there is no definite evidence that this leads to a reduction in opiate 
consumption, the achievement of early milestones, or a reduction in hospital stay. The roles 
of individual agents in achieving pain relief and the use of percutaneous wound catheter for 
postoperative doses are also unclear. There are few reports of complications, including falls 
and delayed mobilization, when femoral nerve blocks are used. Wound infiltration analgesia 
should be used at the preference of the surgeon and anaesthetist provided regular review of 
their practice is undertaken to identify any untoward side effects. Further randomized trials 
with sufficient sample size comparing each outcome, including pain scores, opiate 
consumption, and length of hospital stay, should be undertaken.  
 3.3	Infection	control	
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3.3.1	Knee	
Periprosthetic joint infection frequently necessitates a two-stage revision, in the knee 
frequently using articulating antibiotic cement spacers. The chemotherapeutic benefit of 
cyclical loading of cement spacers was investigated in a basic science study I led (14). 
 
The effects of articulation, specifically cyclical fatigue loading, on the elution of antibiotics 
from polymethylmethacrylate cement knee spacers has not been clearly defined. The 
maintenance of joint movement is an advantage in maintaining the condition of the soft 
tissues, but the question arises as to whether the articulation per se influences the biology and 
pharmacokinetics of antibiotic elution. Tobramycin has a broad antimicrobial action with 
minimal effect on polymethylmethacrylate strength, while vancomycin is effective against 
methicillin- resistant Staphylococcus aureus and Staph. epidermidis with similarly low 
adverse biomechanical effects on polymethylmethacrylate (84–86).  Our in vitro study 
considered the differential effect of static or dynamic loading on the elution of vancomycin 
and tobramycin with a null hypothesis proposing that the cyclical loading of cement spacers 
has no significant effect on elution. 
 
The results provide evidence that, in addition to the benefit to the soft tissues claimed for 
articulating spacers, the dynamic loading of cement knee spacers per se affords a biological 
advantage by significantly enhancing antibiotic elution.  The precise mechanism of antibiotic 
release from bone cement is uncertain. It is generally thought that it is directly released from 
the surface of the bone cement in the initial phase, and then subsequently released from a 
network of cracks and voids (87–90). Absorption of water to bone cement is thought to have 
a role in controlling the slow phase of antibiotic release (88–90).  Our study suggests that 
cyclical dynamic loading enhances this process, probably by a mechanism of cyclical 
changes in the microstructure of the bone cement. 
 
Further related work has been published by other authors to evaluate whether the indentation 
of bone cement spacers with a MacDonald dissector increased the elution of antibiotic in 
vitro (91).  Using an ‘area under the curve’ analysis, gentamicin elution was seen to be 
increased with cement indentation.  Colleagues and I submitted a letter of reply to this article, 
raising methodological concerns regarding the buffering solution used, the effect of cyclical 
loading amplitude and the mechanical effect of multiple indentations on the biomechanical 
properties of the construct (33).  
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3.3.2	Hip	
 
I subsequently co-authored a study evaluating a novel surgical technique for achieving the 
same cyclical loading of cement spacers in the hip (15). Using cement augmentation of the 
acetabulum in revision hip arthroplasty for infection, this technique afforded enhanced 
mechanical stability in addition to improved antibiotic elution. 
 
In summary, following thorough debridement, a cement acetabular shelf is formed utilising 
cancellous screws inserted into the supra-acetabular rim; upon which antibiotic loaded bone 
cement/ polymethylmethacrylate is allowed to set. This construct affords improved acetabular 
coverage and hence improved hip stability, whilst articulation with a standard femoral cement 
spacer provides the potential benefit of increased antibiotic local elution. 
 
In this small published case series, fifteen infected hip prostheses underwent removal, cement 
acetabular augmentation and insertion of a femoral cement spacer. Eleven hips had successful 
infection eradication and subsequently underwent a second stage revision procedure a mean 
duration of 15 weeks (range 9–48 weeks) after the first stage.  
 
No dislocations or fractures of the cement spacers were observed. In addition, no cases of 
antibiotic-associated renal toxicity have occurred, although this technique should be used 
with caution in patients with significant renal impairment. Second-stage reconstruction was 
considered only when there was clinical and serological evidence of infection eradication. 
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Chapter	4	-	Minimising	post-operative	complications	
 4.1	Venous	thromboembolism	
 
In a series of six published papers I have evaluated various aspects of venous 
thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism 
(PE), some of the commonest complications following hip and knee replacement surgery, and 
how this can be minimised (24,21,18,27,25,23).  
 
Current estimates suggest that if no measures are taken following hip or knee replacement 
surgery, the incidence of fatal PE is approximately 0.4%; equating to over 5,000 fatalities a 
year for the 1.5 million surgical procedures. I published a review of thromboprophylaxis in 
orthopaedic surgery in 2010 highlighting that numerous guidelines and evidence have been 
published, though none to date incorporate newer treatment modalities such as oral factor Xa 
inhibitors (24). The individual patient VTE risk reflects combined patient and surgery 
specific factors (see Box 1 below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Box 1: Surgical risk factors for VTE 
 
 
Historically there was undoubtedly clear evidence for the need for VTE prophylaxis because 
the incidence of VTE events after THR approached 50% in patients in whom no preventive 
measures were taken (92). Contemporary surgical procedures and postoperative regimens 
have drastically changed over the last three decades, and the incidence of untreated VTE is 
now likely to be substantially lower. 
 
The review highlighted that VTE prophylaxis is multi-factorial and both the clinician and 
patient should be aware of this. However, the plethora of published guidelines on this subject 
is a cause of potential confusion and there are several factors that cause resistance to their 
Lower limb surgery higher risk than upper limb 
Degree of soft tissue/bone dissection 
Joint or limb position during surgery 
Positioning of retractors during surgery 
Length of surgery 
Amount of blood loss 
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implementation, including a lack of awareness, perceived conflicting evidence, practicality, 
the low overall incidence and bias. 
 
Education of the clinician and patient is vital because not only is the incidence of VTE 
greatest after the patient has usually been discharged, but also patient; compliance with the 
general measures will help reduce risk. With the likelihood of numerous future publications 
on this topic, the clinician should endeavour to remain up to date with the best available 
contemporary evidence to guide clinical practice. 
 
Studies investigating the incidence of postoperative VTE demonstrate that the mean time to 
thromboembolism is greater than previously estimated. Two large meta-analyses advocate 
VTE prophylaxis be continued for up to 4 weeks following total hip arthroplasty surgery 
(THA) (93,94). Concern now exists that the length of treatment varies depending upon the 
prophylaxis used. 
 
Two commonly used pharmaceutical options for VTE prophlaxis in the UK are low 
molecular weight heparin (LMWH) and oral Factor Xa inhibitors (e.g. rivaroxaban). I 
published a two-part study to assess, using a local audit and international survey, the duration 
of VTE prophylaxis currently achieved with LMWH and to examine whether this may be 
improved with the use of rivaroxaban, an oral Factor Xa inhibitor (21). 
 
The survey demonstrated that four out of 39 (10.2%) units that routinely prescribe LMWH do 
so for at least 4 weeks following surgery. The audit demonstrated that rivaroxaban afforded a 
superior mean duration of postoperative VTE prophylaxis (35 days versus 5.4 days; P < 0.05) 
and superior patient satisfaction. There was no difference in the incidence of bleeding, wound 
infection or thrombotic complications.  
 
Therefore, patients are exposed to an increased VTE risk following hip replacement surgery 
due to the inadequate prescription of LMWH. This is poor clinical practice, contrary to 
current evidence-based guidelines and has potential medicolegal implications. However, 
rivaroxaban affords a superior patient compliance compared with subcutaneous LMWH, thus 
ensuring that patients receive VTE prophylaxis for the current recommended period of time. 
 
This study was then supported and superseded by a larger study (n = 3,145) on patient–
reported compliance with rivaroxaban following hip and knee arthroplasty (18) whereby 
patients completed an anonymous self-administered questionnaire six weeks after surgery. 
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Postoperatively 2947 (94%, 2947/3145) received rivaroxaban. Two thousand eight hundred 
and twenty-four patients (96%, 2824/2947) completed all in-hospital doses. Seven per cent 
(203/2824) of patients did not attend the 6-week follow-up. Two thousand one hundred sixty-
three (83%, 2163/2621) completed all prescribed doses, 98 (4%, 98/2621) were non-
compliant and 360 (14%, 360/2621) had incomplete data. Gender, age, body mass index and 
preoperative haemoglobin all correlated with non-compliance (P > 0.05). Type and side of 
surgery did not correlate with compliance.  Patient-reported non-compliance for rivaroxaban 
is 4% which compares favourably to other VTE prophylaxis modalities. 	4.2	Heparin	induced	thrombocytopenia	
 
Heparin induced thrombocytopenia (HIT) is associated with thrombosis, independent of 
heparin type, dose or route of administration and is one of the most important immuno-
haematological problems in clinical medicine. With the increased use of low molecular 
weight heparin (LMWH) for venous thromboembolism prophylaxis following hip and knee 
arthroplasty surgery, orthopaedic clinicians need to be aware of HIT and its management.  
We published a review article highlighting the incidence, required monitoring, treatment and 
lack of insight about HIT (25). 
 
In summary, the use of a simple monitoring protocol can facilitate the prevention of HIT, 
based upon guidelines from the British Society of Haematology (95). 
 
• All patients who receive heparin (of any form) should have a platelet count on day 
one of commencing treatment.   
• All patients receiving LMWH should have platelet counts every 2-4 days from day 4 
– 14 whilst on treatment 
• If the platelet count drops by 50% or below normal lab limits, HIT should be 
considered and heparin stopped and haematological consultation obtained. 
 
This review article was subsequently followed by an local audit and international survey of 
HIT following surgery (23). An initial patient survey demonstrated that only 2 out of 48 at-
risk patients (4%) had a full blood count performed more than four days after commencing 
LMWH.  Following the dissemination and implementation of the above guidelines, a second 
survey demonstrated a significant improvement (P < 0.05), with 23 out of 40 (57.5%) at-risk 
patients having a full blood count performed more than four days after commencing LMWH. 
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The secondary survey demonstrated a significant improvement (P < 0.05) in the monitoring 
of HIT compared with the primary survey (57.5% compared to 4%). 
 
This audit demonstrated that the risk of HIT, a potential fatal complication of LWMH use, 
can be substantially reduced by the simple clinical audit. In addition, a subsequent telephone 
survey highlighted a low awareness of both the condition of heparin-induced 
thrombocytopenia and the BSH guidelines and no units routinely monitored for HIT.  
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Chapter	5	–	Clinical	outcomes	
 
Evaluating the overall outcomes remains a topic of much ongoing research and debate.  
Numerous methods are employed and overall may be categorised into two groups: 
• Non-patient reported outcome measures(non-PROMS) 
• Patient reported outcome measures (PROMs) 
 5.1	Non-patient	reported	outcomes	measures	
 
I have evaluated and published objective non-PROMs data for total hip replacement surgery 
for fractures in octogenarians (96). The purpose of this study was to establish the safety 
profile, survival and short-term results for patients of 80 years and over who received THA 
for fracture according to United Kingdom National Guidelines (97). Functional outcome 
scores such as the Oxford/Harris Hip Scores were not performed. 
 
Over a two-year period, 354 patients aged over 80 years were admitted with a displaced 
intracapsular hip fracture. Using defined clinical guidelines, 38 patients underwent THA with 
a median age of 84 years, mean follow-up of 20 months. There were no dislocations or 
periprosthetic fractures and patient survival was 97% at 30 days and 87% at one year. There 
was one revision for deep infection. 
 
The management of hip fracture in elderly patients is an increasingly important aspect of 
orthopaedic care worldwide. This study shows that THA is a safe and efficient use of 
resources when performed in selected patients over 80 years old. This represents a significant 
caseload for orthopaedic services within the United Kingdom and is likely to increase in the 
future. In the UK projections estimate that the incidence will rise from 70,000 patient events 
per year in the UK to 101,000 by 2020 (98,99). The potential cost of treating all fragility 
fractures in this patient population is £2.2 billion per year (100). Several randomised studies 
have supported the use of arthroplasty over internal fixation of displaced intracapsular 
fractures (101,102). 
 
This study demonstrates that THA in suitably selected octogenarians can produce excellent 
short term results without a high risk of complication. However, evidence regarding the long-
term cost-effectiveness and patient related outcomes of these patients will require a much 
larger patient cohort. An increasingly active elderly population now expects optimal 
functional capability following a fracture of the femoral neck. This study demonstrates that 
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total hip arthroplasty for selected octogenarians afford a low complication rate with the 
majority of patients returning to independent living. 
 
In a separate study the measurement of patella height, key to effective knee function 
following total knee replacement, was evaluated (26). In particular, the relative 
reproducibility and accuracy of four ratios used to measure patellar height, namely the 
Blackburne-Peel, Caton-Deschamps, Insall-Salvati and modified Insall-Salvati, before and 
after total knee arthroplasty. The radiographic study analysed 720 measurements per each of 
two independent observers.  It demonstrated that the theoretical advantage of using the Insall-
Salvati and modified Insall-Salvati ratios in measuring true patellar height after total knee 
arthroplasty needs to be balanced against their significant inter-observer variability and 
inferior reliability when compared with other ratios. 
 
Whilst numerous methods exist for measuring a patella height, both clinicians and academics 
should be aware of their inherent limitations.  This is something that can be extrapolated to 
numerous clinical measurements. 	5.2	Patient	reported	outcome	measures	
 
Patient-reported outcome measures are standardized, validated questionnaires that are 
completed by patients to measure their own functional status and general health. They were 
originally designed for use in clinical trials (103). Since 2009, wider use of patient-reported 
outcome measures within the NHS has been proposed to augment mortality data from 
Hospital Episode Statistics, which are considered an insufficient measure of quality.  
 
Specific examples of the processes and outcomes that may be quantified with patient-reported 
outcome measures data 
 
Processes  
1. Communication: improved communication between patient and health-care provider  
2. Concordance: agreement between patient and health-care provider about problems 
and solutions  
3. Provider behaviours: changes in health-care providers’ diagnosis and treatment of 
patient conditions  
4. Patient behaviours: patient self-efficacy, adherence and behavioural change. 
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Outcomes  
1. Patient satisfaction: patient-reported satisfaction with the consultation, treatment or 
care overall  
2. Health status: patients’ health and wellbeing as indicated by clinical measures or 
patient reports  
3. Resource use: patients’ subsequent use of health and other services. 
 
Furthermore, controversies exist regarding the widespread implementation, data collection 
and interpretation of PROMs within the UK and internationally (104). I published a review 
article that considered some of the relevant issues inherent in collecting and analysing 
patient-reported outcome measures data (20). 
 
In a further study, for which I was the lead author, standard PROMs for total hip replacement 
were evaluated in relation to patient satisfaction (22). The rationale for this study was that the 
routine collection of patient-reported outcome measures (PROMs) has been introduced in 
several countries, not only to quantify success but also as a possible means of defining a 
threshold for surgery(104). 
 
Prospective data for a cohort of patients undergoing total hip replacement from two large 
academic centres were collected, and pre-operative and one-year post-operative WOMAC 
scores and a 25-point satisfaction questionnaire were obtained for 446 patients. Satisfaction 
scores were dichotomised into either improvement or deterioration 
 
Satisfaction was compared using receiver operating characteristic (ROC) analysis against pre-
operative, post-operative and δ WOMAC scores.  The results demonstrated that pre-operative 
WOMAC score does not predict the post-operative WOMAC score or patient satisfaction 
after THA.  The results imply that WOMAC scores can therefore not be used to prioritise 
patient care. 
 
Expanding the use of PROMs to prioritise patients for surgery remains controversial and 
currently lacks a substantial base of evidence. A recent study based in the United Kingdom 
which prospectively analysed a cohort of 1,523 total knee arthroplasties (TKAs) and 1,784 
THAs demonstrated that the pre-operative Oxford hip and knee scores did not predict post-
operative patient satisfaction and should not be used to prioritise care (104). Thus, both 
WOMAC and Oxford hip and knee scores are unsuitable for predicting outcomes and 
satisfaction, and therefore should not be used to prioritise patient care. 
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Whilst the use of PROMs is valued for its transparency with the aim to improve the quality of 
surgical care, their use is not without difficulty. Further large studies are required to refine 
and quantify the use of PROMs in all aspects of lower limb arthroplasty surgery.  
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Chapter	6	-	Conclusions	
 
This thesis highlights multi-faceted nature required to optimise the outcomes of hip and knee 
replacement surgery, which are increasingly common surgical procedures. The collection of 
24 published peer reviewed articles I have co-authored represents only a small fraction of the 
possible interventions and evaluations. In addition, numerous innovations are likely to be 
developed in this field in the coming years and this study highlights the need for each to be 
rigorously evaluated. 
  
Furthermore, understanding the complex interaction between the human, prosthetic, 
physiological and pharmaceutical factors that influence patient outcome, some of which have 
been evaluated in this study, remains not fully understood. These interactional factors are 
inherent in the complexity of patient care in its entirety, not only in orthopaedic surgery.  As 
such, the understanding multifactorial systems is relevant to the wider field of medicine    
 
It remains clear that further research is required in every aspect of surgical care along the 
patient pathway for lower limb arthroplasty. As modern western societies have an 
increasingly populous and ageing demographic, global fiscal constraints will dictate a close 
evaluation of all aspects of care to optimise clinical outcomes of lower limb arthroplasty. 
Clinicians, scientists and academics must continue to question and evaluate all interventions, 
with the aim of delivering surgery that is both safe and of the highest quality. 
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Chapter	7	-	Future	Work	
 
This thesis brings into relief several aspects that warrant further investigation and would 
afford a positive impact on the knowledge base and clinical care.  The following are further 
research questions I wish to pursue. 
 
1. What is the effect of physiotherapist-lead clinics on lower limb arthroplasty operation 
rates?   
A retrospective case study may provide sufficient clarity to afford a significant 
differential operation rates & time-to-surgery for two patient cohorts, namely those 
referred directly to secondary care and those referred via a physiotherapy-lead clinic.  
The study would follow on from the retrospective case-series analysis of Multi-
professional triage teams (MPTT) (Rogers, Kabir & Bradley 2008) and be augmented 
with a cost-benefit analysis.  The rationale for such a study is the continuing changes 
in the access to secondary care lack clinical or financial evidence.  The results of such 
a retrospective case study could form part a service improvement audit cycle, thereby 
leading to a prospective study directly comparing physiotherapy-lead clinics with 
traditional surgeon-lead clinics. 
 
2. What is the cost-utility outcome of an expanded pre-operative screening protocol for 
elective orthopaedic surgery? 
Pre-operative screening forms a critical stage in the patient pathway for elective 
orthopaedic surgery and there is the potential for further reductions in clinical risk 
with concurrent cost saving.  The optimal amount of pre-operative health screening to 
maximise clinical and cost benefit is not defined.  Furthermore, it is probable that a 
non-linear correlation exists between increasing financial cost (of healthcare 
screening) and clinical benefit.  Defining this correlation will have potential 
significant clinical and economic benefits.  A retrospective case series study may 
afford sufficient data to allow regression analysis to highlight the cost-utility of the 
individual components of pre-operative assessment.  However, retrospective studies 
may have insufficient statistical power, but afford data for power analysis to plan 
prospective studies. 
 
3. How surgical risk is defined in lower limb arthroplasty patients?  
The reviews included within this thesis highlight the need for a formal systematic 
review, considering the current published evidence, which defines high perioperative 
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risk for lower limb arthroplasty.  Currently no specific definition exists for high risk 
directly validated for hip and knee surgery.  In addition, there are no existing 
registered relevant protocols published on PROSPERO – International prospective 
register of systematic review1.   
To conduct a systematic review on surgical risk for lower limb arthroplasty, search 
terms must be adjusted to incorporate elective and trauma surgery, with publication 
date limits to ensure relevance to modern surgical practice. 
 
4. How do we stratify risk for hip fracture patients proceeding to total hip arthroplasty? 
Based upon the data & information used from the systematic review of surgical risk 
(see point 2 above) I would aim to develop a validated risk scoring system for patients 
who have sustained hip fractures and are proceeding to joint replacement surgery.  
The data points for such a scoring system are likely to incorporate assessments of 
numerous physiological, pathological and social parameters.  Considering the ongoing 
healthcare fiscal constraints, a scoring system will need to incorporate a cost analysis 
element.  To my knowledge, no pathology-specific scoring systems currently involve 
clinical and economic components, which could be viewed a significant omission 
considering the projected burden of hip fractures. 
 
5. What is the comparative cost of cemented versus uncemented hip replacements? 
This research question will necessitate the design and development of a randomised 
clinical trial to identify the current and projected costs of the two main types of hip 
replacements.  A full health economic analysis of the entire patient pathway would be 
required and the study could utilise mandatory data, such as the UK National Joint 
Registry.  Such a randomised cost-based study, combining clinical and dedicated 
fiscal outcomes, could provide a template for the analysis of other facets of surgical 
care. 
 
  
6. What is the comparative venous thromboembolic event (VTE) risk following lower 
limb arthroplasty.  A prospective multi-centre clinical study of aspirin versus low 
molecular weight heparin and oral antithrombotic agents. 
                                                
1 Centre for Reviews and Dissemination, University of York, UK. 
https://www.crd.york.ac.uk/PROSPERO 
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This continues to be an important clinical question with proponents for and against 
the use of aspirin for VTE thromboprophylaxis following hip and knee replacements.  
The studies presented in this thesis highlight a clear rationale for Level 1 evidence on 
this topic.  I aim to instigate such a study with the involvement and collaboration of 
numerous key stakeholders, including the National Institute for Clinical Excellence 
(NICE), British Hip Society (BHS)/British Association for Surgeon of the Knee 
(BASK), British Orthopaedic Association (BOA), British Haematological Society, 
and Royal College of General Practice (RCGP).  An initial expression of interest and 
support from all stakeholders will be essential, followed by an agreement of 
methodology.  This study will require non-pharma funding and will involve high 
recruitment numbers to meet statistical significance. In addition, a practical design to 
compare aspirin against NICE – approved anticoagulation will be needed to facilitate 
recruitment. The primary outcome measures would include the rate of clinical 
detected, and imaging confirmed, venous thromboembolic event at three weeks after 
knee replacement and four weeks after hip replacements.  These periods being the 
NICE - recommended duration of chemoprophylaxis following lower limb 
arthroplasty.  The patient cohorts will need to be matched for pre-operative 
thromboembolic risk using approved and validated scoring systems currently in 
clinical use. 
 
7. Why does vancomycin elution from bone cement not increase with weight bearing 
articulation?   
The basic science publications presented in this thesis demonstrate the differential 
elution characteristics of tobramycin and vancomycin from bone cement under 
weight-bearing articulation ex-vivo.  Our understanding of the interaction between 
antibiotics, bone cement (polymethyl methacrylate) and loading is incomplete.  
Furthermore, the clinical implication of this is unclear.  A translational clinical study 
comparing the clinical outcomes of 1st stage revision total knee replacements using 
articulating bone cement spacers with either tobramycin and vancomycin should be 
conducted.  Such a prospective clinic study should be undertaken in a small number 
of tertiary centres that undertake a high volume of such cases.  In addition, and with 
the appropriate consent and ethical approval it would be feasible to conduct a double-
blinded study. 
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8. How do we define patient satisfaction after lower limb arthroplasty? 
This thesis has demonstrated that numerous validated Patient Reported Outcomes 
Measure (PROMs), including Oxford Hip Score (OHS) & Western Ontario 
MacMaster scores (WOMAC), do not correlation with patient satisfaction after lower 
limb arthroplasty.  If patient satisfaction is deemed a key outcome measure, then it 
must be incorporated, or correlated, to a specific PROM.  I am currently undertaking a 
systematic literature review to evaluate whether any such measures currently exist.   
 
Furthermore, there are increasing reports that inappropriate criteria, such as pre-
operative Oxford Hip Score and Body Mass Index, are now used to ration the access 
to healthcare, despite a clear lack of scientific evidence.  This highlights the need to 
critically review whether these scoring systems are being implemented correctly and 
if there is a role for an amended or update PROM that more readily reflects patient 
satisfaction. 
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High-risk patients and perioperative
practice
reported in 2011 that existing comorbidities, rather than
preoperative anaemia, were independently associated with
major morbidity and mortality.5
High-risk surgical patients are frequently older with a
greater risk of impaired nutritional status, and screening
tools aim to identify poor nutritional reserve.6 Greene et al.
reported a five-time increase in postoperative wound com-
plications among patients with decreased nutritional sta-
tus, identified by a lymphocyte count of <1500 cells/mm,
and a sevenfold increase when preoperative albumin was
<3.5 g/dl.7 
Nasal colonisation with Staphylococcus aureus (MSSA),
especially with methicillin-resistant S. aureus (MRSA), has
also been shown to be a risk factor for surgical site infec-
tions.8 Staphylococcus nasal colonisation among
orthopaedic patients was shown to be 18% for MSSA and
2.17% for MRSA.9 Institutionalised and nursing home
patients are at an increased risk for positive nasal colonisa-
tion by S. aureus.9 Among other risk factors for positive
colonisation are haemodialysis, immunodeficiency and
increased age.10
Within the National Health Service (NHS), high-risk
elective patients are usually assessed and identified prior to
surgery. However, the subsequent management of these
patients is frequently compromised from a lack of intensive
treatment unit or high dependency unit beds, with surgeons
and anaesthetists faced with the decision as to whether or
not to proceed with the planned surgery. Not uncommon-
ly, and out of misguided kindness to the patient and rela-
tives, the surgery is undertaken without the suitable
resources available due to the pressure to attain targets and
avoid surgical cancellations. In the majority of cases no
adverse outcomes occur; however, the lack of resources is
one of the principal reasons the figures highlighted in the
recent NCEPOD report are so bad.1
NCEPOD
The purpose of the NCEPOD is to assist in maintaining and
improving standards of medical and surgical care by review-
ing the management of patients, by undertaking confiden-
tial surveys and research, and by maintaining and
improving the quality of patient care and publishing their
results. The 2011 report documented an overall mortality
at 30 days of 1.6%; with the mortality in the ‘high-risk’ group
being 6.2% compared with 0.4% in their low-risk group.
Overall, the NCEPOD rated the care of ‘high-risk’ surgical
patients as ‘good’ in only 48%. In order to address this dis-
parity, and improve clinical care, they made a number of
principle recommendations (see Table 1).
This is the latest report highlighting the worse than
expected management of such patients in the United
Kingdom (UK). The 2007 NCEPOD report ‘Trauma: who
cares?’ identified deficiencies in both organisation and clin-
ical care leading to almost 60% of patients receiving a stan-
dard of care below that of good practice.11
In an ageing population, the number of patients at high surgi-
cal risk is increasing. There are a number of identified risk
factors for inpatient mortality following surgical procedures.
Within the National Health Service, high-risk elective patients
are usually assessed and identified prior to surgery. However,
the subsequent management of these patients is frequently
compromised from a lack of intensive treatment unit or high
dependency unit beds, with surgeons and anaesthetists faced
with the decision as to whether or not to proceed with the
planned surgery. Often, the surgery is undertaken without the
suitable resources available due to the pressure to achieve
targets and avoid surgical cancellations.
In order to maintain and improve standards of medical and
surgical care it is important to review the management of
patients, by undertaking confidential surveys and research,
and by maintaining and improving the quality of patient care
and publishing their results. The number of high-risk patients
is high and is likely to significantly increase in coming years.
Improving the mortality in this patient cohort should be con-
sidered a priority in the UK and other countries.
IDENTIFIED ISSUE
A substantial subset of surgical patients are deemed high
surgical risk. In December 2011, the National Confidential
Enquiry into Patient Outcome and Death (NCEPOD) pub-
lished a report entitled ‘Knowing the risk – A review of the
peri-operative care of surgical patients’.1 This report high-
lighted the process of care for patients aged 16 years and
over, who underwent inpatient surgery (both elective and
emergency), and their outcome at 30 days. It reported a wor-
ryingly high mortality rate in ‘high-risk’ surgical patients,
when compared with other healthcare systems such as the
USA.2
RELEVANCE
With an ageing population, the caseload of high-risk surgical
patients is likely to increase significantly in coming years with
a significant impact on the resources of intensive care and high
dependency units. The findings of the 2011 NCEPOD report
have substantial implications for clinical practice.
There are a number of identified risk factors for inpatient
mortality following surgical procedures. Using a predictive
model, Bhattacharyya et al. identified five critical risk fac-
tors for postoperative mortality: chronic renal failure, con-
gestive heart failure, chronic obstructive pulmonary
disease, hip fracture and an age of greater than 70 years.3
The mortality rate was 0.25% for patients with no critical
risk factors, demonstrating a linear increase with addition-
al critical risk factors.3Up to 39% of general surgical patients
have preoperative anaemia, defined according to WHO cri-
teria: Hb <12.0 g/dl for females and Hb <13.0 g/dl for males,
which has been associated with an increased perioperative
morbidity and mortality.4 However, the role of preopera-
tive anaemia as a single predictive factor of poor outcome
in elective surgery remains controversial. Mantella et al.
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To date there is no concordance among anaesthetists, sur-
geons or researchers as to the definition of a ‘high-risk’ sur-
gical patient. The NCEPOD utilised an anaesthetist-led
clinical assessment, with no prescribed parameters, to ascer-
tain whether each case was deemed high or low risk. In 2011
the Royal College of Surgeons of England and Department
of Health reported on the ‘Peri-operative care of the higher
risk general surgical patient’.12 They used a preoperative esti-
mated mortality rate of greater than or equal to 5% to define
the ‘high-risk’ surgical patient. Campling et al. published the
30-day mortality following any operation to be between
0.7% and 1.7%, and considered a ‘high-risk’ patient to be
when their risk of death was greater than or equal to twice
that of the general population or if they had an absolute risk
of death to be greater than or equal to 5%.13 The challenge
that faces surgeons and anaesthetists is to try and identify
these patients and try to reduce their mortality risk. 
IMPROVEMENTS IN THE CARE OF THE ‘HIGH-RISK’
SURGICAL PATIENT
The NCEPOD report identified four areas for improvement
in the care of the ‘high-risk’ surgical patients:
1. Identification of the ‘high-risk’ group
2. Improved preoperative assessment, triage and prepara-
tion
3. Improved intraoperative care
4. Improved use of postoperative resources.
The difficulty in identifying this ‘high-risk’ surgical group
has been highlighted. It has been estimated that a signifi-
cant surgical caseload, between 5% and 10%, can be con-
sidered in this category, while anaesthetists involved in the
NCEPOD study identified 20% of the surgical patients as
‘high risk’.1 Despite numerous definitions, scoring systems
and investigations to identify ‘high-risk’ patients in the lit-
erature, none has been accepted as the definitive method or
definition.
In contrast to the NCEPOD report,1 where 20% of elec-
tive ‘high-risk’ surgical patients were not seen in a preop-
erative assessment clinic, the vast majority of elective
orthopaedic patients undergo a preoperative assessment,
usually in conjunction with anaesthetic input. The NCE-
POD reported a higher 30-day mortality in ‘high-risk’
patients not seen in a preoperative assessment clinic. There
has been a recent proposal for a role of Primary Care to
include identifying fitness for surgery.14 In addition to the
optimisation of medical comorbidities, including volaemic
and nutritional status, there has been interest in optimising
physiological reserve with the use of exercise regimens. This
is also an ideal setting to confirm the suitability for proceed-
ing with surgical intervention. Considering that a frank dis-
cussion of the risks, including mortality risk, is integral to
‘informed consent’ it is notable that the NCEPOD found
only 7% of patients had any mention of mortality on their
written consent forms.
It is well documented that fluid optimisation and intra-
operative monitoring of cardiac output improve outcome
in ‘high-risk’ patients.15–18 Despite this, cardiac monitoring
was rarely used in these patients and inadequate intraoper-
ative monitoring was associated with a threefold increase in
mortality in the NCEPOD study.1 Patients who suffered
intraoperative complications had a 30-day mortality of
13.2% compared with 5.7% in those without.
In many other countries, patients who undergo major
surgery routinely receive a higher level of postoperative care
than is delivered in the UK to NHS patients. This may in
part be due to the overall health resources allocated to crit-
ical care but is also related to relative inefficiency in that a
high number of critical care units operate with fewer than
six beds. The NCEPOD determined that only 20% of sur-
gical patients categorised as ‘high risk’ were managed post-
operatively in a critical care facility; the vast majority were
returned to ward care.1 Almost half of the ‘high-risk’
patients who died never went to a critical care facility. For
those ‘high-risk’ patients not discharged from surgery to a
higher level of care, only 74% had records of being moni-
tored by an early warning scoring system, or ‘track and trig-
ger’ system, to detect deterioration in physiological status.
A substantial increase in the number of critical care beds is
unlikely in the current fiscal climate, and therefore the chal-
lenge is to ensure patients receive the appropriate level of
postoperative care required to optimise outcomes.
Enhanced recovery pathways (ERPs) are becoming
increasingly common, with the aim of improving outcomes,
speeding up recovery and reducing complications, adverse
events and general morbidity. An ERP focuses on optimis-
Table 1. Principle recommendations; NCEPOD ‘Knowing the risk – a review of the peri-
operative care of surgical patients’1
• There is a need to introduce a UK wide system that allows rapid and easy identification of
patients who are at high risk of postoperative mortality and morbidity. (Departments of Health in
England, Wales & Northern Ireland)
• All elective high-risk patients should be seen and fully investigated in pre-assessment clinics.
Arrangements should be in place to ensure more urgent surgical patients have the same robust
work-up. (Clinical Directors and Consultants)
• An assessment of mortality risk should be made explicit to the patient and recorded clearly on
the consent form and in the medical record. (Consultants)
• The postoperative care of the high-risk surgical patient needs to be improved. Each Trust must
make provision for sufficient critical care beds or pathways of care to provide appropriate
support in the postoperative period. (Medical Directors)
• To aid planning for provision of facilities for high-risk patients, each Trust should analyse the
volume of work considered to be high risk and quantify the critical care requirements of this
cohort. This assessment and plan should be reported to the Trust Board on an annual basis.
(Medical Directors)
Table 2. Generic principles of enhanced recovery pathways 
Preoperative
• Thorough preoperative intervention to optimise health and medical condition
• Management of patient expectation through preoperative education and counselling
• Organisation of discharge arrangements
Intraoperative
• Atraumatic and minimally invasive surgical techniques
• Shortened surgical times
• Optimised anaesthesia – usually regional anaesthetic techniques with light sedation
• Promotion of normovolaemia, normothermia and prevention of hypoxia
Postoperative
• Early physiotherapy intervention and promotion of ambulation
• Regular and effective analgesia with avoidance of opiates where possible
• Rapid introduction of normal hydration and feeding
• Promotion of a ‘wellness’ model of care – catheter, drains and drips are removed as soon as
possible, and independence with washing, dressing and socialisation is promoted
Discharge
• Patients are discharged home
• Criteria-based discharge protocol managed by the multidisciplinary team
• Patients have clear instructions on how to progress rehabilitation independently
ACUTE RESPIRATORY DISTRESS SYNDROME UPDATE 
ing each aspect of the patient’s journey and promotes the
patient as an active participant in their recovery and reha-
bilitation post-surgery (see Table 2). Successful pathways are
delivered by multidisciplinary teams and the improvements
to the quality of care are largely thought to be due to the
increased organisation of the care that is delivered.19
DISCUSSION
Unfortunately the recent NCEPOD report is further evi-
dence of the difficulties in the management of ‘high-risk’
surgical patients.1 With the high caseload of such patients
and the widespread implementation of protocol-driven
clinical care, intensive care physicians and surgeons must
ensure a high-quality service to this patient cohort. 
The recent NCEPOD recommendations may be insuffi-
cient, as the data only describe the clinical care for the most
seriously ill patients within the NHS. In a healthcare system
with no residual surplus capacity or funding, the trauma
patient with often life-threatening injuries undergoes surgery
frequently with suboptimal postoperative care resources.
The definition of quality and the ability to measure of
quality-related outcome measures remains controversial.
Numerous studies have highlighted the difficulties in inter-
preting patient-reported outcome measures (PROMS).20–30
While the debate exists regarding the widespread use of
PROMS, the NHS must not ignore the most longstanding
and definitive outcome measure available, namely mortal-
ity. Intensive care physicians and surgeons are managing a
higher number of high-risk patients and adequate resources
should be available; a situation not currently occurring
based on the evidence of the NCEPOD report.1 In the longer
term clinicians, with a duty of care, must ensure adequate
resources and facilities are available for such patients. The
NCEPOD report clearly demonstrates that currently avoid-
able deaths are regularly occurring.1 
In conclusion, the caseload of high-risk patients is sub-
stantial and is likely to significantly increase in coming years.
Improving the mortality in this patient cohort should be
considered a priority in the UK and other countries.
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Total Hip Arthroplasty for Adult Hip Dysplasia
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David Backstein, MD, FRCSC, Oleg Safir, MD, FRCSC, and Allan E. Gross, MD, FRCSC
Investigation performed at the Division of Orthopaedic Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada
! Preoperative planning is essential to define anatomy, clarify the operative approach and exposure, and ensure that
suitable implants are available.
! Concerns exist regarding the long-term effectiveness and safety of hip resurfacing arthroplasty for the young
dysplastic hip.
! In light of current evidence, concerns exist regarding the use of metal-on-metal articulations for hip arthroplasty in
the young dysplastic hip.
! The ideal bearing surface is not known, although the longest data available support the use of metal-on-
polyethylene.
Introduction and Etiology
Developmental dysplasia of the hip (DDH) presents as hip in-
congruence secondary to low or high dislocation1. Pathological
changes include flattening or inversion of the labrum and capsular
structures (limbus) in association with hypoplasia of the capital
femoral ossific nucleus and abnormal acetabular development
with a high inclination and reduced femoral head coverage. The
increasing use of ultrasound has produced earlier diagnosis to
allow earlier treatment and a resultant improved prognosis2.
The term dysplasia fails to convey the varied underlying
pathology, and the term congenital hip disease has been advo-
cated3-5. The term developmental dysplasia of the hip (DDH) is
used worldwide and shall be used in this article, although it fails
to convey the often congenital etiology of this condition4,6.
Incidence
The incidence of established neonatal hip dislocation in un-
treated populations is approximately one to two per 1000, and
that of neonatal hip instability is between fifteen and twenty per
10007. Thus, a large proportion of cases of neonatal instability
resolve in the first few weeks of life without treatment. Sub-
stantial geographical and ethnic variations exist, with a high
incidence reported in northern Scandinavia8.
DDH provides a large caseload for the orthopaedic sur-
geon7,9,10. Lloyd-Roberts et al. reported that hip dysplasia was
attributable to one-third of cases of osteoarthritis, with relative
acetabular retroversion being a common associated factor11,12.
Wroblewski noted that an in-turned acetabular labrum was a
common feature of hips that had osteoarthritis secondary to
dysplasia13.
Diagnosis
Adult patients with DDH sequelae typically report groin pain
that is exacerbated with physical activity. Young adults may re-
port lateral hip pain, exacerbated by crossing the affected leg over
and stretching the hip abductors14. Labral tears or chondral
pathology may present with locking, catching, or giving way14,15.
Painless clicking can result from the iliopsoas tendon snapping
over the uncovered anterior aspect of the femoral head16.
Hip range of motion is generally preserved unless severe
subluxation or secondary osteoarthritis is present14. Young adults
with hip dysplasia may exhibit increased internal rotation due to
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any aspect of this work. One or more of the authors, or his or her institution, has had a financial relationship, in the thirty-six months prior to submission of
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greater femoral anteversion. Decreased internal rotation of the
hip may be a sign of secondary osteoarthritis. The impingement
test, with hip flexion, adduction, and internal rotation, is sensitive
for detection of labral pathology or impingement of the femoral
head-neck junction against the anterior acetabulum. Physical ex-
amination of the hip, in particular assessment of extension,
abduction, and external rotation, may reveal instability14. An
accurate measurement of limb lengths with use of clinical ex-
amination and radiographs, and a detailed neurovascular exam-
ination of the lower extremities, is essential for all patients.
Initial radiographs should include a lateral radiograph
of the hip and a standing anteroposterior radiograph of the
pelvis for assessment of the To¨nnis angle and lateral center-
edge angle of Wiberg (Fig. 1-A). A lateral center-edge angle
of >25! is considered normal, 20! to 25! is considered bor-
derline normal, and <20! indicates dysplasia and is pathologi-
cal17. The association between DDH and osteoarthritis of the
hip was confirmed by Murphy et al., who demonstrated that
osteoarthritis of the hip developed by the seventh decade of life
in all patients who had moderate to severe dysplasia (lateral
center-edge angle <15!)18.
The To¨nnis angle measures the inclination of the weight-
bearing zone of the acetabulum, (normal, <10!; Fig. 1-B). The
ventral center-edge angle is measured in a manner similar
to the lateral center-edge angle and should be 20! to 25! or
greater on the false-profile view; measurements of <20! suggests
deficiency in anterior acetabular coverage of the femoral
head14.
The role for computed tomography is limited to planning
for acetabular re-directional osteotomy. Magnetic resonance
imaging is useful for the assessment of symptomatic hips (e.g.,
hips with disorders such as a labral tear or chondral defect) that
show no signs of structural abnormality on radiographs. Hip
arthroscopy should be reserved for hips that have minimal ra-
diographic abnormalities but in which intra-articular pathology
is suspected15.
Classifications
Numerous classification systems have been described for DDH19,20
although those described by Hartofilakidis et al.4,5,21 and Crowe
et al.22 are the ones that are most commonly used (Table I).
The classification system ofHartofilakidis et al.4,5,21 describes
the anatomical abnormalities in DDH: mild dysplasia (Type A)
(Fig. 2-A), low dislocation (Type B) (Fig. 2-B), and high dislo-
cation (Type C) (Fig. 2-C). The classification system of Crowe
et al.22 can be quantified in one of two ways: first, on the extent
of proximal migration of the femoral head as compared with
the height of the undeformed femoral head (i.e., Type-I hips
Fig. 1-A
Radiograph showing lateral center-edge angle of Wiberg.
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have migrated <50% of the height of the undeformed femoral
head; Type-II, 50% to 74%; Type-III, 75% to 100%; and Type-IV,
>100%), and second, by dividing the vertical distance between the
interteardrop line and the femoral head-neck junction by the
vertical distance between the line connecting the ischial tuberos-
ities and the line connecting the iliac crests (Type I, <0.10; Type II,
0.10 to 0.15; Type III, 0.16 to 0.20; and Type IV, >0.20) (Fig. 3).
Both classification systems have been demonstrated
to be reliable and reproducible23-25. In a study in which 145
radiographs were assessed by three experienced surgeons
working in different units, the range of kappa values for the
interobserver error was 0.90 to 0.92 and 0.85 to 0.93 for the
classification systems of Crowe et al. and Hartofilakidis et al.,
respectively23. Similar ranges of kappa values were obtained
for intraobserver error. However, the need for a whole pelvic
radiograph, the variability of the location of the femoral
head-neck junction, and the assumption that proximal mi-
gration is directly proportional to severity are drawbacks
of the classification of Crowe et al. Similarly, when using
the classification system of Hartofilakidis et al., although it
is difficult to differentiate borderline cases, the system does
have the advantage of providing insight into the structural
anatomical changes to be encountered at the time of hip
surgery.
In summary, these two classification systems assess the
hip from different perspectives: Crowe et al. is quantitative and
Hartofilakidis et al. is qualitative, and both can be used for clinical
or research purposes.
Treatment Options
Nonoperative treatment for hip dysplasia includes nonsteroidal
anti-inflammatory drugs, which are known to have improved
efficacy when combined with other treatments such as physio-
therapy, activity modification, and patient education26,27.
Joint-Preserving Surgery
While this review focuses on arthroplasty techniques for the
dysplastic hip, periacetabular osteotomy and femoral osteot-
omies may be considered if minimal articular cartilage degen-
eration has occurred15,28-30.
Realignment of the congruous dysplastic acetabulumwith a
periacetabular osteotomy can reduce symptoms for some years,
even if a degree of osteoarthritis exists31,32. Beneficial outcomes have
been reported for patients with To¨nnis grade-3 or 4 radiographic
osteoarthritis, providing that an improvement in the cartilage-
space interval is achieved33. However, there is a substantial learning
curve for the periacetabular osteotomy surgery and a complication
rate of as much as 15%34,35. Evidence suggests that periacetabular
Fig 1-B
Radiograph showing the To¨nnis angle.
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osteotomy affords a good outcome for patients who are less than
thirty years old and have good-to-excellent hip-joint congruency at
the time of the operation36.
Total hip arthroplasty is possible after a periacetabular oste-
otomy. Parvizi et al. analyzed forty-one patients with this condition,
and their results demonstrated a reduction in pain and good bone
stock after implantation of the acetabular component. However,
following a periacetabular osteotomy, the acetabulum had a ten-
dency to be retroverted in twenty-three of the forty-one hips37.
Arthroplasty
Preoperative Planning
Thorough preoperative planning is essential to clarify the op-
erative technique and surgical approach, assess available bone
stock, and determine the position and choice of the femoral
and acetabular implants.
Good-quality, calibrated radiographs are needed to size
and correctly plan the position of the components, which can be
done digitally or with traditional acetate templates. Decisions
should be made regarding the approach, type, and length of any
proximal femoral osteotomy; the approximate size and type of
implants to be used; the need for bone graft (autologous, allo-
graft, or bone substitutes); and the possibility of a wake-up test if
substantial limb-lengthening (i.e., >3 cm) is expected.
Operative Approach
A trochanteric osteotomy or slide provides superior access to
the hip joint and also the capability to restore abductor bio-
mechanics by advancing the trochanter distally38. Copious ir-
rigation minimizes the risk of thermal necrosis during a
proximal femoral osteotomy. At our institution, reduction of
the trochanteric osteotomy is achieved with use of cerclage
wires and the placement of autologous bone graft, especially
distally. Excessive soft-tissue dissection from osseous fragments
is avoided to minimize the risk of osteonecrosis.
Use of a modification of the trochanteric slide, so as
to maintain the integrity of the external rotators and the
posterior capsule, will reduce the risk of dislocation while
preserving the continuity of the vastus lateralis muscle with
the osteotomized trochanter and the hip abductors39. If per-
formed carefully, a trochanteric slide can be repeated on a pre-
viously osteotomized greater trochanter with good results40. The
posterior approach is also commonly used and provides good
exposure in less severely dysplastic hips; in addition, with
careful repair of the short external rotator muscles, the risk of
dislocation should be similar to a transgluteal or trochanteric
slide approach41-43.
If a subtrochanteric shortening derotational osteotomy is
required, the use of a trochanteric osteotomy may compromise
the fixation of the proximal sleeve of the femoral component.
Furthermore, the subtrochanteric derotational osteotomy allows
correction of the posterior position of the greater trochanter at
the time of the insertion of the femoral component, further
stabilizing the subtrochanteric osteotomy.
An excellent exposure was described after using the Smith-
Petersen approach for severely dysplastic hips, but that approach
Fig. 2-A
Figs. 2-A, 2-B, and 2-C The classification system of Hartofilakidis et al. for hip dysplasia. Fig. 2-A shows mild dysplasia (Type A); the hip has a flattened
femoral head (coxa plana) and a To¨nnis angle of >10!, and the femoral head remains within the true acetabulum.
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was associated with a high reported rate of femoral nerve palsy44.
The iliofemoral approach provides excellent extensive exposure,
although a large-muscle dissection is required with no benefit
demonstrated over other approaches45.
A large iliac-crest muscle release to lower the hip center has
been described46. However, it is not clear how much soft-tissue
release is required before the trial components are inserted,
and such a soft-tissue release increases the risk of weakness
and instability.
Acetabular Reconstruction
Acetabular reconstruction is critical. The acetabular cup is ideally
placed at the site of the true acetabulum; however, a high—but
not lateral—position may be acceptable47-52.
A high hip center utilizes live host bone, thus reducing
the requirement for bone graft, and is technically easier than
determining the level of the true acetabulum. However, there
are several disadvantages of a cup positioned in the ilium, in-
cluding a persisting limp and high dislocation rate44,51. Excessive
shear stresses and a high rate of component loosening are seen
in hips that have a high hip center51. The main predictors of
loosening are a lack of lateral osseous support, the degree of
preoperative dislocation, and the height of the acetabular
component relative to the true acetabulum49. If there is ade-
quate bone stock on the anterior and posterior aspects of the
acetabular component, 75% to 80% coverage of the acetabular
cup is adequate53,54.
In a recent study of fifty-three cementless cups inserted in
dysplastic hips, with a minimum follow-up of ten years, the
polyethylene wear rate was significantly greater when the cup
was positioned in >45! of inclination (p = 0.045) or if the cup
was placed lateral to the acetabular teardrop by >25 mm (p =
0.001)55. In addition, aseptic loosening of the femoral compo-
nent was significantly greater when the cup was placed >25 mm
superior to the teardrop (p = 0.049).
An acetabular component should ideally achieve 75% to
80% bone coverage, and a suboptimal small cup size is fre-
quently required due to the relative lack of available bone to
stabilize a high-center cup. The small cup size results in a re-
duced femoral head-neck ratio and inferior wear properties.
A high hip center does not allow for anatomical limb length-
ening, and further revision surgery is difficult due to the lack
of bone stock. A combination of a suboptimal head-neck
ratio, the high shear stresses, and the limited limb-lengthening
Fig. 2-B Fig. 2-C
Fig. 2-B shows low dislocation (Type B); the false acetabulum is continuous with the true acetabulum. Fig. 2-C shows high dislocation (Type C); the false
acetabulum is noncontinuous with the true acetabulum.
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correction results in a high dislocation rate, as the lesser tro-
chanter may impinge on the ischium.
The intraoperative identification of the true acetabulum
can be difficult due to the abnormal anatomy. The confluence
of the ischium and the pubis identifies the true level, and the
surgical exposure should be adequate to visualize these land-
marks. The fovea should be cleared of residual soft tissue to
evaluate acetabular depth, and intraoperative radiographs may
be used to confirm acetabular height and depth.
Achieving optimal medialization of the cup can be diffi-
cult while avoiding overreaming, producing a reduction in bone
stock, and risking medial migration of the cup, loss of position,
and fatigue fractures of the acetabulum22. If the correct ana-
tomical height of the true acetabulum has been identified, the
degree of medialization can be determined after initial reaming
by drilling and measuring the depth of a small hole in the floor
of the acetabulum56. Reaming should continue to approxi-
mately 3 to 4 mm from the inner cortex, thus leaving suffi-
cient bone stock for future revision surgery. A trial cup should
be used to ensure coverage of at least 70% and, if this is not
achieved, then bone-grafting should be considered.
Cementless acetabular components afford bone ingrowth
and enhance longevity by resisting tensile and shear stresses at the
host-prosthesis interface57-60. Modern acetabular components,
with porous metal backing, have shown enhanced ingrowth and
may reduce the amount of host-bone coverage that is necessary61,62.
Restoration of Bone Stock
Anterolateral acetabular bone deficiency poses an important
problem in total hip arthroplasty for dysplasia. Several surgical
options exist, including a high hip center52, placement of the
acetabular component in a medialized or protruded position5,
or structural bone-grafting to the superolateral aspect of the
acetabulum (also known as a shelf graft)60.
Shelf Graft
A shelf graft provides osteoconductive lateral support with the
potential for enhanced bone stock for revision surgery63. This
technique provides reliable early clinical results64 with encouraging
long-term results60,63,65-67.
The operative technique has been described56,60. Femoral
head autograft (or rarely allograft) can be used to construct a shelf
graft68. Residual cartilage is reamed away to expose subchondral
bone. The graft is placed at, or just within, the superior edge of the
acetabulum (Figs. 4-A and 4-B) and initially secured with 3.2-mm
drill bits placed in an oblique-to-vertical direction through the
Fig. 3
Radiograph showingmeasurements for the classification of Crowe et al. Vertical distance between the reference interteardrop line (line 1) and the femoral
head-neck junction (line 2). Vertical distance between the line connecting the ischial tuberosities (line 3) and the line connecting the iliac crests (line 4).
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graft into the pelvis, with each drill bit subsequently replaced with
Arbeitsgemeinschaft fu¨r Osteosynthesefragen (AO) 4.5-mm can-
cellous screws. An acetabular reamer is used to ream the graft until
congruent with the previously reamed host acetabulum. After the
cup is inserted, morselized autograft is placed at the graft-host
junction (also known as a flying-buttress graft) to promote union.
Morsi et al. reported on thirty-three cementless cups that
were inserted with structural allograft or autograft60. A 94%
success rate was demonstrated (mean follow-up, 6.6 years), with
all grafts united to the host bone. Those authors advocated the
use of cementless cups with structural autografts, provided that
the graft supported less than 50% of the cup. This same series
was updated at a mean follow-up time of fourteen years, with
graft-host bone union achieved in 93% and with ten patients
requiring revision for loosening of the acetabular component63.
Only two of these revisions required further structural allograft
for inadequate bone stock, indicating that the initial autografts
restored bone stock for revision surgery63. Similar results have
been replicated by other authors69.
Bone-Cement Augmentation and Reinforcement Rings
Encouraging early results have been reported with bone cement
that was used to fill superior acetabular defects48,70,71. Gill et al.
reported on two series of reconstructions in which reinforcement
rings or cages were used72. In the initial series, a Mu¨ller rein-
forcement ring (also known as a roof ring) was used in eighty-
seven consecutive patients with severe dysplasia, more than forty
of whom received a morselized autologous femoral-head graft.
The authors advocated restoration of the anatomical hip center
with use of an acetabular roof reinforcement ring; bone graft was
used medially and superiorly to augment bone stock. Gill et al.
recommended that bone cement should not replace bone stock,
as the authors believed that it contributed to aseptic loosening72.
Subsequently, Gill et al., in a series of thirty-three hips (two
of which were revised as a result of aseptic loosening), reported
on the use of a Ganz ring and used an inferior hook position in
the obturator foramen to provide further stability73.
In summary, for patients with DDH, it is preferable to
place the cup at the level of the true acetabulum, at an appro-
priate inclination, rather than in the superior, lateral, and vertical
position of the false acetabulum. Structural bone graft, bone
cement augmentation, and reinforcement rings are possible op-
tions when a large portion of the acetabular component remains
uncovered.
Femoral Reconstruction
A small femoral intramedullary canal, femoral hypoplasia,
marked femoral anteversion, a posterior position of the greater
trochanter, and previous osteotomies are possible problems dur-
ing femoral component insertion74,75. If the hip center is lowered,
a femoral shortening osteotomy may be necessary to avoid
excessive tension on neurovascular structures, in particular the
TABLE I Principal Classification Systems of Hip Dysplasia
Classification Type Description Acetabular Anatomy During Surgery
Crowe et al.22 I Proximal displacement <0.10 of pelvic height
or less than 50% subluxation
II Displacement of 0.10 to 0.15 or subluxation
50% to 74%
III Displacement of 0.16 to 0.20 or subluxation
75% to 100%
IV Displacement >0.20 or subluxation >100%
Hartofilakidis
et al.4,5,21
Dysplasia (Type A) The femoral head is contained within the
original acetabulum despite the degree
of subluxation
Segmental deficiency of the
superior wall
Secondary shallowness due to
fossa-covering osteophyte
Low dislocation
(Type B)
The femoral head articulates with a false
acetabulum, which partially covers the true
acetabulum to a varying degree
Complete absence of the
superior wall
Anterior and posterior
segmental deficiency
Narrow opening and inadequate
depth of the true acetabulum
High dislocation
(Type C)
The femoral head is completely out of the
true acetabulum and migrated superiorly
and posteriorly to a varying degree
Segmental deficiency of the entire
acetabulum with narrow opening
Inadequate depth
Excessive anteversion
Abnormal distribution of bone
stock, mainly located superoposteriorly
in relation to the true acetabulum
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sciatic nerve76,77. Careful femoral canal preparation minimizes the
risk of cortical perforation with a guidewire, as does the use of
intraoperative radiographs, which ensures the accurate passage of
the intramedullary guidewire22.
For mild dysplasia, a small-size conventional femoral
component can be considered. For severe dysplasia, a straight
and narrow stem with limited medial curvature is beneficial,
since there is frequently little remaining calcar following the
femoral neck osteotomy. A derotational femoral osteotomy
may be required for femoral anteversion of >40!, and a cus-
tom or modular implant allowing version adjustment of
the femoral neck will be needed78,79. Modern, small, straight
taper-stemmed implants can be rotated to neutralize femoral
anteversion and mitigate the need for a derotational femoral
osteotomy.
The importance of femoral component modularity was
highlighted by Silber and Engh, who reported that sixteen of
nineteen patients required modular components due to vari-
ation in femoral size and shape and the loss of the metaphyseal
flare80.
When a subtrochanteric osteotomy is performed, ce-
mentless components are commonly used to avoid cement
leakage and resultant nonunion at the osteotomy site74,76,81.
However, Charity et al. reported good results from their series
of fifteen patients with severe dysplasia who underwent sub-
trochanteric osteotomy and subsequent insertion of a pol-
ished, smooth, cemented femoral component82.
Femoral Osteotomy
When the hip center is reconstructed at the level of the true
acetabulum, lengthening the lower limb by >4 cm carries the risk
of sciatic nerve palsy83,84. A number of intraoperative methods of
measuring limb length have been described; however, to date,
none have been demonstrated to be superior85. The amount
of femoral shortening that will be required can be determined
intraoperatively and compared with the preoperative deter-
mination of limb lengths through the use of templates and
radiographs.
Proximal or subtrochanteric osteotomies have been de-
scribed for femoral shortening. Subtrochanteric osteotomies
performed with transverse, step, oblique, or double-chevron
cuts allow for both angular and rotational correction in addi-
tion to shortening, and the results of several clinical studies
support their use74,77,81,86-88.
In summary, anatomical variations may be encountered
when preparing for femoral-component insertion in patients
Fig. 4-A
Preoperative (Fig. 4-A) and postoperative (Fig. 4-B) radiographs of a dysplastic hip that received acetabular reconstruction with autologous shelf graft
supported superiorly by autologous morselized bone graft (also known as the flying-buttress graft).
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with hip dysplasia. The modularity of modern revision com-
ponents is greatly beneficial; however, a femoral osteotomy
may be required and thorough preoperative planning will aid
decision-making regarding femoral reconstruction.
Resurfacing Arthroplasty
The third generation of hip resurfacing arthroplasty implants
have a cemented femoral component and a press-fit acetabular
component89. The advantages of this technique include the
conservation of the femoral neck, minimal wear, and a reduced
risk of dislocation due to the large diameter of both compo-
nents90-93. Such advantages would be of benefit to the young
patient with DDH. However, concerns exist regarding the
failure rates of first and second-generation implants94,95, the rate
of femoral neck fracture96, metal hypersensitivity, and increased
serum levels of metal ions97-100.
Few studies specifically address metal-on-metal hip re-
surfacing arthroplasty for DDH patients who have arthritic
changes. Early techniques and hip-resurfacing implants were
associated with high rates of femoral neck fractures and femoral-
side loosening for mild dysplasia101. Amstutz et al. addressed
previous failures of hip resurfacing in patients with mild dys-
plasia by using new techniques for femoral component fixation
and meticulous bone preparation and demonstrated that the
short-term results for mildly dysplastic hips are similar to the
survivorship of hip resurfacing arthroplasty in nondysplastic
hips102. Furthermore, the acetabular components in the series of
Amstutz et al. remained well fixed at follow-up times of two to
eleven years. However, long-term studies of resurfacing for DDH
are needed to address specific patient selection criteria, long-
term complications and survivorship, and metal ion release.
In consideration of the use of hip resurfacing arthro-
plasty in general, a recent systematic review of the literature
showed that none of the hip-resurfacing arthroplasty implants
met full ten-year benchmark implant survival and only thir-
teen studies demonstrated satisfactory three-year survival103.
This study concludes that, until longer-term data are avail-
able, concerns remain regarding the effectiveness and safety
of hip resurfacing arthroplasty. While the most common
mode of failure was aseptic loosening, there is large variation
in the rate of femoral neck fracture, the principal cause of
which is not fully understood. In addition, a meta-analysis
of forty-six studies comparing hip resurfacing arthroplasty
with total hip arthroplasty and published in 2010 concluded
that, although the functional outcomes associated with hip
resurfacing arthroplasty are better or the same as those as-
sociated with total hip arthroplasty, there is an increased risk
of heterotopic ossification and aseptic loosening after hip
resurfacing arthroplasty and the revision rate of hip re-
surfacing arthroplasty is twice that of total hip arthroplasty104.
Fig. 4-B
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Metal-on-Metal Arthroplasty
The use of metal-on-metal articulation in both total hip ar-
throplasty and resurfacing arthroplasty remains controversial,
with growing concern regarding the incidence of symptomatic
periprosthetic inflammatory reactions105-107. A high inclination
angle of the acetabular component risks edge-loading and sub-
sequent increased component wear and an elevated serum
metal-ion concentration97-100,108-110. This process has also been
associated with periprosthetic inflammatory masses111.
Recent retrieval analysis suggests that the problems related
to high wear rate in metal-on-metal hip resurfacing arthroplasty
are likely to be similar for all types of metal-on-metal hip ar-
throplasty112. Edge-loading occurredmore often in hip resurfacing
arthroplasty due to the retention of the femoral neck, which
caused impingement-type edge-loading, particularly when the
acetabular component had been implanted with a low inclination
and either excessive or insufficient version. However, acetabular
version in isolation has not been shown to influence the rate of
wear in retrieved metal-on-metal hip resurfacing components113.
Considering the recent evidence regarding the safety and
effectiveness of metal-on-metal articulations for both hip re-
surfacing arthroplasty and total hip arthroplasty, metal-on-
metal articulations cannot be advocated for the young DDH
patient. Indeed, as a result of concerns, in April 2010 the United
KingdomMedicines and Healthcare Products Regulatory Agency
issued a medical device alert regarding the safety of all types of
metal-on-metal hips114.
Outcomes and Complications
The complication rate associated with arthroplasty surgery is
higher in patients with hip dysplasia than it is in patients who
have osteoarthritis, and this difference cannot be accounted for
by the younger age at which dysplastic patients present for
arthroplasty48,49,72,84,115.
The rate of sciatic nerve palsy following total hip arthro-
plasty in patients with dysplastic hips has been reported as being
higher by ten times or more as compared with the rate seen in
patients with nondysplastic hips22,45,64,70,83. Garvin et al. suggested
that 2 cm is the safe limit of limb-lengthening84. Edwards et al.
proposed that the risk of sciatic nerve palsy is greatly increased
with lengthening of >4 cm116. Suggested precautions include the
use of electromyographic monitoring and the use of a wake-up
test similar to that used in scoliosis surgery79,117. It is suggested that
if limb-lengthening occurs, the sciatic nerve should be exposed
and palpated intraoperatively with the knee in flexion and ex-
tension to assess the degree of tension. If there is any suggestion
of too much tension in the nerve, then a wake-up test should
be performed. This test involves reducing the level of anesthesia
to allow the patient, while on the operating table, to respond to
command—specifically, ankle dorsiflexion to confirm sciatic-
nerve motor function117. This procedure needs to be fully ex-
plained to the patient prior to surgery and patient consentmust be
obtained, and the anesthetist must also be aware of the potential
need to perform this test. Furthermore, if limb-lengthening is
done, the ipsilateral knee should be kept flexed immediately fol-
lowing surgery to reduce tension on the sciatic nerve.
The highest rates of hip dislocation have been reported
following arthroplasty for dysplasia64,70,84. It is thought that the
risk of dislocation may result from trochanteric nonunion (so-
called trochanteric escape) or the impingement of the femoral
component on the anterior acetabular column with the hip in
flexion and internal rotation. The risk of impingement is greatest
with a high hip center and a medialized cup and can be partially
resolved by using a femoral component with an increased offset.
The femoral deformities inherent in patients with se-
vere hip dysplasia increase the risk of intraoperative femoral
fracture118,119. Thus, as highlighted before, much care must be
taken when preparing the femoral canal so as to avoid cortical
perforation, and the use of a guidewire to ensure intramed-
ullary position is highly recommended. If a cortical perfora-
tion is identified intraoperatively, the femoral component
used must then bypass the perforation by at least two cortical
diameters and the use of a cortical onlay allograft should also
be considered.
Obesity is an increasingly common coexisting problem
for young adult patients who present for joint replacement120.
Recent data support hip arthroplasty in the presence of morbid
obesity because the postoperative outcome was not affected
and thus the withholding of surgery on the basis of body mass
index was considered unjustified121. However, this study and
others have also reported that obesity is a risk factor for pros-
thetic infection121-123.
There is a higher infection rate reported for total hip ar-
throplasty performed for dysplasia as compared with total hip
arthroplasty performed for osteoarthritis70,124,125. The cause is
probably multifactorial, including the complexity and duration
of the operations, the large exposure and extensive dissection,
soft-tissue stripping, and the frequent use of bone graft.
Summary
The anatomical features of hip dysplasia necessitate thorough
preoperative planning to ensure that the most appropriate
implants, surgical approach, and bone-restoration techniques
are used. Currently, long-term clinical data support the use of
a metal-on-polyethylene bearing; however, clinicians and pa-
tients alike should be aware of the increased complication rate
that has been associated with total hip arthroplasty when
performed for the treatment of adult hip dysplasia. n
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As the indications for total hip arthroplasty increase, the prevalence of extensive proximal femoral bone loss will increase as a
consequence of massive osteolysis, stress shielding andmultiple revisions. Proximal femoral bone stock deficiency provides a major
challenge for revision hip arthroplasty and is likely to account for a significant future caseload. Various surgical techniques have
been advocated included impaction allografting, distal press-fit fixation and massive endoprosthetic reconstruction. This review
article provides a systematic review of the current literature to assess the outcome of revision hip arthroplasty using allograft to
reconstruction massive proximal femoral bone loss.
1. Introduction
As the need for total hip arthroplasty increases, the incidence
of extensive proximal femoral bone loss will increase as a
consequence of massive osteolysis, stress shielding and mul-
tiple revisions [1–5]. Proximal femoral bone stock deficiency
provides a major challenge for revision hip arthroplasty and
is likely to account for a significant future caseload [6].
Various surgical techniques have been advocated includ-
ed impaction allografting techniques [7, 8], distal press-fit
fixation [9, 10], and massive endoprosthetic reconstruction
[11–13]. Individual studies have reported a 58% to 84%
survivorship of massive endoprosthetic reconstruction (or
megaprostheses) with average followup ranging from 5 to 10
years [11–13]. A recent retrospective review of 403 proximal
femoral replacements (endoprosthetic reconstructions) from
five institutions reported a 10- and 15-year survival rate of
75%, with mechanical causes being the commonest mode of
failure [14].
A proximal femoral allograft reconstruction requires the
use of a prosthesis bridging the host-allograft junction and
obtaining fixation in the distal femur. The enhancement of
future bone stock is an important advantage purported to
this method of reconstruction that has been utilized in
proximal femoral bone loss secondary to tumors and aseptic
osteolysis. Diﬀerences in the morphology of the host-
allograft junction, the use of cement, and the method of
attachment of the host abductor musculature have all been
described.
The three principal aims of this systematic review were as
follows:
(1) to document variations in the surgical techniques
used,
(2) to assess the clinical outcome of allograft prosthesis
composites (APC) for massive proximal femoral
bone loss,
(3) to quantify complication rates in relation to the
surgical technique used.
2. Methods
A comprehensive search of the MEDLINE, EMBASE, and
the National Institutes of Health online database PubMed
from the earliest records to the time of review (January 2011)
was performed. The following Medical Subject Headings
(MeSH) terms were used: “allograft,” “composite graft” in the
manuscript title, and “proximal femoral” in the manuscript
abstract. The keywords were used as both text words and
Medical Search Headings (MeSH terms).
2 Advances in Orthopedics
Two authors (B. A. Rogers, A. Sternheim) independently
applied the search strategy to the diﬀerent databases and
reviewed the selected references. Titles, abstracts and papers
were reviewed independently.
The following inclusion criteria were used:
(1) studies retrieved by the database search using the
Medical Subject Headings detailed above,
(2) studies specifically reporting outcomes relating to
proximal femur composite.
The following exclusion criteria were used:
(1) non-English language,
(2) case reports,
(3) review articles,
(4) not relating to human surgery,
(5) patients with advanced oncological pathology,
(6) followup less than 2 years.
Where more than one publication existed relating to
the outcomes of same cohort of patients from the same
institution, the most recent publication only was used.
Full-text manuscripts were obtained and reviewed for the
studies identified using the above criteria. The method of
review followed the authoritative methodology described by
Mohit [15].
Allograft-prosthetic composite (APC) is a technique used
to restore bone stock andmechanical stability to the proximal
femur (see Figures 1(a)–1(d), and 2). The studies analyzed in
this literature review consider a single technique, APC, rather
than a single diagnosis; this technique has been utilized for
oncological and nononcological surgery.
Eight studies report on APC used in non-oncological
conditions (septic or aseptic loosening) and six report on
surgeries performed for malignant or nonmalignant proxi-
mal femoral pathology. Two studies report on patient cohorts
with both indications.
The primary outcome of interest was further revision
of the femoral component and the secondary outcomes of
interest were other complications such as infection, disloca-
tion, and nonunion.
Statistical analysis was performed on the selected papers
to assess the pooled success rate. The eﬀect (proportion) was
calculated for every individual study and the pooled eﬀect
considering all the studies.
3. Results
3.1. Studies. Sixteen studies reported on outcomes of prox-
imal femoral composite allograft used to reconstruct major
bone defects (see Table 1). All studies were retrospective
case series and provide level IV evidence. All studies were
published within the last fifteen years. Average followup
ranged from 2 to 16.2 years. The total number of allograft
reconstructions reported in all the studies was 498. The
surgical techniques, clinical outcomes and complications
were collated for all these published studies.
3.2. Surgical Techniques. The described surgical techniques
varied, as shown in Tables 2 and 3.
Four studies described the complete resection of the
proximal femur as the approach employed; however, the
transtrochanteric approach was the most common reported.
Regarding the morphology of the osteotomy used at
the junction between the proximal allograft and distal host
femur, 8 studies reported a transverse femoral osteotomy, 3
that were augmented with plate fixation to enhance stability
at the allograft-host junction. The remainder of the studies
reported either a step or oblique femoral osteotomy.
The management of the proximal host femur varied. In
9 studies the proximal host femur was fully resected, with 5
studies using the split host proximal femur as an onlay graft
after the APC had been inserted. Two studies did not detail
this aspect of the surgical technique. Four studies reported
the use of cortical strut allografts to reinforce the allograft-
host junction [6, 18, 22, 29], with one study reporting use in
every case [22].
The techniques used for fixation of the prosthesis to the
allograft, and for distal fixation to the host femur is shown in
Table 3. There are 14 studies reporting cemented fixation of
the prosthesis to the allograft; however, distal fixation varied
with 6 uncemented, 4 cemented, 5 studies employed a variety
of techniques and one study did not report.
3.3. Clinical Outcomes. The primary outcome of interest was
further revision of the femoral component, and Table 4
shows the reported failure rate and success rate for the
allograft prosthesis composite in each study. The success rate
was defined as the reported survivorship of the APC.
The total cohort included 498 patients with a mean
follow up of 8.1 years (range 2 to 16.2 years). The pooled
success rate was 81% (95% CI 77%–86%).
However, the number of cases and length of followup
varied substantially between the studies. For example, Roque
et al. reported an 82% survivorship rate for 73 allograft pros-
thesis reconstructions at 6.7 years followup [23], whereas
Safir et al. reported 15 year Kaplan-Meier survivorship data
on 50 patients of 82% [19].
3.4. Complications. Table 4 details the reported major com-
plications. The infection rate ranged from 0% to over 21%,
with a pooled mean of 8%. The two studies with a reported
infection rate of over 20% had only 14 and 15 patients,
respectively [13, 29]. Conversely, the four studies reporting
the lowest infection rates (0 to 4%) had a mean patient
cohort of 40 patients [6, 16, 17, 20].
Dislocation is a significant postoperative complication,
however five out of the sixteen studies did not report the
incidence of dislocation [13, 24, 25, 27, 28]. For the eleven
studies that did report dislocation rate the mean was 12.8%
with a range 0% [16, 23] to 40% [18]. The mean reported
dislocation rate in studies that used a technique of splitting
the host proximal femur to use as an onlay graft was
9.8%, compared to 14.9% in studies that resected the entire
proximal femur.
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Figure 1: (a) Prosthesis cemented into allograft. (b) Trochanteric slide approach to hip, with lateral cortex osteotomy to facilitate removal
of in situ femoral component. (c) Allograft-prosthesis composite inserted into host, with junctional step cut. (d) Remnants of host proximal
femur are fixed around allograft, especially at the allograft-host junction, and the greater trochanter reattached.
Figure 2: A radiograph 17 years after proximal femoral allograft
(reprinted from Safir et al. [19]).
Failure of the APC, either resulting from aseptic loos-
ening or fracture (Table 4) ranges from 0% to 28%. The
mean reported aseptic loosening or fracture rate was 13.7%
for studies that used cement for fixation into distal host
femur, compared to 9.1% for those studies using uncemented
fixation in the distal host femur. However, the diﬀerence was
not statistically diﬀerent.
4. Discussion
4.1. Clinical Outcome. Severe proximal femoral bone loss
is creating an increasing caseload of complex cases for the
reconstructive hip surgeon [6]. The use of allograft prosthesis
composite (APC) is one surgical solution used to address
this problem and restore mechanical stability to the proximal
femur. This analysis reviews the surgical techniques, clinical
outcomes and complication, incorporating a total patient
cohort of 498 from sixteen studies with a mean follow up of
8.1 years (range 2 to 16.2 years). The pooled success rate was
81% (95% CI 77%–86%), see Table 4, and provides evidence
that this technique is valid and durable when performed by
suitable trained and experienced surgeons, in institutions
with the facilities to support such complex surgery.
4.2. Surgical Approaches and Complications. Surgical tech-
nique varied between the studies with regard to surgical
approach, storage technique of the allograft bone, fixation
techniques of the prosthesis to the proximal allograft, distal
host femur and the junction between the allograft and host
bone (see Table 2).
Several diﬀerent surgical approaches were utilized in the
reported studies. Four studies all pertain to tumour resection
used a direct lateral approach with complete resection of the
proximal femur. Trochanteric slide osteotomy was used in
two studies both reported on patients who had revision of
a failed hip arthroplasty. A transtrochanteric approach was
reported by Vastel et al. and led to a high rate of trochanteric
nonunion (25/34) with the authors recommending the use
of a trochanteric plate to avoid proximal migration of the
trochanter [20].
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Table 1: Sixteen studies using allograft prosthetic composite in the treatment of proximal femoral bone loss, number of patients per study,
primary diagnosis, and mean followup.
Study n Primary diagnosis Mean followup (yrs)
1 Chandler et al. [6] 30 Aseptic 2
2 Langlais et al. [16] 21 Tumor 6
3 Haddad et al. [17] 55 Tumor, Aseptic, Septic revision 8.8
4 Zehr et al. [13] 14 Tumor 10
5 Zmolek and Dorr [18] 15 Aseptic failure 2
6 Safir et al. [19] 50 Septic, aseptic 16.2
7 Vastel et al. [20] 44 Aseptic failure 7.1
8 Babis et al. [21] 72 Aseptic 12
9 Lee et al. [22] 15 Aseptic, septic loosening 4.2
10 Roque et al. [23] 73 Tumor 6.7
11 Biau et al. [24] 32 Tumor 5.6
12 Donati et al. [25] 22 Tumor 4.8
13 Farid et al. [26] 20 Tumor 6.3
14 Graham and Stockley [27] 25 Aseptic, septic loosening 4.5
15 Muscolo et al. [28] 37 Tumor 7.5
16 J. W. Wang and C. J. Wang [29] 15 Aseptic, septic loosening 7.6
Table 2: Surgical techniques used including approach, the type of femoral osteotomy performed at the host bone-allograft junction, and
whether the host proximal femur was resected or split and used as an onlay graft. NR: not reported. Study numbers correlate with Table 1.
Study n Surgical approach Femoral osteotomy Host proximal femur
1 30 Trochanteric slide Step cut (7) transverse (23) NR
2 21 Complete resection Step cut Resected
3 55 NR Transverse (28), step cut (12) Resected
4 14 Complete resection NR Resected
5 15 Posterolateral (9), trochanteric Slide (2) Oblique Resected
6 50 Trochanteric slide Step cut Split and onlay
7 44 Transtrochanteric Transverse Split and onlay
8 72 Hardinge (44), posterior (11), transtrochanteric (17) Step cut (62), telescoping (10) Split and onlay
9 15 Transtrochanteric Transverse (9), step cut (6) NR
10 73 Complete resection NR Resected
11 32 Trochanteric slide (12), resection (20) Transverse Resected
12 22 Complete resection Transverse Resected
13 20 NR NR Resected
14 25 Trochanteric slide Step cut Split and onlay
15 37 Posterolateral (28), transtrochanteric (10) Transverse Resected
16 15 Transtrochanteric Transverse Split and onlay
Trochanteric nonunion and abductor strength are also
influenced by surgical approach. The trochanteric slide
osteotomy aims to maintain the continuum of tissue from
the abductors and the greater trochanter to the vastus later-
alis. This approach has been reported to have a higher rate
of trochanteric union [30]. The trochanteric slide osteotomy
has been further modified to maintain the external rotators
and thus improve hip stability [30–32].
The junctional osteotomy between the host femur and
the proximal allograft was transverse, oblique or step-cut (see
Table 2). A step-cut osteotomy may oﬀer more rotational
stability while an oblique osteotomy may oﬀer more surface
area for bone in-growth compared to a transverse osteotomy.
Langlais et al. reported on two cases of loosening with
junctional failure that they attributed to a lack of a step-
cut osteotomy at the junction [16]. This junction may
be further reinforced with strut allografts [6, 18, 22, 29].
Nonunion of the junction between the native femur and
the proximal allograft causes macro motion at the junction
that is treated with bone grafting, plating, and/or a strut
allograft [16]. Host-allograft junctional nonunion may be
reduced by augmentation with additional autologous bone
graft and supporting it with either a plate or a strut allograft.
Several studies highlight the bone union at the host-allograft
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Table 3: Table showing methods of implantation of prosthesis into allograft to form the allograft prosthesis composite (APC) and methods
for securing APC to distal host femur. NR: not reported. Study numbers correlate with Table 1.
Study Allograft-prosthesis fixation APC-host bone fixation
1 Cemented Uncemented
2 Cemented Cemented
3 Cemented Cemented
4 Cemented (16), uncemented (2) Cemented(14), Uncemented(2), + plating(2)
5 Uncemented Uncemented + plating
6 Cemented Uncemented
7 Cemented Cemented
8 Cemented Uncemented (44), cemented (22)
9 Cemented Uncemented (12), cemented (3)
10 NR NR
11 Cemented Cemented
12 Cemented Uncemented
13 Cemented Varied
14 Cemented Uncemented
15 Cemented Uncemented + plating
16 Cemented Uncemented (13), cemented (2), + plating
Table 4: Table showing complications of prosthesis into allograft to form the allograft prosthesis composite (APC) andmethods for securing
APC to distal host femur. The total cohort included 498 patients with amean follow up of 8.1 years (range 2 to 16.2 years). The pooled success
rate was 81% (95% CI 77%–86%). Success rate: APC not revised. NR: not reported. Study numbers correlate with Table 1.
Study n Failed constructs Success rate Infection Dislocation Aseptic loosening or fracture
1 30 3 90% 1 (3.3%) 5 (16.7%) 4 (13.3%)
2 21 2 82% 0 0 6 (28.6%)
3 55 6 85% 2 (3.6%) 4 (7.3%) 5 (9.1%)
4 14 4 78% 3 (21.4%) NR 1 (7.1%)
5 15 3 73% 1 (6.7%) 6 (40%) 2 (13.3%)
6 50 8 84% 2 (4%) 4 (8%) 7 (14.0%)
7 44 4 91% 1 (2.3%) 6 (13.6%) 3 (6.8%)
8 72 19 66% 5 (6.9%) 8 (11.1)
14 Loosening (4), resorption (3), nonunion (2),
fracture (4), stem fracture (1)
9 15 2 87% 1 (6.7%) 1 (6.7%) 1 (6.7%)
10 73 13 82% 8 (10.9%) 0 11 (15.1%)
11 32 9 72% 4 (12.5%) NR 5 (15.6%)
12 22 2 91% 1 (4.5%) NR 1 (4.6%)
13 20 1 95% 1 (5.0%) 2 (10%) 0
14 25 2 92% 1 (4.0%) NR 2 (8.0%)
15 37 10 73% 3 (8.1%) NR 7 (18.9%)
16 15 5 67% 3 (20%) 1 (6.7) 4 (20.7%)
junction as a key factor in achieving stability of the composite
graft, and thereby lowering the chance of mechanical failure
[17, 19, 21, 33].
Cement fixation of the prosthesis to the allograft with
cementless fixation to the host femur was used in seven
studies (see Table 3) [6, 19, 24, 25, 27–29]. The rationale
for cement fixation in the allograft-prosthesis composite is
that in-growth and on-growth would not be expected at
the allograft prosthesis interface. Only Zmolek and Dorr
reported a fully uncemented fixation of the prosthesis and
allograft in 11 patients with similar rates of success compared
to other studies [18].
Regarding distal fixation to the host femur, an unce-
mented technique was principally employed in nine studies
[6, 18, 19, 22, 24, 25, 27–29], cemented in four studies
[13, 16, 17, 20], mixed cemented and uncemented distal
fixation in one study [21], and one study did not report
whether or cement was used (see Table 3).
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For the studies that utilized cementless distal fixation,
some employed a press-fit or interference technique whereas
others used an oblique or step-cut junctional osteotomy.
Safir et al. used an uncemented technique in the distal
host femur with a step-cut or oblique osteotomy aﬀording
direct loading at the allograft-host femur junction [19]. The
authors support the concept that direct loading of the host-
allograft junction minimizes allograft resorption. The distal
femur being initially reamed to the optimal size, with the
proximal femoral allograft also reamed and broached until
a good fit was achieved for the long-stem femoral prosthesis.
The mismatch in the medullary sizes of the host bone and
the allograft resulted in a good press-fit fixation never being
achieved between the femoral stem and the distal host femur.
Further, the allograft was never over reamed to accommodate
a larger femoral component for the host femur. In contrast,
Haddad et al. cemented the prosthesis to the distal femur
thus stress shielding, the allograft and commented that this
may explain the high rate of graft resorption (17%) observed
[17].
Overall, cemented fixation in the distal host bone was
associated with a higher rate of aseptic loosening or fracture
(13.7%) when compared to uncemented distal fixation
(9.1%; see Table 4). Whilst the diﬀerence was not statistically
significant, the benefit of uncemented distal fixation is the
reduced risk of junctional nonunion between the host femur
and allograft.
The population cohorts, the duration, and complexity
of the surgery result in infection rates for APC being
greater than that for primary hip arthroplasty (see Table 4).
Considering these factors, the pooled 8% infection rate is
not unacceptable. The infection rate is; however, related to
quantity performed with the lowest infection rates (0 to 4%)
being reported in those studies with the greater number of
cases [6, 16, 17, 20]. Although observer bias may influence
this data, a greater caseload and experience is likely to be
beneficial.
The use of native proximal femur with its soft-tissue
attachments as an onlay graft around the composite allograft
was reported in five studies [19–21, 27, 29]. This vascularised
viable bone can promote in-growth into the allograft and
preserves the abductor mechanism and short external rota-
tors. These five studies report a lower mean dislocation rate
of 9.8%, compared to 14.9% (see Table 4). From the surgical
approaches detailed in these studies, the risk of dislocation
may be minimized by:
(1) preservation of the host posterior capsular structures
if possible,
(2) good biomechanical reconstruction of length, version
and oﬀset of the prosthesis-allograft construct,
(3) maintaining the bone-soft tissue attachment to the
host femur, to provide both mechanical stability and
to act as a vascularised graft.
A constrained acetabular liner may be considered in cases
of minimal abductor musculature.
5. Conclusion
The continued followup and analysis of this technique
should be encouraged to refine and develop the manage-
ment of massive proximal femoral bone loss. This review
demonstrates that proximal femoral allografts for revision
hip arthroplasty in femoral segmental bone loss do provide
a durable solution, with current available evidence reporting
a survivorship of 80%. Whilst a range of surgical techniques
have been described, this study highlights the following:
(1) high caseload is associated with a lower infection rate,
(2) uncemented distal fixation is associated with a re-
duced the risk of aseptic loosening or fracture,
(3) if available, using the host femur as an onlay graft
enhances hip stability whilst acting as a vascularised
graft.
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Proximal Femoral Allograft in Revision
Hip Surgery With Severe Femoral Bone Loss
A Systematic Review and Meta-Analysis
Benedict A. Rogers, MSc, MRCGP, FRCS(orth),* Amir Sternheim, MD, FRCS,*
Maria De Iorio, PhD,y David Backstein, MD, MEd, FRCSC,*
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Abstract: This study provides an objective appraisal of available evidence regarding the outcome
of proximal femoral allograft for reconstruction of massive proximal femoral bone loss. The
primary outcomes were rates of success, structural failure, and infection. A systematic literature
review identified 16 studies with a minimum 2-year follow-up. Estimated pooled effect analysis
performed with heterogeneity quantified using I2 and τ2. The total cohort included 498 patients
with a mean follow-up of 8.1 years. The pooled success rate was 81%, pooled structural failure
rate of 15%, and pooled infection rate of 8%. Significant heterogeneity was observed in structural
failure rates (I2 = 47.9, τ2 = 0.29, P b .05). Proximal femoral allografts afford viable reconstruction
for massive femoral bone loss when performed by experienced. Keywords: proximal femoral
allograft, outcome, meta-analysis, systematic review.
© 2012 Elsevier Inc. All rights reserved.
As the need for revision total hip arthroplasty increases,
surgeons are increasing, forced to deal with extensive
proximal femoral bone loss as a consequence of massive
osteolysis, stress shielding, and multiple revisions [1-5].
Proximal femoral bone stock deficiency provides a major
challenge for revision hip arthroplasty and is likely to
account for a significant future caseload [6].
Various surgical techniques have been advocated for
treatment of proximal femoral bone loss including
impaction allografting techniques [7,8], distal press-fit
fixation [9,10] and massive endoprosthetic reconstruc-
tion (megaprostheses) [11-13]. A previous study has
reported a 5- to 10-year megaprosthesis survivorship of
58% to 84% [14]. A recent retrospective review of 403
proximal femoral arthroplasties (endoprosthetic recon-
structions) from 5 institutions reported a 10- and
15-year survival rate of 75%, with mechanical causes
being the most common mode of failure [15].
Proximal femoral allograft (PFA) composites combine
the use of a long-stem femoral prosthesis and allograft
bone. A femoral prosthesis is placed distally within the
medullary canal of the host femur, whereas the
proximal portion of the stem is positioned and secured
within a proximal femur allograft, for example, see
Figs 1A to C. The allograft provides initial stability by
acting as a strut graft and enhances future bone stock.
The potential for enhanced future bone stock may
simplify future additional revision surgery and serves as
an attachment surface for soft tissues and bone.
There is relatively little published literature describing
the outcomes of PFA composites, and all are retrospec-
tive case series. The caseload for this surgical technique
results from patients with massive femoral bone loss
having previously undergone either multiple revision
arthroplasty surgery or proximal femoral resection for
oncological pathology.
To draw firmer conclusions about overall survival in
PFA cases, a meta-analysis of all available data is
necessary. Although most studies are retrospective, a
meta-analysis is appropriate if strict methodological
guidelines are followed [16].
The objective of this systematic review and meta-
analysis was to provide an objective appraisal of the
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available evidence regarding the outcome of hip
arthroplasty surgery using allograft to reconstruct
massive proximal femoral bone loss. The primary out-
comes of interest were the reported rates of success,
structural failure, and infection, whereas the secondary
outcomes were the reported rates of major revision
surgery to the PFA, dislocation, and nonunion.
Methods
This reviewwas based on the Cochranemethodology for
conducting systematic reviews and meta-analysis [17,18].
Study Selection Criteria
Studies reporting the outcome of PFA composites after
previous revision hip arthroplasty or proximal femoral
resection were identified for this meta-analysis.
A search of the National Library of Medicine (Med-
line), National Institutes of Health (PubMed), and
EMBASE databases from the earliest records to the
time of review (February 2011) was performed. The
following Medical Subject Headings (MeSH) terms were
used: allograft, composite graft in the article title, and
proximal femoral in the article abstract.
The keywords were used as both text words andMeSH
terms. These were arranged by means of varying
combinations of the Boolean operators AND, NOT, and
OR, and the results were limited to publications
published in English or those that had been translated
to English. There were no limitations set on publication
date. The PubMed search was then refined to include
clinical studies in adult humans. The results were cross-
checked with other databases, namely, Google and
Google Scholar. The bibliographies of the retrieved trials
were examined for additional articles.
The following inclusion criteria were used:
1. studies retrieved by the database search using the
MeSH detailed above; and
2. studies specifically reporting outcomes relating to
“proximal femur composite” or “allograft prosthesis
composite (APC).”
The following exclusion criteria were used:
1. non-English language;
2. case reports;
3. review articles;
4. not relating to human surgery;
5. patients with advanced oncological pathology; and
6. follow-up of less than 2 years.
Thus, studies that reported patients who were lost to
follow-up within 2 years of surgery were excluded. For
retrospective studies, publications reporting on the same
cohort group from the same institution were limited to
the most recent publication. Patients who underwent
the index resection because of a tumor and later went on
to fail because of a local recurrence of the tumor were
excluded from outcome analysis.
Article Collection and Analysis
Two authors (BR and AS) independently applied the
search strategy to the different databases and reviewed
the selected references. Titles, abstracts, and articles
were reviewed independently in a sequential and
systematic manner (see Fig. 2). A systematic review of
each article was performed to assess the methodology,
the surgical techniques, and area of bias in accordance
with previous published guidelines on literature review
[19]. The level of evidence for each article was assessed
Fig. 1. (A) Prosthesis cemented into allograft. (B) Allograft-
prosthesis composite inserted into host with junctional step-
cut. (C) Remnants of host proximal femur are fixed around
allograft, especially at the allograft-host junction, and the
greater trochanter is reattached. (Figs. 1A-C is reprinted from
Blackley et al [1]).
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according to the guidelines of the Journal of Bone and
Joint Surgery (American Volume) [20]. The extracted
data form was then agreed upon. Data were extracted
independently by the 2 authors (BR and AS) and were
later reviewed jointly to produce the most accurate data.
Disagreement was resolved with the senior authors
(AEG, DB, and OS).
Outcome Measures
Regarding the primary outcomes measures, full
statistical meta-analysis, with forest plot graphic repre-
sentation, was performed for the reported success rate,
mechanical failure rate due to fracture or evident
loosening of the allograft and/or prosthesis, and the
infection rate.
Major revision surgery was defined as removal or
replacement of the APC due to infection or mechanical
failure (loosening or fracture). The rate of major revision
surgery was reported without full meta-analysis because
it is directly influenced by the other 3 primary outcomes.
Further secondary outcome measures of interest were
dislocation rate and the reported nonunion rate, whether
surgically revised. Full statistical meta-analysis was not
performed with regard the secondary outcomemeasures.
Meta-analysis
Statistical meta-analysis was performed on the
selected articles, with forest plots produced for 3
outcomes: pooled success rate, failure rate (combined
fracture or loosening), and infection rate. For each of
these 3 outcomes, the effect (proportion) was calculat-
ed for every individual study and the pooled effect
considering all the studies. The meta-analysis was
based upon the Freeman-Tukey double arcsine trans-
formation of the frequencies.
Both fixed and random effect model analyses were
performed, and the 95% confidence intervals (CIs),
stated. With a fixed effect analysis, all of the studies were
considered conducted under similar conditions with
similar subjects; therefore, the only difference between
studies being the power to detect the outcome of
interest, whereas the random effect model assumes
that there is a different underlying effect for each study.
The different effects are combined to estimate an overall
effect by taking into account this additional source of
variation. Many investigators consider the random
effects approach to be a more natural choice than fixed
effects, for example, in medical decision-making con-
texts [21-23].
The heterogeneity associated with the studies incor-
porated in the meta-analysis was assessed using both the
I2 and τ2 statistics. The I2 statistic describes the
percentage of variation across studies that are due to
heterogeneity rather than chance [24,25]. It is a simple
expression of inconsistency of the studies' results and
depends upon the extent of overlap in CIs across studies.
The magnitude of heterogeneity was quantified using a
point estimate of the among-study variance of true
effects called τ2. P b .05 was deemed significant.
Publication Bias
The number of unpublished studies on this surgical
technique is unknown, and thus, such a meta-analysis is
at risk for publication bias. The overestimated signifi-
cance of published studies may cause a significant “base
rate fallacy” that results from a skewed distribution of
effect sizes.
A funnel plot was used to graphically visualize the
relationship between sample size and effect size and,
therefore, the degree of publication bias. The studies
were arranged by sample size on a linear y-axis, and
reported success rate or effect size, on a linear x-axis.
Results
Article Selection
The initial literature search strategy provided 74
possible studies. Subsequent reading of the abstracts
led to exclusion of 51 of these studies, and the full-
published articles were obtained for the remainder. The
articles were assessed, and 2 were excluded for
insufficient data pertaining to outcome success and
failure, 2 were review articles, and 3 studies were
excluded because they originated from institutions that
had subsequently published updated studies that were
included. Overall, 16 studies met the inclusion criteria
and were identified as appropriate for this meta-analysis
Fig. 2. Flow chart of searchmethods used to identify 16 articles
for full article review and statistical meta-analysis.
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(see Fig. 2 and Table 1; available online at www.
arthroplastyjournal.org).
Data Collection
The level of evidence, according to the Journal of Bone
and Joint Surgery (American Volume) guidelines, for
each article was identified [20]. All articles including in
this study had provide level IV evidence.
For each article, the following were quantified: the
number of cases, mean follow-up time in years, and the
reported success, failure, infection, nonunion, disloca-
tion, and revision rates (see Table 1; available online at
www.arthroplastyjournal.org).
The cumulative number of patients treated with a
PFA was 498, and the mean duration of follow-up for
the included studies was 7.35 years (range, 2-16.2
years). The mean study size was 31 patients (range,
11-73 patients).
Pooled Success Rate
The reported success rates ranged from 66% [26] to
95% [14] (see Table 1; available online at www.
arthroplastyjournal.org and Fig. 3). The fixed effect
and random effects pooled estimates of success were
both 81% (see Fig. 3). The 95% CI was slightly wider for
the random effects analysis (0.77-0.86) compared with
that of the fixed effect (0.78-0.86).
There was no significant data heterogeneity within the
pooled success rate analysis (P = .0635).
Pooled Failure Rate
The quantifiable reported structural failures of PFA
reconstructions included fracture and aseptic loosening.
The range of reported structural failures was from 0%
[14] to 55% [27].
The pooled estimated of structural failure rate was
15% with both fixed (95% CI, 0.12-0.18) and random
(95% CI, 0.10-0.19) effects model analysis (see Fig. 4).
There was a significant level of data heterogeneity
regarding pooled failure as an outcome (P = .0171),
principally the result of a single outlying study [27].
Pooled Infection Rate
The reported infection rates ranged from 0% [27] to
20% [28]. The fixed and random effect pooled estimates
of infection were 8% (95% CI, 0.06-0.11), see Fig. 5.
There was no significant data heterogeneity (P = .6892)
regarding infection as an outcome.
Heterogeneity of Outcomes
Table 2 shows the relative heterogeneity of the 3
outcome measures used in the meta-analysis (success,
structural failure, and infection). The data relating to
structural failure of PFA reconstructions have the high-
est degree (I2) and magnitude (τ2) of heterogeneity and
are the only outcome with statistically significant
heterogeneity (P b .05).
Publication Bias
The linear scale funnel plot for the selected articles is
shown in Fig. 6. The center of the funnel on the x-axis
has been defined by the pooled estimate of the success
rate, namely, 0.81 (see Fig. 3). Ten studies report a
success rate greater than the pooled estimate of success,
and 6 reported a lower success rate. There is an even
distribution of studies within the funnel plot.
Outcomes Not Amenable to Meta-Analysis
Because of confounding factors, the 3 outcomes
commonly reported were not amenable to meta-
analysis, namely, nonunion, revision surgery of the
PFA, and dislocation. The absolute rates for these
outcomes are shown in Table 1; available online at
Fig. 3. Meta-analysis forest plot for success rate after PFA reconstruction. The allocated study number corresponds to those listed
in Table 1; available online at www.arthroplastyjournal.org.
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www.arthroplastyjournal.org. The nonunion rate ran-
ged from 7% [26] to 77% [29] (mean, 25.25%). The
reported dislocation rate ranged from 0% [27,30] to
54.5% [31] (mean, 12.8%). The rate of revision surgery
ranged from 5% [14] to 33.9% [26] (mean, 16.8%).
Discussion
Severe proximal femoral bone loss is creating an
increasing caseload of complex cases for the reconstruc-
tive hip surgeon [6]. The use of PFAs is one surgical
solution used to address this problem and restores
mechanical stability to the proximal femur. The studies
analyzed in this literature review and meta-analysis
consider a single technique, PFA, rather than a single
diagnosis with this technique implemented for both
oncological and nononcological orthopedic surgery.
A further subanalysis comparing oncological against
nononcological surgery was considered; however, these
subgroups were too small to provide adequate statistical
power, and furthermore, most studies combined the 2
subgroups of patients and reported the data together.
The meta-analysis incorporates a total patient cohort
of 498 from 16 studies. With a pooled survivorship rate
of more than 80% (see Fig. 3), it provides evidence that
this surgical technique is valid and durable when
performed by suitable, trained, and experienced sur-
geons in institutions with the facilities to support such
complex surgery.
The large-range structural failures (0% [14] to 55%
[27]) secondary to fracture (allograft and/or prosthesis)
and aseptic loosening had a pooled estimate of 15% (see
Fig. 4). However, a single outlying study [27] signifi-
cantly influenced this result and caused a significant
Fig. 4. Meta-analysis forest plot for fracture or loosening rate after PFA reconstruction. The allocated study number corresponds
to those listed in Table 1; available online at www.arthroplastyjournal.org.
Fig. 5. Meta-analysis forest plot for infection rate after PFA reconstruction. The allocated study number corresponds to those
listed in Table 1; available online at www.arthroplastyjournal.org.
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degree of statistical heterogeneity (P = .0171). All the
remaining studies reported structural failure rates of less
than 30% (see Fig. 4). There were insufficient data
regarding allograft resorption to specifically address it as
a cause of mechanical failure.
The population cohorts and the duration and com-
plexity of the surgery result in infection rates higher
than that for primary hip arthroplasty. However,
considering these factors, the pooled 8% infection rate
is not unacceptable (see Fig. 5).
Major revision surgery rates for removal or replace-
ment of the PFA were 5% [14] to 33.9% [26] with a
mean of 16.8%. The major revision surgery rate closely
reflects the reported combined loosening/infection rate,
with the nonoperative treatment of some complications
accounting for the discrepancy between the 2.
Dislocation is a significant postoperative complication;
however, 5 of the 16 studies did not report the
incidence of dislocation [13,29,32-34]. For the 11
studies that did report dislocation rate, the mean was
12.8% with a range of 0% [27,30] to 54% [31].
Numerous confounding factors contribute to this
complication, including the number of previous surger-
ies, surgical approach used, alignment and position of
the acetabular component, soft tissue tension, and
function, none of which could be controlled to allow a
valid meta-analysis and pooled estimate.
Two studies did not report the rate of trochanteric
nonunion [13,30]. The reported incidence of nonunion
varied considerably from 7% [26] to 77% [29] with a
mean of 25.25%. However, concerns regarding the
exact definition of nonunion used precluded stringent
statistical analysis.
The rates of revision surgery for dislocation, trochan-
teric nonunion, and host-allograft junctional nonunion
were reported in only 8 of the 16 studies. Furthermore,
where reported, there was insufficient detail regarding
such surgery to afford an objective and valid analysis.
For example, the rates of liner exchange, bone grafting,
and trochanteric takedown were not reported.
The systematic review highlighted some important
surgical factors, not amenable to statistical analysis, that
influence the success of this technique, surgical ap-
proach, allograft preparation and storage, and allograft
fixation to host bone.
Surgical Approach
Surgical technique varied between the studies with
regard to surgical approach, storage technique of the
allograft bone, fixation techniques of the prosthesis to
the proximal allograft, distal host femur, and the
junction between the allograft and host bone.
Trochanteric nonunion and abductor strength are
also influenced by surgical approach. The trochanteric
slide osteotomy aims to maintain the continuum of
tissue from the abductors and the greater trochanter to
the vastus lateralis. This approach maintains a higher
rate of trochanteric union [35]. When trochanteric
nonunion occurs after a trochanteric slide osteotomy,
proximal migration of the trochanter is avoided. The
Table 2. Comparison of Heterogeneity Parameters for the 3
Primary Outcome Measures Used in the Meta-Analysis
Pooled Outcome Measure I2 τ2 P
Success rate 37.7 0.0192 .635
Structural failure rate 47.9 0.029 .0171
Infection rate 0 0 .6892
Fig. 6. Funnel plot for the 16 studies used in this meta-analysis using linear scale for reported percentage success rate (x-axis) and
linear scale for study sample size (y-axis).
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trochanteric slide osteotomy has been further modified
to maintain the external rotators and thus improve hip
stability [35-37].
Allograft Preparation and Storage
Allograft preparation and storage varied between
studies. Nonirradiated fresh allograft, stored just above
0°C, was used in 5 studies to help preserve osteocyte
viability [6,27,30,31,38]. However, a further 4 studies
used irradiated deep-frozen bone at −80°C, providing a
nonviable structural graft with a lower immunogenic
and infection risk [26,33,39,40]. One study reports the
use of irradiated and nonirradiated allografts [32], and 2
studies did not report the storage and use of irradiation
of the allograft [34,41].
Allograft Fixation
Cement fixation of the prosthesis to the allograft with
uncemented fixation to the host femur was used in 7
studies [6,28,29,32-34,41]. The rationale for cement
fixation in the allograft-prosthesis composite is that in-
growth and on-growth would not be expected at the
allograft prosthesis interface. Only Zmolek and Dorr [31]
reported a fully uncemented fixation of the prosthesis
and allograft in 11 patients with similar rates of success
compared with other studies.
Regarding the distal fixation of prosthesis to the host
bone, an uncemented technique within distal host bone
was principally used in 9 studies [6,28,29,31-34,40,41],
and cemented distal fixation was used in 4 studies
[13,27,39,42]. One study reported a mixture of cases
using both techniques [26]. Two studies did not report
whether cement was used [14,30].
Several studies highlight the bone union at the host-
allograft junction as a key factor in achieving stability of
the composite graft and thereby lowering the chance of
mechanical failure [26,41-43]. The junctional osteot-
omy between the host femur and the proximal allograft
was either transverse, oblique, or step cut. A step cut
osteotomy may offer more rotational stability, whereas
an oblique osteotomy may offer more surface area for
bone in-growth compared with a transverse osteotomy.
There are strengths to this meta-analysis that provide a
statistical examination of scientific studies. Two inde-
pendent authors conducted a thorough literature search,
and published studies were included regardless of their
publication date. This was a contemporary review with
75% of the studies published within the last decade. The
cumulative data set (n = 498) is substantially larger than
any one study. A potential weakness of a meta-analysis
conducted on small sample size studies is the inherent
risk of publication bias. However, the funnel plot (see
Fig. 6) demonstrates a graphically symmetrical distribu-
tion profile of studies, including small studies with
results inferior to the pooled estimate of success, which
reduces the risk of publication bias.
The limitations of this meta-analysis include the
inability of the methods to control the source of any
potential bias considering the level IV evidence of all the
incorporated studies. The validity of a meta-analysis is
influenced by the quality of the constituent studies. In
addition, one cannot know howmany studies have been
performed, and the results are not published.
However, logistic and ethical issues make it unlikely
that future studies on this surgical technique will
provide level III evidence or higher. Furthermore,
although qualitative heterogenicity may exist between
the studies, all the studies were conducted at academic
orthopedic units and had been accepted by international
peer-reviewed orthopedic journals.
In conclusion, although continued follow-up and
critical analysis of this technique should be encouraged,
this systematic review and meta-analysis support the
use of PFAs for the reconstruction of massive femoral
bone loss.
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Table 1. Publication List Detailing, Underlying Diagnosis, Number of Cases, Length of Follow-Up, and Success and
Complication Rates
Study
Publication
Year n Follow-up (y) Success Success (%) Failure Infection Nonunion Revision Dislocation
1 Chandler et al [6] 1994 30 2 27 90 3 1 3 3 5
2 Langlais et al [27] 2003 11 6 9 82 6 0 2 6 0
3 Haddad et al [42] 2000 40 8.8 34 85 4 2 18 2 4
4 Zehr et al [13] 1996 18 10 14 78 3 3 N/R 2 N/R
5 Zmolek and Dorr [31] 1993 11 2 8 73 8 1 1 7 6
6 Safir et al [41] 2009 50 16.2 42 84 4 2 12 3 4
7 Vastel et al [39] 2007 43 7.1 39 91 19 1 25 19 6
8 Babis et al [26] 2010 56 12 37 66 2 5 4 2 8
9 Lee et al [40] 2009 15 4.2 13 87 13 1 2 13 1
10 Roque et al [30] 2009 73 6.7 60 82 9 8 N/R 9 0
11 Biau et al [32] 2010 32 5.6 23 72 2 4 3 2 N/R
12 Donati et al [29] 2009 22 4.8 20 91 1 1 17 1 N/R
13 Farid et al [14] 2006 20 6.3 19 95 2 1 1 2 2
14 Graham and Stockley [33] 2004 25 4.5 23 92 10 1 9 10 N/R
15 Muscolo [34] 2010 37 7.5 27 73 5 3 5 5 N/R
16 Wang and Wang [28] 2004 15 7.6 10 67 3 3 4 3 1
N/R indicates not reported.
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The treatment of substantial proximal femoral bone loss in young patients with 
developmental dysplasia of the hip (DDH) is challenging. We retrospectively analysed the 
outcome of 28 patients (30 hips) with DDH who underwent revision total hip replacement 
(THR) in the presence of a deficient proximal femur, which was reconstructed with an 
allograft prosthetic composite. The mean follow-up was 15 years (8.5 to 25.5). The mean 
number of previous THRs was three (1 to 8). The mean age at primary THR and at the index 
reconstruction was 41 years (18 to 61) and 58.1 years (32 to 72), respectively. The indication 
for revision included mechanical loosening in 24 hips, infection in three and peri-prosthetic 
fracture in three.
Six patients required removal and replacement of the allograft prosthetic composite, five for 
mechanical loosening and one for infection. The survivorship at ten, 15 and 20 years was 93% 
(95% confidence interval (CI) 91 to 100), 75.5% (95% CI 60 to 95) and 75.5% (95% CI 60 to 95), 
respectively, with 25, eight, and four patients at risk, respectively. Additionally, two junctional 
nonunions between the allograft and host femur required bone grafting and plating.
An allograft prosthetic composite affords a good long-term outcome in the management 
of proximal femoral bone loss in revision THR in patients with DDH, while preserving distal 
host bone.
Developmental dysplasia of the hip (DDH)
may be associated with anatomical malforma-
tions including a shallow acetabulum, proxi-
mal subluxation or dislocation of the hip,
excessive anteversion of the femoral neck, a
relatively posterior greater trochanter, a nar-
row femoral canal and abnormal bone quality
around the hip.1 These patients often require
total hip replacement (THR) at a young age.
Proximal femoral bone loss and early femoral
prosthetic loosening may subsequently develop
due to the anatomical abnormalities and the
high functional demand of these young
patients. This may lead to many revision pro-
cedures, further proximal femoral loss and an
ectatic distal femoral canal.1
The complication rate following THR is
higher in patients with dysplasia than in those
with degenerative osteoarthritis; this cannot be
fully accounted for by the younger age at which
patients with dysplasia present for surgery.2-6
These complications include sciatic nerve palsy,
with an incidence of between 0.5% and 1%,
increasing to 3% to 15% in dysplastic hips,7-11
dislocation (5% to 11%),5,9,11 peri-operative
femoral fracture,12,13 and a higher rate of infec-
tion compared with that encountered in the
treatment of osteoarthritis.11,14,15 These
complications lead to a higher rate of revision
at a younger age, which in turn increases the
risk of proximal femoral bone loss as a result of
mechanical loosening, infection and peri-
prosthetic fracture.
Various surgical techniques have been
advocated to manage proximal femoral bone
loss, including impaction allografting,16,17
distal press-fit fixation of a longer stem,18,19
massive endoprosthetic reconstruction20-22
and the use of an allograft prosthesis compos-
ite (APC).23-27 Survivorship of between 58%
and 84% has been reported for massive endo-
prosthetic reconstruction with follow-up
ranging from five to ten years.20-22 The tech-
nique of APC reconstruction uses a long
stemmed prosthesis that spans the host-
allograft bone junction.25,28
The aim of this study was to assess retro-
spectively the long-term outcome and compli-
cations related to revision THR using a
proximal femoral APC for the reconstruction
of massive proximal femoral bone loss in
patients with DDH. The primary outcome of
interest was further revision, and the second-
ary outcomes of interest included other com-
plications such as infection, dislocation and
nonunion.
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Patients and Methods
From our prospectively collected database, we identified all
patients who had undergone revision THR using an APC for
a failed THR undertaken for DDH between 1984 and 2002.
The indication for an APC was full circumferential bone
loss of at least 8 cm in length, extending into the diaphysis.
Inclusion criteria were previous THR for DDH and a type 4
or 5 bone defect of the proximal femur according to the
Gross classification.29 A type 4 defect is a full circumferential
bone loss of > 8 cm in length extending into the diaphysis. A
type 5 defect is similar with an associated peri-prosthetic
fracture. Both were treated with an APC incorporating a
long stemmed prosthesis. A total of 38 patients met the inclu-
sion criteria. Exclusion criteria included patients living
abroad, those with < 24 months follow-up and those who
had died due to unrelated causes or who had been lost to fol-
low-up within 24 months of surgery. This led to the exclu-
sion of eight patients. The study included four patients who
died after ten years of follow-up.
There were a total of 30 hips in 28 patients (25 females,
three males) who were followed for a mean of 15 years (8.5
to 25.5). The mean age at primary THR was 41 years (18 to
61). The median number of previous joint replacements on
the affected hip prior to the index revision procedure was
three (1 to 8). The mean age at the revision with the APC
was 58.1 years (32 to 72). The cause for the index revision
THR was aseptic loosening of the femoral component in
24 patients, peri-prosthetic fracture in three and infection
(second stage revision) in three.
All procedures were performed by the senior surgeon
(AEG) through a trochanteric slide approach. The long
stem of an APC bridges the host-allograft junction, which is
fashioned as a step-cut or oblique osteotomy in order to aid
rotational and axial stability of the construct. The prosthe-
sis is cemented proximally in the allograft and uncemented
distally in the host bone. The prostheses used were
23 Gross long stem allograft prostheses (DePuy/Johnson &
Johnson, Warsaw, Indiana), five Charnley long stem pros-
theses (DePuy, Leeds, United Kingdom) and two ZMR
prostheses (Zimmer, Warsaw, Indiana).
 Allograft was stored at -70°C after being irradiated with
2.5 Mrad according to the American Association of Tissue
Banks accredited tissue bank guidelines.30 Cultures of the
graft were taken before immersion in warm 50% povidone
iodine solution. The graft was prepared on a separate sterile
surgical table by a second surgical team. The femoral head
of the allograft was excised at the base of the lesser tro-
chanter to facilitate insertion of the implant and adjustment
of version. Lengthening of the leg was not carried out via
the neck cut, but rather by the length of the allograft below
the lesser trochanter. A stable graft-host junction is a crucial
part of the technique and was achieved with either a step
cut or an oblique osteotomy. The greater trochanter of the
allograft was excised, allowing attachment of the host tro-
chanter (Fig. 1). Reaming the allograft was then carried out
prior to insertion and cementing of the implant. The host
canal at the metaphysis was generally larger than the dia-
physeal canal of the allograft and therefore a distal press-fit
was not achieved. Stability was achieved once union
occurred at the graft host junction. Junctional union may
be improved with morcellised autograft bone and stability
may be enhanced with the addition of strut allografts. The
remaining proximal femoral host bone, and its associated
soft tissue, was preserved during the extended osteotomy
and used as a vascularised onlay graft around the APC.
The post-operative rehabilitation protocol included non-
weight-bearing for eight to 12 weeks until there was radio-
logical evidence of union at the graft-host junction. At this
time, abductor muscle strengthening exercises were com-
menced, including active straight leg abduction.
 The length of the allograft was measured from the base
of the lesser trochanter to the distal end of the graft, exclud-
ing the step cut distally and the greater trochanter proxi-
mally. The mean length of the 30 allografts was 12.2 cm (6
to 22). Patients were reviewed at six weeks, three months,
six months, one year and then annually. Clinical assessment
included an evaluation of leg length, wound, range of
movement and neurological status. Radiological assess-
ment included an anteroposterior (AP) pelvic view, and an
AP and lateral view of the hip and entire femur. Functional
outcome was assessed with the original Harris hip score
(HHS)31 before the revision surgery and at final follow-up.
Radiological evaluation focused on 20 patients with a
unrevised APC (Figs 2 and 3). The radiographs at final
review were assessed by two authors (AS, BAR).
Fig. 1a
Diagrams showing a) the allograft prosthesis
composite (APC) constructed from a proximal
femoral allograft with a step-cut or oblique dis-
tal osteotomy, with the greater trochanter
resected to make room for the host greater tro-
chanter when it exists, and b) the APC unce-
mented distally in host bone.
Fig. 1b
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Four patients who had the index surgery in the 1990s and
1980s have since died and radiographs were unavailable.
Our institution converted to digital imaging in 2003 and
this resulted in loss of the hard-copy radiographs for these
four patients, for whom we used the most recent radiolog-
ical assessment in their notes. We assessed graft union,
implant migration and graft resorption. Graft union was
assessed at the graft host interface and was considered to
occur when there was evidence of trabecular bridging. We
judged clinically relevant implant migration to be present
when > 5 mm of migration was evident between radio-
graphs obtained at last follow-up and those obtained previ-
ously.32
Graft resorption was classified using the method
described by Gross and Hutchinson.25,33 ‘Mild’ resorption
involved partial-thickness resorption of < 1 cm in length,
‘moderate’ resorption involved partial-thickness resorption
of > 1 cm in length, and ‘severe’ resorption involved full-
thickness resorption of any length. This was assessed in all
Gruen zones34 excluding zone 1 (trochanteric insertion)
and zone 4 (graft host junction). We expressed inter-
observer variability as a percentage of the difference in
observations between the two observers for each radiolog-
ical observation. Our interobserver agreement for graft
union and implant migration was 100% (20 of 20), and for
graft resorption was 90% (18 of 20), which were the result
of discrepancies between ‘mild’ and ‘moderate’ resorption
and ‘no’ and ‘mild’ resorption.
The primary outcome was revision surgery for failure of
the APC composite. Secondary outcomes were further sur-
gery for bone grafting and plating of the graft-host junc-
tion, radiological outcomes, functional outcome (HHS)
and post-operative rates of complication, dislocation, frac-
ture and nerve injury.
 A total of 11 further revision procedures were under-
taken due to acetabular loosening or recurrent dislocation.
In all these cases the APC constructs were assessed intra-
operatively by the senior author (AEG) and were not
deemed to have failed; the acetabular component had failed
and these hips were therefore excluded from the primary
outcome survivorship analysis.
Statistical analysis. This was performed using SPSS software
(SPSS Inc., Chicago, Illinois). The APC survivorship was cal-
culated by the Kaplan-Meier method with 95% confidence
intervals (CI) with revision of the APC for loosening as the pri-
mary end point. Cox regression analysis was used to deter-
mine correlations between failure and APC length and/or
number of revision surgeries. The overall outcome was calcu-
lated with any additional surgery on the femoral side as
the primary endpoint. The HHSs were analysed with a paired
t-test. A p-value < 0.05 was taken to be statistically significant.
Results
The APC survival rate was 93% (95% CI 91 to 100) at ten
years when 25 patients were at risk, 75.5% (95% CI 60 to
95) at 15 years when eight patients were at risk and 75.5%
(95% CI 60 to 95) at 20 years when four patients were at
risk. This included six revisions to replace a failed APC. Of
these failures, five were due to mechanical loosening that
occurred at a mean of ten years (6 to 12.8) and one due to
infection. All these patients underwent revision with a new
APC (Fig. 4). The failure due to infection occurred 30 months
after index surgery. The patient was treated initially with
excision arthroplasty and antibiotic therapy. A new APC was
undertaken as a second stage procedure eight years later and
has since been functioning satisfactorily for 16 years.
Fig. 2b
Radiographs of a left hip allograft prosthesis composite (APC) showing
a) union at the junction between host bone and the APC and b) the distal
end of the long prosthesis in the proper position in the distal femur func-
tioning well at 18 years’ follow-up.
Fig. 2a
Fig. 3a
Radiographs of a right hip allograft prosthesis composite (APC) showing
a) junctional nonunion and b) subsidence of the prosthesis into the knee
joint which occurred ten years after surgery.
Fig. 3b
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Kaplan-Meier analysis for overall survival of the APC
including any surgery on the femoral side as an endpoint
(Fig. 5) included five patients with mechanical loosening,
one infection, two with nonunion of the graft-host junction
and one peri-prosthetic fracture. This gave a ten-year sur-
vival of 83% (95% CI 71 to 98) when 24 patients were at
risk. The 15-year survival was 65% (95% CI 48 to 87)
when six patients were at risk. Junctional nonunion
occurred in two patients and was successfully treated with
bone graft and plating at 12 and 86 months after index sur-
gery, respectively. Both patients have long-term uneventful
follow-ups of 13 and 24 years, respectively. One patient
sustained a peri-prosthetic fracture ten years after the index
procedure distal to the APC, which was treated with a plate
and strut allograft. The result was satisfactory at eight years
post-operatively.
 Revision for replacement of the APC did not correlate
with the length of the APC (p = 0.22, Cox regression) or with
the number of previous THRs (p = 0.81, Cox regression).
Revision of the acetabular component due to dislocation
or loosening occurred in 11 patients at a mean of nine years
(six months to 23.2 years) from index surgery. These were
not considered failures of the APC. Revision of both the
acetabular component and the APC occurred in two
patients although in both patients several years elapsed
between the acetabular and the femoral revisions (6.5 and
seven years, respectively).
There were four patients with recurrent dislocation, one
at three months, two at six months, and one at 17.6 years.
These patients were found to have acetabular loosening and
underwent acetabular revision. Nerve injury occurred in one
patient who had a post-operative foot drop following length-
ening of < 2 cm. The foot drop resolved spontaneously after
six months. There were no intra-operative fractures. The
mean pre-operative leg-length discrepancy was 3 cm (0 to 7)
and 1.5 cm (0 to 7) at one year post-operatively.
The mean pre-operative HSS was 31.93 (4.6 to 49.5),
which improved to 71.52 (44.4 to 96.4) at one year post-
operatively. At final follow-up it was 67.60 (12.6 to 86.7)
(Table I). Both the one-year post-operative and the final
follow-up scores were significantly better than the pre-
operative scores (t-test, p < 0.001).
Radiological assessment in 20 patients with a successful
APC and contemporary radiographs at final follow-up
found no evidence of subsidence or nonunion. Mild to
moderate allograft resorption was found in four hips. Tro-
chanteric nonunion and migration > 2 cm was observed in
four hips.
Discussion
Proximal femoral bone loss in revision THR for DDH is a
significant problem. When such bone loss includes the isth-
mus the option for distal uncemented press-fit fixation is
lost. The remaining treatment options include an APC, a
cemented endoprosthesis or total femoral replacement.
These should be viewed as salvage procedures. The long-
term outcomes of APC presented in this study should be
viewed in that context.
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Fig. 4
Kaplan-Meier survival curve with 95% confidence interval for overall
survival of the allograft prosthesis composite (APC) including any sur-
gery on the femoral side as an endpoint. This included five patients with
mechanical loosening, one infection, two nonunions of the graft-host
junction and one peri-prosthetic fracture.
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Fig. 5
Kaplan-Meier survival curve with 95% confidence interval for allograft
prosthesis composite (APC) with removal and replacement of the APC as
an endpoint. This included five patients with mechanical loosening and
one infection.
Table I. Grading for Harris hip scores pre-operatively, at one year and at latest follow-up
Poor (< 70) Fair (70 to 79) Good (80 to 89) Excellent (90 to 100) 
Pre-operative (n, %) 30 (100)  0 (0) 0 (0) 0 (0)
One year (n, %)  8 (26.7) 15 (50) 6 (20) 1 (3.3)
Last follow-up (n, %) 18 (60)  6 (20) 6 (20) 0 (0)
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A search of our institutional database showed that out of
198 revision THRs in DDH patients, in 38 cases (19%)
APCs were used to reconstruct defects in the proximal
femur. The young age of these patients makes preservation
of the bone stock for the future a significant issue. The tech-
nique, with the prosthesis neither cemented nor press-fitted
into the distal femur, allows loading of the graft-host bone
junction, and a step-cut or oblique osteotomy achieves
axial and rotational stability. This load-sharing construct
minimises stress shielding and bone resorption of the distal
femur. The key to the long-term success of the APC is union
at the graft-host bone junction. Failure of an APC begins
with failure at this junction. Since the APC is neither
cemented nor press-fitted into the distal femur, it may be
removed and replaced with a new APC with minimal distal
host bone loss when it fails. In all six patients with failure of
their APC there was nonunion at the host-graft junction
and the existing APC was replaced with a new one.
A potential weakness of this study is its retrospective
nature. Given that the study examines patients at long-term
follow-up, many of the pre-operative and immediate post-
operative radiographs were not available. We relied on the
original operative note, the prospectively collected database
and the most recent radiographs. A further weakness is that
the primary THRs had been performed at different institu-
tions and presented to the senior author (AEG) for revision
surgery. There was only written data regarding the native hip.
Several retrospective case series describe the use of APC
in revision THR or after proximal femoral resection for
oncological disease.23-27 We could find no published studies
considering femoral bone loss managed with APC in
patients with DDH, although our database indicates
that 41% of APCs were performed for DDH (38 of
92 patients).28 Cementing an implant into the distal host
bone risks unloading the remaining proximal host bone
which might result in increased resorption.26 In such a sce-
nario, further femoral revision causes additional bone loss
when removing cement from the host femur. Endopros-
thetic reconstruction is an alternative solution for the man-
agement of proximal femoral bone loss. A recent
retrospective review of patients who received large endo-
prostheses after resection of a tumour, from five institu-
tions, reported survival at ten and 15 years of 75% and
73%, respectively, from 403 proximal femoral replace-
ments, with mechanical causes being the most common
mode of failure.35
In this study of 30 patients, the rate of all further hip sur-
gery at a mean of 15 years was 70% (21 out of 30): five
APC revisions for aseptic loosening, one two-stage revision
for infection, one periprosthetic fracture, two junctional
nonunions and 11 acetabular component revisions. Nerve
injury occurred in only one patient and resolved completely
with conservative treatment and there were no intra-
operative fractures.
The modified trochanteric slide approach to the hip is
advantageous as it maintains a continuum between the
abductors and vastus lateralis thus lowering the rate of
trochanteric nonunion.36,37 However, when trochanteric
union fails a trochanteric escape is still possible, as seen in
four patients in this study, though none suffered a disloca-
tion. Recurrent surgery to the hip is detrimental to the
abductor musculature with most patients having some
degree of Trendelenburg lurch.38 The trochanteric slide oste-
otomy also enables optimal exposure of the acetabulum.
The four patients who had recurrent dislocation all had
mechanical loosening of the acetabular component, which
was revised in isolation.
The overall functional outcome as assessed by the HHS
was significantly better at the final follow-up compared
with the pre-operative situation (p < 0.001), but the mean
overall score (67.6) is still classified as poor (< 70).
We have found excellent long-term survivorship of APCs
when used for revision surgery on patients with extensive
femoral bone loss who had undergone primary THR for
DDH. When the APC fails further revision may be under-
taken to another APC without additional loss of host fem-
oral bone stock. Despite excellent survivorship, the authors
caution that functional outcomes are not ideal and that the
APC should only be considered when diaphyseal fixation is
not possible.
Supplementary material
A table detailing the mode of failure in nine hips and
further procedures required is available with the elec-
tronic version of this article on our website www.jbjs.bone-
andjoint.org.uk
No benefits in any form have been received or will be received from a commer-
cial party related directly or indirectly to the subject of this article.
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The Reconstruction of Periprosthetic
Pelvic Discontinuity
Benedict A. Rogers, MA, MSc, FRCS(Orth),*
Paul M. Whittingham-Jones, FRCS(orth),y
Philip A. Mitchell, FRCS(orth),y Oleg A. Safir, MD, MEd, FRCSC,*
Martin D. Bircher, FRCS,y and Allan E. Gross, MD, FRCSC*
Abstract: The surgical techniques and outcomes of acetabular reconstruction for periprosthetic
pelvic discontinuity cases are reported. The mean time to surgery for 9 patients with acute pelvic
discontinuity was 16.3 days, with 8 patients (88%) having posterior column plating and a porous
metal acetabular cup. No cases required revision surgery, with a mean follow-up of 34 months
(range, 24-67months). Of the 62 chronic pelvic discontinuity cases, 20 had an ilioischial cage, with a
revision rate of 29%. Therewere 42 cup-cage reconstructionswith an 8-year survivorship of 86.3%,
with a mean follow-up of 35 months (range, 24-93months). Stable reconstruction of chronic pelvic
discontinuity was achievable by distraction using a cup-cage acetabular reconstruction; however,
satisfactory stability of acute pelvic discontinuity was achieved with compression of the posterior
column using screw augmentation of the acetabular shell supplemented by posterior column
plating. Keywords: pelvic discontinuity, acetabular revision, bone loss, ilioischial cage, cup cage.
© 2012 Elsevier Inc. All rights reserved.
Massive acetabular bone loss provides a challenge for the
reconstructive surgeon. Periprosthetic pelvic disconti-
nuity describes the loss of structural bone between the
superior and inferior aspects of the pelvis, resulting from
bone loss or fracture through the acetabulum [1,2].
Although relatively rare at present, the incidence is
likely to rise with an aging, active population and an
increasing caseload of primary and revision total hip
arthroplasty [1,3-6].
Recent improvement in biomaterials such as porous
trabecularmetal have affordeda superior capacity for bone
ingrowth that makes the use of hemispherical uncemen-
ted cups feasible for acetabular revisionwithmarked bone
loss [7-10]. Unlike the algorithms for management of
native acetabular fractures, the treatment of periprosthetic
pelvic discontinuity is less well defined [2,8,11-14].
The biology and biomechanical stability differs between
acute and chronic pelvic discontinuity, and the recon-
structive surgical techniques should differ accordingly.
The purpose of this study is to report the surgical tech-
niques, outcomes, and complications of acetabular
reconstruction for both acute and chronic pelvic dis-
continuity treated at 2 tertiary referral orthopedic units.
Methods
Institutional board approval was obtained. This 2-
center study identified 71 cases of pelvic discontinuity
that were classified into acute, less than 12 weeks from
primary surgery, or chronic, greater than 12 weeks from
primary surgery. All cases were treated at academic
tertiary referral units, and all surgeries were performed
by senior surgeons.
The patients' demographics in both case series are
shown in Table 1. In all patients, pelvic discontinuity was
based on the radiologic findings and confirmed intrao-
peratively by the senior author, with the hemipelvis
being separated superiorly and inferiorly because of loss
of the host bone or fracture through the acetabular
columns. Routine radiographic and clinical follow-up
was undertaken, and the incidence of complications or
revision surgery was obtained.
Acute Case Series
Nine cases of acute pelvic discontinuity secondary
were identified, with a mean age of 67.4 years (range,
30-83 years) and a mean follow-up of 34 months
(range, 24-67 months). All cases were female. These
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cases were managed by senior surgeons at an academic
orthopedic department (P.A.M., S.H.B., M.B.), a tertiary
referral unit for both pelvic and acetabular trauma and
hip reconstruction.
Blunt trauma was the cause of the pelvic discontinuity
in 4 cases; iatrogenic trauma during the insertion of
uncemented acetabular cups was the cause in the
remaining 5 cases. Of the 9 acute cases, most had only
1 previous operation, a primary total hip arthroplasty,
on the affected side; whereas a single patient had 2
previous surgeries. All patients with acute pelvic
discontinuity had uncemented acetabular components
in situ.
The initial diagnosis and referral and preoperative
planning used plain radiographs and computed tomog-
raphy. The criteria described by Berry [15] were used to
diagnose pelvic discontinuity including a visible trans-
verse pelvic fracture on anteroposterior pelvic or Judet
radiographs,medial offset of the inferior part of the pelvis
in relation to the superior part of the pelvis as seen by
a break in the ilioischial line, and rotation of the
hemipelvis as indicated by asymmetry of the obturator
ring on the true anteroposterior pelvic radiograph. How-
ever, the senior operating surgeon confirmed the defini-
tive diagnosis of pelvic discontinuity once the entire
acetabulum was directly visualized intraoperatively.
A transverse or “T” pattern fracture was seen in most
the acute pelvic discontinuity acetabuli. All cases were
performed using a posterior or Kocher-Langenbeck
approach, and the details of the surgical management
of these cases are detailed in Table 2; (available online
at www.arthroplastyjournal.org). Acetabular recon-
struction used modular trabecular metal acetabular
components in all cases. In most cases (8/9), the
posterior column was stabilized with a reconstruction
plate initially in addition to revising the acetabulum.
Chronic Case Series
There were 62 cases of chronic pelvic discontinuity,
secondary to septic or aseptic periprosthetic bone loss,
with a mean age of 67.5 years (range, 27-88 years) and a
mean follow-up of 35 months (range, 24-93 months).
The reconstructive techniques used for the chronic
pelvic discontinuity series include an ilioischial cage or
a cup-cage reconstruction [8], performed by or under the
direct supervision of one of the senior authors (A.E.G.).
Of these 62 cases, 18 (29%) concurrently underwent
femoral component revision. The diagnosis was fre-
quently not obvious before surgery, despite the routine
use of pelvic computed tomographic scans and Judet
view radiographs. Therefore, a high index of suspicion
was maintained during surgery, with a pelvic disconti-
nuity specifically checked after initial gentle reaming.
Operative Technique
A modified trochanteric slide or extended trochanteric
osteotomy was performed to obtain an adequate ex-
posure of the acetabular and has previously been
described [16-18]. Maintaining the continuity of the
vastus lateralis and abductors by using a trochanteric
osteotomy affords a good exposure with acceptable rates
of limp and nonunion [16-19]. The acetabulum was
gently reamed, the degree of acetabular bone loss was
assessed, and the diagnosis of pelvic discontinuity was
confirmed. The subsequent reconstruction involved
either an ilioischial cage (ZCA or Burch-Schneider;
Zimmer, Warsaw, Ind) or a cup cage.
The surgical technique for an ilioischial cage recon-
struction used by the senior author has previously
been described [20]. Morselized bone graft is used in all
cases, and 4 cases had additional structural corticocan-
cellous allograft. The appropriate reconstruction cage
was chosen based on the size of the bone-grafted
acetabulum using acetabular reamers, trial cups, and
then a trial reconstruction cage. The inferior flange was
either slotted or screwed to the ischium. The superior
flange was carefully molded to the lateral acetabular
dome of the ilium, with several screws placed through
the cage into the dome positioning the flange on the
host bone. A polyethylene liner was cemented into the
ilioischial cage, ensuring an acetabular orientation of
about 45° and 15° to 20° of anteversion.
The surgical technique for a cup cage has also been
previously described [8]. The rationale for this con-
struct is that an ilioischial cage provides initial stability
to the reconstruction while shielding the trabecular
metal cementless acetabular component from mechan-
ical forces until biologic stabilization has taken place,
which gives the entire construct its long-term stability.
The acetabulum is prepared as described previously, and
the defect was sized for a trabecular metal revision
shell and a suitable-sized Trabecular Metal Acetabular
Revision System cage (Zimmer) to bridge the ilium to
the ischium.Morselized bone graft, a mixture of allograft
and autograft, is firmly compressed into the acetabulum
using spherical compressors. Screw fixation was used to
augment the initial press-fit fixation of the acetabular
component, and occasionally, this necessitated new drill
holes being made through the trabecular metal of the
acetabular component. The initial press fit was achieved
with nomore than 1 to 2mm of underreaming. It should
Table 1. Demographics and Follow-Up for Acute And Chronic
Pelvic Discontinuity
Acute Chronic
n 9 62
Mean age (y) 67.4 67.5
Age range (y) 30-83 27-88
Male, n (%) 0 (0) 15 (24.1)
Female, n (%) 9 (100) 47 (75.9)
Mean follow-up (mo) 34 35
Follow-up range (mo) 24-67 24-93
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be noted that the drilling of new holes through a metal
is only approved by the manufacture for the revision
acetabular shell component (00-700-56-20; Zimmer).
The fixation of the cage was made inferiorly with a slot
into the substance of the ischium inferiorly in all
patients, thus reducing the risks of screw fracture, cage
migration, and sciatic nerve damage [20]. The superior
flange of the cage was secured with screws; with care
to avoid damaging the extrapelvic (superior gluteal
nerve and artery) or intrapelvic (internal iliac and
obturator vessels) structures [21-23]. A polyethylene
liner was cemented into the cage in the appropriate
inclination and version, with cement interdigitating
through the holes in the cage to reduce micromotion
between the cage and the acetabular component.
The percentage host bone contact to the acetabular
shell component was estimated intraoperatively by a
method previously reported [24]. In summary, with the
trial cup in, each quadrant of the acetabular hemisphere
was assessed separately for contact with the host bone,
morselized bone graft, or no contact with the bone
(uncoverage). Contact with each one of those surfaces
was expressed in 20% segments for each quadrant
(representing 5% segments for the whole hemisphere).
The overall contact was calculated by joining the quad-
rant scores and was recorded on designated forms.
Statistical Analysis
For both the acute and the chronic case series, revision
acetabular surgery either for any cause or for failure of
the pelvic discontinuity reconstruction (metalwork
failure) was used as the primary outcome measure.
Where appropriate, Kaplan-Meier survivorship analysis
was performed with respect to these outcomes.
Results
Acute
Six (67%) of the cases used autologous morselized
bone graft in addition to the acetabular component. Two
patients died of unrelated causes, although at the last
follow-up, both hip reconstructions remained intact.
Overall, at the last follow-up, the reconstruction of
acute cases had a 100% survivorship, with none of the
cases had undergone further revision surgery. There
were no reported cases of infection or subsequent dis-
location; however, 3 cases had some abductor dysfunc-
tion and a limp.
A single case showed radiographic evidence of ischial
nonunion but with no associated symptoms, and the
patient has not undergone further surgery.
Prereconstruction and postreconstruction radio-
graphs for the reconstruction of acute periprosthetic
pelvic discontinuity are shown in Figs. 1 and 2, dem-
onstrating open reduction and internal fixation of the
posterior column, revision acetabular cup, and screw
supplementation.
Chronic
The commonest primary diagnosis for the previous
primary total hip arthroplasty in the chronic pelvic dis-
continuity case series was osteoarthritis (28/62), fol-
lowed by inflammatory arthropathy (13/62). Four
patients had neoplastic bone as the reported primary
diagnosis for the previous total hip arthroplasty, includ-
ing chondrosarcoma andmetastatic lung carcinoma, and
2 patients had unspecified neoplastic bone lesions.
Fig. 1. Radiograph demonstrating an acute periprosthetic
pelvic discontinuity with an uncemented total hip arthroplasty.
Fig. 2. Radiograph demonstrating acetabular reconstruction
of acute periprosthetic pelvic discontinuity (as shown in Fig. 2)
with posterior column plating and a large porous metal
acetabular component 28 months after surgery.
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The revision rate for the cup-cage reconstructions
was 9.5% (4/42 cases), with 2 cases revised for instabil-
ity and 2 for a failed reconstruction. The revision rate
for the ilioischial cage reconstructions was 28.5% (2/7
cases) and 30.7% (4/13 cases) for the ZCA and Burch-
Schneider cages, respectively. Of the 6 ilioischial cage
reconstructions that required revision, 5 were for failed
cages and only 1 for instability.
The incidence of complications and revision rates for
different reconstructions, including the mean time to
further revision surgery, are shown in Table 3.
The cup sizes used and the amount of contact between
the acetabular cup and bleeding host bone after ream-
ing for each of the separate reconstructions used for
chronic pelvic discontinuity are shown in Table 4;
(available online at www.arthroplastyjournal.org). The
overall mode and median cup size was 62-mm outer
diameter, with a range of 46 to 80 mm. The mode and
median femoral head size used was 32 mm, with a range
of 28-40 mm. Eighteen (29%) of the chronic case series
had concurrent revision of the femoral component, with
13 of these being modular femoral components (ZMR;
Zimmer). For each of the 3 reconstructive methods
used, the percentage contact with the host bone was
consistently low, with the mean for each method being
between 25% and 28% (see Table 4). Of the 62 chronic
pelvic discontinuity cases, 5 incorporated structural
allograft for the acetabular reconstruction, with 57
having morselized allograft.
The reported postoperative complications after the
acetabular reconstruction of chronic pelvic discontinuity
are detailed in Table 3. Of the 7 reported dislocations, 3
cases required open reduction, during which one had
augmentation of polyethylene liner and the other had a
constrained liner inserted. The remaining 4 cases of
dislocation were managed with a closed reduction. Two
cases developed infection, both superficial to the fascia
lata, and underwent debridement, washout, and a
course of intravenous and then oral antibiotics. Both
cases did not require further surgery and at the last
follow-up, no infection was clinically evident.
The overall revision rate, at the last follow-up, was
9.5% for cup-cage acetabular reconstruction compared
with 28.5% and 30.7%, respectively, for ZCA or Burch-
Schneider ilioischial cage reconstruction (see Table 3).
The Kaplan-Meier survivorship analysis for the chron-
ic pelvic discontinuity cases managed with cup-cage
reconstruction is shown in Figs. 3 and 4. Using any
acetabular revision as an end point, the 8-year survi-
vorship was 86.3% (see Fig. 3). However, using revision
for a failed pelvic discontinuity reconstruction as an end
point, such as metalwork failure and excluding revisions
for hip instability, the 8-year survivorship was 93.8%
(see Fig. 4).
Table 3. Complications Associated With the Surgical
Management of Chronic Pelvic Discontinuity
Complication
Cup Cage
(n = 42)
ZCA
(n = 7)
Burch-
Schneider
(n = 13)
Total
(n = 62)
Dislocations 6 0 1 7
Infections 1 1 0 2
Loose/Failed 1 0 1 2
Nerve lesion 1 0 0 1
Cup migration* 1 0 0 1
Deaths 1 0 3 4
Revisions—
instability
2 (4.7%) 0 1 (7.7%) 3 (4.8%)
Revision—
failed cage
2 (4.7%) 2 (28.5%) 3 (23.1%) 7 (11.3%)
Mean follow-up
(mo)
32 34 42 35
Revision total 4 (9.5%) 2 (28.5%) 4 (30.7%) 10 (16.1%)
Time to revision
(mo) †
6.5 16 19 NA
NA indicates not applicable.
* Radiographic cup migration observed, although not revised.
† Mean time from reconstruction to subsequent acetabular revision.
Fig. 3. Kaplan-Meier survivorship graph for chronic pelvic discontinuity patients treated with cup-cage reconstruction, with any
revision as an end point.
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Radiographs are presented, demonstrating cup-cage re-
constructions for failed ilioischial cage (see Figs. 5 and 6).
Discussion
Although the incidence of pelvic discontinuity has
been reported at 0.9% of all revision total hip arthro-
plasties, the caseload is likely to increase with an aging
and active population [1,3-5,25]. The inherent instabil-
ity and lack of bone stock provide a challenge for
acetabular revision surgery and risk factors including
female sex, older patients, massive bone loss, osteopo-
rosis, and rheumatoid arthritis [1]. Several surgical
techniques have been advocated for treatment of peri-
prosthetic pelvic discontinuity (or dissociation), includ-
ing ilioischial cages [12], plate fixation of structural
allografts [26], triflange cups [27], Steinmann pin
fixation [13], acetabular revision with addition pelvic
screws [2], acetabular reinforcement rings [28], oblong
cups [29], and cup-cage reconstruction [8].
Despite numerous published studies reporting the
case series of various treatment options (see Table 5),
to date, no clear consensus to treatment has been pro-
posed. In 2005, Sporer et al [30] suggested that the
treatment of pelvic discontinuity is dependent on the
remaining host bone, the potential for healing of
the discontinuity, and the potential for biologic in-
growth of the acetabular components. The aim was to
achieve cementless biologic fixation when possible, and
an alternative reconstruction when insufficient stability
was obtainable. If bone healing potential exists, some
authors [31,32] proposed that compression of the pos-
terior column should be achieved, either with a plate
or trabecular metal cup acting as an “internal plate.”
Plate fixation achieved posterior column compression
using the standard biologic principles of fracture fixa-
tion. A trabecular metal cup, augmented with acetabular
screws above and below the discontinuity, may also
afford sufficient biologic stability to afford bone union.
Alternatively, with insufficient host bone healing
potential, they suggest that the discontinuity should be
bridged and treated in distraction. The initial biome-
chanical stability of a modular acetabular reconstruc-
tion is substantially enhanced with distraction of the
pelvic discontinuity compared with compression, par-
ticularly in an environment with minimal host bone
healing potential. A large-diameter, trabecular metal,
revision acetabular component provides the suitable
biomechanical properties to both afford a stable initial
distraction of a pelvic discontinuity and generate biologic
stability by encouraging bone ingrowth [7,9,10,33-35].
However, the report by Sporer et al [30] did not
provide supporting clinical evidence and concluded that
“the long term clinical results of this treatment remain
unknown.” Insufficient bone healing may result from
Fig. 4. Kaplan-Meier survivorship graph for patients with chronic pelvic discontinuity managed with a cup-cage reconstruction,
with revision for a failed pelvic discontinuity reconstruction as an end point.
Fig. 5. Radiograph demonstrating a periprosthetic pelvic
discontinuity secondary to a failed ilioischial cage
reconstruction.
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either quantitative (osteoporosis or severe osteolysis) or
qualitative (infection or neoplastic) bone pathology.
Chronic Pelvic Discontinuity
The difficulty in achieving adequate stability with
chronic pelvic discontinuity or major column defects
was demonstrated in a case series reported by Stiehl et al
[26]. Acetabular reconstruction with bulk allograft was
supported with anterior and posterior column 3.5-mm
AO reconstruction plates. With 10 cases of pelvic dis-
continuity, 6 required revision surgery, and with a
further 7 cases with major column defects, the overall
cases series of 17 had a revision rate of 47%. The authors
conclude that because of these poor clinical results, this
technique could not be recommended.
Several studies have shown that ilioischial rings afford
a good clinical outcome for acetabular reconstruction
bone defects that do not require bulk allograft or with
coexisting pelvic discontinuity [36,37]. However, con-
cerns regarding the high complication of standard
ilioischial cages have led the senior author (A.E.G.) to
develop the cup-cage technique [8,20]. Goodman et al
[20] reported a consecutive series of 61 ilioischial
reconstruction rings performed for severe acetabular
bone loss, with 10 cases having pelvic discontinuity. Of
these 10 cases, 4 needed revision surgery for failure
of the ilioischial cage reconstruction, and the outcomes
of this previously reported cohort have been incorpo-
rated into the data of this study. Figs. 5 and 6 dem-
onstrate such a failed ilioischial cage, revised to a cup-
cage acetabular reconstruction. Other studies have
reported failure rates of up to 50% for ilioischial cage
reconstructions of pelvic discontinuity [38].
The work of Bobyn and others [33] has highlighted
the beneficial biomechanical properties of porous tan-
talum metal, including high porosity, high coefficient of
friction, and a Young modulus similar to bone. These
properties have made this biomaterial increasingly
popular in revision hip arthroplasty [7,9,10,34,35]. The
use of porous tantalum in the reconstruction of pelvic
discontinuity is attractive because bone ingrowth can be
achieved with less than 50% of bleeding host bone
contact [8,24]. The results of this study demonstrate a
consistently low percentage of contact between the
cup and the bleeding acetabular bone for all of the
reconstruction techniques used in chronic pelvic discon-
tinuity (see Table 4; (available online at www.
arthroplastyjournal.org). Therefore, we recommend
the use of porous tantalum components in the recon-
struction of such cases because of the ability of
Fig. 6. Radiograph 32 months after a cup-cage reconstruction
performed for periprosthetic pelvic discontinuity secondary to
a failed ilioischial cage (see Fig. 5).
Table 5. Literature Review of the Surgical Treatment of Pelvic Discontinuity
N Mean Follow-Up Acute or Chronic Journal Year of Publication Level of Evidence
Christie et al [27] 39 4.4 y Chronic CORR 2001 IV
Berry et al [1] 27 3 y Chronic JBJS (Am) 1999 IV
Koster et al [29] 4 3.6 y Chronic J. Arthroplasty 2006 IV
Paprosky et al [12] 16 2.6 y Chronic CORR 2006 IV
Bostrom et al [38] 6 30 mo Chronic CORR 2006 IV
Springer et al [14] 7 18 mo Acute JBJS (Am) 2005 IV
Kerboull et al [39] 12 10 y Chronic CORR 2000 IV
Peters et al [40] 15 29 mo Chronic J Arthroplasty 2004 IV
Lietman et al [41] 11 5 mo Chronic Orthopedics 2001 IV
Kosashvili et al [8] 26 44.6 mo Chronic JBJS (Br) 2009 IV
Eggli et al [28] 7 96 mo Chronic CORR 2002 IV
van Haaren et al [42] 6 7 y Chronic JBJS (Br) 2007 IV
Stiehl et al [26] 10 83 mo Chronic J Arthroplasty 2000 IV
Goodman et al [20] 10 3.3 y Chronic J Arthroplasty 2004 IV
This study 71 3 y Acute (9) and chronic (62) – 2011 IV
CORR indicates Clinical Orthopedics and Related Research; JBJS Journal of Bone and Joint Surgery; (Br), British Volume; (Am), American Volume.
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bone ingrowth to be achieved with a low percentage
of bleeding.
A large porous tantalum revision shell provides distrac-
tion that stabilizes the pelvic discontinuitywhile forming a
bridging construct between the ilium and the ischium. A
revision shell used in this manner is usually too vertical
and retroverted to safely accommodate an acetabular
liner. In addition, because of the inherent instability of
pelvic discontinuity, additional protection is required to
allow bone ingrowth, and this is achievedwith a cup-cage
reconstruction. By supplementing the construct with an
ilioischial cage, a polyethylene liner can, thus, be
cemented at the correct inclination and version, indepen-
dent of the position and version of the acetabular shell.
Acute Pelvic Discontinuity
The results presented in this study demonstrate that
acute periprosthetic pelvic discontinuity can be success-
fully treated with compression of the posterior column,
principally using a plate supplementing a trabecular
metal acetabular revision shell. This clinical evidence
suggests that cases of acute periprosthetic pelvic discon-
tinuity possess bone healing potential if compression
is achieved, assuming normal bone metabolism (ie, no
infective or neoplastic conditions). Compression of the
posterior column may be provided via an “extra”-
acetabular method, specifically a posterior column
plate as principally demonstrated in this study. Alterna-
tively, “intra”-acetabular compression can be provided
by an uncemented shell augmented with screws above
and below a pelvic discontinuity. The results of this study
provide medium-term clinical evidence supporting the
treatment principles outlined by Sporer et al [30].
Female patients and rheumatoid arthritis are signifi-
cant risk factors for pelvic discontinuity, and excessive
reaming should be avoided to maintain columnar sup-
port of the acetabulum [15]. This study, in addition to
previous case series, demonstrates that transverse or
T-pattern fractures are the commonest associated with
acute pelvic discontinuity [14]. The relative stability of
these fracture patterns probably differs. Low T-pattern
fractures, commonly involving the inferior pubic ramus,
are frequently significantly displaced and are likely to be
unstable, necessitating open reduction and plate fixation
before the insertion of an acetabular component.
Currently, no published clinical evidence that quantifies
the relative stability of different fracture patterns in
acute periprosthetic pelvic discontinuity exists. Because
of the massive bone loss seen with chronic pelvic
discontinuity, the description of fracture patterns is not
applicable, or indeed comparable, to the acute cases.
The contrast in reconstructive techniques used in cases
of acute and chronic pelvic discontinuity supports the
algorithmic treatment protocol initially proposed by
Sporer and Paprosky [10] and Sporer et al [30], whereby
the lack of the potential for bone healing in chronic cases
dictates that initial stability is achieved with distraction,
and biologic cementless fixation subsequently develops.
Porous metal components currently provide the best
characteristics for this. In comparison, adequate stabil-
ity is produced in acute cases by compression of the
posterior column in conjunction with an uncemented
acetabular component.
In conclusion, this study, the largest reported series,
demonstrates that stable reconstruction of chronic pelvic
discontinuity is achievable with a cup-cage acetabular
reconstruction owing to the inherent beneficial bio-
logic and biomechanical properties of porous tantalum
metal. This method provides stability by distraction.
However, satisfactory stability of acute pelvic disconti-
nuity can be achieved by providing compression using
screw augmentation of the acetabular shell and/or pos-
terior column plating.
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Bone loss around the knee in the setting of total knee arthroplasty remains a diﬃcult and challenging problem for orthopaedic
surgeons. There are a number of options for dealing with smaller and contained bone loss; however, massive segmental bone
loss has fewer options. Small, contained defects can be treated with cement, morselized autograft/allograft or metal augments.
Segmental bone loss cannot be dealt with through simple addition of cement, morselized autograft/allograft, or metal augments.
For younger or higher demand patients, the use of allograft is a good option as it provides a durable construct with high rates of
union while restoring bone stock for future revisions. Older patients, or those who are low demand, may be better candidates for
a tumour prosthesis, which provides immediate ability to weight bear and mobilize.
1. Introduction
Dealing with bone loss when performing primary or revision
total knee arthroplasty is a challenge for the arthroplasty
surgeon. Previous infections, tumour, and trauma can all
result in bone loss that makes a standard primary total knee
arthroplasty impossible without restoration of bone stock.
More commonly, bone loss in revision knee arthroplasty
is a frequent problem and may occur for any of the
aforementioned reasons, osteolysis, periprosthetic fracture,
or iatrogenically when components are being removed from
host bone.
Patients with posttraumatic osteoarthritis or deformity
requiring knee arthroplasty often have bone loss in the tibia,
femur, or both. In this situation, the surgeon must determine
the extent of bone loss and whether it may be dealt with by
simple autogenous bone grafting, cement, metal augments,
porous metal supplementation, or allograft of various sizes.
Large uncontained defects of the knee may be treated with
use of a large or massive allograft in conjunction with the
total knee.
2. Classification
There is no universally accepted classification that is cur-
rently used for describing bone loss in knee arthroplasty.
Engh developed the Anderson Orthopaedic Research Insti-
tute (AORI) classification system that helps to guide treat-
ment for both femoral and tibial sides in revision knee
arthroplasty (see Table 1) [1].
Mount Sinai Hospital in Toronto, Canada, has developed
a classification system, which simply divides the defects
into contained or uncontained categories to be used in the
arthroplasty setting (see Table 2) [2–8].
Both classification systems attempt to characterize the
defects present and assist the surgeon in developing a
treatment algorithm for dealing with bone loss, although
the AORI classification is more explicit in detailing various
treatment options.
3. Allograft Characteristics
Allograft harvesting should be done according to the criteria
of the American Association of Tissue Banks, in sterile
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Table 1: Classification of femoral and tibial bone loss [1].
(a) AORI femoral bone loss classification
AORI femur
grade
Deficit MCL/LCL
Bone
reconstruction
F1
Intact
metaphyseal bone
Intact Cement or
particulate graft
F2a
Metaphyseal loss
single condyle
Intact Cement or
metal augment
F2b
Metaphyseal loss
both condyles
Intact
Cement, metal
augment or
structural graft
F3
Deficient
metaphysis
Compromised
Structural
allograft or
segmental
replacement
(b) AORI Tibial Bone Loss Classification
AORI tibial
grade
Deficit MCL/LCL
Bone
reconstruction
T1
Intact
metaphyseal bone
Intact Cement or
particulate graft
T2a
Metaphyseal loss
med or lat
Plateau
Intact Cement or
metal augment
T2b
Metaphyseal loss
and lat plateau
Intact
Cement, metal
augment or
structural graft
T3⋆
Deficient
metaphysis
Compromised
Structural
allograft or
segmental
replacement
⋆Possible extensor mechanism compromise.
Table 2: Classification of Tibial and Femoral Bone Loss [8].
Type Type of Bone Loss Description
(1) No notable loss of bone
stock
There may be erosion of the
endosteal bone, but no
involvement of the cortex.
There has been no
migration of the primary
component, and bone is
largely intact.
(2) Contained loss of bone
stock with cortical thinning
The canal is widened, but
there is still an intact
cortical sleeve.
(3)
Uncontained (segmental)
loss of bone stock involving
<50% of medial and/or
lateral condyle
Uncontained bone loss
represents less than 50% of
medial and/or lateral
femoral and/or tibial
condyle and is less than
15mm in depth.
(4)
Uncontained (segmental)
loss of bone stock >50% of
medial and/or lateral
condyle
Uncontained bone loss
represents more than 50%
of medial and/or lateral
femoral and/or tibial
condyle and is more than
15mm in depth.
conditions and in our institution followed by irradiating the
tissue at 25,000Gy and storage at −70◦C [9]. Although some
believe that donor allograft does not have to be matched
to the recipient’s anatomy, others argue that modifying
the allograft weakens it. If the allograft is size matched,
application of the graft becomes easier to use in the patient
and maintains its inherent strength. Also, allografts that
are oversized may make the soft-tissue closure diﬃcult or
impossible to perform which is a serious intraoperative
complication. To ensure this does not happen, we rec-
ommend taking preoperative calibrated radiographs of the
allograft and comparing this with the patient’s radiographs
[2].
4. Indications
The primary indications for using structural allografts in
the setting of arthroplasty are (a) large uncontained defects
that are outside the range of metal augments or thicker
polyethylene inserts (see Figures 1 and 2), (b) patients that
are active and require bone-stock restoration for potential
future operations, and (c) patients who are physically
well enough to tolerate both the surgical procedure and
rehabilitation required for successful outcomes. A relative
contraindication is a patient actively smoking, and cessation
programs must be implemented prior to surgery. Lastly,
presence of active infection is an absolute contraindication
for allograft in the arthroplasty patient.
5. Preoperative Preparation and Planning
In the setting of previous infection or posttraumatic defects,
active infection must be ruled out. C-reactive Protein,
erythrocyte sedimentation rate, and possible knee aspirate
should be performed prior to planning any knee arthroplasty
procedure especially with use of allografts. Once infection is
ruled out, careful planning should include 4 foot standing
radiographs of both limbs, standard AP, lateral, and skyline
views and, if required, a CT scan. CT scanning can help
with determination of whether the defect is contained or
uncontained and overall dimensions. As always, these inves-
tigations must be combined with a thorough physical exam
of the patient, which includes limb alignment, ligamentous
stability, and a neurovascular exam.
Preoperative planning incorporates all aspects of the
physical exam and investigations but also entails determining
surgical approach, dealing with diﬃcult exposure, allograft
availability, and arthroplasty component selection. When
massive allografts are used, a stemmed implant is required to
obtain adequate stability of the component between the host-
allograft bone junction. Furthermore, if there is significant
ligamentous instability, there should be implants available
with higher degrees of constraint.
6. Operative Techniques
Old operative reports detailing prior surgical approaches
should be obtained to help the surgeon decide on the optimal
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Figure 1: AP radiograph showing a knee with severe polyethylene wear and evidence of major bone loss (a). A CT scan showing massive
bone loss of the medial and lateral femoral condyles due to osteolysis (b). (reprinted from Backstein et al. [2]).
(a) (b)
Figure 2: A radiograph shows uncontained bone loss in the medial
femoral condyle secondary to osteolysis (a). A radiograph showing
revision TKA with reconstruction of the medial femoral condyle
using structural allograft fixed with screws (b).
exposure. Ideally, use of a midline incision and a parapatellar
arthrotomy (medial or lateral) should be reused in the
revision surgery to minimize the remaining blood supply to
the skin and patella.
During the exposure, presence of scar tissue, quadriceps,
and patellar tendon contracture and deformity must be
adequately dealt with to assist in performing the proce-
dure. Tibial tubercle osteotomy, quadriceps snip, lateral
parapatellar arthrotomy, and in situ bony cuts and removal
of accessible implants are a few of the adjuncts that can
help the surgeon with exposure. It is critical to avoid
excessive disruption of the soft-tissue envelope, as wound
problems can be a frequent complication of these complex
reconstructions [10].
During exposure and debridement, a frozen section
should be sent to the pathologist to rule out infection. We
typically use a count of less than 5 neutrophils per high
power field as a negative result [11]. If infection is suspected
or confirmed, the planned surgical procedure is abandoned
and a dynamic or static spacer with antibiotic impregnated
cement is used until the infection is cleared.
Debridement of nonviable bone and necrotic tissue
should also be done during the exposure. The level of de-
bridement should be done to expose healthy bleeding tissue.
Implants are removed with microoscillating saws, gigli saws,
flexible osteotomes, or through osteotomies. This part of the
procedure should be done with care as creating further bone
loss increases the complexity of the reconstruction. Further-
more, the quality of the host bone is often osteoporotic and
fragile from prior infection, osteolysis, or disuse.
Once exposure is completed, the area of bone loss should
be evaluated and classified to determine the type of allograft
required for treatment. Ideally, the intraoperative findings
should not be unexpected and simply confirm the pathology
that was seen in preoperative imaging.
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7. Segmental Allografts
Small contained defects less than 10mm can be treated with
morselized autograft, allograft, or cement alone. Uncon-
tained defects that are less than 10–20mm in size can be
treated with metal augments alone; however, larger defects
can be dealt with structural allograft or tumour implants
[12]. Bone loss of the proximal tibia that involves the entire
surface can be treated withmetal augments and a thicker pol-
yethylene insert, but the upper limit for this is 45mm. An al-
ternative option is structural allograft or tumour prosthesis.
If a structural allograft is going to be used, having two
surgical teams present is ideal. This decreases the anaesthetic
time the patient must endure and is the most eﬃcient use
of operating room time. One surgical team should have a
sterile back table available to prepare the allograft, while
the other team simultaneously does the exposure and bony
preparation of the patient.
The major principles of the revision are to determine
the level of the joint line that should be measured from the
distal femur or proximal fibula. Typically intact host bone is
easier to judge where the true joint line should exist. From
the medial epicondyle, the joint line is 25–30mm distal,
and, from the tip of the fibula, it is 10–15mm proximal.
Occasionally intraoperative radiographs of the aﬀected and
normal knee may be utilized to find the anatomic joint line.
Ligamentous structures must also be evaluated to determine
whether or not further constraint will be required in the
implants. The surgeon must be careful to preserve these
attachments during the exposure, debridement, and implant
removal.
The goal of the reconstruction should also include balan-
cing the flexion and extension gaps to have a good functional
outcome for the patient. Appropriate bone resection and
trial implantation position are critical in obtaining this
intraoperatively.
The tibial and femoral canals are reamed to have good
press fit for trial stems. If needed, oﬀset stems can be used
to better align the femoral and tibial trays. Once the trial
implants are appropriately positioned, the amount of bone
loss should be reevaluated. Irregularly shaped areas of seg-
mental bone loss that is too large for metal augments can be
treated with structural allograft. These areas should be made
into more geometric defects with the use of precise cutting
guides or freehand with an oscillating or reciprocating saw.
Once the defects are reshaped, preferably into a square or
rectangular shape, they are measured for the height and
width. On the back table, the allograft is cut into almost iden-
tical size, but slightly larger. We prefer to use bone from the
donor that is from the same anatomic region. Osteoporotic
allograft bone should be avoided, as this does not have the
structural integrity required for support of the implant. If the
geometry allows it, a press fit into the defect can be achieved.
Certain cases of bone loss caused by infection or osteolysis
may result in mixed contained-uncontained defects that can
be treated with the press-fit technique. The locations of these
areas of bone loss are frequently located at the implant-
host interface near the joint line or between medial and
(a) (b)
Figure 3: Intraoperative pictures of allograft-prosthesis composite
(APC), AP view (a) and lateral view (b).
lateral columns of the distal femur. In our experience, the
addition of supplementary plate fixation does not enhance
the allograft stability andmay result in a stress riser,due to the
additional stiﬀness, if a plate was placed near the allograft-
host bone interface. [Editorial: Meaning extra screw holes
through the plate weakens the allograft].
There are certain circumstances when the press-fit of
the allograft into a defect is not suﬃcient and fixation is
required. The technique we prefer to employ is to place
the allograft into the desired position and place provisional
K-wires. We then continue our reaming and preparation
of the trial implants with the allograft in situ. Placement
of definitive fixation in the form of cancellous screws with
washers should be done with the trial stems in place. This
must be done to avoid screws blocking the path of the
final stemmed implant. The use of a stemmed implant is
critical as it shields the allograft from excessive force. Once
the allograft is secured we recheck all bony cuts prior to
implanting the definitive prosthesis.
8. Allograft-Prosthetic Composites
Massive segmental bone loss of either the femur or tibia
cannot be treated with cement, augments, or segmental
allograft bone alone and require an allograft-prosthetic
component (APC) or tumour prosthesis. These defects are
uncontained and are frequently circumferential and involve
>25mm of the femur or >45mm of the tibia.
After the failed implant is removed and debridement
completed, the defects are once again evaluated. If it is de-
cided that a femoral allograft-prosthetic composite is re-
squired, the collateral ligaments must be maintained as pre-
viously mentioned. Ideally the epicondyle attachments are
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Figure 4: Radiograph showing a supracondylar periprosthetic fracture with major bone loss ((a) and (b)). An AP radiograph showing a
revision with femoral allograft-implant composite (c).
removed with some host bone present for later reattachment
to the allograft. Once this is done, an oblique cut is made in
the host bone where the prosthetic-composite interface is to
be. Alternatively, a step cut may be employed with the longer
limb on the host bone side ideally. This may be slightly
more challenging to perform and accurately match the host
graft interface. Regardless, either an oblique cut or step cut
provides good rotational control of the allograft. If this is
not feasible, the allograft may be intussuscepted into the
host diaphysis if the host canal is patulous. This telescoping
of the two interfaces imparts some stability and increases the
contact area between the host allograft that may improve the
ability of the allograft to incorporate [2].
9. Tibial Allograft-Prosthetic Composite
The allograft-prosthetic composite of the tibia is fashioned
to size based on careful measurements of the host tibia after
a thorough debridement is performed. As always, making
the allograft larger and longer than may actually be required
is good practice as it is always easier to trim the graft “down
to size” if needed. This saves time and avoids unnecessary
waste of allograft. As in any stemmed implant, the host
canal is reamed to secure a press-fit stem that should bypass
the allograft-host junction by two cortical diameters or by
approximately 5 cm. The proximal extent of the allograft
should restore the normal biomechanics of the knee and
that ultimately means the joint line of the implant should
be 10–15mm proximal to the tip of the fibular head. Again,
use of the step or oblique cut is utilized to optimize the
stability of the implant. Rotational position is a challenge to
determine; however, use of anatomical landmarks such as the
tibial tubercle, patellar tendon, and patellar tracking all assist
the surgeon in placing the allograft in the correct rotation.
This rotational and joint-line position should be judged
with the trial implants in place. The knee should be taken
through a range of motion to examine the patellar height and
tracking. Minor adjustments can be made easily at this stage
to improve the knee biomechanics. When the surgeon is
satisfied with the rotation and height, the position should be
marked with cautery and a marking pen. This assists in final
implantation of the APC into the proper overall orientation.
10. Femoral Allograft-Prosthetic Composite
The epicondylar attachments of the collaterals, which were
preserved during exposure, are critical in the securing of the
femoral APC. As in the tibia, the femoral canals are reamed
to securely fit a stemmed implant with proximal fixation into
the host bone of two cortical diameters or a minimum of
5 cm. On the back table, the femoral APC is prepared with
the revision cutting guides to make the appropriate bone
resections (see Figure 3). The epicondylar attachments of the
collaterals are secured to the allograft through transosseous
drill-hole tunnels where the collateral ligaments would be
in a native distal femur. Sutures are passed through these
tunnels and left long to attach the host collaterals once the
APC is implanted.
The trial femoral components with their securely fitted
stems are implanted into the host diaphysis. The flexion and
extension gaps are checked and adjusted as needed. If the
extension gap is tight, distal femoral resection of the allograft
is performed, and, if the flexion gap is tight, the components
are translated anteriorly or downsized. If both flexion and
extension gaps are tight, we recommend adjusting cuts on
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the femoral side and downsizing rather than taking any
more of the native proximal tibia. This will also ensure that
overstuﬃng of the knee does not occur and makes wound
closure less diﬃcult.
When it is time to implant the stems of either the femoral
or tibial side, a critical principle is to avoid cementing of
the stems to the host bone. Conversely the allograft side of
the stem and implant-allograft interface must be cemented to
provide stability to construct. Meticulous cement technique
needs to be utilized to ensure the allograft-implant interface
has the requisite stability to allow early motion and rehabil-
itation (see Figure 4). Thus, a copiously irrigated allograft,
which is carefully dried, is requisite prior to cementing.
Use of low-dose antibiotic containing cement is acceptable;
however, we do not add additional antibiotic to the cement
as it weakens it and may potentially result in a poor cement
mantle. The cement is allowed to harden the APC, and, once
this is done, it is implanted into the host canal through
a press fit. Rotational position should be aligned to the
previous cautery or marker line as it is impacted. No cement
should be present between the allograft-host bone junction
as it would potentially interfere with graft incorporation. We
emphasize avoidance of cementing stems to the host bone as
it can make future revisions extremely diﬃcult.
Once components are implanted, the collaterals are
attached using the previously placed heavy suture into
the allograft epicondyles. Roughening up the allograft
epicondyles and suturing the host epicondylar bony wafers
may assist in incorporating the ligaments to the APC.
Collaterals are tightened maximally in 90 degrees of knee
flexion. Supplemental cerclage wiring of the remaining
epicondyle host bone can be done to reinforce the sutures.
At this point, we place morselized autograft at the
host-allograft junction and attempt to suture a periosteal or
synovial flap around the autograft to secure it. Additional
fixation may be required if the step or oblique cuts do not
impart adequate stability. We suggest using additional screws
rather than a cortical strut, as the strut increases bulk to the
construct and may compromise the soft tissues. Similarly,
our preference is to avoid plate fixation to the allograft as
multiple drill holes weaken the graft and make it susceptible
to fracture or accelerated vascularization and resorption.
This can be a catastrophic complication.
Overall stability of the knee is rechecked with the
implants in situ. It should be anticipated early if a highly
constrained implant is required based on physical exam and
imaging. It is subtler in determining whether a posterior
stabilized polyethylene insert or varus-valgus high-post con-
strained liner is required.We prefer to use the least constraint
possible to avoid transfer of stress to the APC interface.
In general terms, we avoid the highly constrained im-
plants such as a rotating hinge implant, as the force transfer
to the APC junction is significant and may lead to early
failure.
11. Extensor Mechanism Allograft
During primary or revision arthroplasty the extensor mecha-
nism can be deficient secondary to tubercle avulsion, tendon
rupture, proximal tibial bone loss, or erosion of the extensor
mechanism from infection. During revision, arthroplasty
scarring of the quadriceps and patellar tendon makes the
extensor mechanism particularly vulnerable to disruption.
The extensor mechanism allograft is obtained from the
bone bank with the complete quadriceps tendon, patellar
tendon, and tibial tubercle attached. It is critical to have
enough bone at the patellar tendon attachment for distal fit
into the host bone.
Once the primary or revision implants are placed, the
remnant of the host patella is shelled out of its periosteal
sleeve. Distal tubercle is debrided, and a reverse “V” shape
osteotomy is made in the area of the native tubercle. This
type of osteotomy allows good press fit of the allograft and
also resists proximal migration of the allograft tubercle [13].
The allograft is then placed with the host patellar
remnant and allograft patella at the same level. This ideally
should lie in the femoral trochlear groove of the implant.
Once this height is judged, the allograft is marked at the
tibial tubercle that should be very close to the native tubercle
of the patient. Four small drill holes are made into the
host tibia for wire passage. The graft is then shaped with a
microsagittal saw to fit into the reverse “V” osteotomy site. It
is press fit into the recipient site and held with transosseous
cerclage wires. Proximally, the allograft quadriceps is then
sutured. The allograft quadriceps tendon is attached to
the remaining host quadriceps tendon in a running locked
fashion with heavy, nonabsorbable suture such as fiber-wire.
This is then reinforced with multiple interrupted sutures.
At this point, the knee is taken through range of motion to
check stability and tracking. Adjustments may still be made
at this stage. If tracking and stability are adequate, multiple
sutures are placed into the parapatellar tendon region. The
knee arthrotomy approach is closed in the usually fashion
[14].
12. Soft-Tissue Envelope
Closure of the wound may be challenging, and the most
common reason for this is oversized allograft, followed
by oversized components. To avoid this problem, careful
implant and allograft selection is critical. Tibial tubercle
osteotomy is attached with large fragment partially threaded
cancellous screws or with transosseous wiring. Quadriceps
tendon turn-down or snips are repaired with heavy suture.
Closure of the parapatellar arthrotomy is done with heavy
suture done in a continuous manner with reinforced inter-
rupted sutures. Deep drains are placed at the preference of
the surgeon and subcutaneous and skin layers are closed
in the usual fashion. Anticipated wound closure problems
should be discussed prior to surgery with your plastics
colleagues. If soft-tissue coverage is a problem, rotational
flaps and skin-grafting may be necessary [10].
13. Postoperative Care and Rehabilitation
Range of motion is a critical component of recovery, and
these should be started as soon as possible provided the
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wound coverage is adequate and there are no extensor mech-
anism issues. If a tibial tubercle osteotomy or quadriceps
turndown is performed, we restrict active extension for 6–
8 weeks. Restrictions on weightbearing are maintained for 8
weeks followed by progressive increases to full weightbearing
once graft incorporation is seen on sequential radiographs.
This may take 3–6 months depending on the reconstruction
and biology of the patient.
14. Complications
As with all complex reconstructions, preoperative planning
is critical in ensuring no untoward intraoperative surprises.
We strongly believe that deviating from a carefully thought-
out preoperative plan may result in poor outcomes. Critical
steps involve allograft and implant sizing and dealing with
anticipated wound complications early and aggressively.
Furthermore, optimizing the patient’s perioperative health
status is crucial, and this must include smoking abstinence.
Despite careful planning, complications still occur. Graft
fracture, rapid revascularization, and early resorption lead
to weakening of the APC and eventual failure. Another
problematic scenario is a periprosthetic fracture that results
in further bone loss [15]. Infections are also more prevalent
in complex revision surgery. These must be aggressively
treated with early debridement, antibiotics, and possible
staged revision. As mentioned earlier, wound problems
should be treated aggressively with appropriate consultation
made to plastic surgery.
Occasionally, the combination of infection and wound
problems results in an amputation although this is fortu-
nately a rare occurrence.
15. Results
The use of segmental and structural allografts has been
used in both contained and uncontained defects around the
knee in arthroplasty for over two decades. The primary data
for this comes in the setting of revision knee arthroplasty
and has encouraging results. In one of the earliest papers,
Stockley et al. reported 20 knees that had undergone a
combination of structural allograft and morselized allograft
with 85% survivorship at 4.2 years [16]. There were 2
graft fractures and 3 infections in their series. The lowest
reported survivorship is that from Ghazavi et al. with only
67% survivorship at 5 years in their 30 patients [17].
However, when looking at the majority of the literature, most
authors report 80–93% survivorship of their constructs at 5
years. The survivorship numbers drop oﬀ at 10 years with
Clatworthy et al. showing a drop of 92% at 5 year to 79% at
10 years [18]. Reference [19] had 46 patients at 10 years with
91% survivorship for femoral head allograft in tibial defects.
A recent publication by Richards et al. compared cohorts
with severe bone loss of bone around total knee arthroplasty
using femoral allograft compared with metal augments [20].
Despite the presence of more significant bone loss in the
allograft group, these had better clinical outcome scores
than the control cohort. This strengthens the argument for
allograft use in patients with severe bone loss.
Lastly, Backstein et al. have one of the largest cohorts
to date with 61 patients. The survival rate at 5.4 years was
85.2% [2]. Of note in this series, the infection rate was 6.5%
(4/61); however, a high union rate of 98.4% (60/61) was seen
radiographically.
16. Summary
Dealing with bone loss is a significant challenge to arthro-
plasty surgeons. We believe that structural allograft is a
viable method for dealing with this problem with the added
benefit of restoring bone stock. These complex procedures
should be performed by surgeons with expertise in revision
arthroplasty and with access to a dedicated bone bank.
Allograft reconstruction is not indicated in the low demand
or elderly patients who would benefit from implantation
of an endoprosthesis, which allows rapid mobilization and
recovery.
The optimal allograft candidate is a young, higher de-
mand and relatively healthy patient that is likely to require
further revisions in the future and can adhere to the rehabil-
itation protocol. The restoration of bone stock is a key com-
ponent in choosing allograft in the reconstruction. Overall,
this method of treatment has good outcomes in the literature
despite the complex nature of the procedures.
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Introduction
Hip fracture surgery frequently results in a drop in haemoglobin
(Hb) and the potential need for blood transfusion [1–3]. For
cemented hip hemiarthroplasties, the reported average operative
blood loss is approximately 500 mL [4]. Blood loss can result from
the initial fracture as well as from surgery, and can remain hidden
for a period of time after surgery [5,6]. Postoperative anaemia after
hip fracture surgery is related to an inferior functional recovery,
and a detrimental effect on mortality [1,7].
Allogenic blood transfusions are expensive and have associated
risks [8–12]. As a result, numerous methods of blood conservation
have been investigated, including preoperative blood donation,
perioperative blood salvage, controlled hypotension and the use of
pharmacological agents [13–16]. Drugs such as epsilon-aminoca-
proic acid, Recombinant Human Erythropoietin, and Aprotinin
have been shown effective, but routine use are limited by low cost-
effectiveness in orthopaedic surgery [17,18].
Tranexamic acid (TXA) is an antifibrinolytic agent that binds
with plasminogen to competitively block lysine binding sites. This
prevents plasminogen interaction with fibrin, thus inhibiting
plasmin induced fibrinolysis and clot breakdown. Tissues injured
during surgery release tissue plasminogen activator and activate
the fibrinolytic system, during which TXA can exert its effects. The
half-life of TXA is approximately 120 min and is renally excreted
[19]. The optimal dosage and schedules for TXA administration in
hip fracture surgery remain unknown [20–22]. Previous studies
have suggested that low-dose regimes (<30 mg/kg, or 1 g) is
adequate for most adults [23–25]. Administration of TXA before
hyperfibrinolysis was also suggested to be more effective [20,22,26].
1 g of TXA given intravenously before skin incision should therefore
be adequate for most hip hemiarthroplasty procedures.
Over the past decade, there has been growing evidence to
demonstrate the blood conservational effects of TXA in a range of
surgical procedures [25,27–29]. A thorough literature search (see
Appendix A) however shows limited studies investigating the
specific use of TXA for hip hemiarthroplasty surgery, despite this
patient cohort being particularly susceptible to the effects of blood
loss [5,7,16]. The aim of this study is to evaluate the effect of TXA
use on postoperative transfusion rates and Hb levels following
hemiarthroplasty surgery for hip fractures.
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A B S T R A C T
Tranexamic acid (TXA) has been shown to reduce perioperative blood loss in elective lower limb
arthroplasty surgery. There are potentially even greater physiological benefits in minimising blood loss
in hip fracture surgery, however limited evidence exists for TXA use in hemiarthroplasty surgery. This
study investigates the effect of TXA use on postoperative transfusion rates and haemoglobin (Hb) levels
specifically following hemiarthroplasty surgery for hip fractures.
A retrospective cohort study was conducted for consecutive hip hemiarthroplasties for fractures
between June 2013 and October 2014 comparing patients with or without prophylactic TXA before
incision.
During the study, 305 hemiarthroplasties were performed with 271 cases eligible. TXA was given in
84 (31%) cases, and both patient groups were matched for known confounding factors. Patients given
TXA had a lower transfusion rate (6% vs. 19%. p = 0.005) and less blood loss (Hb drop > 20 g/L) on day
1 post surgery (26% vs. 42%; p = 0.014). One transfusion was prevented with every 8 patients given
prophylactic TXA. There were no differences in the 30 and 90-day mortality rates with TXA use.
Tranexamic acid is safe, cost-effective and reduces the need for blood transfusion and should be
considered in all patients undergoing hip hemiarthroplasty for fractures.
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Patients and methods
This retrospective cohort study was conducted between June
2013 and November 2014 in a single centre (Royal Sussex County
Hospital, Brighton, UK); a high volume regional Major Trauma
Centre (MTC). Inclusion criteria were consecutive patients
undergoing hip hemiarthroplasty for fracture. Exclusion criteria
included revision surgery, pre-operative transfusion, use of an
Austin Moore prosthesis and cases with an incomplete dataset.
Fractures were typically operated on within 36 h of presentation
using an Exeter Unitrax implant (Stryker, MI). Low functional
demand patients with significant medical co-morbidities had an
uncemented Austin Moore prosthesis.
During the study period no hospital protocol determined the
use of TXA in hip fracture surgery, and thus whether patients
received prophylactic TXA or not was according to surgeon
preference. Patients who received TXA were given a bolus of 1 g
intravenously on induction. All patients received routine venous
thromboembolism prophylaxis with Tinzaparin 4500 units post-
operatively unless contraindicated according to hospital policy.
The indication to transfuse was decided on a case-by-case basis, to
maintain a postoperative Hb above 80 g/L.
The patient dataset collected included: Age, gender, premorbid
residency/mobility, abbreviated mini mental state score (AMTS),
American Society of Anaesthesiologists (ASA) grade, anaesthetic
type, surgeon grade, Hb levels (preoperative on admission and
postoperative day 1 to 3), transfusion requirement, length of stay,
mortality and morbidities. The data was collected from Bluespier
Theatre Manger (Bluespier International, Droitwich, UK), electron-
ic blood reporting system (WinPath), the National Hip Fracture
Database (NHFD), and further correlated with patient notes.
The primary outcome was transfusion within 14 days of
surgery. Secondary outcomes were significant Hb drop (defined as
>20 g/dL) on post-operative day 1 and day 3 and mortality at
30 and 90 days.
Data was analysed using SPSS version 19. Unless otherwise
stated, the Fisher’s exact or Chi square tests were used for
categorical data, and T-test for continuous data, with significance
set at 5%. Retrospective two-tailed power analysis was done for
the primary outcome measure (96.1%). Results are presented as
percentages (with numbers in brackets).
Results
In the study period 305 hemiarthroplasties were performed
with 271 cases fulfilled the inclusion criteria and were analysed.
The patient demographics are summarised in Fig. 1Eighty-four
patients (31%) received prophylactic TXA. There were no signifi-
cant difference between the TXA vs. no-TXA groups in terms of age,
gender, premorbid function, preoperative Hb, anticoagulation use,
ASA, anaesthetic type and surgical approach. Table 1 shows the
detailed pre-operative comparison between TXA vs. no-TXA
cohorts.
The overall transfusion rate was 15% (40 patients). Patients not
given TXA were 3 times more likely to require transfusion than
patients given TXA (19% vs. 6%; p = 0.005). For every 8 patients
given prophylactic TXA, 1 transfusion was prevented, giving a
Number Needed to Treat (NNT) of 8 and an absolute risk reduction
(ARR) of 12.76%.
The number of cases with significant day 1 Hb drop (>20 g/L)
was significantly lower in patients given TXA (26% vs. 42%;
p = 0.014). There was no significant difference in mortality
between groups at 30 and 90 days (p = 1.00). The postoperative
comparisons between the 2 cohorts are detailed in Table 2.
Discussion
TXA is known to be an effective and safe agent for reducing
surgical blood loss [19,27,29], though there are limited reports on
its use in hip hemiarthroplasty surgery. Hip hemiarthroplasty may
result in less blood loss per se than total hip or knee arthroplasty
surgery [30], but this patient group is physiologically more
susceptible to postoperative anaemia. Such reasons include; older
305 consec u!ve  hip 
hemiarthroplas! es 
34 cases  exclude:  
• 18 Aus!n Moore  
• 10 Incomplete data  
• 6  Pre-opera! ve blood t ransfus ion 271 eligible  cases 
186 female, 85 male 
Mean age 85
Pa!ent  rece ived 
TXA  
n=84 (31 %)
Pa!ent  di d not 
received TX A  
n=187  (69 %)
Fig. 1. Flow diagram illustrating the demographics of studied population.
Table 1
Pre-Intervention details of patients undergoing hip hemiarthroplasty for fracture.
Case
(TXA, n = 84)
Control
(no-TXA, n = 187)
p Value*
Demographics
Age (mean, years) 85.95 ! 7.60 84.66 ! 7.69 0.20
Gender 0.12
Female 61.9% (52) 71.66% (134)
Male 38.10% (32) 28.34% (53)
Mean pre-op Hb 125.14 ! 14.94 123.33 ! 16.56 0.39
Medications
On antiplatelet 35.7% (30) 36.36% (68) 1.00
Aspirin 26.19% (22) 24.60% (46) 0.76
Clopidogrel 9.52% (8) 10.70% (20) 0.83
Warfarin 4.76% (4) 8.56% (16) 0.32
Rivaroxaban 0% (0) 1.07% (2) 1.00
Pre-morbid residency 0.39
Own home 78% (66) 73.796% (138)
Residential home 7.14% (6) 10.16% (19)
Nursing care 14.285% (12) 13.3689% (25)
Hospital 0 2.67% (5)
Mobility 0.11
No aid 23.81% (20) 28.34% (53)
One aid 32.14% (27) 29.41% (55)
Two aids 30.24% (17) 27.27% (51)
Indoor only 14.29% (12) 5.35% (10)
No mobility 9.52% (8) 9.63% (18)
Preoperative AMTS 0.52
"7 50% (42) 44.92% (84)
>7 50% (42) 55.08% (103)
Surgery
Anasethetic type 0.77
GA ! block 27.38% (23) 29.95% (56)
Spinal 72.62% (61) 70.05% (131)
ASA grade 0.83
1 2.38% (2) 1.60% (3)
2 29.76% (25) 25.13% (47)
3 59.52% (50) 64.17% (120)
4 8.33% (7) 9.09% (17)
Surgical approach 0.52
Anterolateral 94.05% (79) 96.26% (180)
Posterior 5.95% (5) 3.74% (7)
Surgeon grade
Consultant 21.43% (18) 19.25% (36) 0.74
Trauma Fellow 22.62% (19) 9.63% (18) 0.01
Specialist Registrar 53.57% (45) 65.78% (123) 0.06
Surgical trainee 2.38% (2) 5.35% (10) 0.35
Continuous values expressed as mean ! standard deviation. AMTS—abbreviated mini
mental test score.
* Fisher’s exact or Chi square test for categorical data, T-test for continuous data.
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age, female gender, lower admission Hb, higher ASA grade, frailty
and greater co-existing co-morbidities [2,6,31]. Blood conservation
is therefore particularly important in hip fracture patients to
prevent complications related to acute postoperative anaemia.
TXA is an attractive option for routine clinical use.
This study demonstrates a significant reduction in postopera-
tive transfusion rate and Hb drop with TXA use in hip
hemiarthroplasty surgery, with no increase in 30 and 90 day
mortality. These results are consistent with previous studies in the
literature [25,26,28,29,32,33]. Similar effects of TXA are also
demonstrated in randomised control trials (RTC) involving hip
fracture surgeries [3,26,34,35]. Sadeghi and Mehr-Aein [3], and
Vijay et al. [35] both reported a significant reduction in transfusion
rates with TXA use versus placebo. In the THIF study (TXA in Hip
Fracture surgery), Zufferey et al. [26] also reported the same trend
with a 30% relative reduction in transfusion rates with TXA use.
Summary of the results from these studies is shown in Table 3. The
significant heterogeneity between these studies in terms of study
population, methodologies and outcome measures should be taken
into account on interpretation. In particular, higher blood loss and
transfusion requirements in surgeries for extracapsular hip
fractures compared to intracapsular hip fractures [6,10,12,36]
may lead to variations in the treatment effect of TXA reported.
Although the RCT conducted by Emara et al. [34] showed a
reduced transfusion rate with TXA use in hip hemiarthroplasty
surgery (5% in TXA versus 35% in placebo group p < 0.05), their
study population excluded a significant portion of patients that
define the hip fracture population. First, patients with significant
cardiorespiratory co-morbidities and preoperative anaemia, which
are both prevalent features in the elderly hip fracture population,
were excluded from the trial [2,5,31]. In addition, patients
recruited into the trial were between 50 and 60 years of age,
which is significantly younger than that reported in our study and
by the UK National Hip Fracture Database (NHFD), which had an
average age of 84 [37]. The pragmatic observational nature of our
study therefore has the advantage of capturing real-life practice in
an un-preselected population. Our patient demographic in
comparison with the NHFD is shown in Table 4, and the similarities
suggest that our study population is representative of the hip
fracture population seen in everyday practice across the UK.
Despite the wide use of TXA there is concern regarding
increased venous thrombosis [3,19,34]. Zufferey et al. [26]
reported a 3-fold increase in vascular events (DVT, PE, CVA, MI)
at 6 weeks with intravenous TXA use in hip fracture surgery, but
this was not statistically significant. A number of meta-analyses
find no increase in thromboembolic complications, but were
unable to draw conclusions regarding the safety of TXA due to
potential bias [25,27,29,32]. In our study, no difference was
demonstrated in the incidence of venous thromboembolic (VTE)
complications, however not to statistical significance due to low
complication rates. Inconsistent symptom reporting in this patient
cohort and the lack of routine postoperative VTE investigations
could have led to missed VTE events, particularly those that were
asymptomatic. We believe mortality is a robust surrogate for
clinically significant thromboembolic events in this cohort and we
found no difference at either 30 or 90 days post-operatively. A
recent population based study by Poeran et al. [33] involving
872,416 patients showed no increase in thromboembolic events.
Table 2
Postoperative outcome comparison of patient groups.
Case (TXA, n = 84) Control (no-TXA, n = 187) p Value*
RBC transfusion
Transfusion rate 5.95% (5) 18.72% (35) 0.01
Avg. units per patient 2.6 2.23 0.43
Postop Hb (g/L)
Day 1 Hb drop >20 g/L 26.19% (22) 42.25% (79) 0.01
Day 1 Hby 110.80 ! 16.39 (84) 106.67 ! 14.04 (185) 0.03
Day 3 Hb 105.73 ! 14.07 (30) 99.04 ! 14.88 (72) 0.04
Day 1 Hb dropy 14.35 ! 10.77 (84) 17.18 ! 10.99 (185) 0.05
Day 3 Hb drop 20.57 ! 11.68 (30) 25.79 ! 13.14 (72) 0.05
Mortality
30 day 4.76% (4) 4.81% (9) 1.00
90 day 9.52% (8) 10.16% (19) 1.00
Thromboembolic event
Detected DVT/PE 1.19 (1) 2.14 (4) 1.00
Length of stay
Avg. length of stay (days) 21 ! 15.49 18 ! 18.05 0.26
Continuous values expressed as mean ! standard deviation. DVT—deep vein thrombosis, PE—pulmonary embolism.
* Fisher’s exact or Chi square test for categorical data, T-test for continuous data.
y 2 Cases with postoperative transfusion on day 0 excluded from calculation.
Table 3
Synthesis of results from randomised control trials of TXA use in hip fracture surgery.
TXA regime Sample size Blood loss (mL) Transfusion
rate (%)
Transfusion
index
No. of hip
hemi-arthroplasties
Current study 1 g bolus preop Case 84 – 6 2.6 84
Controls 187 – 19 2.2 187
Emara et al. [34] 10 mg/kg bolus preop
then 5 mg/kg/h infusion
Case 20 640* 5 – 20
Controls 20 1100* 35 – 20
Zufferey et al. [26] 15 mg/kg bolus preop and 3 h later Case 57 975 42 2.0 1
Controls 53 1178 60 1.5 1
Sadeghi and
Mehr-Aein [3]
15 mg/kg bolus preop Case 32 960 37 1.25 N/A
Controls 35 1484 57 1.95
Vijay et al [35] 500 mg bolus preop
then 10 mg/kg/h infusion
Case 45 39* 16 – N/A
Controls 45 91* 40 –
* Surgical drain volume.
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In fact they reported a significantly lower rate of myocardial
infarctions, acute renal failure, PEs and in-hospital mortality with
TXA use in joint replacement surgery.
Topical administration of TXA is less well reported than
intravenous use. It has been suggested that topical administration
may reduce systemic exposure, thereby reducing risk of thrombo-
embolic events. Emara et al. [34] compared intravenous TXA versus
topical TXA in a RCT involving 60 hip hemiarthroplasties. Topical
TXA were administered by bathing 1.5 g of TXA with 100 mL of
saline in the surgical field for 5 min. The authors found that both
routes were equally as effective and reported less thrombotic
events with topical TXA use.
Routine use of TXA may also provide additional cost–benefits. A
single 1 g dose of intravenous TXA costs £1.50 [38]. In contrast, the
cost of a 1 unit of packed red cells is £124.85 at our Trust. Adding to
this are the cost of blood grouping and cross matching both at
£15.97. In our study, 1 transfusion was prevented with every
8 patients given prophylactic TXA (NNT = 8). Extrapolating the
data for our trust, it would cost only £271.50 per year to give TXA
to every patient undergoing hip hemiarthroplasties; we would
in addition save approximately 23 transfusions costing up to
£6312.62 per year. Using the arthroplasty data reported by the
NHFD 2014, this would equate to an approximate UK–wide cost
saving of over £1 million per annum. Cost-effectiveness of TXA has
also been shown in a number of studies. [32,33,39,40] Irisson et al.
[40] reported a 25% cost reduction with the use of TXA compared
with other blood conservation strategies.
Due to the retrospective design of our study, we cannot
eliminate selection bias, principally the surgeons’ decision to use
TXA, and postoperative transfusion decisions by the attending
ward doctors. The rationale for these decisions was not docu-
mented in individual cases. Based on anecdotal observation in our
unit, patients may be given TXA because of a perceived higher risk
of blood loss. However, we could not find a single factor that
increased TXA use in a particular patient subgroup. Although we
had a significantly larger control group, both patient cohorts were
well matched for preoperative Hb levels and all other major
confounding factors. Retrospective power analysis for the primary
outcome measure was 96.1%. We found a greater use of TXA by
trauma fellows–possibly a result of interested awareness. Howev-
er, trauma fellows accounted for only 14% of cases performed, and
excluding all such cases, did not significantly change the results.
Conclusion
Compiling our findings with the evidence from the most recent
literature, the blood conservational effects of TXA is well
established and appears to be safe and cost-effective. Blood
management is particularly important for hip fracture patients.
This study supports the use of tranexamic acid in hemiarthroplasty
surgery for hip fractures.
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ABSTRACT
Pain relief following total knee arthro-
plasty (TKA) is challenging because early 
mobilization and rehabilitation are es-
sential for a successful outcome. Postop-
erative pain can limit recovery, leading 
to reduced mobility and prolonged hos-
pitalization. There are potential benefits 
of infiltrating high volumes of local anes-
thetics around the soft tissues of replaced 
hip and knee joints. The risk of systemic 
toxicity is minimized with diluted local 
anesthetic solution, which also allows 
a high volume to be used. One of the 
As a result of reading this article, physicians should be able to:
1. Understand the high-quality evidence regarding the use of multimodal 
high-volume local wound infiltration in total knee arthroplasty.
2. Understand the contents of the drugs used, intraoperative infiltration 
techniques, and postoperative placement and use of a wound catheter.
3. Explain the effects of using wound infiltration in immediate postoperative 
pain relief, early mobilization, and length of hospital stay after total knee 
arthroplasty.
4. Understand the safety and complications associated with this technique.
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principal advantages is that analgesia 
agents are administered intraoperatively 
by the surgeon, thereby minimizing the 
need for additional invasive procedures. 
The authors conducted a systematic re-
view to evaluate whether high-volume 
multimodal wound infiltration reduces 
pain and opiate intake while enhancing 
early rehabilitation and discharge when 
used in patients undergoing TKA. Only 
randomized controlled studies were in-
cluded. Although better pain relief in 
the immediate postoperative period with 
wound infiltration is gained after TKA, 
there is no definite evidence that this 
leads to a reduction in opiate consump-
tion, the achievement of early milestones, 
or a reduction in hospital stay. The roles 
of individual agents in achieving pain re-
lief and the use of percutaneous wound 
catheter for postoperative doses are also 
unclear. There are few reports of compli-
cations, including falls and delayed mo-
bilization, when femoral nerve blocks are 
used. Wound infiltration analgesia should 
be used at the preference of the surgeon 
and anesthetist provided regular review 
of their practice is undertaken to identify 
any untoward side effects. Further ran-
domized trials with sufficient sample size 
comparing each outcome, including pain 
scores, opiate consumption, and length 
of hospital stay, should be undertaken. 
[Orthopedics. 2014; 37(6):403-412.]
Pain relief following total knee ar-throplasty (TKA) is challenging because early mobilization and re-
habilitation are essential for a successful 
outcome.1 Postoperative pain can limit 
recovery, leading to reduced mobility 
and prolonged hospitalization.2 Local an-
esthetic agents block impulse transmis-
sion from some, but not all, peripheral 
pain receptors following major surgery.3 
In addition, if infiltrated in large quanti-
ties, universal local anesthetic sodium 
channel block may lead to detrimental 
cardiac and neurological effects. It has 
been proposed that the release of inflam-
matory mediators and proteins secondary 
to cytolysis induces a stress response in 
the brain and the spinal cord, stimulating 
pain,4 even with a full block of peripheral 
receptors.
Recent clinical evidence has high-
lighted the potential benefits of infiltrating 
high volumes of local anesthetics around 
the soft tissues of replaced hip and knee 
joints.5 The risk of systemic toxicity is 
minimized with diluted local anesthetic 
solution, which also allows a high vol-
ume to be used. The possible loss of ef-
ficacy resulting from this dilution can be 
compensated with the addition of adjuvant 
agents such as adrenaline and nonsteroidal 
anti-inflammatory drugs (NSAIDs). An-
algesia may be prolonged up to 48 hours 
with long-acting local anesthetics and the 
administration of supplemental doses via a 
wound catheter at regular intervals.6
Local infiltration analgesia uses a sys-
tematic infiltration of the periarticular soft 
tissues with a mixture of ropivacaine (a 
long-acting local anesthetic with a supe-
rior cardiotoxicity profile), ketorolac (an 
NSAID), and adrenaline (a vasoconstric-
tor).6-8 In their series of 325 patients un-
dergoing total hip and knee arthroplasty, 
Kerr and Kohan6 reported excellent pain 
control and just one overnight hospital 
stay in 71% of patients. Due to the sim-
plicity and relative safety of the proce-
dure, it has gained widespread acceptance 
and use. One of the principal advantages 
is that analgesia agents are administered 
intraoperatively by the surgeon and sub-
sequently by the ward staff, thereby mini-
mizing the need for additional invasive 
procedures. However, some methodologi-
cal concerns have been expressed regard-
ing the validity of comparing its efficacy 
with that of other analgesic modalities.2,9
The current systematic review was de-
signed to synthesize the available clinical 
evidence on the efficacy of high-volume 
multimodal wound infiltration following 
TKA, in particular intraoperative adminis-
tration with and without the supplemental 
dosage through a suitably placed wound 
catheter. The aim of this study was to eval-
uate whether high-volume multimodal 
wound infiltration reduces pain and opiate 
intake while enhancing early rehabilita-
tion and discharge when used in patients 
undergoing TKA.
MATERIALS AND METHODS
A literature search was conducted in 
June 2012. The databases reviewed in-
cluded Medline and Embase. The search 
terms included pain, postoperative, 
wound infiltration, total knee replacement/ 
arthroplasty, wound catheter, and intra-/
extra-articular injection. All studies iden-
tified using these search terms were then 
integrated using the Boolean and, which 
was subsequently scrutinized manually by 
the authors to extract the studies that fit 
the inclusion and exclusion criteria. Stud-
ies were limited to randomized trials in 
English and available through the Internet 
studying adults between the years 2000 to 
2012. Studies published in the past decade 
were searched to ensure current evidence 
and the latest perspective on the issue. 
Furthermore, randomized controlled trials 
were included to ensure that highest level 
of evidence. All published articles were 
identified with the above search strategy. 
They were first screened using the title 
and the abstract to extract relevant stud-
ies that could be included in a systematic 
review, which was restricted to patients 
undergoing TKA. A manual search of the 
reference lists from selected articles was 
also performed to further increase the 
number of publications with relevant data.
Inclusion Criteria
Inclusion criteria were the following:
1. Randomized controlled trials report-
ing results on perioperative wound infil-
tration in primary unilateral TKA
2. Use of wound catheters
3. Defined research questions
4. Adequately described methodology
5. Use of intermittent injections or 
continuous infusions
6. Well-defined outcome measures
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Exclusion Criteria
Exclusion criteria were the following:
1. Systemic reviews and meta-analyses
2. Nonrandomized trials
3. Studies not published in English
4. Studies published prior to 2000
5. Bilateral TKA with infiltration of 
both knees
6. Unicompartmental TKA
7. Studies on knee arthroscopic sur-
gery, hip replacements, and nonorthope-
dic surgical procedures
8. No comparator group 
9. Nonrandomized
10. Outcome measures not well de-
fined
11. No validated patient-reported func-
tional outcome scores
Data Extraction
Once the authors identified the studies 
that appeared to meet the inclusion crite-
ria, they read through the abstracts of the 
studies to find those that were relevant 
and fulfilled all of the inclusion criteria. 
Ideally, at this stage, both authors inde-
pendently read each article to assess the 
adequacy of the search results and extract 
data according to their defined inclusion 
and exclusion criteria to ensure that the 
evidence gathered was adequate and rel-
evant. Dissenting opinions regarding a 
study’s inclusion were resolved with in-
formal discussions between the authors.
The authors included data on pain 
intensity as measured by the visual ana-
log scale (VAS) from 0 to 10, where 0 
represents no pain and 10 represents the 
worst imaginable pain. Postoperative re-
habilitation was recorded in hours, opiate 
consumption in milligrams, and length of 
stay in days.
Outcomes as Endpoints
The following 2 primary endpoints 
were used, and any study not providing 
either was excluded:
1. Visual analog scale score on at least 
2 time points separated by more than 4 
hours (ie, 4 and 24 and 48 hours)
2. Morphine equivalent consumption 
(in milligrams) during these time periods
In addition, a number of secondary 
endpoints were analyzed (if reported), in-
cluding, but not limited to:
1. Length of hospital stay in days
2. Side effects, including nausea and/or 
vomiting, headache, dizziness, numbness, 
and infection
3. Complications, including infection, 
nerve injuries, and hematomas
RESULTS
A total of 344 studies were found in 
the Medline database, and 19 were found 
in Embase. Thus, a total of 363 abstracts 
were identified that fulfilled the initial 
search strategy. From these abstracts, 44 
studies were considered to be relevant to 
the study’s design and had all of the in-
clusion criteria and none of the exclusion 
criteria described previously. Of these, 
18 randomized prospective studies were 
included in this systematic review, which 
had the necessary data as outlined previ-
ously. All studies identified in Embase 
were included in Medline except one, 
which was separately analyzed. These 
studies are summarized in Tables 1 and 2. 
The search suggested that intraopera-
tive wound infiltration with high-volume 
local anesthetic infiltration provides ad-
equate pain relief for at least the first 6 to 
12 hours. However, most of these studies 
suffer from methodological inadequa-
cies and insufficient blinding (Table 3). 
The assessment of postoperative pain 
and opiate consumption is not fully de-
scribed. Furthermore, data are lacking on 
the consumption and quality of periph-
eral analgesia or epidural (continuous/
intermittent) analgesia techniques used in 
control groups. Data on the use of compa-
rable systemic analgesia between groups 
are lacking in some studies.3,9 There is no 
conclusive evidence on the use of wound 
catheters and postoperative doses of local 
anesthetics imparting any significant an-
algesic effects after TKA.7,8,10 However, 
a similar conclusion cannot be drawn 
on the use of intra- or extra-articular/ 
intracapsular administration of the drugs. 
There seems to be a distinct advantage in 
administering the local anesthetic agents 
Table 1
Search Results From 
Medline Database on 
Wound Infiltration in
 Total Knee Arthroplasty 
Pain=469,378
  Postoperative complications (OR)a= 
    5,451,344
  Wound infiltration (OR)=5,179,326
  Knee replacement (OR)=427,335
  Wound catheter (OR)=196,778
  Injection (OR)=5733
  1 and 2 and 3 and 4 and 5 and 6  
    (AND)=344
  Manual search (AND)=32
  Limits appliedb=17
aParentheses contain the Boolean used 
while expanding each search term. 
bLimits were randomized trials, adults, 
2000-2012, in English, available from the 
Internet.
Table 2
Search Results From 
Embase on Wound
 Infiltration in
Total Knee Arthroplasty
Pain=840,225
  Postoperative complications (OR)a= 
    685,542
  Wound infiltration (OR)=208,384
  Knee replacement (OR)=12,420
  Knee arthroplasty (OR)=23,419
  Wound catheter (OR)=284,755
  Injection (OR)=5625
  1 and 2 and 3 and 4 and 5 and 6  
    (AND)=19
  Manual search (AND)=19
  Limits appliedb=1
aParentheses contain the Boolean used 
while expanding each search term. 
bLimits were randomized trials, adults, 
2000-2012, in English, available from the 
Internet.
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in the capsule rather than as an intra-
articular injection. The latter seems 
to make no clinical difference in pain 
relief.11,12 This is further supported by 
some studies that involved a single 
intra-articular injection leading to no 
significant pain relief.13-15 However, 
one trial with a small sample size 
reported significant pain relief after 
intra-articular ropivacaine injection 
following TKA.16 The assessment of 
pain was not clearly defined in this 
study and was obtained once in 24 
hours with no specification on the pa-
tient’s activity. Therefore, the results 
of this study should be analyzed with 
caution.
Other factors may have a posi-
tive effect on wound infiltration with 
wound catheters, including infiltrating 
the subcutaneous tissues generously 
during the intraoperative injection,17 
injecting the posterior capsule with 
the maximum volume of the local an-
aesthetic,18 and using a compression 
bandage that may prolong the effect 
of the local anesthetics.19 Parvataneni 
et al20 reported no reduction in post-
operative pain with wound infiltration 
combined with multimodal oral anal-
gesia compared with a control group 
receiving femoral nerve block. How-
ever, the protocol for local infiltration 
was ill defined; therefore, the results 
are difficult to interpret. Bianconi 
et al21 showed significant pain relief 
with local anesthetic infiltration in to-
tal hip and knee arthroplasty patients. 
The data on pain relief are combined 
for hip and knee arthroplasty, which 
makes the assessment of the effective-
ness of this technique in TKA alone 
impossible.
The effects of perioperative lo-
cal wound infiltration on length of 
hospital stay are variable. Although 
many studies reported a positive out-
come, the organizational issues were 
not fully accounted for. This makes 
interpretation of results difficult be-
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cause most authors did not justify or ex-
plain these factors transparently enough to 
reach a satisfactory conclusion.22 Another 
recent well-designed study reported a re-
duction in opiate requirement and NSAID 
usage following local wound infiltration 
after TKA in 3 groups with (a) epidural 
analgesia or (b) wound infiltration with 
ropivacaine 150 mg and epinephrine 0.5 
mg combined with ketorolac 30 mg and 
morphine 5 mg given either locally or (c) 
intravenously.23 Epidural analgesia was 
maintained for 48 hours. More impor-
tantly, the authors recorded a significant 
reduction in length of stay in the treatment 
group (median, 5 vs 3.5 vs 4 days, respec-
tively).
Carli et al24 reported significant reduc-
tion in pain scores following intraopera-
tive wound infiltration (intraoperatively 
and 24 hours postoperatively) vs a con-
tinuous femoral nerve block and both 
groups receiving the same multimodal 
nonopioid analgesia (COX-2 inhibitor 
and paracetamol) after TKA compared 
with traditional femoral nerve block. They 
found no difference in opiate require-
ment or attainment of early rehabilitation 
milestones in the treatment group. Both 
groups had a median length of stay of 5 
days. However, the authors did not report 
the specific role of wound infiltration in 
length of stay. Patients in both groups 
were allowed to fully mobilize 3 days 
postoperatively, which may have affected 
the length of stay results in this study. 
Similar results were reported in another 
study that reported significant reduction 
in pain and opiate use in the group having 
wound infiltration along with early attain-
ment of discharge criteria (3 vs 5 days).25 
They had no serious side effects or com-
plications with this technique.
Reeves et al26 found no difference in 
terms of pain score, opiate consumption, 
and subjective evaluation of patient sat-
isfaction in 2 treatment groups with con-
tinuous infiltration of a high dose (0.375% 
ropivacaine) and a low dose (0.2% ropi-
vacaine) vs a control group receiving sa-
line. They had 2 cases of postoperative 
knee infection in the infiltration group, 
which was not reported in other studies. 
However, the continuous infusion may 
explain this complication rate compared 
with intermittent postoperative top-up 
doses. Another concern often raised was 
the result of using autotransfusion drains 
in TKA with wound infiltration. Two 
studies examined ropivacaine concen-
trations in the drain fluids and systemic 
side effects of local anesthetics after au-
tologous blood transfusion following 
TKA.27,28 Both studies confirmed a safe 
blood level of ropivacaine in the drain 
blood and no side effects, confirming the 
safety of using drains and autotransfu-
sion with wound infiltration. Furthermore, 
one study reported significant reduction 
in intraoperative blood loss along with 
reduced pain and need for rescue opiate 
analgesia in patients who received wound 
infiltration while undergoing TKA. This 
outcome might be explained by the local 
vasoconstriction caused by adrenaline.29 
Other authors did not achieve such out-
comes.26,30 It has also been reported that 
postoperative wound healing, infection, 
blood pressure, heart rate, rash, respirato-
ry depression, urinary retention, and deep 
vein thrombosis were similar in patients 
with wound infiltration, but nausea and 
vomiting were significantly less frequent 
in the treatment group, probably second-
ary to reduced opiate uptake.31
DISCUSSION
A systematic review is a powerful tool 
to assess the efficacy of interventions 
and of their likelihood to cause harm in 
a scientific and transparent manner. This 
estimates the relevance of interventions 
in a clinical context by gathering evi-
dence from all relevant trials—and more 
commonly from high-quality randomized 
controlled studies when available. The 
systematic review is structured to reduce 
bias in the collection, appraisal, and inter-
pretation of relevant studies using trans-
parent methodology. This has proven to 
extract evidence that was not apparent in 
individual studies.32 This methodology 
includes the definition of a clear, often 
narrow, question to be answered; a struc-
tured literature search with well-defined 
inclusion and exclusion criteria; a qual-
ity assessment of retrieved reports; and 
standardized data handling and analysis.33 
Poor pain management in the postopera-
tive period can cause several long-term se-
quel, including chronic pain syndromes,34 
increased postoperative morbidities, and 
poor quality of life.35 Novel pain man-
agement standard requires adequate post-
operative pain management to be a key 
strategy to avoid any untoward long-time 
pain-related complication.36
The inherent simplicity of the wound 
catheter technique is that it can easily be 
placed in situ by the operating surgeon. 
Furthermore, the postoperative top-up 
doses can be administered by the nursing 
staff, avoiding regular specialist medical 
input. This, combined with the ease of 
postoperative mobilization by patients, 
has led to the frequent use of wound cath-
eters.37
The current authors’ search has re-
vealed a number of randomized con-
trolled trials examining the efficacy of 
perioperative local wound infiltration in 
patients undergoing TKA. This illustrates 
the interest this approach has evoked 
among orthopedic surgeons and anesthe-
tists. However, all of these studies have 
resulted in conflicting evidence. Although 
most studies were randomized, the sample 
sizes were often not adequate,8,10,11,16,38,39 
allowing them to erroneously accept the 
null hypothesis (type 2 error). Moreover, 
the comparator groups were often het-
erogeneous (eg, femoral block, epidural, 
etc.), making a logical summation of their 
results virtually impossible. Some facts 
that have emerged from one study show 
that (1) wound infiltration does not cause 
dangerous levels of ropivacaine in the 
blood; (2) autologous transfusion is safe 
when combined with wound infiltration; 
(3) systemic side effects related to opiates 
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are probably few in the immediate peri-
operative period, especially nausea and 
vomiting; and (4) additional alterations in 
the technique, like injecting the posterior 
capsule and using compression bandages, 
are useful in improving pain management 
with wound infiltration.21
However, there is no definite evidence 
on more important aspects, including (1) 
postoperative pain scores, (2) postopera-
tive opiate consumption, and (3) reduction 
in length of stay. The literature is highly di-
vided in recommending wound infiltration 
for achieving these benefits. Furthermore, 
although most studies have reported no 
significant complications, one study men-
tions postoperative infection in the knee.26 
Hence, no general recommendations can 
currently be made to support this tech-
nique. It is apparent that wound infiltra-
tion gives pain relief in the initial 6 to 12 
hours postoperatively. However, the role 
of other drugs, like NSAIDs and adrena-
line, has not been clearly evaluated. Few 
studies have addressed this role.23,40 These 
studies showed some superiority of local 
infiltration with ketorolac (NSAID) com-
pared with systemic infusion, although 
it is known that analgesia is obtained by 
administration of NSAIDs, either locally 
or systemically, with minor clinical differ-
ence in terms of pain relief.40 Most stud-
ies have not taken into account the effects 
of the optimized multiple oral analgesics 
often offered to patients in treatment and 
comparator groups in the immediate post-
operative period. Another study reported 
a reduction in opiate consumption and 
better perioperative pain relief leading to 
a reduction in length of stay with wound 
infiltration and intra-articular adminis-
tration of ropivacaine compared with 
systemic administration of NSAIDs and 
continuous epidural infusion.41 A recent 
trial reported similar opiate consumption 
and length of stay with wound infiltration 
following TKA compared with femoral 
nerve block.39 However, pain with move-
ment of the knee in the immediate postop-
erative period was significantly lower in 
the treatment group. This is important be-
cause postoperative knee motion is a key 
rehabilitation step following TKA. The 
achievement of adequate knee joint move-
ment determines how quickly patients can 
be safely discharged.
There are no clear beneficial effects 
of top-up doses with wound infiltration 
in the postoperative period. Furthermore, 
this can lead to potential introduction of 
infection in the joint. Hence, this area 
needs further research to determine the 
optimal number and duration of top-up 
doses that provide patients with the best 
pain relief without increasing the risk of 
infection secondary to prolonged catheter 
placement in the knee joint. The role of 
other emerging agents may be of inter-
est. Apart from paracetamol and NSAIDs, 
COX-2 inhibitors, gabapentinoids, and 
glucocorticoid injections have been tried 
along with wound infiltration.18,42 The 
role of gabapentin and pregabalin in post-
operative pain relief after joint replace-
ment has been reported.43 A single high-
dose methylprednisolone injection in the 
joint can provide additional analgesia and 
reduce opiate intake following TKA.38 
The evidence favoring these agents is 
sparse. More randomized controlled trials 
with sufficient sample sizes need to be un-
dertaken to assess the safety, efficacy, and 
side effects of these agents.
There is some evidence that when used 
in conjunction with femoral nerve blocks, 
a single intraoperative injection can result 
in significant pain relief in the immedi-
ate postoperative period.8,24 However, the 
nerve block technique has its own inher-
ent problems, including nerve damage,44 
delayed mobilization, and falls due to 
motor blockade.45 Furthermore, when 
used with wound infiltration, it becomes 
unclear which technique (nerve block or 
local anesthetics) actually resulted in pain 
relief. Thus, wound infiltration should be 
used in isolation to avoid the potential 
complications associated with femoral 
nerve block.46 The latter has the advan-
tage of allowing patient mobilization on 
the day of surgery, resulting in fast-track 
rehabilitation.1
A limitation of the current review is 
that the search was confined to Medline 
and Embase. Although the authors tried 
to manually search the references to en-
sure all relevant studies were included, it 
is possible some may have been missed. 
Furthermore, the authors did not search 
other databases, such as Cochrane and 
CINAHL. The authors did not include 
grey literature (eg, conference presenta-
tions and abstracts) that might contain 
more evidence regarding this technique. 
However, it is unlikely that a seriously 
performed randomized controlled trial is 
confined to a presentation without being 
published. The authors made no attempt 
to statistically compare the results because 
this was beyond the scope of this article; 
hence, this article contains some elements 
of a narrative review. The authors have not 
assessed cost analyses because that was 
not a part of their research question.
CONCLUSION
This article summarizes the current 
evidence and the implications of using 
perioperative wound infiltration analge-
sia with multimodal high-volume local 
anesthetic agents combined with addi-
tional agents like adrenaline and NSAIDs 
in patients undergoing TKA. The studies 
are heterogeneous with different methods 
and comparators, making valid compari-
son among the studies difficult. However, 
almost all of the studies reported better 
pain relief in the immediate postopera-
tive period with wound infiltration. It is 
unclear whether this actually leads to 
a reduction in opiate consumption, the 
achievement of early milestones, or a 
reduction in length of hospital stay. The 
role of individual agents in achieving pain 
relief and the benefits of using a percuta-
neous wound catheter is also unclear. No 
study compares the individual agents with 
each other; therefore, it is unclear whether 
NSAIDs or adrenaline are needed in the 
mixture for wound infiltration. The role 
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of a wound catheter is also not well es-
tablished in terms of frequency of admin-
istration of bolus doses, continuous infu-
sion, and optimal duration of leaving it in 
a replaced knee postoperatively. Although 
few recent reviews have condemned this 
technique,47,48 the evidence is unclear on 
whether to accept or reject wound infiltra-
tion. Currently, wound infiltration analge-
sia should be used at the preference of the 
surgeon and anesthetist provided regular 
review of their practice is undertaken to 
identify any untoward side effects. Further 
randomized trials with sufficient sample 
sizes comparing each outcome, includ-
ing pain scores, opiate consumption, and 
length of hospital stay, should be under-
taken.
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Antibiotic-loaded cement spacers in ﬁrst-stage revision hip arthroplasty for infection are associated with a
high dislocation and fracture rate. This technical note describes a novel surgical technique, utilizing screws
and cement, improving acetabular coverage and reducing the risk of mechanical failure.
Fifteen infected hip prostheses underwent removal, cement acetabular augmentation and insertion of a
femoral cement spacer. Eleven hips had successful infection eradication and subsequently underwent a
second stage revision procedure a mean duration of 15 weeks (9–48) after the ﬁrst stage. No dislocations or
fractures of the cement spacers were observed. This technique affords the potential to reduce the duration of
time cement spacers remaining in situ, provides enhanced mechanical stability and improved antibiotic
elution through cement-on-cement articulation.
© 2014 Published by Elsevier Inc.
Operative Technique
Patients were placed in the lateral decubitus position with the
affected hip up and the administration of antibiotics withheld until
biopsy specimens had been obtained. Surgical approach was based on
preoperative templating, with 12 cases requiring an extended
trochanteric osteotomy and 3 cases using a modiﬁed trochanteric
slide osteotomy to provide adequate exposure and access for removal
of the femoral and acetabular components [1–3].
The surgical exposure included the excision of all the sinus tracks,
drainage of all abscesses and the removal of all the in situ components
and any potentially infected tissues, including cement. Once the
exposure was performed, and the hip dislocated, deep tissue samples
from the hip and acetabulum were taken. Ideally, three sets of deep
cultures were obtained, including joint ﬂuid, soft tissue and bone.
The in situ femoral components were removedwith a combination
of ﬂexible osteotomes, use of the extended osteotomy and cortical
windows. Care was taken to ensure the removal of any remaining
cement, whilst avoiding iatrogenic femoral fracture. Regarding the
acetabular component, any ilial screwswere removed and the implant
was checked for gross loosening. If the component was well ﬁxed,
removal was achieved by the use of sequential curved blade styles
(Explant Acetabular Cup Removal System, Zimmer Warsaw, IN).
The entire acetabular rim was then visualized along with a small
area of the supra-acetabular ilium exposed subperiostealy to avoid
damage to the superior gluteal vessels and nerve. Three 3.5-mm
unicortical drill holes were made in the juxta-acetabular ilium,
approximately 1 cm apart and each 1 cm cephalad to the rim of the
superior acetabular, if this region remained intact following debride-
ment of all infected tissue. Three 6.5-mm × 45–50-mm cancellous
screws were inserted perpendicular to the surface of the ilium, with
approximately 20–25 mm of the screw shaft remained outside the
bone (see Fig. 1).
The femoral cement spacer was then prepared on a back table in a
standard fashion using a speciﬁc mold (StageOne Hip Spacer Mold,
Biomet, Warsaw, IN). Preoperative radiographic templates were used
to select the most appropriate size femoral component from the four
sizes available.
When cured, the femoral cement spacer was inserted with
reference to either the greater or lesser trochanter, if still present, to
a depth that recreated the physiological limb length. Our protocol was
to mix a total of 8 g of antibiotic per 40 g of cement polymer (Surgical
Simplex, Limerick, Ireland). Unless otherwise dictated by preopera-
tive cultures and sensitivity of the infected joint ﬂuid, 4 g of both
vancomycin and ceftazidime per 40 g of cement was used at our
institution. Typically three to four bags of cement were used in total
per case.
Following reduction of the femoral cement spacer, there was
typically a substantial amount of uncoverage, approximately 30%–
40%, of the cement femoral head. The surface of the ilium along which
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the cancellous screws had been inserted was meticulously dried and
any remaining soft tissue removed in order to avoid cement
debonding. A separate bag of antibiotic loaded cement was then
used to form an acetabular augment that was placed around and
covering the three ilial screws. The cement acetabular augment was
positioned in the posterolateral aspect of the acetabular rim. The
surface of the reduced femoral component provided a contour for this
augment. Some gentle passive movement of the hip joint while the
acetabular cement was setting prevented the acetabular cement
bonding to femoral cement component. Closure of the wound was
performed in a standard manner for the approach used. Postoperative
radiograph of the procedure is shown in Fig. 2.
Postoperative Regime
Patients were mobilized with partial weight bearing, up to 50% of
total body weight, from the ﬁrst postoperative day. Antibiotics were
administered via a long intravenous line for a period of least 6 weeks,
the choice of antibiotic depending on the sensitivity of the organisms
cultured from the deep tissue biopsies. Routine clinical and radio-
graphic follow-up was conducted.
In our institution, no cases of antibiotic-associated renal toxicity have
occurred, although this technique should be used with caution in
patients with signiﬁcant renal impairment. Second-stage recon-
struction was only considered when there was clinical and
serological evidence of infection eradication, consistent with the
Musculoskeletal Infection Society [4]. In equivocal cases, an addi-
tional hip aspirate was obtained to exclude infection before
proceeding with deﬁnitive reconstruction.
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Fig. 1. Intraoperative photograph following reduction of the femoral cement spacer,
demonstrating a substantial amount of uncoverage (approximately 30%–40%) of the
cement femoral head and supra-acetabular screws in situ prior to augmentation
with cement.
Fig. 2. Radiograph of patient (as Fig. 5) following ﬁrst-stage revision right hip
arthroplasty using cement acetabular augmentation.
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Two-stage revision surgery for infected total knee replacement offers the highest rate of 
success for the elimination of infection. The use of articulating antibiotic-laden cement 
spacers during the first stage to eradicate infection also allows protection of the soft tissues 
against excessive scarring and stiffness. We have investigated the effect of cyclical loading 
of cement spacers on the elution of antibiotics. Femoral and tibial spacers containing 
vancomycin at a constant concentration and tobramycin of varying concentrations were 
studied in vitro. The specimens were immersed and loaded cyclically to 250 N, with a flexion 
excursion of 45°, for 35 000 cycles. The buffered solution was sampled at set intervals and 
the antibiotic concentration was established so that the elution could be calculated. 
Unloaded samples were used as a control group for statistical comparison.
The elution of tobramycin increased proportionately with its concentration in cement and 
was significantly higher at all sampling times from five minutes to 1680 minutes in loaded 
components compared with the control group (p = 0.021 and p = 0.003, respectively). A 
similar trend was observed with elution of vancomycin, but this failed to reach statistical 
significance at five, 1320 and 1560 minutes (p = 0.0508, p = 0.067 and p = 0.347, respectively). 
However, cyclically loaded and control components showed an increased elution of 
vancomycin with increasing tobramycin concentration in the specimens, despite all 
components having the same vancomycin concentration. The concentration of tobramycin 
influences both tobramycin and vancomycin elution from bone cement. Cyclical loading of 
the cement spacers enhanced the elution of vancomycin and tobramycin.
Infection after total knee replacement (TKR) is
an infrequent but devastating complication
which is difficult to treat. The poor availability
of antibiotics at the site of infection, the presence
of a biofilm reducing the exposure of bacteria to
the antibiotics and the relative immunodeficient
zone around an implant are all factors which
influence the efficacy of treatment.1-3
There are considerable financial costs and
clinical implications from infection including
increased morbidity and prolonged or repeated
hospital admissions.4,5 Most studies report an
incidence of infection of 1% to 2% after pri-
mary TKR,6-8 but this may increase to over 4%
in patients with rheumatoid arthritis and an
incidence of over 12% has been reported in
certain groups of patients.9,10 The cost of revi-
sion knee surgery as a result of infection is
more than twice the cost of an aseptic revision,
and several times that of a primary TKR.4,5
Two-stage revision TKR, with the use of
antibiotic-impregnated polymethylmethacry-
late (PMMA) cement spacers is a widely prac-
tised method of managing this problem.11,12
After the removal of the primary prosthesis
with thorough debridement, the cement spacer
is implanted followed by an extended course of
antibiotics. A second-stage procedure is subse-
quently performed when the patient is consid-
ered to be free of infection.13,14 Cement spacers
assist in the delivery of antibiotics, maintain
limb length and therefore tissue tension, and
reduce the formation of soft-tissue contracture
or arthrofibrosis, thereby simplifying re-
implantation of the new components at the
second stage.15-17 Spacers can be articulating
or non-articulating (static) and there is debate
regarding the benefits of each type.18 The non-
articulating type provides a high concentration
of antibiotics locally, maintains the joint space
and limits the possible risk of introducing the
inoculum further into the surrounding tissues
by restricting movement of the knee. Several
studies have shown their effectiveness.19,20 By
contrast, articulating spacers allow joint move-
ment and help to maintain soft-tissue func-
tion.21,22 Arthrofibrosis is minimised and
function is better than that following the use of
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non-articulating spacers.22,23 Several forms of spacer have
been described and they can be custom-made during the
operation or commercially available as prefabricated
components.15,24-27
The addition of antibiotics to cement, especially in liquid
form, adversely affects tensile and compressive
strength.17,28,29 Ideal properties of an antibiotic which is
mixed with cement include minimal adverse biomechanical
effects on PMMA, water solubility; a broad spectrum of
antimicrobial action, thermal stability and low allergen-
icity. As a consequence, there are only a few which fit these
criteria. They include tobramycin, vancomycin, gentamicin
and cephalosporins.15,30 Since gentamicin is commonly a
component of the cement used in primary TKR, organisms
may acquire gentamicin-resistance.31
The release of antibiotics from cement has been studied
both in vitro and with in vivo animal models. Static in vitro
models have shown a high level of release of local antibiotic
from cement which is affected by several factors including
the surface area, porosity and the amount, type and number
of antibiotics.11,15
However, the effects of articulation, specifically cyclical
fatigue loading, on the elution of antibiotics from cement
knee spacers has not been clearly defined. The maintenance
of joint movement is an advantage in maintaining the
condition of the soft tissues, but the question arises as to
whether the articulation per se influences the biology and
pharmacokinetics of antibiotic elution. Tobramycin has a
broad antimicrobial action with minimal effect on PMMA
strength, while vancomycin is effective against methicillin-
resistant Staphylococcus aureus and Staph. epidermidis
with similarly low adverse biomechanical effects on
PMMA.28,32,33
Our in vitro study considered the differential effect of
static or dynamic loading on the elution of vancomycin and
tobramycin with a null hypothesis proposing that the cyclical
loading of cement spacers has no significant effect on elution.
Patients and Methods
Preparation of samples. All the samples were prepared in
an identical manner. Antibiotic-loaded spacers were
prepared by the injection of Palacos R (Heraeus Kulzer
GmbH, Hanau, Germany) standard radio-opaque cement
into Biomet stage-one 70 mm silicone spacer moulds
(Biomet Inc., Warsaw, Indiana). The addition of a constant
concentration of vancomycin with incremental quantities
of tobramycin was investigated (Table I). Vancomycin and
tobramycin are two of the most commonly used anti-
microbials partly because of their availability in powder
form.16 The dosing schedule used in our study correlated
with that of admixtures reported in numerous clinical and
in vitro studies.15,16,24,32,34-36 Before the polymerisation of
cement, the cement monomer was chilled at -20°C for five
minutes in order to extend the working time required to
achieve a thorough mix of monomer and copolymer in the
presence of added antibiotics. Vancomycin and tobramycin
in their selected amounts and Palacos cement powder were
blended for one minute in a small hand orthopaedic cement
mixer (DePuy, Blackpool, United Kingdom) before
polymerisation. The cement was mixed for one minute
prior to being injected in the moulds, according to the man-
ufacturer’s instructions, in air at room temperature (23°C ±
1°C), using a CemVac mixing system (DePuy CMW, Black-
pool, United Kingdom). The cement was then injected into
the silicone moulds and left to polymerise for a minimum of
two hours. After curing, excess material, as a result of the
moulding process, was removed from the femoral compo-
nent taking care not to damage the surface of the condyles.
The non-articulating surface of the tibial component was
ground to a thickness of 10 mm. Both components were
rinsed in distilled water and dried before testing.
Dynamic testing protocol. Three sets of spacers were pre-
pared for each of the three concentrations of antibiotics in
the cement (Table I). The femoral component was attached
to a polymer block conforming to the geometry of the
spacer using waterproof silicone sealant (Figs 1 and 2). This
was allowed to cure before testing. The femoral and tibial
components were placed in the environmental chamber,
maintained at 37°C and attached to the actuators as shown
in Figure 2 (Instron 8874 servo hydraulic testing machine;
Instron, Norwood, Massachusetts). The spacer was
immersed in 1 l of phosphate-buffered saline (PBS). The
femoral component was aligned relative to the tibial compo-
nent in 22.5° of flexion. In order to reproduce the maximum
tibiofemoral contact force of 2.5 times body-weight at 13%
of the gait cycle,37 the tibial component was then loaded on
to the femoral component with a force of 0.1375 kN.
Dynamic loading was initiated as per the schedule detailed
Table I. Details of the low, medium and high datasets relating the concentration of antibiotic used, the number of spacers used (for the static control
group and dynamic testing) and the total number of samples taken per time interval
Static spacers Dynamic spacers
Mass of 
vancomycin* (g)
Mass of 
tobramycin* (g) Number
Number of samples 
per time interval
Total number of sam-
ples per time interval Number
Number of samples 
per time interval
Total number of samples
per time interval
Low 1 1.2 2 3 6 4 3 12
Medium 1 2.4 2 3 6 4 3 12
High 1 3.6 2 3 6 4 3 12
* per 40 g of cement powder
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in Table II. The femoral component was cycled at a fre-
quency of 1 Hz and an amplitude of 22.5° and the tibial
component was loaded at a frequency of 1 Hz with an
amplitude 0.1125 kN. The loading cycle (sinusoidal wave-
form, amplitude of 22.5° (maximum arc of movement of the
femoral component), maximum load of 0.25 kN, R = 0.1,
frequency (f) = 1 Hz) was selected to represent walking with
crutches. The resistance value (R) is a material stiffness test.
It expresses a material’s resistance to deformation as a func-
tion of the ratio of transmitted lateral pressure to applied
vertical pressure. At each interval of the sampling, as indi-
cated in Table II, cyclical loading was paused, the solution
agitated to ensure an even distribution of the antibiotics,
and three samples (5 ml) of solution collected from sepa-
rated locations of the environmental chamber and stored at
-20°C. The concentration of antibiotics, and hence elution,
of these samples was measured by a TDx FLx Immunology
Analyser (Abbott Laboratories, Abbott Park, Illinois).
As a control, two spacers for each concentration of anti-
biotics were prepared. The control samples were immersed
in PBS and samples were taken in accordance with the
schedule for dynamic testing. Thereafter, samples were
taken twice daily, for four weeks. At the end of each day
30 ml of PBS were added to ensure that the sample
remained fully immersed in solution.
Statistical analysis. The data points regarding the concen-
tration of antibiotic, measured using enzyme-linked immu-
noassay, for each time interval were obtained from a mean
of six samples from the two static controls per concentra-
tion (three per spacer) and the 12 samples for the dynamic
testing from the four dynamic spacers per concentration
(three per spacer; Table I).
Non-parametric statistical analysis of variance (ANOVA)
was performed to compare the mean elution between the
static and dynamic groups. A p-value ≤ 0.05 was considered
to be statistically significant.
Results
Control group. The elution of both tobramycin and vanco-
mycin, from all three concentrations of the static control
samples, is shown graphically in Figure 3. There was a bipha-
sic elution pattern with an initial rapid rate of antibiotic
Table II. Details of the sampling schedule for the dynamic and static groups
Number of cycles
Sample number Time elapsed (minutes) Dynamic test Static control
00        5      3 ot 1  
00        021  6 ot 4  
00007   042  9 ot 7  
0000 41063  21 ot 01
0000 41023151 ot 31
0000 12044181 ot 61
0000 82065112 ot 91
0000 53086142 ot 22
Fig. 1 
Photograph of a Palacos knee cement spacer
prepared using Biomet stage-one 70 mm silicone
moulds and loaded with vancomycin and
tobramycin.
Fig. 2
Photograph of the experimental apparatus for dynamic testing. Knee
spacers are immersed in phosphate buffered saline and loaded cyclically.
The white arrows indicate the direction of loading.
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release which slowed to a steady state from 400 minutes. The
interval in the data points after 400 minutes represented the
overnight pause in the experiment (see Table II).
In the static control group vancomycin eluted at a higher
rate than tobramycin. Furthermore, as the tobramycin
concentration was increased in the cement mixture (the
low, medium and high data sets), there was a corresponding
increase in the release of vancomycin.
Dynamic testing: tobramycin elution. The rates of elution
of tobramycin from the different concentrations of cement
undergoing dynamic testing are shown in Figure 4 with
comparison with the corresponding static control group.
Dynamic testing in comparison with the control group
increased the elution of tobramycin. The release was dose-
related, with an increasing concentration of tobramycin in
the cement affording a corresponding increase in its elution.
Furthermore, the dose-related elution response was exag-
gerated by dynamic testing. The mean elution of tobra-
mycin between the static and dynamic groups was
examined by ANOVA (Table III). Dynamic cyclical loading
was associated with a significantly higher tobramycin elu-
tion at all sampling points. 
Therefore, with respect to tobramycin elution, we can
reject the null hypothesis and state that there is a statisti-
cally significant higher elution under dynamic loading
compared with static loading.
Dynamic testing: vancomycin elution. The rates of elution
of vancomycin in the different cement concentrations
undergoing dynamic testing in comparison with the corres-
ponding static group are shown in Figure 5.
Similarly to tobramycin, there was a dose-related
increase in the elution of vancomycin as the concentration
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Graphs showing the low, medium and high datasets for the concentration of antibiotics used in the mixing of cement according to Table I for a) tobramy-
cin elution from static (control) spacers and b) vancomycin elution from static (control) spacers. The error bars show 95% confidence intervals.
Fig. 3b
0
0
5
10
15
M
ea
n 
co
nc
en
tr
at
io
n 
(m
g/
L)
20
25
30
35
200 400 600 800 1000
Time (mins)
1200 1400 1600 1800
DYN-low
STATIC-low
DYN-medium
STATIC-medium
DYN-high
STATIC-high
Fig. 4
Graph showing the comparison of tobramycin elution between
static and dynamic (DYN) spacers at the low, medium and high con-
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Table III. Comparison (p-value, ANOVA*) of the mean elution of each
antibiotic at each time interval under static and dynamic conditions
p-value
Duration of dynamic loading (minutes) Vancomycin Tobramycin
5 0.0508†     0.021
  120 0.049     0.006
  240 0.027 < 0.001
  360 0.031 < 0.001
1320 0.067† < 0.001
1440 0.010 < 0.001
1560 0.347†     0.001
1680 0.029     0.003
* ANOVA, analysis of variance
† not significant
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of tobramycin within the cement was increased. Thus,
increasing the concentration of tobramycin in the cement
augmented the release of vancomycin during dynamic test-
ing in a dose-related manner.
There was a clear trend of increasing the elution of van-
comycin with dynamic testing (Fig. 5) and this increase over
the static samples was statistically significant (Table III)
with the exception of the sampling time points of five, 1320
and 1560 minutes.
For the elution of vancomycin, the null hypothesis can
also be rejected since, overall, higher elution occurred
under dynamic loading which was statistically significant.
Discussion
Our results show that there was a biphasic elution of both
vancomycin and tobramycin in the static control, with a
rapid initial release followed by a plateau in the rate of
release after approximately 400 minutes (Fig. 3). Further-
more, the elution of both vancomycin and tobramycin was
enhanced by an increasing concentration of tobramycin in
the bone cement. This enhancement was more pronounced
for the vancomycin elution.
For any concentration of antibiotic cement studied,
dynamic loading increased elution compared with the
corresponding static control group. Although dynamic
loading improved elution per se, its effect on elution was
further increased, in a dose-dependent manner, by the pres-
ence of tobramycin in the cement.
For tobramycin, a highly statistically significant dose-
related increase was observed with dynamic loading
compared with the control group (Fig. 5, Table III).
Regarding vancomycin, a similar dose-related trend was
seen, with statistical significance in all but three time inter-
vals (Fig. 5, Table III). At five minutes, the p-value regard-
ing vancomycin was 0.0508.
Therefore, by adding tobramycin to bone cement, there
was enhanced static elution of vancomycin and tobra-
mycin. This enhanced elution was significantly augmented
by dynamic loading (Figs 4 and 5, Table III).
The mechanical benefits of maintaining joint movement
during a two-stage revision TKR have been well docu-
mented.23,24,26 There is debate regarding the use of static or
dynamic spacers. Static spacers have the theoretical advan-
tage of reducing the inoculum being introduced into the
surrounding soft tissues, which are also free from tension,
augmenting antimicrobial action.23,38
However, other reports have indicated a biomechanical
advantage of dynamic over static knee spacers.21,24 The
biological effect of dynamic cyclical loading per se on
cement spacers, specifically differential antibiotic elution,
has not previously been clarified since previous investiga-
tions have used static in vitro and animal in vivo models.
Nevertheless, these previous non-dynamic studies have
shown that the antibiotics are released in a biphasic manner
in a dose-dependent way39 and that the presence of vanco-
mycin increases the release of tobramycin.40
It is uncertain how the addition of a second antibiotic
enhances the release of another antibiotic, although it has
been proposed that the second antibiotic increases the
porosity of the cement thereby improving the release.40 Evi-
dence elsewhere has shown that the addition of lactose to
bone cement increases antibiotic release, as does increasing
the surface roughness and surface area.39 This complemen-
tary release of antibiotic has been termed by Penner et al40
as passive opportunism. However, at present in vitro testing
has not shown the ability of antibiotic bone cement to erad-
icate completely infection caused by bacteria which adhere
to biomaterials.41,42
Antibiotic elution characteristics have been quantified
from studies on various mammalian species.17,35,43-47 A
common pattern of a peak in the blood concentration after
a few hours followed by a gradual reduction in concentra-
tion has been found, which was replicated in our study.
These animal studies demonstrated that the local tissue
concentration of antibiotic was considerably higher than
that in the serum, and remained so for several weeks. How-
ever, the measured antibiotic concentration within the hae-
matoma reduced within a matter of days.
For staphylococcal species, vancomycin has a minimum
inhibitory concentration of 0.25 mg/l to 1.0 mg/l and a
minimum bactericidal concentration of 0.25 mg/l, while
tobramycin has a minimum inhibitory concentration of
0.12 mg/l to 1.0 mg/l and a minimum bactericidal concen-
tration of 0.1 mg/l to 32.0 mg/l.48,49 It is accepted that a
level of at least eight times the minimum inhibitory concen-
tration is required for successful treatment, especially con-
sidering the in vivo dilution which occurs with time.50 The
antibiotic elutions achieved in our study with dynamic
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Graph showing the comparison of vancomycin elution between
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loading were over ten times the respective minimum inhib-
itory concentration, 15 mg/l to 50 mg/l for vancomycin and
12 mg/l to 26 mg/l for tobramycin (Figs 4 and 5).
Masri et al13 using data obtained by joint aspiration
before a second-stage revision total hip replacement or
TKR have given the clinical guidelines for effective anti-
biotic concentration. Vancomycin had an inferior release
rate if used in isolation, and again the combination of
tobramycin with vancomycin gave encouraging results. The
release of vancomycin, as assessed by joint aspiration, was
found to reduce after four months to levels below the
threshold for microbiological activity. However, the addi-
tion of tobramycin prolonged its time of beneficial vanco-
mycin. On the strength of these clinical results, they
recommended that tobramycin be used in a concentration
of 3.6 g per 40 g of bone cement, provided that the articu-
lating spacer did not remain in situ for longer than three to
four months. Although providing guidelines, their study
was limited by the lack of a control group, confounding
patient factors, possible differences in the cement and anti-
biotic blending techniques and the inclusion of both hips
and knees. Our dynamic in vitro study, with a static control
group was not compromised by similar methodological
limitations. Our results have shown a better elution of
tobramycin from bone cement compared with vancomycin
for both static and dynamic loading, consistent with the
findings of other studies using static in vitro models.40,51
The method of antibiotic mixing with cement was stan-
dardised in our study since there is some evidence that
cement properties can be altered by the method of blending
of vancomycin and tobramycin.52
The addition of antibiotics to bone cement gives inferior
mechanical properties, including reduced strength under
both tensile and compressive loading.17,28,29 These proper-
ties have not been reported for the admixture of tobra-
mycin and vancomycin. Although we have shown in vitro
that a mixture of antibiotics under dynamic loading pro-
duces enhanced elution, the efficacy of low sustained
release of antibiotics in a clinical setting remains unclear.
Ideally, there should be an optimal antibiotic concentration
at the site of the potential infection at the time of the sur-
gery, and the benefit of continuing for a longer duration is
not substantiated.53
In the presence of renal impairment, extended release of
either tobramycin (an aminoglycoside) or vancomycin
(a glycopeptide) could potentially increase the risk of
nephrotoxicity and ototoxicity. The peak serum concentra-
tions required for the treatment of infection in other organ
systems range from 4 mg/l to 10 mg/l for tobramycin to
30 mg/ to 40 mg/l for vancomycin.54,55 Our results for the
elution of tobramycin and vancomycin into a simulated syn-
ovial fluid were similar in range. It is unlikely therefore that
concentrations would approach nephrotoxic serum levels.
An additional concern is that the widespread use of sim-
ilar antibiotic mixtures may hasten the emergence of resis-
tant strains. The clinician should always attempt therefore
to adjust any antibiotic treatment, whatever the delivery
method, in response to known tissue culture and sensitivity.56
The precise mechanism of antibiotic release from bone
cement is uncertain. It is generally thought that it is directly
released from the surface of the bone cement in the initial
phase, and then subsequently released from a network of
cracks and voids.39,57-59 Absorption of water to bone
cement is thought to have a role in controlling the slow
phase of antibiotic release.56-61 Our study suggests that
cyclical dynamic loading enhances this process, probably
by a mechanism of cyclical changes in the microstructure of
the bone cement.
Our results provide evidence that, in addition to the benefit
to the soft tissues claimed for articulating spacers, the dynamic
loading of cement knee spacers per se affords a biological
advantage by significantly enhancing antibiotic elution.
Listen live
Listen to the abstract of this article at 
www.jbjs.org.uk/interactive/audio
The authors would like to acknowledge the assistance of Dr A. Taylor (Aurora
Medical Ltd, Southampton, United Kingdom) in the preparation of this manu-
script. The authors would also like to thank Heraeus Kulzer GmbH (Hanau, Ger-
many) for the quantitative antibiotic analysis.
No benefits in any form have been received or will be received from a com-
mercial party related directly or indirectly to the subject of this article.
References
1. Winkelmann W, Schulitz KP, Knothe H, Schoening B. Concentration in bone and
haematoma of the aminoglycoside antibiotic tobramycin. Infection 1978;6:277-82 (in
German).
2. Mah TF, O’Toole GA. Mechanisms of biofilm resistance to antimicrobial agents.
Trends Microbiol 2001;9:34-9.
3. Gristina AG. Implant failure and the immuno-incompetent fibro-inflammatory zone.
Clin Orthop 1994;298:106-18.
4. Barrack RL, Sawhney J, Hsu J, Cofield RH. Cost analysis of revision total hip
arthroplasty: a 5-year followup study. Clin Orthop 1999;369:175-8.
5. Crowe JF, Sculco TP, Kahn B. Revision total hip arthroplasty: hospital cost and
reimbursement analysis. Clin Orthop 2003;413:175-82.
6. Grogan TJ, Dorey F, Rollins J, Amstutz HC. Deep sepsis following total knee
arthroplasty: ten-year experience at the University of California at Los Angeles Med-
ical Center. J Bone Joint Surg [Am] 1986;68-A:226-34.
7. Wilson MG, Kelley K, Thornhill TS. Infection as a complication of total knee-
replacement arthroplasty: risk factors and treatment in sixty-seven cases. J Bone
Joint Surg [Am] 1990;72-A:878-83.
8. Willis-Owen CA, Konyves A, Martin DK. Factors affecting the incidence of infec-
tion in hip and knee replacement: an analysis of 5277 cases. J Bone Joint Surg [Br]
2010;92-B:1128-33.
9. Bengtson S, Blomgren G, Knutson K, Wigren A, Lidgren L. Hematogenous infec-
tion after knee arthroplasty. Acta Orthop Scand 1987;58:529-34.
10. Bengtson S, Borgquist L, Lidgren L. Cost analysis of prophylaxis with antibiotics
to prevent infected knee arthroplasty. BMJ 1989;299:719-20.
11. Haddad FS, Masri BA, Campbell D, et al. The PROSTALAC functional spacer in
two-stage revision for infected knee replacements: prosthesis of antibiotic-loaded
acrylic cement. J Bone Joint Surg [Br] 2000;82-B:807-12.
12. Windsor RE, Insall JN, Urs WK, Miller DV, Brause BD. Two-stage reimplanta-
tion for the salvage of total knee arthroplasty complicated by infection: further follow-
up and refinement of indications. J Bone Joint Surg [Am] 1990;72-A:272-8.
13. Masri BA, Duncan CP, Beauchamp CP. Long-term elution of antibiotics from
bone-cement: an in vivo study using the prosthesis of antibiotic-loaded acrylic cement
(PROSTALAC) system. J Arthroplasty 1998;13:331-8.
14. Haddad FS, Bridgens A. Infection following hip replacement: solution options.
Orthopedics 2008;31:907-8.
15. Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone
cement for treatment of infected joint replacements. Clin Orthop 2004;427:79-85.
920 B. A. ROGERS, F. R. MIDDLETON, N. SHEARWOOD-PORTER, S. KINCH, A. ROQUES, N. W. BRADLEY, M. BROWNE
THE JOURNAL OF BONE AND JOINT SURGERY
16. Hanssen AD. Prophylactic use of antibiotic bone cement: an emerging standard: in
opposition. J Arthroplasty 2004;19(Suppl 1):73-7.
17. Marks KE, Nelson CL, Lautenschlager EP. Antibiotic-impregnated acrylic bone
cement. J Bone Joint Surg [Am] 1976;58-A:358-64.
18. Jacobs C, Christensen CP, Berend ME. Static and mobile antibiotic-impregnated
cement spacers for the management of prosthetic joint infection. J Am Acad Orthop
Surg 2009;17:356-68.
19. Villanueva-Martinez M, Rios-Luna A, Pereiro J, Fahandez-Saddi H, Villamor
A. Hand-made articulating spacers in two-stage revision for infected total knee
arthroplasty: good outcome in 30 patients. Acta Orthop 2008;79:674-82.
20. Bose WJ, Gearen PF, Randall JC, Petty W. Long-term outcome of 42 knees with
chronic infection after total knee arthroplasty. Clin Orthop 1995;319:285-96.
21. Freeman MG, Fehring TK, Odum SM, et al. Functional advantage of articulating
versus static spacers in 2-stage revision for total knee arthroplasty infection. J
Arthroplasty 2007;22:1116-21.
22. Emerson RH Jr, Muncie M, Tarbox TR, Higgins LL. Comparison of a static with a
mobile spacer in total knee infection. Clin Orthop 2002;404:132-8.
23. Evans RP. Successful treatment of total hip and knee infection with articulating anti-
biotic components: a modified treatment method. Clin Orthop 2004;427:37-46.
24. Hofmann AA, Goldberg T, Tanner AM, Kurtin SM. Treatment of infected total
knee arthroplasty using an articulating spacer: 2- to 12-year experience. Clin Orthop
2005;430:125-31.
25. Pitto RP, Spika IA. Antibiotic-loaded bone cement spacers in two-stage manage-
ment of infected total knee arthroplasty. Int Orthop 2004;28:129-33.
26. Fehring TK, Odum S, Calton TF, Mason JB. The Ranawat Award: articulating ver-
sus static spacers in revision total knee arthroplasty for sepsis. Clin Orthop
2000;380:9-16.
27. Takahira N, Itoman M, Higashi K, et al. Treatment outcome of two-stage revision
total hip arthroplasty for infected hip arthroplasty using antibiotic-impregnated
cement spacer. J Orthop Sci 2003;8:26-31.
28. Seldes RM, Winiarsky R, Jordan LC, et al. Liquid gentamicin in bone cement: a
laboratory study of a potentially more cost-effective cement spacer. J Bone Joint Surg
[Am] 2005;87-A:268-72.
29. He Y, Trotignon JP, Loty B, Tcharkhtchi A, Verdu J. Effect of antibiotics on the
properties of poly(methylmethacrylate)-based bone cement. J Biomed Mater Res
2002;63:800-6.
30. Joseph TN, Chen AL, Di Cesare PE. Use of antibiotic-impregnated cement in total
joint arthroplasty. J Am Acad Orthop Surg 2003;11:38-47.
31. Stefánsdóttir A, Johansson D, Knutson K, Lidgren L, Robertsson O. Microbiol-
ogy of the infected knee arthroplasty: report from the Swedish Knee Arthroplasty Reg-
ister on 426 surgically revised cases. Scand J Infect Dis  2009;41:831-40.
32. Scott CP, Higham PA, Dumbleton JH. Effectiveness of bone cement containing
tobramycin: an in vitro susceptibility study of 99 organisms found in infected joint
arthroplasty. J Bone Joint Surg [Br] 1999;81-B:440-3.
33. Baleani M, Persson C, Zolezzi C, et al. Biological and biomechanical effects of
vancomycin and meropenem in acrylic bone cement. J Arthroplasty 2008;23:1232-8.
34. Hendriks JG, van Horn JR, van der Mei HC, Busscher HJ. Backgrounds of anti-
biotic-loaded bone cement and prosthesis-related infection. Biomaterials
2004;25:545-56.
35. Schurman DJ, Trindade C, Hirshman HP, et al. Antibiotic-acrylic bone cement
composites: studies of gentamicin and Palacos. J Bone Joint Surg [Am] 1978;60-
A:978-84.
36. Urabe K, Naruse K, Hattori H, et al. In vitro comparison of elution characteristics
of vancomycin from calcium phosphate cement and polymethylmethacrylate. J
Orthop Sci 2009;14:784-93.
37. Liu W, Maitland ME. The effect of hamstring muscle compensation for anterior lax-
ity in the ACL-deficient knee during gait. J Biomech 2000;33:871-9.
38. Haleem AA, Berry DJ, Hanssen AD. Mid-term to long-term followup of two-stage
reimplantation for infected total knee arthroplasty. Clin Orthop 2004;428:35-9.
39. Virto MR, Frutos P, Torrado S, Frutos G. Gentamicin release from modified acrylic
bone cements with lactose and hydroxypropylmethylcellulose. Biomaterials
2003;24:79-87.
40. Penner MJ, Masri BA, Duncan CP. Elution characteristics of vancomycin and
tobramycin combined in acrylic bone-cement. J Arthroplasty 1996;11:939-44.
41. van de Belt H, Neut D, Schenk W, et al. Gentamicin release from polymethyl-
methacrylate bone cements and Staphylococcus aureus biofilm formation. Acta
Orthop Scand 2000;71:625-9.
42. van de Belt H, Neut D, Schenk W, et al. Staphylococcus aureus biofilm formation
on different gentamicin-loaded polymethylmethacrylate bone cements. Biomaterials
2001;22:1607-11.
43. Picknell B, Mizen L, Sutherland R. Antibacterial activity of antibiotics in acrylic
bone cement. J Bone Joint Surg [Br] 1977;59-B:302-7.
44. Rodeheaver GT, Rukstalis D, Bono M, Bellamy W. A new model of bone infec-
tion used to evaluate the efficacy of antibiotic-impregnated polymethylmethacrylate
cement. Clin Orthop 1983;178:303-11.
45. Hoff SF, Fitzgerald RH Jr, Kelly PJ. The depot administration of penicillin G and
gentamicin in acrylic bone cement. J Bone Joint Surg [Am] 1981;63-A:798-804.
46. Wahlig H, Buchholz HW. Experimental and clinical studies on the release of gen-
tamicin from bone cement. Chirurg 1972;43:441-5 (in German).
47. Baker AS, Greenham LW. Release of gentamicin from acrylic bone cement: elution
and diffusion studies. J Bone Joint Surg [Am] 1988;70-A:1551-7.
48. Greene N, Holtom PD, Warren CA, et al. In vitro elution of tobramycin and vanco-
mycin polymethylmethacrylate beads and spacers from Simplex and Palacos. Am J
Orthop (Belle Mead NJ) 1998;27:201-5.
49. Reimer LG, Mirrett S, Reller LB. Comparison of in vitro activity of moxalactam
(LY127935) with cefazolin, amikacin, tobramycin, carbenicillin, piperacillin, and ticar-
cillin against 420 blood culture isolates. Antimicrob Agents Chemother 1980;17:412-
16.
50. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials: treatment
optimisation. Expert Opin Drug Metab Toxicol 2005;1:351-61.
51. Adams K, Couch L, Cierny G, Calhoun J, Mader JT. In vitro and in vivo evaluation
of antibiotic diffusion from antibiotic-impregnated polymethylmethacrylete beads.
Clin Orthop 1992;278:244-52.
52. Lewis G, Janna S, Bhattaram A. Influence of the method of blending an antibiotic
powder with an acrylic bone cement powder on physical, mechanical, and thermal
properties of the cured cement. Biomaterials 2005;26:4317-25.
53. Guven GS, Uzun O. Principles of good use of antibiotics in hospitals. J Hosp Infect
2003;52:91-6.
54. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an
aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
Antimicrob Agents Chemother 1999;43:1549-55.
55. Chan GL. Alternative dosing strategy for aminoglycosides: impact on efficacy, neph-
rotoxicity, and ototoxicity. DICP 1989;23:788-94.
56. van de Belt H, Neut D, van Horn JR, et al. .....or not to treat? Nat Med 1999;5:358-
9.
57. van de Belt H, Neut D, Uges DR, et al. Surface roughness, porosity and wettability
of gentamicin-loaded bone cements and their antibiotic release. Biomaterials
2000;21:1981-7.
58. van de Belt H, Neut D, Schenk W, et al. Infection of orthopedic implants and the
use of antibiotic-loaded bone cements: a review. Acta Orthop Scand 2001;72:557-71.
59. Law HT, Fleming RH, Gilmore MF, McCarthy ID, Hughes SP. In vitro measure-
ment and computer modelling of the diffusion of antibiotic in bone cement. J Biomed
Eng 1986;8:149-55.
60. Bayston R, Milner RD. The sustained release of antimicrobial drugs from bone
cement: an appraisal of laboratory investigations and their significance. J Bone Joint
Surg [Br] 1982;64-B:460-4.
61. Unemori M, Matsuya Y, Matsuya S, Akashi A, Akamine A. Water absorption of
poly(methylmethacrylate) containing 4-methacryloxyethyl trimellitic anhydride. Biom-
aterials 2003;24:1381-7.
 Appendix	15	
 
Rogers BA, Phillips S, Foote J, Drabu KJ.  
Is there adequate provision of venous thromboembolism prophylaxis following hip 
arthroplasty? An audit and international survey.  
Ann R Coll Surg Engl. 2010 Nov;92(8):668–72. 
 
Contribution by BA Rogers. 
Concept 
Data collection & analysis 
Manuscript writing & editing 
 
Citation Metrics 
 
Web Of Science:  6 
Google Scholar:  11 
Altmetrics:    24 
Tweets:  1 
Facebook:  0 
Mendeley readers: 23 
 
	 	
157 
Ann R Coll Surg Engl 2010; 92: 668–672668
Venous thrombo-embolism (VTE) prophylaxis following
orthopaedic surgery remains a controversial topic and the
incidence of fatal pulmonary embolism is approximately
0.4% if no measures are taken, equating to over 5000 fatal-
ities a year for the 1.5 million hip and knee replacements
performed in Europe.1–3 The 2009 National Confidential
Enquiry into Patient Outcome and Death (NCEPOD) report
has highlighted that prophylaxis against VTE was less than
ideal, with nearly 50% of surgical patients not receiving
VTE precautions.4 Furthermore, the current President of
The Royal College of Surgeons of England has urged sur-
geons to make the ‘prevention of VTE a clinical priority’.5
Recent studies investigating the incidence of postopera-
tive VTE demonstrate that the mean time to thrombo-
embolism is greater than previously estimated. Two large
meta-analyses advocate VTE prophylaxis be continued for
up to 4 weeks following total hip arthroplasty surgery
(THA).6,7 The Global Orthopaedic Registry recently pub-
lished that the mean duration to peak incidence of venous
thrombo-embolism following THA to be 21.5 days.8 Concern
now exists that the length of treatment varies depending
upon the prophylaxis used.
Few pharmaceutical options exist for VTE prophylaxis
and rivaroxaban (Xarelto®, Bayer), a new once-daily oral
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ABSTRACT
INTRODUCTION The peak incidence of venous thrombo-embolism (VTE) occurs 3 weeks following hip arthroplasty surgery and
current guidelines proposing VTE prophylaxis continuing for 4 weeks after surgery. This study first compares the duration of
treatment and satisfaction between patients prescribed low molecular weight heparin (LMWH) and rivaroxaban, a new oral
Factor Xa inhibitor, following elective hip arthroplasty; and second, surveys the duration of LMWH use in other units.
SUBJECTS AND METHODS An international survey detailing the use of LMWH was performed. A prospective audit was per-
formed of 100 hip replacements, with 50 prescribed 40 mg once daily of subcutaneous enoxaparin and subsequently 50
patients prescribed 10 mg once daily of oral rivaroxaban. The duration of treatment, patient satisfaction and complications for
both cohorts was quantified and compared against published evidence-based guidelines.
RESULTS The survey demonstrated that four out of 39 (10.2%) units that routinely prescribe LMWH do so for at least 4 weeks
following surgery. The audit demonstrated that rivaroxaban afforded a superior mean duration of postoperative VTE prophylaxis
(35 days vs 5.4 days; P < 0.05) and superior patient satisfaction. There was no difference in the incidence of bleeding, wound
infection or thrombotic complications.
CONCLUSIONS This study demonstrates that patients are exposed to an increased VTE risk following hip replacement surgery
due to the inadequate prescription of LMWH. This is poor clinical practice, contrary to current evidence-based guidelines and
has potential medicolegal implications. The prescription of rivaroxaban affords a superior patient compliance compared with
subcutaneous LMWH, thus ensuring that patients receive VTE prophylaxis for the current recommend period of time.
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Factor Xa inhibitor, is licensed in the UK for VTE prophylax-
is following elective lower limb arthroplasty surgery.9
Published evidence has demonstrated the efficacy of
rivaroxaban to be equal to LMWH.10,11 In the UK, LMWH is
commonly used following lower limb arthroplasty, support-
ed by the recommendations of the National Institute for
Health and Clinical Excellence (NICE) that have been
recently been updated to incorporate oral VTE prophylaxis,
such as rivaroxaban and dabigatran (Pradaxa®, Boehringer
Ingelheim).12–14 These guidelines advocate an extended
period of VTE prophylaxis of 28–35 days following hip
arthroplasty surgery.14
The rationale of this two-part study was to assess, using
a local audit and international survey, the duration of VTE
prophylaxis currently achieved with LMWH and to examine
whether this may be improved with the use of rivaroxaban,
an oral Factor Xa inhibitor.
Subjects and Methods
Local departmental approval had been granted for the pre-
scription of rivaroxaban following hip arthroplasty surgery, in
conjunction with the discussions with the anaesthetic and
pharmacy departments. All surgical procedures were per-
formed or directly supervised by the senior author (KJD).
Verbal and written consent was obtained for all patients
and the inclusion criteria were all primary and revision hip
arthroplasty surgery in patients with an American Society of
Anesthesiologists (ASA) score of 1. The exclusion criteria
for this study were; previous anticoagulation therapy, clot-
ting or bleeding abnormalities, significant medical co-mor-
bidities with an ASA score of 2 or more and patient with-
holding consent.
An initial retrospective survey of 56 consecutive patients
who were prescribed 4 weeks of once daily dose of 40 mg of
enoxaparin (Clexane®, Sanofi-Aventis), a low molecular
weight heparin (LMWH) administrated subcutaneously.
This was routine practice in our department for all patients
following primary or revision hip arthroplasty surgery. For
each patient, we documented the duration of prophylaxis
received, the incidence of any notable complications and a
simple patient satisfaction rating score from 1–5 (most dis-
satisfied, dissatisfied, ambivalent, satisfied, most satisfied).
Following assessment of the results from the initial sur-
vey, and in collaboration with the anaesthetic and pharma-
cy colleagues, a planned introduction of rivaroxaban was
instigated, in accordance with the current evidence for
extended VTE prophylaxis, to continue for 35 days following
THA surgery.
The prospective portion of this audit commenced imme-
diately following the analysis of the initial survey and there
was no other change in patient management. An initial con-
secutive cohort of 54 patients were prescribed a once daily
oral dose of 40 mg rivaroxaban, commenced within 24-h of
surgery. Patients received a standard rivaroxaban informa-
tion sheet prior to surgery and had the opportunity to ask
questions when pre-operative consent was obtained.
A local and international survey of 50 English-speaking
orthopaedic units regarding current VTE prophylaxis prac-
tice following THA surgery was performed by both post and
telephone, with a proforma utilised for standardisation.
Responses were obtained from 43 units, a response rate of
86%. The local survey included district general and teach-
ing hospitals from all UK regions, with the international
survey was limited to large university departments in
Australia and Canada.
This was an unsponsored study and we confirm there
was no conflict of interest and no financial support has been
received in relation to this research. Statistical analysis was
carried out using SPSS v11.0.
Results
There was no statistical difference in the demographics or
the numbers of primary and revision hip arthroplasty sur-
gery performed for each cohort, as shown in Table 1.
The initial retrospective survey of 56 patients prescribed
LMWH, the mean duration of treatment of 5.4 days (range,
2–16 days). Further, only 39 out of these 56 patients (69%)
received LMWH every day whilst an in-patient. The mean
patient satisfaction rating for LMWH was 1.2 out of 5. The
secondary survey of 54 patients prescribed rivaroxaban, the
mean duration of treatment was 35 days (no variance), with
all patients reported taking exactly 35 days. The mean
patient satisfaction rating for this patient cohort was 3.5 out
of 5, significantly superior (P < 0.05) to LMWH. The com-
parison of the mean duration of treatment and respective
satisfaction ratings for both cohorts is shown in Figures 1
LMWH Rivaroxaban P-value
group group
Total number 56 54a >> 0.05
Male 23 26b
Female 33 28b
Age (years) 72 (41–85) 67 (35–79)a
Primary THA 45 47a
Revision THA 11 7a
Statistical tests: aStudent’s t-test; bchi–squared test.
Table 1 Patient demographics and associated surgical
procedure for low molecular weight heparin (LMWH) and
rivaroxaban cohorts
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and 2. There was a statistically significant difference (P =
0.003) in the duration of treatment between the two cohorts.
However, there was no statistical difference in the docu-
mented associated complications for both cohorts are
shown in Table 2. One patient in the LMWH cohort devel-
oped a pulmonary embolism 23 days following surgery and
was re-admitted under the care of the physicians and was
anti-coagulated with warfarin.
The results of the national and international postal and
telephone survey regarding the use of LMWH in
orthopaedic units for elective hip arthroplasty survey are
shown in Table 3. Overall, of the 43 orthopaedic units sur-
veyed, 39 routinely prescribe LMWH following surgery.
However, only four units out of the 39 (10.2%), prescribe
LMWH for at least 5 weeks.
Discussion
The risk of post-discharge symptomatic thrombosis follow-
ing hip surgery can be reduced by two-thirds if VTE prophy-
laxis is continued for at least 28 days.15–18. The issue now
exists as to how VTE prophylaxis can best be provided for
28–35 days following a surgical procedure that routinely
requires a hospital stay of less than 7 days?
In light of the evidential support for a 35-day extended
period of VTE prophylaxis following hip arthroplasty sur-
gery, the survey results presented in this study, in addition
to those of large multicentre arthroplasty registries, high-
light that few patients receive LMWH for an adequate dura-
tion.19,20 The results of a large postal survey of orthopaedic
surgeons showed only 42% prescribe an extended duration
of VTE prophylaxis beyond discharge, nearly all of which
use aspirin.21 However, the use of aspirin for extended VTE
prophylaxis is now questioned since the Pulmonary
Embolism Prevention (PEP) study of over 4000 total hip and
knee replacements concluded that aspirin provides no ben-
efit over placebo, whilst the 160 mg dosage has an associat-
ed significant risk of gastrointestinal bleeding.22
Patients
prescribed
Use LMWH 4 weeks of
LMWH
Canada/Australia 10/12 2/10
UK district general hospital 23/25 2/23
UK teaching hospital 6/6 0/6
Table 3 National and international survey of use and
duration of use of low molecular weight heparin (LMWH)
LMWH Rivaroxaban P-value
group group
Significant bleeding 3 1 >> 0.05
Wound dehiscence 0 0
Wound infection 3 1
DVT 0 0
Pulmonary embolism 1 0
Table 2 Documented adverse affects with no significant
differences between the low molecular weight heparin
(LMWH) and rivaroxaban cohorts
Figure 2 Patient satisfaction scores for low molecular weight
heparin (LMWH) and rivaroxaban, demonstrate a significantly
greater satisfaction with rivaroxaban (P < 0.05). (1–5, most dissat-
isfied, dissatisfied, ambivalent, satisfied, most satisfied).
Figure 1 Duration of treatment with low molecular weight heparin
(LMWH) and rivaroxaban reported by patients following hip arthro-
plasty surgery.
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Extensive evidence exists supporting the efficacy of
LMWH in VTE prophylaxis following lower limb joint
arthroplasty; however, logistical and medical concerns exist
regarding its use for an extended period of 28–35 days.23–25
Furthermore, heparin-induced thrombocytopenia (HIT) is a
known complication of LMWH use and guidelines recom-
mend that all patients should be monitored for this poten-
tially fatal condition.26,27 However, recent evidence shows
few patients are monitored for HIT and indeed very few
orthopaedic surgeons are aware of the relevant guide-
lines.28,29 The practicalities of daily subcutaneous injections
for up to 35 days can cause difficulties, often necessitating a
nurse to administer LMWH to the patient, at considerable
financial cost. Therefore, LMWH does provide adequate
VTE prophylaxis provided it is correctly administered, for
the correct duration and suitable monitoring for HIT is car-
ried out.
Rivaroxaban is a new oral Factor Xa inhibitor that is
licensed in the UK for VTE prophylaxis following lower
limb arthroplasty.27 Several multicentre studies compare
LMWH with rivaroxaban to support its introduction into cli-
nician practice.10,30–32 In summary, rivaroxaban has been
demonstrated to be at least as effective as LMWH for VTE
prophylaxis. The results of this study demonstrate that it is
simple to introduce, and it affords a superior duration of
prophylaxis in comparison to LMWH. All the patients in the
rivaroxaban cohort received 35 days of treatment.
Undoubtedly, the convenience of the oral preparation is the
principal factor explaining this, highlighted by the associat-
ed superior patient satisfaction. The lack of the requirement
for HIT monitoring is a further benefit.
Whilst the documented complications in Table 2 show a
higher number of adverse effects in the LMWH cohort,
including bleeding, wound infection and one case of pul-
monary embolism, the low numbers in this study preclude
any statistical judgement from being made.
In addition to rivaroxaban, a direct Factor Xa inhibitor,
dabigatran (Pradaxa®, Boehringer Ingelheim) a direct
thrombin inhibitor has also been similarly licensed for VTE
prophylaxis. Recent studies provide evidence for the effica-
cy of dabigatran in comparison to LMWH; however, to date,
no study has directly compared rivaroxaban with dabig-
tran.33–35 One area of debate is the bleeding risk profile of
these therapeutic agents; however, since the only data
available use surrogate comparisons with LMWH, no statis-
tical difference has yet been shown.14 Long-term studies
will hopefully provide clarification in the future.
The financial cost of the wide-spread introduction of a
new drug must be considered. Using current pricing sched-
ules from the British National Formulary,27 the cost of 4
weeks’ treatment with rivaroxaban (Xarelto® 10 mg once
daily oral, Bayer) is £157, compared with £117 for a similar
course of enoxaparin (Clexane® 40 mg once daily subcuta-
neous, Sanofi-Aventis). However, if one factors in the costs
involved with actually administering enoxaparin, possibly
including a district nurse, and correctly monitoring for HIT
with regular platelet counts, the difference in cost is likely
to be minimal. Furthermore, a UK cost analysis has been
incorporated into the technology appraisal guidance by
NICE,36 concluding that both rivaroxaban and dabigatran
were ‘an appropriate use of NHS resources’.
Conclusions
This study highlights that the duration of VTE prophylaxis fol-
lowing hip arthroplasty surgery currently achieved with
LMWH is inadequate in light of the evidence-based guidelines
for extended prophylaxis of 35 days. Further, we demonstrate
that this inadequate treatment may be improved with the use
of rivaroxaban, a new oral Factor Xa inhibitor.
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This prospective study examines patient non-compliance (NC) for an oral factor Xa inhibitor (Rivaroxaban)
when used as venous thromboembolic (VTE) prophylaxis following lower limb arthroplasty. A total of 3145
patients underwent surgery fromMay 2010 to December 2011. At 6 weeks patients completed an anonymous
self-administered questionnaire. Postoperatively 2947 (94%, 2947/3145) received Rivaroxaban. 2824 (96%,
2824/2947) completed all in-hospital doses. Seven percent (203/2824) of patients did not attend the 6-week
follow-up. Two thousand one hundred sixty-three (83%, 2163/2621) completed all prescribed doses, 98 (4%,
98/2621) were NC and 360 (14%, 360/2621) had incomplete data. Gender, age, body mass index and
preoperative hemoglobin all correlated with NC (p b 0.05). Type and side of surgery did not correlate with
compliance (p N 0.05). Patient-reported NC for Rivaroxaban is 4% which compares favorably to other VTE
prophylaxis modalities.
Crown Copyright © 2014 Published by Elsevier Inc. All rights reserved.
Oral factor Xa inhibitors are small-molecule direct inhibitors that
target a single enzyme in the coagulation cascade. Theywere designed
to overcome the limitations of traditional anticoagulants, namely the
need for monitoring of International Normalized Ratio (INR) and
administration by injection. Several randomized trials have demon-
strated that oral factor Xa inhibitors are as efﬁcacious as other
traditional modalities for the prevention of postoperative VTE and
have similar safety proﬁles [1–6].
When present, up to one third of detected thrombi are located in
proximal lower limb vasculature which are more likely to embolize,
potentially causing fatal pulmonary emboli (PE) [7]. Extensive
evidence suggests enhanced activation of coagulation for at least
4 weeks after total hip arthroplasty (THA) [8,9] and the increased risk
of symptomatic venous thromboembolism (VTE) continues for up to
3 months after THA [9–14]. In a further study of nearly 24,000 THA
patients, 76% of the thromboembolic events were diagnosed after
hospital discharge [12].
The proportion of THA and total knee arthroplasty (TKA) patients
who receive any form of prophylaxis ranges from 88% to 100%
[12,15,16]. There are several published guidelines regarding the
duration of thromboprophylaxis following lower limb arthroplasty
surgery (Table 1) and several chemotherapeutic options have been
advocated including aspirin [19,20], coumadin [21–23], low-molecu-
lar-weight heparins (LMWH) [24–26], direct thrombin inhibitors
[27,28], and oral factor Xa Inhibitors [29–31].
The level of compliance with evidence-based guidelines for the
prevention of VTE has been questioned following orthopedic and
general surgical procedures [16]. In the light of increased risk of
VTE-related problems following lower limb arthroplasty and a
clear trend in both Europe and North America for shorter periods of
in-patient hospitalization, patient non-compliance (NC) to outpa-
tient VTE prophylactic prescribed medications is increasingly
important. Studies have highlighted concerns regarding non-
compliance rates for coumadin [32] with the required monitoring
of INR and LMWH [32–34] with the risk of heparin-induced
thrombocytopenia [35,36]. These studies have reported rates of
non-compliance from 27% to 37% for LMWH [32,34] and 52% to 77%
for coumadin [32].
Following the WHO deﬁnition, medication non-compliance can be
deﬁned as the extent to which patients' drug-taking behavior deviates
from the instructions provided by the health care provider [37,38].
There is no clinically based deﬁnition for VTE NC, owing to the lack of
The Journal of Arthroplasty 29 (2014) 1463–1467
Disclosure: The Institution received an education grant from Bayer Healthcare Inc.
in support of this study. Neither the authors nor a member of their immediate family
received payments or other beneﬁts or a commitment or agreement to provide such
beneﬁts from a commercial entity.
The Conﬂict of Interest statement associated with this article can be found at http://
dx.doi.org/10.1016/j.arth.2013.02.001.
Reprint requests: Andrew D. Carrothers, MBChB, FRCS(Orth), 4 Green Man Lane,
Harston, Cambridge, Canada CB22 7PY.
http://dx.doi.org/10.1016/j.arth.2013.02.001
0883-5403/Crown Copyright © 2014 Published by Elsevier Inc. All rights reserved.
Contents lists available at ScienceDirect
The Journal of Arthroplasty
j ourna l homepage: www.arth rop lasty journa l .o rg
evidence as to the number of “missed VTE prophylaxis doses” that
increase the risk of thrombosis or pulmonary embolism.
Newer oral anticoagulants may play an important role in
increasing the effectiveness, safety and convenience of VTE prophy-
laxis, which in turn may decrease VTE NC [34,39]. The aims of this
studywere to evaluate the rate of compliance to a prescribed course of
factor Xa inhibitor (Rivaroxaban, Bayer Schering Pharma AG, Berlin,
Germany) following hip and knee arthroplasty, and to examine
factors that may be associated with treatment compliance. Although
these newer oral thromboprophylactic agents are now available, the
patients' compliance rate is as yet unknown in the orthopedic
arthroplasty cohort of patients. This study compares the compliance
rate of Rivaroxaban to the established literature compliance rates of
other traditional VTE preventative modalities. The NC patients were
then compared to the compliant group for age, gender, body mass
index, type of surgery, preoperative hemoglobin level and receiving a
blood transfusion or any bleeding issues after discharge from hospital
to examine for NC patient risk factors.
Materials and Methods
Prospectively collected data of all patients who had undergone
total hip and knee arthroplasty from May 3, 2010 to December 14,
2011 at a multi-surgeon, single, tertiary orthopedic center were
reviewed. All patients were treated with rivaroxaban following
primary and revision total hip and total knee arthroplasty who did
not present on long-term anticoagulation or had contraindications to
use of the drug: poor renal function, poor liver function, allergy to this
medication and cytochromeP3A4 stimulating and inhibiting drugs per
drug monograph.
Patients were prescribed a 15-day course of rivaroxaban starting
on postoperative day 1 and completed as an outpatient. The current
recommendations from the manufacturer are 14 days of treatment
starting 6–8 h post-surgery for total knee arthroplasty and 35 days for
total hip arthroplasty. We consulted with our local experts on
thromboembolism and after review of the literature we felt that
there was good evidence for at least 10 days of treatment but limited
evidence for longer treatment. With respect to starting 6–8 h of
surgery, we wanted to balance effective thromboprophylaxis with
effective hemostasis. The new agent, rivaroxaban, had a faster onset to
therapeutic anticoagulation than warfarin and we felt that we were
not exposing patients to unnecessary risk by starting their thrombo-
prophylaxis themorning after surgery. With respect to the duration of
treatment, we argued that the operative times are now shorter, the
soft tissue incisions are smaller, the patients are mobilized weight
bearing the day after surgery and our institution's average length of
stay is 4.4 ± 1.8 days for primary unilateral total knee arthroplasty
and 4.5 ± 2.4 days for primary unilateral total hip arthroplasty. Based
on these reasons, we felt that most patients are mobile by 15 days
following surgery and should be at low risk for thromboembolic
events by that time post-surgery.
As standard of care, patients were seen at approximately 6 weeks
following surgery at which time they were given a self-administered
questionnaire. Patients were asked to answer the following questions:
1) Were you given a prescription for medication (Rivaroxaban) to
prevent blood clots when you were discharged from hospital?
2) Did you take that medication daily until it was ﬁnished?
Additionally, they were asked whether they had experienced any
bleeding issues with the medication or if they had received a blood
transfusion since discharge from hospital. Responses were documen-
ted as “yes” and “no.” Throughout this study we used the World
Health Organisation (WHO) deﬁnition for anemia: hemoglobin
b 130 g/l for males and b 120 g/l for females.
In concordance to the current published literature on VTE modality,
non-compliance, for the purpose of this study has been deﬁned as the
patient omitting a single dose or more of their discharge postoperative
VTE prophylaxis medication. The compliance of patients' prescribed
15-day therapy was then calculated and compared to the published
literature compliance rates of other thromboprophylaxis agents.
Approval for using the existent database was obtained from the
Research Ethics Board at Sunnybrook Health Science Center.
The corporation, Bayer Healthcare, provided funding for this
project as an education grant. They provided funding without any
conditions. They did not have access to data collection, data entry,
data analysis or writing of the manuscript. No prior approval was
required by the company prior to submission.
Statistical Analysis
Descriptive statistics [means, standard deviation (SD)] were
calculated. Fisher' exact tests and chi-square (χ2) tests were used to
examine the relationship between compliance and patient gender,
type of surgery and post-discharge blood transfusion or bleeding
issues. Logistic regressions were used to examine the impact of age,
BMI, and preoperative hemoglobin (predictor variables) on the binary
variable of compliance (response variable).
Results
A total of 3145 patients [1214 (39%) men, 1931 (61%) females,
mean age 66 (SD: 11, range 17–94)] underwent lower limb
arthroplasty at the Holland Orthopaedic & Arthritic Centre, Sunny-
brook Health Sciences Centre (Fig. 1). These were performed by nine
fellowship-trained arthroplasty surgeons. Types of surgeries were as
follow: 1676 (53%) primary TKA, 1166 (37%) primary THA, 174 (6%)
revision TKA, 126 (4%) revision THA, and 3 uni-compartmental TKA
(0.1%) during a period of 20 months (Table 2). The average length of
stay was 4.4 ± 1.8 days for primary unilateral total knee arthroplasty
and 4.5 ± 2.4 days for primary unilateral total hip arthroplasty.
Of 3145 patients, 2947 (94%) were started postoperatively on
Rivaroxaban, of which 2824 (96%) completed all in-hospital doses
(Fig. 1). Rivaroxaban was discontinued if the surgical team had
concerns about hemostasis at the surgical site, non-surgical site
bleeding (IV cannula site, femoral nerve block catheter site,
hematuria) or if there was a thromboembolic event. In the presence
of a proximal DVT or PE the patient was treated with a therapeutic
dose of low-molecular-weight heparin andmaintained on therapeutic
anticoagulation with warfarin for 3–6 months. If there was signiﬁcant
elevation in either the patient's creatinine level or liver function tests,
a change to another thromboprophylactic drug was made.
Table 1
Published Guidelines Regarding the Duration of Thromboprophylaxis Following Total
Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA).
Clinical Group
Duration of Thromboprophylaxis Surgery (d)
THA TKA
ICS International Consensus
Statement [17]
28–42 Unstated
(manufacturer
guidelines)
ACCP American College of
Chest Physicians [7]
10–35 Minimum 10
AAOS American Academy of
Orthopaedic Surgeons
Recommend but
duration to be
discussed with patient
Recommend but
duration to be
discussed with patient
GLORY Global Orthopaedic
Registry [18]
Minimum 10 Minimum 10
NICE National Institute of
Clinical Excellence (UK)
28–35 10–14
SIGN Scottish Intercollegiate
Guidelines Network (UK)
35 14
Optimal duration
unclear
Optimal duration
unclear
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Six-week follow-up was attended by 2621 (93%) of patients. Of
2621 patients, 2163 (83%) reported that they had completed all doses.
Of the remaining patients, 98 (4%, 98/2621) reported that they did not
complete all doses and 360 (14%, 360/2621) patients hadmissing data
on one of the relevant questions. In the worst-case scenario, when all
missing data including those patientswho did not attend their 6-week
follow-up appointment (203/2824) are considered as NC, the
compliance rate is 77% (661/2824).
We further examined the impact of gender, age, BMI, preoperative
hemoglobin, and post-discharge bleeding issues and need for blood
transfusion on Rivaroxaban NC (Table 3). Women tended to be more
NC (68% vs. 32%, χ2 = 8.61, p = 0.003). Type of surgery (THA vs.
TKA; primary vs. revision) and side (unilateral vs. bilateral) were not
associated with compliance (p N 0.05). Having a blood transfusion in
hospital had a negative impact on completion of all doses of
rivaroxaban. Overall 37% of NC had an in-hospital blood transfusion
(vs. 16% of NC who did not have a blood transfusion (χ2 = 26,
p b 0.0001).
The NC groupwasmore likely to be older (mean age 70 vs. 65 years,
Waldχ2 = 77, p = b 0.0001), have a smaller BMI (meanBMI 29 vs. 31,
Wald χ2 = 11.45, p = 0.0007) and also have a lower preoperative
hemoglobin (mean Hb 138 vs. 141, Wald χ2 = 19.36, p b 0.0001).
In total, 23 patients reported receiving a blood transfusion post-
hospital discharge at their 6-week review. Of these 10 (43%) patients
were in the NC group (χ2 = 13.95, p b 0.0001). Incidence of bleeding
issues reported at 6 weeks was not related to compliance (p N 0.05).
Seven pulmonary emboli (PE) and 6 deep vein thrombosis (DVT)
were reported at 6 weeks postoperatively. Four (4%) of 98 non-
compliant patients developed a PE compared to 3 (0.1%) of 2163
patients in the compliant group. This was statistically signiﬁcant
(Fisher's exact test = 0.01, p b 0.0001). One (1%) of 98 non-compliant
patients developed a DVT compared to 5 (0.2%) of 2163 patients who
were in the compliant group. The number of DVTs was not signiﬁcantly
different between groups (Fisher's exact test = 0.2, p = 0.23).
Discussion
Outpatient NC to prescribed medications is an ongoing problem, of
whichmuch has been published in the literature. Up to 20% of patients
fail to collect their prescribed drug and are therefore non-compliant
from the start [40]. From those patients who do collect their
prescribed medications, rates of compliance have been shown to be
related to many factors including the following: the enthusiasm of the
prescribing doctor, the disease being treated or primarily prevented
(VTE prophylaxis) and the patient's perception of the importance of
the disease [41]. Certainly a more detailed understanding of NC
explanatory factors is essential for the development of sophisticated
patient compliance programs. In particular, factors such as the
detailed recommendations given by general practitioners, the
patient–doctor relationship, the patients' education regarding throm-
bosis risk and psychological factors describing patients' behavior and
thinking require more detailed investigation [42].
Fig. 1. Flowchart showing the structure of the study patient population.
Table 2
Patient Cohort Demographics.
Patient Demographics (N = 3145 Total Arthroplasty Cases)
Sex 1214 (39%) male 1931 (61%) female
Age (y) Mean age 66 SD 11 (range 11–74)
Type of surgery Primary TKA
1676 (53%)
Primary THA
1166 (37%)
Revision TKA
174 (6%)
Revision THA
126 (4%)
Knee uni-compartmental
3 (0.1%)
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Caron and Roth [43] showed that doctors could not predict their
patients' compliance more accurately than by chance. Speciﬁc
methods must be used if compliance is to be accurately assessed.
Direct questioning is useful in establishing whether a patient is
compliant, particularly when an anonymous questionnaire is used. In
this manner the patient does not perceive any possible future
detrimental effect or treatment bias due to NC. Other objective
means of assessing compliance include the following: tablet counting,
measuring the concentration of the drug in body ﬂuids, measuring a
marker substance added to the drug or measuring the pharmacolog-
ical effect.
Due to the lack of evidence as to the number of missed VTE
prophylaxis modality doses which increase the risk of thrombosis or
pulmonary embolism, there is currently no clinically based deﬁnition
for VTE NC. In concordance to the current published literature on VTE
modality NC, we have deﬁned “non-compliance” as the patient
omitting a single dose or more of their discharge home postoperative
VTE prophylaxis medication.
Evidence exists for an extended period of thromboprophylaxis
after hospital discharge following TKA and THA [12,44]. Warwick et al.
[18] reported a multicenter study of nearly 15,000 cases, with the
mean time to venous thromboembolism of 21.5 days for THA and
9.7 days for TKA. Oral anticoagulants therefore have a signiﬁcant
potential role in an extended period of VTE prophylaxis.
Coumadin is inexpensive and effective if used as recommended
with a long history of VTE prophylaxis in North America [7]. In Europe,
concerns regarding coumadin's unpredictable pharmacological proﬁle
with an interval to therapeutic effect up to 60 hours, drug and food
interactions, varied patient response and the need for frequent
laboratory monitoring have resulted in its use being almost
completely abandoned [45,46]. New treatment strategies for couma-
din including pharmacogenetic dosing and a lower target INR range
are currently under investigation [47].
Injectable LMWH remains the dominant form of VTE prophylaxis
in Europe. Wilke and Muller [48] reviewed the literature for those
patients who had major orthopedic surgery and been discharged
home with LWMH VTE prophylaxis and found an NC rate of 13%–37%,
depending on their measurement indicator. This is in keeping with
other published NC rates with LMWH [42,49]. Compliance remains a
signiﬁcant issue for LMWH used for VTE prophylaxis following
orthopedic surgery.
In a multicenter study of over 8000 patients evaluating the
compliance of surgeonswith the American College of Chest Physicians
(ACCP) guidelines on VTE prophylaxis, Friedman et al. [32] reported
that only 47% of THR cases and 61% of TKR cases were compliant with
the guidelines. Subset analysis of these cases showed that coumadin
had an inferior compliance rate compared to LMWH (33% vs. 63%
respectively for THA and 48% vs. 73% respectively for TKA).
Aspirin has been proposed for VTE prophylaxis supported by the
evidence reported by the multicenter Pulmonary Embolism Preven-
tion (PEP) collaboration [19]. A comparative study of 4088 patients
following THA failed to show a clear beneﬁt to using aspirin as the
primary method of VTE prophylaxis [50]. A meta-analysis has shown
that the relative rates of VTE, diagnosed by venography, lung scan or
angiography, following TKA with aspirin, coumadin and LMWH were
53%, 45% and 29% respectively [26]. In addition, in the published 2012
9th edition American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines, one panel member believed strongly that
aspirin alone should not be included as an option for prevention of
VTE in orthopedic patients [7].
Oral factor Xa inhibitors provide VTE prophylaxis without the
potential pharmacologic problems that exist with coumadin, aspirin
or LMWH outlined above. In addition, a pilot study of 100 patients
suggested that improved compliance was possible with introduction
of Rivaroxaban in comparison to LMWH [33].
The results presented in this study demonstrate that when
compared with other VTE therapy modalities patients are at least as
likely to complete a standardized extended period of thrombopro-
phylaxis regime on an oral factor Xa inhibitor. The direct stated NC
rate of prescribed Rivaroxaban was 4% (98/2621). If those patients
with missing data (14%, 360/2621) are assumed to be NC then the NC
rate increases to 17% (458/2621). If all 203 of 2824 patients lost to
their 6-week follow-up are considered NC, then the worse-case NC
rate for Rivaroxaban is 23% (661/2824). This compares to the NC for
injectable LMWH which has multiple published studies demonstrat-
ing NC rates of 5%–40%.
Age, sex and BMI were shown to be signiﬁcant in terms of non-
compliance. Older patients (70 years vs. 65 years), females (68% vs.
32%) and heavier patients (BMI 31 vs. BMI 29) were more likely to not
complete their prescribed Rivaroxaban course. This differs from
previous studies [30,31], though it is difﬁcult to infer reasons why.
Within the NC group there was a greater incidence of PE
(p b 0.0001) postoperatively. There was no difference between the
compliant and NC groups in the incidence of reported DVT. Although
examining VTE incidence was not the purpose for this study, it is an
interesting ﬁnding and can only increase the importance of VTE
prevention compliance.
Though the results of the study are favorable for compliance of a
thromboprophylaxis regime on an oral factor Xa inhibitor, there are
limitations to the conclusions. The study was based on a self-reported
questionnaire that ultimately depended on patient's recollection of
which medications they took and if they completed the entire course.
Previously described methods of tablet counting or pharmacologic
analysis were not performed. No rigorous screening for DVT or PE was
performed as part of the study protocol therefore their actual
prevalence may be understated. However, this study was designed
to use medical and surgical relevant end points while capturing
clinical experience with this medication. We investigated patients for
suspected DVT with Doppler ultrasound while in hospital. Patients
with suspected PE were investigated with CT angiogram. The
prevalence of DVT and PE may have been higher if routine screening
had been in place but we believe that this protocol captured clinically
relevant end points, namely symptomatic proximal DVT and clinically
relevant PE. In addition we accept that a longer period of
thromboprophylaxis (e.g. 35 days for THA) may result in even
lower compliance rates, as has been shown in other studies for
different drugs.
In conclusion, this study demonstrates that the prescription of
Rivaroxaban for VTE prophylaxis for 15 days following lower limb
arthroplasty surgery results in excellent compliance compared to
the published literature rates for both subcutaneous LMWH and
coumadin. Further studies need to be performed in order to fully
understand and allow direct comparison of patient compliance for
DVT/PE thromboprophylaxis drugs after elective orthopedic arthro-
plasty surgery.
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Aims
There is uncertainty regarding the optimal means of thromboprophylaxis following total hip 
and knee arthroplasty (THA, TKA). This systematic review presents the evidence for 
acetylsalicylic acid (aspirin) as a thromboprophylactic agent in THA and TKA and compares 
it with other chemoprophylactic agents.
Materials and Methods
A search of literature published between 2004 and 2014 was performed in accordance with 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A total of 
13 studies were eligible for inclusion.
Results
Evidence from one good quality randomised controlled trial (RCT) showed no difference in 
rates of venous thrombo-embolism (VTE) in patients given aspirin or low molecular weight 
heparin (LMWH) following TKA. There was insufficient evidence from trials with moderate 
to severe risk of bias being present to suggest aspirin is more or less effective than LMWH, 
warfarin or dabigatran for the prevention of VTE in TKA or THA. Compared with aspirin, 
rates of asymptomatic deep vein thrombosis (DVT) in TKA may be reduced with rivaroxaban 
but insufficient evidence exists to demonstrate an effect on incidence of symptomatic DVT. 
Compared with aspirin there is evidence of more wound complications following THA and 
TKA with dabigatran and in TKA with rivaroxaban. Some studies highlighted concerns over 
bleeding complications and efficacy of aspirin.
Conclusion
The results suggest aspirin may be considered a suitable alternative to other 
thromboprophylactic agents following THA and TKA. Further investigation is required to 
fully evaluate the safety and efficacy of aspirin.
Cite this article: Bone Joint J 2016;98-B:1056–61.
There is considerable uncertainty over the opti-
mal method of venous thromboembolism
(VTE) prophylaxis in hip and knee arthro-
plasty patients, with numerous guidelines in
existence worldwide. The American Academy
of Orthopaedic Surgeons (AAOS) recommends
acetylsalicylic acid (aspirin) as a suitable
thromboprophylactic agent1 and, following
criticism of its previous guidance for inade-
quate balancing of medical risk with bleeding
complications, the American College of Chest
Physicians (ACCP)2,3 has followed suit.4 The
United Kingdom’s National Institute of Health
and Care Excellence (NICE), by contrast does
not recommend its use, nor does Nicolaides et
al’s5 international consensus statement. Nei-
ther study evaluates aspirin’s efficacy in the
context of contemporary surgical, anaesthetic
and enhanced recovery techniques.6
We present a systematic review of the evi-
dence regarding the thromboprophylactic effi-
cacy of aspirin compared with other agents
following total hip (THA) and total knee
arthroplasty (TKA) using modern surgical and
anaesthetic techniques.
Materials and Methods
This study was registered with the Interna-
tional prospective register of systematic
reviews (PROSPERO) Centre for Reviews and
Dissemination, University of York and con-
ducted in accordance with the Preferred
Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines.7 A
search of NHS Evidence, TRIP, the Cochrane
Database of Systematic Reviews, MEDLINE
and EMBASE databases was performed using
the NHS Evidence Healthcare Databases
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Advanced Search platform. Papers published between
1 January 2004 and 23 September 2015 were included, to
increase the likelihood that they described modern arthro-
plasty and anaesthetic techniques. There were no language
restrictions in the initial search but the availability of an
English language translation was an inclusion criterion.
We used the Oxford Centre for Evidence-Based Medicine
(OCEBM) working group guidance8 to define levels of evi-
dence with the initial intention of including only level I evi-
dence, later widening this to level III after identifying that
too few results were retained to permit meaningful analysis.
Analysis for inclusion was performed by two authors (DW
and WP), with clarification of peri-operative protocols
sought from authors where these were unclear. Any disa-
greement on level of evidence or inclusion was resolved by
consensus or by the senior authors (BR and SC). A PRISMA
flowchart is in Figure 1.
Randomised controlled trials (RCT) were assessed for
quality using the Cochrane Handbook for Systematic
Reviews of Interventions9 and non-randomised studies
using the Cochrane Risk of Bias Assessment Tool for Non-
Randomized Studies of Interventions (ACROBAT-NRSI).10
These tools assess a number of domains including selection,
reporting and detection bias and grade the overall risk of
bias as low, moderate, severe or unclear. Primary outcomes
were any form of venous thromboembolic event and sec-
ondary ones were wound complications including ooze and
infection. The methods of diagnosis of VTE employed in
the relevant study were also noted.
Results
Summary. A total of five studies comparing aspirin with
other forms of VTE prophylaxis offered level I evidence and
eight studies offered level III. Evidence from one good quality
RCT of 778 patients showed no difference in the rates of
VTE in patients given aspirin or low molecular weight hepa-
rin (LMWH) following TKA.11 There was insufficient evi-
dence from trials with moderate to severe risk of bias to
suggest aspirin is more or less effective than LMWH, war-
farin or dabigatran for the prevention of VTE following
TKA or THA. There is evidence, with moderate risk of
bias, of increased incidence of wound complications after
THA and TKA when dabigatran is used for VTE prophy-
laxis. Rivaroxaban may reduce the rate of asymptomatic
DVT in TKA, but insufficient evidence exists to suggest
superiority over aspirin in symptomatic DVT. It may, fur-
thermore, be associated with increased blood loss and
wound complications. Significant heterogeneity in throm-
boprophylactic regimens and assessment made direct
comparisons difficult. A summary of trials is included in
the supplementary material.
THA. Only one RCT with a moderate risk of bias that
examined 121 patients, showed reduced rates of asympto-
matic VTE identified on venography with aspirin and pneu-
matic compression (no DVT) compared with LMWH alone
(13 of 17 DVT) in TKA and THA.12
A total of three further level III studies evaluated THA
alone. Out of these, one showed no difference in rates of PE
or DVT when comparing LMWH and aspirin in 673
patients, but reported a decreased incidence of wound com-
plications in patients taking aspirin (1% versus 7.9%
p ≤ 0.01).13 A second involving 123 patients compared dab-
igatran and aspirin, demonstrating prolonged wound ooze
(p = 0.003) and length of stay (p = 0.002) with dabigatran.14
A comparison of aspirin and warfarin for patients undergo-
ing single-stage bilateral THA showed no difference in the
incidence of VTE or wound complications in 644 subjects.15
In all, five level III studies examined both THA and TKA
together, with only one showing an increased risk of DVT
in the TKA subgroup alone.
TKA. A total of four RCTs investigated VTE prophylaxis in
TKA alone. The first was good quality with low risk of
bias, studying aspirin and LMWH groups in 778 patients.
It demonstrated no significant difference between aspirin
and LMWH in rates of VTE or wound problems, although
a trend (p = 0.091) toward increased wound complications
with LMWH was observed.11 The trial was stopped early
due to recruitment difficulties subsequent to the advent of
newer oral anticoagulants. The second RCT had an unclear
or serious risk of bias and identified no significant differ-
ence in the rates of asymptomatic VTE with aspirin and
pneumatic compression versus LMWH and pneumatic
compression in 274 patients. An increased post-operative
drain volume was seen with aspirin (p = 0.03) but was not
associated with an increased requirement for transfusion.16
The third RCT had a moderate or unclear risk of bias
and compared aspirin, LMWH and rivaroxaban in 324
patients.17 The incidence of asymptomatic DVT was signif-
icantly higher in the aspirin group, compared with rivar-
oxaban (16.4% versus 2.9%, p = 0.014) although there
was no significant difference in rates of symptomatic DVT.
Wound complications and average hidden blood loss,
which represents all peri-operative blood loss and is calcu-
lated by the change in pre- and post-operative body red
blood cell content as defined by Sehat et al,18 were both
higher with rivaroxaban compared to aspirin (4.9% versus
1.8%, p = 0.014 and 1.7L versus 1.3L, p = 0.04). No sta-
tistical difference existed between aspirin and LMWH in
any outcome measure.17
The fourth RCT pertaining specifically to TKA com-
pared aspirin and LMWH followed by rivaroxaban in 120
patients. It had a severe or unclear risk of bias and demon-
strated no statistical difference in rates of asymptomatic
DVT, but blood loss was higher in the rivaroxaban group
(p ≤ 0.05).19
There was one level III study which had a serious risk of
bias and compared aspirin with warfarin in THA and TKA
in 696 patients. Overall, an increased rate of VTE was seen
in the aspirin group. Subgroup analysis revealed this effect
was limited to TKA.20
Aspirin versus LMWH. A total of four RCTs compared aspi-
rin with LMWH. One good quality RCT with 778 partici-
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pants showed aspirin was non-inferior to LMWH
(p ≤ 0.001) for the prevention of VTE in TKA, with a trend
towards increased wound complications with LMWH
(p = 0.09).11 Another showed no difference in rates of VTE
in TKA in 274 patients, but increased post-operative drain
volume with aspirin (p = 0.03).16 The third, examining 121
patients, showed an increased rate of DVT in patients tak-
ing LMWH compared with aspirin and pneumatic com-
pression in TKA and THA (p = 0.002). Subgroup analysis
showed this effect was confined to THA.12 The final RCT
reported no significant differences in rates of DVT or
wound complications in 324 TKA patients.17
A total of three further level III studies compared aspirin
to LMWH in both THA and TKA populations. One exam-
ining 1728 patients reported a decreased rate of VTE with
aspirin compared with LMWH (0.3% aspirin versus 2.4%
LMWH, p = 0.047) but this was confounded by the fact
that LMWH was given to all patients taking aspirin until
discharge, when treatment diverged.21 This study provided
the sole evidence for differing rates of VTE between agents.
Another study including 500 patients showed a trend
toward decreased rates of VTE with aspirin but failed to
reach significance (aspirin 0.2% versus 1.4% LMWH
p = 0.07).22 This study also identified a decreased transfu-
sion requirement with aspirin (0.39 units aspirin versus
0.57 units LMWH, p = 0.001) although there was no dif-
ference in bleeding complications.
A final study showed no difference in rates of VTE with
aspirin vs LMWH in 2246 patients with no reporting of
wound or bleeding complications.23 One study on TKA alone
with 673 patients reported a decreased rate of wound compli-
cations in patients on aspirin (1% versus 7.9%, p ≤ 0.01).13
Aspirin versus warfarin. A total of three studies compared
aspirin with warfarin. One, with serious risk of bias,
demonstrated decreased rates of symptomatic PE and DVT
in 696 patients in THA and TKA with no difference in mor-
tality or incidence of bleeding or wound problems.20
Another study with moderate or unclear risk of bias
included 2246 patients and compared aspirin with LMWH
(followed by aspirin) or warfarin (followed by aspirin)23 in
THA and TKA. No differences in the incidence of VTE
were shown.23 The final study, also at serious risk of bias,
demonstrated no differences in rates of DVT or wound
complications between aspirin and warfarin in 644 patients
undergoing bilateral THA.15
Aspirin versus novel oral anticoagulants (NOACs). A total of
three studies compared aspirin with dabigatran, all of which
carried moderate risk of bias. A paper examining 1728
patients demonstrated a decreased rate of symptomatic VTE,
wound complications and length of stay with aspirin com-
pared with dabigatran in TKA and THA. All patients received
LMWH whilst in hospital and aspirin or dabigatran as an out-
patient.21 A further paper showed a decrease in time to wound
dryness (3.2 versus 6.4 days p ≤ 0.01) with aspirin in 110
patients undergoing THA and TKA.24 The final study of 123
patients compared wound discharge and length of stay, dem-
onstrating an increased wound discharge and length of stay in
the dabigatran group, compared with the LMWH in hospital
and aspirin as an outpatient group in THA.14
Rivaroxaban in TKA was evaluated by two RCTs. The
first study with 120 patients, showed no difference in
asymptomatic DVT rate and no wound complications in
either group but higher blood loss with rivaroxaban.19 The
second, examining 324 patients, showed fewer asympto-
matic DVTs with rivaroxaban, but no difference in sympto-
matic DVTs and a significant increase in wound
complications and hidden blood loss (as defined above)
with rivaroxaban.17
Registry data. A total of four sets of registry data were iden-
tified, including two from the National Joint Registry
279 records screened
13 studies in final review
243 records excluded 
Identification
Screening
Eligibility
Inclusion
285 records identified by database search
279 records after duplicates removed
36 full text articles assessed 
for eligibility
23 full text articles excluded
17 below level III evidence
1 article in foreign language with no 
translation available
2 review articles
3 studies where patients receiving aspirin 
were not clearly identified
Fig. 1
Flowchart of study selection.
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(NJR) in England and Wales. Both had populations in
excess of 100 000 patients and demonstrated no difference
in rates of DVT or PE between aspirin and LMWH.25,26
One study of THA patients alone showed increased mortal-
ity with the aspirin group (0.65% versus 0.51% p = 0.04),25
and the other an increased rate of return to theatre with
aspirin (0.26% versus 0.19% p = 0.01).26 A study of over
17 000 patients from the United States showed no differ-
ence in VTE rates between aspirin, warfarin, LMWH or
mechanical prophylaxis alone.27 A further United States
registry report of almost 100 000 TKAs showed no differ-
ence in adjusted outcomes between aspirin and LMWH, but
noted the rate of VTE was higher in those taking warfarin.28
Peri-operative protocols. Table I details anaesthetic and
recovery protocols. The majority of studies encouraged the
use of spinal anaesthesia where possible and employed
early mobilisation, defined as mobilising on the day of sur-
gery or first post-operative day. Mechanical prophylaxis
was used in conjunction with chemoprophylactic agents in
all but one study.12
Discussion
The quality of early RCTs of aspirin in VTE prophylaxis is
poor and current guidance based on them is confounded by
the absence of modern peri-operative practice in their pro-
tocols. This lends inappropriate weight to the choice of
chemical agent, when protection is nowadays conferred by
multimodal regimens.6
Mortality rates from VTE following lower limb arthro-
plasty are low,29-32 with a recent meta-analysis reporting
that half of such deaths are the consequence of cardio-
pulmonary events,29 half of which in turn were due to PE,
irrespective of the thromboprophylactic regimen used.29
Whilst aspirin prophylaxis against VTE may confer an
additional cardioprotective effect,33 this is yet to be demon-
strated.34 The NJR shows a higher mortality in patients
taking aspirin after THA25 but heterogeneity in operative
and peri-operative factors make this difficult to interpret.
The rate of PE in arthroplasty patients is so low that the
sample size required for an RCT would render it impracti-
cal. Extended VTE prophylaxis has been shown to reduce
rates of both PE and DVT35 but in absence of a proof of cau-
sation of PE by lower limb DVT, the use of asymptomatic
DVT as an end point has been questioned.36,37 Composite
outcomes relating to more common events afford greater
statistical efficiency and may provide greater clarity.38
Wound complications and infection following THA and
TKA are clinically important, with the rate of infection
increasing with prolonged wound ooze.39 Any agent which
decreases the risk of prolonged wound discharge may,
therefore, reduce infection rates.40 Prolonged wound ooze
has been reported with NOACs, and this review provides
evidence that aspirin may confer advantages over NOACs
in relation to length of stay, wound ooze and blood
loss.17,21,24 While some reports suggest increased rates of
wound complications with LMWH the evidence is more
equivocal, as is that relating to aspirin versus warfarin. Sur-
geons should be mindful of bleeding complications with all
thromboprophylactic agents, including aspirin.
Compliance and patient satisfaction with oral thrombo-
prophylaxis is better than with injectable LMWH41,42 and
the use of aspirin for VTE prophylaxis would afford signif-
icant financial benefits over LMWH.43
This review has some inherent limitations. First, there is
a lack of level I evidence and suitably powered trials are
clearly required. A total of 3400 patients would afford an
adequate non-inferiority trial at 95% power and 5% signif-
icance, assuming a baseline symptomatic VTE event rate of
1% and minimally clinically important difference of 1%.
Secondly, significant inter-study heterogeneity exists.
There were a variety of dosage regimes, often varying
between inpatient and outpatient setting. Studies used dif-
ferent methods of VTE detection and primary endpoints
varied between symptomatic and asymptomatic DVT. Post-
operative recovery protocols varied, as did the use of
mechanical devices. These limitations make direct
Table I. Details of peri-operative protocols
Anaesthesia Mobilisation Other
Zou et al17 Spinal Early mobilisation Range of motion exercises
Jiang 201419 GA & spinal Early mobilisation Range of movement exercises
Anderson et al11 Mainly spinal Early mobilisation
Westrich et al16 Spinal Day 2 mobilisation CPM day 1
Gelfer et al12 GA Early mobilisation
Bloch et al21 Regional when possible Early mobilisation ‘Modern surgical techniques’
Kulshrestha and Kumar13 Spinal Early mobilisation Enhanced rehabilitation 
protocol
Gillette 201323 Spinal Early mobilisation MDT approach
Intermountain Joint Replacement Centre Writing 
Committee 201220
Mainly spinal Early mobilisation
Aquilina et al24 Unknown Unknown
Hamilton et al22 GA Early mobilisation ‘Modern techniques’
Gill et al14 Spinal Early mobilisation
Beksac et al15 Spinal Early mobilisation
GA, general anaesthesia; CPM, continuous passive motion; MD, multidisciplinary
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comparisons difficult and a moderate or severe risk of bias
limited the level of significance of the majority of studies.
It is probable that all thromboprophylactic agents, in
conjunction with modern anaesthesia and early mobilisa-
tion, afford adequate effect. Furthermore, the clinical rele-
vance of symptomatic versus asymptomatic VTE remains
unquantified, whilst the implications of wound complica-
tions is undoubted. Surgeons selecting aspirin should be
aware of some reports of increased bleeding, return to the-
atre and higher mortality rates in THA reported by the
NJR. These concerns are by no means definite and more
recent evidence with over 11 000 patients using aspirin as
thromboprophylaxis showed no difference in VTE along
with a comparable and downward trend in mortality when
compared with NJR data.44
In conclusion, the evidence for aspirin is incomplete, but
there is reason to consider it a suitable alternative to other
chemoprophylactic agents. Its action may well be enhanced
with concomitant use of mechanical prophylaxis. A more
pragmatic approach to developing thromboprophylactic
guidance and to improving the body of evidence for aspirin
in the future is needed, as the large numbers required for
suitably powered RCTs examining rare outcomes are pro-
hibitive.
Take home message: 
Aspirin should be considered an appropriate thromboprophy-
lactic agent in THA and TKA.
Supplementary material
A table showing the results of the included studies
cane be found alongside the paper online at http://
www.bjj.boneandjoint.org.uk/
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Venous thromboembolisnn (VTE), including deep vein thrombosis (DVT) and pulmonary embolism
(PE), is a common cause of cardiovascular mortality and morbidity. Patients undergoing major
orthopaedic surgery, including hip and knee arthroplasty, represent a group that is at particularly
high risk for VTE, especially patients with risk factors (age >60 years, cancer, prior VTE).
Currently, if no measures are taken, the
rate of fatal PE is approximately 0.4%,
which equates to over 5,000 fatalities a
year for the 1.5 million hip and knee
replacements performed in Europe. It is a
significant and potentially fatal problem
after surgery and, although there are
numerous publications/guidelines on
reducing its incidence, none includes newer
treatment modalities such as oral factor Xa
inhibitors.
VTE occurs due to factors that alter the
balance of coagulability, venous stasis and
venous endothelial damage (Virchow's
triad). The prophylactic measures used to
reduce incidence act by modifying one or
more of these factors. Advances in surgical
technique and equipment, such as the
increasing use of arthroscopic techniques,
have helped reduce the risk of
postoperative VTE.
This review provides a synopsis of current
therapeutic options and an algorithm for
treatment. The risk of VTE needs to be
assessed by considering patient and
operative risk factors, before deciding on
the most appropriate modality to reduce
this risk, which may involve physiological,
mechanical or pharmaceutical measures.
Assessment of the patient
There are numerous patient factors that are
known to increase the risk of VTE (Table 1)
(NICE 2007) and, although the relative risk
of one or more of these factors is not
known, it should alert clinicians with the
management and investigations directed
appropriately.
Spine injury patients, especially those who
have a spinal cord injury, have a high
prevalence of DVT, and thromboprophylaxis
should be started as soon as possible,
taking into account any potential bleeding
complications. Evidence to date shows that
low-molecular-weight heparin (LMWH) and
warfarin are effective in preventing
thrombosis
Assessment of surgery
The VTE risk depends on the surgical
procedure, and specific operative risk
factors should be considered (Table 2).
Upper limb surgery has a significantly lower
VTE risk compared with lower limb surgery,
with no evidence to justify the use of
pharmaceutical prophylaxis (Willis et al
2009, Randelli et al 2010).
The evidence for the VTE risk in lower limb
trauma surgery is more complex.
Pharmaceutical VTE prophylaxis is
recommended after hip fracture surgery
(NICE 2007), but there is little evidence for
below-knee trauma or elective surgery (Goel
et al 2009).
Special attention should be drawn to hip and
knee arthroplasty surgery because of the
higher VTE risk. Much research has been
published, and evidence suggests that the
peak incidence of both venographic and
symptomatic thrombosis is at least 10 days
after total knee replacement (TKR) and 21
days after total hip replacement (THR)
(Planes et al 1996, Warwick et al 2007).
Subsequently, it is advocated that
appropriate VTE prophylaxis should continue
for at least this period of time.
General measures
Hydration
Haemoconcentration increases blood
viscosity and reduces blood flow, especially
in the deep veins of the leg in immobile
patients, leading to stasis and thus an
increased risk of VTE. Although no specific
clinical studies have evaluated dehydration
in relation to VTE, it is well known that
relative dehydration has a detrimental
physiological effect. Thus, patients should
be well hydrated before, during and
especially after surgery.
Leg exercises
Again considering venous stasis as a
contributing factor to VTE, patient,
specifically limb immobility after
orthopaedic surgery increases the risk of
DVT about tenfold (Heit et al 2001). In
contrast to historical practice, there is no
evidence to justify complete bed rest for any
condition and every effort should be made
to mobilise the relevant limb as soon as
possible and ideally to mobilise the whole
patient (Allen et al 1999).
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There is good evidence to suggest that spinal anaesthesia is
beneficial in reducing mortality (Rodgers et al 2000)
Active cancer or cancer treatment
Active heart or respiratory failure
Acute medical illness j!
Age >60 years ',
Antiphospholipid syndrorne
Behçet's disease
Central venous catheter in situ
Continuous travel of more than 3
hours approximately 4 weeks before
or after surgery
Immobility (e.g. paralysis or limb in
plaster)
Inflammatory bowel disease (e.g.
Crohn's disease or ulcerative colitis)
Myeloproliferative diseases
Nephrotic syndrome i
Obesity (body mass index a30
kg/m2) I!
Paraproteinaemia
Paroxysmal nocturnal
haemoglobinuria
Personal or family history of VTE
Pregnancy or puerperium
Recent myocardial infarction or
stroke
Severe infection
Use of oral contraceptives or
hormonal replacement thierapy
Varicose veins with associated
phlebitis
Inherited thrombophilias.
levels of coagulation factors (e.g.
factor VIII)
Hyperhomocysteinaemia
Low activated protein C resistance
(e.g. factor V Leiden)
Protein C, S and antithroijnbin
deficiencies
Prothrombin 2021A gene
e.g. high
mutation
Table 1 Patient risk factors for venous
thromboembolism
Spinal or general anaesthetic
The type of anaesthetic has been shown to
affect the complication rate following
surgery. There is good evidence to suggest
that spinal anaesthesia is beneficial in
Assess Patient Risk Factors
See Table 1
Assess Operation Risk
Factors See Table 2
High Risk for VTE?
Optimize cardiovascular status
Mechanical measures
Therapeutic Measures
GECS
IPC
Aspirin IPC Warfarin Riva roxa ban
GECS = graduated elastic compression stockings
IPC = intermittent pneumatic compression
Figure 1 Generic algorithm (From Warwick et al J Bone Joint Surg [Br] 2007;89-B:799-807)
Lower limb has a higher risk
compared with upper limb i
Degree of soft tissue/bone !
dissection needed •
Joint or limb position during surgery
Positioning of retractors during
surgery ;
Length of surgery
Amount of blood loss
Table 1 Surgical risk factors for VTE
reducing mortality (Rodgers et al 2000). The
beneficial effect of a spinal anaesthetic is
likely to be multifactorial, affecting stasis,
coagulability and endothelial integrity, so, if
possible and safe, the patient should have a
spinal anaesthetic. |
Mechanical measures
These devices reduce venous stasis and
include graduated elastic compression
October 2010 / Volume 20 / Issue 10 / ISSN 1467-1026
stockings (GECSs), intermittent pneumatic
compression devices and mechanical foot
pumps
Graduated elastic compression
stockings
There is good meta-analysis evidence for
the effectiveness of GECSs (Amaragiri
2001). Thigh-length stockings are
theoretically superior to knee-length ones,
but to date no conclusive evidence supports
this (Porteous et al 1989). The use of
GECSs should be cautioned in patients with
severe oedema, neuropathy, deformity,
arteriopathy or dermatitis
Calf compression devices
Calf compression devices compress the calf
muscles to a pressure of 35-40 mmHg for
10 seconds every minute, which stimulates
fibrinolysis. They are usually applied
immediately before surgery and frequently
replaced by GECSs because they can cause
discomfort in the conscious patient
(Comerota et al 1997).©
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Pharmaceutical measures
Determining the true effectiveness of
difficult drugs in VTE prophylaxis is difficult
due to several factors:
1. Low absolute incidence of
symptomatic VTE events and death
2. The use of surrogate outcomes, such
as duplex ultrasonography
3. unclear implication of asymptomatic
VTE events
4. The large numbers required to
achieve statistical significance.
As a result, several pharmaceutical agents
have been proposed for VTE prophylaxis
and to date there is controversy as to which
Is superior.
Aspirin
Aspirin is cheap, readily available and
easily administered orally, and has an anti-
platelet function; it has been proposed as
an effective modality of VTE prophylaxis.
The Antiplatelet Trialist Collaboration
reviewed 9,000 randomised patients and
showed that aspirin substantially reduced
the incidence of both DVT and PE in a wide
range of surgical patients (Antiplatelet
Trialists' Collaboration 1994). More
recently, a study of over 4,000 patients,
prescribed aspirin 150 mgfor 6 weeks
after total hip and knee replacement
surgery, demonstrated a fatal PE rate of
0.07% (Cusick & Beverland 2009).
However, a large multicentre study of over
13,000 patients after hip fracture surgery
compared a daily oral dose of 160 mg
aspirin against placebo for VTE prophylaxis,
and showed no significant difference in
death rate and only a 30% risk reduction of
symptomatic VTE (PEP 2000). However,
there are concerns about bleeding from the
surgical site and gastrointestinal tract, with
an associated higher transfusion rate. In
view of this evidence, the VTE prophylaxis
provided by aspirin is not now considered to
be significant enough to be justified
(Warwick 2004) and it is not licensed in the
UK for this indication.
Heparin
Unfractionated heparin
A meta-analysis of 20 studies involving over
7,000 patients showed that LMWH was
superior to standard low-dose heparin with
respect to DVT and resulted in significantly
fewer bleeding complications (Palmer et al
1997).
LiVIWH
A comprehensive meta-analysis has
demonstrated that LMWH is effective in
preventing asymptomatic DVT at discharge
compared with placebo, dextran, low-dose
heparin (LDH) and warfarin (Brookenthal et
al 2001). The overall asymptomatic DVT rate
was 17% (range 7-33%). The asymptomatic
proximal DVT was 7% (range 0-26%);
however, the studies were too small to show
that LMWH had any effect on fatal PE rate.
Excessive bleeding and heparin-induced
thrombocytopenia (HIT) are two issues that
the clinician should be aware of when
prescribing LMWH.
Bieeding
Increased bleeding has been observed in
patients receiving LMWH compared with
warfarin (Francis et al 1997). Further, the
timing of LMWH administration has a
notable effect on the occurrence of major
bleeding (Colwell et al 1999) with over
three-quarters of patients with a major
bleed being administered medication from 0
h to l2 h postoperatively.
Heparin-induced thrombocytopenia
HIT is a known, potentially fatal complication
of LMWH use. Recent evidence has
highlighted poor monitoring of this
condition, especially once a patient has
been discharged home (Rogers et al 2009).
Warfarin
Warfarin, via its direct action on the vitamin
K-dependent clotting factors, has been
shown to reduce asymptomatic DVT
incidence compared with controls and once-
daily aspirin, but is not as effective as
LMWH (Impériale & Speroff 1994).
However, a specific randomised controlled
trial demonstrated that high-dose aspirin
(325 mg twice daily) has a greater efficacy
in reducing asymptomatic proximal DVT than
10 mg warfarin started the night of surgery
and an international normalised ratio (INR)
maintained in the region 1.2-1.5 (Lotke et
al 1996).
Considering the in-patient stay alone, LMWH
is significantly superior to warfarin in
preventing symptomatic VTE; however, the
benefit is lost after hospitalisation (Colwell
et al 1999).
Further, major drawbacks to the use of
warfarin are the need for regular monitoring
of the prothrombin time and a prevalence of
major bleeding of up to 5%.
New oral anticoagulants
Orai direct factor Xa inhibitors
Oral direct factor Xa inhibitors afford an
antithrombotic action by combining directly
with factor X in the coagulation cascade,
without using antithrombin as a mediator.
There are two oral direct factor Xa inhibitors
currently developed - rivaroxaban and
apixaban - with a third - otamixaban -
undergoing trials for use in a cardiology
setting.
There are four large clinical studies relating
to rivaroxaban: for hip replacement the
RECORD 1 (Eriksson et al 2008) and
RECORD 2 (Kakkar et al 2008) studies; and
for knee replacement the RECORD 3
(Lassen et al 2008) and RECORD 4 (Turpie
et al 2009) studies. The evidence from
these large multicentre studies shows the
efficacy of rivaroxaban to be at least
statistically similar to 40 mg/day LMWH.
The results are encouraging, with an oral
preparation afforded a higher patient
compliance and no monitoring for HIT
needed; however, further collaborative
clinical evidence is necessary to ensure
efficacy.
Recently, apixaban has been compared with
LMWH for the prevention of VTE after TKR.
Advance 1 (Lassen et al 2009)
demonstrated similar outcome measures
with enoxaparin and Advance 2 (Lassen et
al 2010) demonstrated reduced primary
outcome measures (namely VTE, PE and
mortality) with apixaban. These are again
encouraging but, disappointingly, there are
no published trials using apixaban after
THR.
Direct thrombin inhibitors
Dabigatran is an oral director thrombin
inhibitor that can be taken once daily. Three
large clinical studies compare dabigatran
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With the likelihood of numerous future publications on this
topic, the clinician should endeavour to remain up to date
with LMWH after THR and TKR, namely the
RENOVATE (Eriksson et al 2007), RE-MODEL
(Eriksson et al 2007) and REMQBIUZE
(Ginsberg et al 2009) studies. The pooled
results showed no difference in the
prevention of VTE compared with LMWH,
and both had similar safety profiles.
However, when analysed separated they
demonstrated conflicting results, with those
from the REMOBILIZE trial suggesting
inferior results with dabigatran compared
with a twice-daily regimen of LMWH
following TKR.
Discussion
Historically there was undoubtedly clear
evidence for the need for VTE prophylaxis
because the incidence of VTE events after
THR approached 50% in patients in whom
no preventive measures were taken
(Johnson et al 1978). Contemporary surgical
procedures and postoperative regimens
have drastically changed over the last three
decades, and the incidence of untreated
VTE is now likely to be substantially lower.
Current existing guidelines
• International Consensusj
Statements (Nicolaides et al
2001) Prevention and treatment
of venous thromboembolism
International Consensus
Statement (guidelines according
to scientific evidence),
• American College of Chest
Physicians (Geerts et al 2008)
Prevention of venous j!
thromboembolism: American
College of Chest Physicians
Evidence-Based Clinicaii Practice
Guidelines (8th edn).
• NICE Clinical Guideline 46 (NICE
2007) Venous thromboembolism:
reducing the risk of venous
thromboembolism (deep vein
thrombosis and pulmonary
embolism) in inpatients
undergoing surgery.
• Scottish Intercollegiate Guideline
Network (SIGN 2002)
Prophylaxis of venous
thromboembolism.
As this review has highlighted, VTE
prophylaxis is multi-factorial and both the
clinician and patient should be aware of
this. However, the plethora of published
guidelines on this subject is a cause of
potential confusion and there are^several
factors that cause resistance to their
implementation, including a lack of
awareness, perceived conflicting evidence,
practicality, the low overall incidence and
bias.
This review does not replace any of the
major guidelines currently available (Table
3); rather provision of an outline of the
treatment modalities available and a
generic algorithm (Figure 1) of the clinical
management should be considered.
Education of the clinician and patient is
vital because not only is the incidence of
VTE greatest after the patient has usually
been discharged, but also patient;
compliance with the general measures
(outlined above) will help greatly to reduce
risk. With the likelihood of numerous future
publications on this topic, the clin'ician
should endeavour to remain up to date with
the best available contemporary evidence to
guide clinical practice.
Key points
• Venous thromboembolism (VTE) is a
potentially fatal complication of
orthopaedic surgery.
• The VTE risk varies depending upon
patient and surgical factors (see Tables
l a n d 2).
• Prevention options include optimising
physiology, mechanical and
pharmaceutical measures (see Figure
1). 1
• Various pharmaceutical options now
exist, and the specific risks arid benefits
of any drug need to be considered for
individual patients. ¡
• Numerous in-depth guidelines exist on
this topic (see Table 3), and the reader
should refer to these for a more detailed
discourse. I
Table 3 Guidelines
References
Allen C, Glasziou P, Del Mar C 1999 Bed rest: a
potentially harmful treatment needing more careful
evaluation Uncet 354 (9186) 1229-33
Amaragiri 2001 Elastic compression stockings for
prevention of deep vein thrombosis (Cochrane
Review)
Antiplatelet Trialists' Collaboration 1994
Collaborative overview of randomised trials of
antiplatelet therapy-Ill: Reduction in venous
thrombosis and pulmonary embolism by antiplatelet
prophylaxis among surgical and medical patients.
Antiplatelet Trialists' Collaboration BMJ 308 (6923)
235-46
Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald
RH, Lonner JH 2001 A meta-analysis of
thromboembolic prophylaxis in total knee
arthroplasty J Arthroplasty 16 (3) 293-300
Colwell Jr. CW, Collis DK, Paulson R, McCutchen
JW, Bigler GT, Lutz S, Hardwick ME 1999
Comparison of enoxaparin and warfarin for the
prevention of venous thromboembolic disease after
total hip arthroplasty. Evaluation during
hospitalization and three months after discharge J
Bone Joint Surg Am 81 (7) 932-40
Comerota AJ, Chouhan V, Harada RN, Sun L
Hosking J, Veermansunemi R, Comerota, Jr. AJ,
Schlappy D, Rao AK 1997 The fibrinolytic effects of
intermittent pneumatic compression: mechanism of
enhanced fibrinolysis Ann Surg 226 (3) 306-13;
discussion 13-4
Cusick LA, Beverland DE 2009 The incidence of
fatal pulmonary embolism after primary hip and
knee replacement in a consecutive series of 4253
patients J Bone Joint Surg Br 91 (5) 645-8
Eriksson Bl, Bonis LC, Friedman RJ, Haas S,
Huisman MV, Kakkar AK, Bändel TJ, Beckmann H,
Muehlhofer E, Misselwitz F, Geerts W 2008
Rivaroxaban versus enoxaparin for
thromboprophylaxis after hip arthroplasty N Engi J
Med 358 (26) 2765-75
Eriksson Bl, Dahl OE, Rosencher N, Kurth AA, van
Dijk CN, Frostick SP, Kalebo P, Christiansen AV,
Hantel S, Hettiarachchi R, Schnee J, BuUer HR 2007
Oral dabigatran etexilate vs. subcutaneous
enoxaparin for the prevention of venous
thromboembolism after total knee replacement: the
RE-MODEL randomized trial J Thromb Haemost 5
(11) 2178-85
Eriksson Bl, Dahl OE, Rosencher N, Kurth AA, van
Dijk CN, Frostick SP, Prins MH, Hettiarachchi R,
Hantel S, Schnee J, Buller HR 2007 Dabigatran
etexilate versus enoxaparin for prevention of venous
thromboembolism after total hip replacement: a
randomised, double-blind, non-inferiority trial Lancet
370 (9591) 949-56
Francis CW, Pellegrini Jr. VD, Totterman S, Boyd Jr.
AD, Marder VJ, Liebert KM, Stulberg BN, Ayers DC,
Rosenberg A, Kessler C, Johanson NA 1997
Prevention of deep-vein thrombosis after total hip
arthroplasty. Comparison of warfarin and dalteparin
J Bone Joint Surg Am 79 (9) 1365-72©
October 2010 / Volume 20 / Issue 10 / ISSN 1467-1026 361
CLINICAL FEATURE
Thromboprophylaxis in orthopaedic surgery:
a clinical review
Continued
Geerts WH, Bergqvist D, Pineo CF, Heit JA, Samama
CM, Lassen MR, Colwell CW 2008 Prevention of
venous thromboembolism: Amencan College of
Chest Physicians Evidence-Based Clinical Practice
Guidelines (8th Edition) Chest 133 (6 SuppO 381S-453S
Ginsberg JS, Davidson BL, Comp PC, Francis CW,
Friedman RJ, Huo MH, Ueberman JR, Muntz JE,
Raskob GE, Clements ML Hantel S, Schnee JM,
Caprini JA 2009 Oral thrombin inhibitor dabigatran
etexilate vs North American enoxaparin regimen for
prevention of venous thromboembolism after knee
arthroplasty surgery J Arthroplasty 24 (1) 1-9
Goel DP, Buckley R, deVries G, Abelseth G, Ni A,
Gray R 2009 Prophylaxis of deep-vein thrombosis in
fractures below the knee: a prospective randomised
controlled trial J Bone Joint Surg Br 91 (3) 388-94
Heit JA, Silverstein MD, Mohr DN, Pettenson TM,
Lohse CM, O'Fallon WM, Melton 3rd U, 2001 The
epidemiology of venous thromboembolism in the
community Thromb Haemost 86 (1) 452-63
Imperiale TF, Speroff T 1994 A meta-analysis of
methods to prevent venous thromboembolism
following total hip replacement JAMA 271 (22)
1780-5
Johnson R, Carmichael JH, Almond HG, Loynes RP
1978 Deep venous thrombosis following Chamley
arthroplasty Clin Orthop Relat Res (132) 24-30
Kakkar AK, Brenner B, Dahl OE, Eriksson Bl, Mouret
P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas
S 2008 Extended duration rivaroxaban versus short-
term enoxaparin for the prevention of venous
thromboembolism after total hip arthroplasty: a
double-blind, randomised controlled trial Lancet
372 (9632) 31-9
Lassen MR, Raskob GE Gallus A, Pineo G, Chen D,
Homick P 2010 Apixaban versus enoxaparin for
thromboprophylaxis after knee replacement
(ADVANCE-2): a randomised double-blind tnal
Lancet 375 (9717) 807-15
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D,
Portman RJ 2009 Apixaban or enoxaparin for
thromboprophylaxis after knee replacement N Engl
J Med 361 (6) 594-604
Lotke PA, Palevsky H, Keenan AM, Meranze S,
Steinberg ME, Ecker ML Kelley MA 1996 Aspirin
and warfarin for thromboembolic disease after total
joint arthroplasty Clin Orthop Relat Res (324)
251-8
Lassen MR, Ageno W, Bonis LG, Lieberman JR,
Rosencher N, Bändel TJ, Misselwitz F, Turpie AG
2008 Rivaroxaban versus enoxaparin for
thromboprophylaxis after total knee arthroplasty N
Engl J Med 358 (26) 2776-86
NICE 2007 Venous thromboembolism: reducing
the risk of venous thromboemboUsm (deep
vein thrombosis and pulmonary embolism) in
inpatients undergoing surgery London, NIGE
Nicolaides AN, Breddin HK, Fareed J, Goldhaber S,
Haas S, Hull R, Kalodiki E, Myers K, Samama M,
Sasahara A 2001 Prevention of venous
thromboembolism. Intemational Consensus
Statement Guidelines compiled in accordance with
the scientific evidence Int Angiol 20 (1) 1-37
Palmer AJ, Koppenhagen K, Kirchhof B, Weber U,
Bergemann R 1997 Efficacy and safety of low
molecular weight heparin, unfractionated heparin
and warfarin for thrombo-embolism prophylaxis in
orthopaedic surgery: a meta-analysis of randomised
clinical trials Haemostasis 27 (2) 75-84
PEP 2000 Prevention of pulmonary embolism and
deep vein thrombosis with tow dose aspirin:
Pulmonary Embolism Prevention (PEP) tnal Lancet
355 (9212) 1295-302
Planes A, Vochelle N, Damnon JY, Fagola M, Bellaud
M, Huet Y 1996 Risk of deep-venous thrombosis
after hospital discharge in patients having
undergone total hip replacement: double-blind
randomised comparison of enoxapann versus
placebo Uncet 348 (9022) 224-8
Porteous MJ, Nicholson EA, Monis LT, James R,
Negus D 1989 Thigh length versus knee length
stockings in the prevention of deep vein thrombosis
Br J Surg 76 (3) 296-7
Randelli P, Gastagna A, Cabitza F, Cabitza P,
Anigoni P, Denti M 2010 Infectious and
thromboembolic complications of arthroscopic
shoulder surgery J Shoulder Elbow Surg 19 (1)
97-101
Rodgers A, Walker N, Schug S, McKee A, Kehlet H,
van Zundert A, Sage D, Futter M, SaviUe G, Glark T,
MacMahon S 2000 Reduction of postoperative
mortality and morbidity with epidural or spinal
anaesthesia: results from overview of randomised
trials BMJ 321 (7275) 1493
Rogere B, Little N, Jones C 2009 Monitoring and
management of heparin-induced thrombocytopenia
Br J Hosp Med (Lond) 70 (11) 630-3
SIGN 2002 Guideline No. 62. Prophylaxis of venous
thromboembolism Available from:
www.sign.ac.uk/guidelines/fulltext/62/index.html
[Accessed September 20101
Turpie AG, Lassen MR, Davidson BL, Bauer KA,
Gent M, Kwong LM, Gushner FD, Lotke PA,
Berkowitz SD, Bändel TJ, Benson A, Misselwitz F
Fisher WD 2009 Rivaroxaban versus enoxaparin for
thromboprophylaxis after total knee arthroplasty
(REC0RD4): a randomised trial Uncet 373 (9676)
1673-80
Wanwick D 2004 New concepts in orthopaedic
thromboprophylaxis J Bone Joint Surg Br 86 (6)
788-92
Warwick D, Friedman RJ, Agnelli G, Gil-Garay E,
Johnson K, FitzGerald G, Turibio FM 2007
Insufficient duration of venous thromboembolism
prophylaxis after total hip or knee replacement
when compared with the time course of
thromboembolic events: findings from the Global
Orthopaedic Registry J Bone Joint Surg Br 89 (6)
799-807
Willis AA, Warren RF, Craig EV, Adler RS, Cordasco
FA, Lyman S, Fealy S 2009 Deep vein thrombosis
after reconstaictive shoulder arthroplasty: a
prospective observational study J Shoulder Elbow
Surg 18 (1) 100-6
About the authors
Benedict A Rogers
MA, MSc, MRCGP, FRCS (orth)
Ciinical Fellow la Lower Limb Reconstruction, Mount
Sinai Hospitai, Toronto, Canada
Nick J Little
MB ChB MSc FRCS (orth)
Specialist Registrar (Trauma & Orthopaedics), Royai
Surrey County Hospitai, Guildford
No competing interests declared
Members can search aii issues of the BJPN/JPP
pubiished since 1998 and downioad articles free of
charge at www.afpp.org.uk.
Access is aiso avaiiable to non-members who pay a
smaii fee for each articie download.
362 October 2010 / Volume 20 / Issue 10 / ISSN 1467-1026
 Appendix	19	
 
Rogers BA, Little N, Jones C.  
Monitoring and management of heparin-induced thrombocytopenia.  
Br J Hosp Med (Lond). 2009 Nov;70(11):630–3 
 
Contribution by BA Rogers. 
Concept & planning 
Manuscript writing & editing 
 
Citation Metrics 
 
Web Of Science:   2 
Google Scholar:   2 
Altmetrics:    0 
Tweets:  
Facebook:  
Mendeley readers: 
 
	 	
182 




 Appendix	20	
 
Rogers BA, Cowie AS.  
The monitoring of heparin induced thrombocytopenia following surgery: an audit and 
international survey.  
J Perioper Pract. 2010 Feb;20(2):66–9. 
 
Contribution by BA Rogers. 
Concept & planning 
Data Collection 
Manuscript writing & editing 
 
Citation Metrics 
 
Web Of Science:   8 
Google Scholar:   10 
Altmetrics:    0 
Tweets:  
Facebook:  
Mendeley readers: 
 
	 	
187 
RESEARCH & AUDIT
KEYWORDS Heparin induced thrombocytopenia (HID / Monitoring / Survey
Provenance and Peer review; Unsolicited contribution: Peer reviewed: Accepted for publication September 2009.
The monitoring of heparin
induced thrombocytopenia
following surgery:
an audit and international survey
by Benedict A Rogers and Andrew S Cov^ /ie
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Heparin-induced thrombocytopenia (HIT) is a serious postoperative complication of low-
molecular-weight heparin (LWMH) prescribed following surgery and recent evidence based
guidelines recommend routine platelet count monitoring for all at-risk patients. With the
implementation of these guidelines this clinical study demonstrated a significant improvement
{2 - 56% p<0.05) in HIT diagnosis in postoperative patients receiving LMWH. An international
survey showed a lack of awareness of heparin-induced thrombocytopenia and its management.
Introduction
Low-molecular-weight heparin (LMWH) is
widely used in the prevention of
thromboembolism in orthopaedic patients,
particularly those undergoing lower limb
joint arthroplasty (Leyvraz et al 1991. Mohr
et al 1993, Wolf 1994). Several types of
LMWH are commonly used including
enoxaparin (Clexane®, Rhône-Poulenc
Rorer). dalteparin (Fragmin®. Pharmacia)
and tinzaparin (Innohep®. LEO), with
bleeding and thrombocytopenia having
been known complications (BNF 2008).
Bleeding may occur at various locations;
operative site, epidural. intrahepatic. and
retroperitoneal sites, gastrointestinal tract
(Antonelli et al 2000. Houde & Steinberg
1999. Shaieb et al 1999. Stern et al 2000).
Intracerebral haemorrhage following the use
of LMWH has occurred following
neurosurgical and orthopaedic procedures,
with serious consequences (Dickinson et al
1998, Lilikakis et a! 2006).
Heparin induced thrombocytopenia (HIT) is
associated with thrombosis, independent of
heparin type, dose or route of
administration (Boshkov et al 1993. Chong
1995, King et al 1984). It resulK from an
antibody-mediated response to heparin
triggering a reduction in the platelet count
(Burgess et al 1995. Gerhard-Herman
2001, Warkentin 1999). The British Society
66
for Haematology (BSH) has produced
evidence based guidelines for the
identification and management of heparin-
induced thrombocytopenia (Baglin et al
2006). In summary the guidelines advocate:
1. All patients require a platelet count on
day of starting treatment.
2. Repeat platelet counts should be
repeated every 2-4 days from days
4 - 14.
This study audits the implementation and
awareness of these guidelines within an
orthopaedic unit and compares current
practice both in the UK and internationally.
Methods
An audit loop consisting of two sequential
surveys detailing the monitoring of at-risk
patients was performed before and after
the introduction of an evidence based
protocol for the monitoring of heparin
Risk of heparin-induced
thrombocytopenia (HIT) identified
Repeat survey 53 patients to
assess implementation of BSH
guidelines
Initial survey of 48 patients to
assess monitoring of platelet
count in post-operative
orthopaedic patients
Dissemination and implementation
of BSH guidelines
Comparison of initial survey
to BSH published
guidelines
: Audit loop for monitoring of heparin-induced thrombocytopenia
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The initial patient survey demonstrated that only 2 out of 48
at-risk patients (4%) had a FBC performed more than four
days after commencing LMWH
Guidelines on management of heparin-induced thrombocytopenia
1. All patients who receive heparin (of any sort) should have a platelet count
on day of starting treatment
2. All surgical patients receiving LMWH, platelet counts should be performed
every 2-4 davs from davs 4-14
3. If platelet count falls by over 50% or below normal lab limits consider HIT,
stop heparin and inform haematologist
Figure 2: Protocol implemented following initial survey
56 patients
Receiving LMWH > 4 days post-op
/
8 patients
Medically unwell or
on warfarin
/
/
1 patients
FBC after 4 days
\
48 patients
Well post-op
r
46 patients
No FBC after 4 days
Figure 3: Initial survey of patients receiving LMWH for greater than 4 days
53 Patients
Receiving LMWH > 4 days post-op
/
13 Patients
Medically unwell or
on warfarin
/
/
23 patients
FBC after 4 days
\
40 patients
Well post-op
17 patients
No FBC after 4 days
Figure 4: Secondary survey, following implementation of BSH guidelines, of patients receiving LMWH for
greater than 4 days
induced thrombocytopenia - see figure 1.
Enoxaparin (Clexane®. Rhône-Poulenc
Rorer} was the only LMWH prescribed for
patients in this study. Hospital and
departmental approval was obtained prior
to commencing this audit Patients who
were medically unwell or commenced on
warfarin were excluded since their inclusion
would not accurately reflect routine HIT
monitoring.
The initial 48 patients vi/ho received LMWH
for longer than 4 days included 35
operative fixations of proximal femoral
fractures, one open reduction and internal
fixation of a distal femoral fracture, and 12
lower limb joint arthroplasties. The mean
average age was 78 years (range 64-93
years), with 29 female and 16 male.
The results of the initial survey were
compared with the evidence based British
Society for Haematology guidelines (Baglin
et al 2006) and discussed at a
departmental meeting. A protocol
recommending a platelet count every 2-4
days in at-risk patients was implemented
(see figure 2). A subsequent survey of 53
patients was conducted, with a mean age
of 76 years (range 52 - 89 years), with 20
male and 28 female.
A telephone survey questioning awareness
of heparin induced thrombocytopenia and
the recent BSH guidelines was conducted.
Statistical analysis of the results was
carried out using a chi-square test with
SPSS V12.0 for Windows.
Results
The initial patient survey demonstrated that
only 2 out of 48 at-risk patients (4%) had a
full blood count (FBC) performed more than
four days after commencing LMWH - see
figure 3.
The second survey demonstrated a
significant improvement (p<0-05). with 23
out of 40 (57.5%) at-risk patients having a
FBC performed more than four days after
commencing LMWH - see figure 4.
The secondary survey demonstrated a
significant improvement (p<0.05) in the
monitoring of HIT compared with the
primary survey (57.5% compared to 4%)-
see figure 5 .©
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Continusd
60 -
50 -
40 -
3 0 -
20 -
10 -
Primary Survey Secondary
Figure 5; Percentage of at-risk patients monitored for heparin-induced thrombocytopenia during the
primary and secondary surveys
> 75% 50 - 75 % < 50 %
Perc«itage of pre-operative platelet count
Figure 6; Chart showing the number of patients having a reduction in platelet count relative to the pre-
operative level
District general/community
hospital
Teaching hospital
Aware of
HIT
5/34
6/12
Aware of BSH
HIT guidelines
1/34
1/12
Monitor platelet
count for patients
on LMWH
0/34
0/12
Table 1; Survey assessing the awareness of the BSH guidelines for heparin-induced thrombocytopenia
From the secondary survey, 23 out of 40
patients had platelet count monitoring as
outlined by the BSH guidelines. The
quantitative change in the platelet count
seen in these patients is shown in Figure 6.
The postoperative platelet count dropped
below 75% of the preoperative level in 13
out of the 23. Two patients demonstrated a
reduction of over 50% in the platelet count
that responded with the subsequent
cessation of LMWH.
A telephone survey of registrars/interns
from 46 orthopaedic units (34 district
general/community hospitals, 12 teaching
hospitals) in 5 countries (England, France.
Scotland. Canada and USA) was conducted.
There was a low awareness of both the
condition of heparin-induced
thrombocytopenia and the BSH guidelines
and no units routinely monitored for HIT
(see Table 1).
Discussion
Low molecular weight heparins have been
used to reduce thromboembolic risk in both
primary care and the hospital setting for at
least twenty years (Ciagett et a! 1995,
Imberti et al 2006. Mohr et al 1993, Wolf
1994). Whilst providing an effective
pharmacological thromboprophylaxsis, their
use in orthopaedic surgery is not without
risk (Bickler et al 2006. Lilikakis et al 2006,
Stem et al 2000).
This clinical audit demonstrates a
significant improvement in platelet count
monitoring for patients at risk of heparin-
induced thrombocytopenia by the
implementation of a simple protocol and an
additional full blood count (approximately
£ 1 per test). However, with nearly 50% of at-
rtsk patients still not being monitored,
improvements are still needed. The
international survey highlights an ongoing
lack of awareness regarding heparin-
induced thrombocytopenia and the
necessary monitoring of platelet counte.
All prescribers of prescription only
medications should be aware not only of the
common side effects but also of the rare
adverse reactions that may have serious
consequences. Following the publication of
case reports showing intracranial
haemorrhages as a consequence of
68 February 2010 / Volume 20 / Issue 2 / ISSN 1467-1026
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heparin-induced thrombocyíopenia
(Lilikakis et al 2006) and evidence based
guidelines (Baglin et al 2006), failure to
routinely monitor for thrombocyíopenia in
patients receiving LMWHs may have
medico-iegal implications.
The conclusions of this study are:
1. Heparin-induced thrombocytopenia
is a rare but potentially fatal
complication of low molecular
weight heparin.
2. Few orthopaedic units are currently
aware of the risk of heparin-induced
thrombocytopenia when prescribing
LMWH.
3. The introduction of a simple
monitoring protocol can facilitate its
early identification and treatment.
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We assessed the reproducibility and accuracy of four ratios used to measure patellar height, 
namely the Blackburne-Peel, Caton-Deschamps, Insall-Salvati and modified Insall-Salvati, 
before and after total knee arthroplasty. The patellar height was measured, by means of the 
four ratios, on the pre- and post-operative lateral radiographs of 44 patients (45 knees) who 
had undergone total knee arthroplasty. Two independent observers measured the films 
sequentially, in identical conditions, totalling 720 measurements per observer. Statistical 
analysis, comparing both observers and ratios, was carried out using the intraclass 
correlation coefficient.
Before operation there was greater interobserver variation using either the Insall-Salvati 
or modified Insall-Salvati ratios than when using the Caton-Deschamps or Blackburne-Peel 
methods. This was because of difficulty in identifying the insertion of the patellar tendon. 
Before operation, there was a minimal difference in reliability between these methods. 
After operation the interobserver difference was greatly reduced using both the Caton-
Deschamps and Blackburne-Peel methods, which use the prosthetic joint line, compared 
with the Insall-Salvati and modified Insall-Salvati, which reference from the insertion of the 
patellar tendon.
The theoretical advantage of using the Insall-Salvati and modified Insall-Salvati ratios in 
measuring 
 
true
 
 patellar height after total knee arthroplasty needs to be balanced against 
their significant interobserver variability and inferior reliability when compared with other 
ratios.
 
The patella plays a crucial role in the bio-
mechanics of the knee by extending the lever
arm of the extensor mechanism, thus improv-
ing the demonstrable strength of quadriceps by
between 30% and 50%.
 
1,2
 
 The articulation of
the patella within the femoral condylar groove
creates a joint reaction force which relates both
to the degree of knee flexion and contraction of
quadriceps. This force in full flexion of the
knee when load-bearing can approach five to
seven times the body-weight.
 
3
 
The height of the patella alters the joint reac-
tion force for any particular point in the flex-
ion-extension cycle of the knee. A high riding
patella, patella alta, may result in chondro-
malacia patellae, tendonitis of both the patellar
and quadriceps tendons, and patellofemoral
instability.
 
4-6
 
 A low riding patella, patella baja
or infera, may be developmental (patella infera
syndrome), or because of trauma, neurological
disorders, or may occur after surgery on the
knee. Limitation of movement, Osgood-
Schlatter disease and patellofemoral arthritis
may   all result from patella baja.
 
7
 
 Patello-
femoral symptoms are responsible for a large
percentage of revisions of total knee arthro-
plasty (TKA).
 
8-11
 
Because the femoral condylar groove is diffi-
cult to define accurately radiologically, several
ratios for the measurement of patellar height
have been developed which relate the patella to
the proximal tibia, namely the Blackburne-
Peel,
 
12
 
 Caton-Deschamps,
 
13
 
 Insall-Salvati
 
6
 
 and
modified Insall-Salvati methods.
 
14
 
There are few studies on the interobserver
variation of the measurement of patellar
height. Berg, Mason and Lucas
 
15
 
 studied 15
patients with three observers and showed that
the Blackburne-Peel method was relatively
reproducible. Seil et al
 
16
 
 also showed that this
method had the lowest interobserver variabil-
ity when assessing patellar height,  in a study
of 21 patients with symptomatic knees. How-
ever, Aparicio et al
 
17
 
 studied lateral radio-
graphs of the knee in 36 children and found
that the Caton-Deschamps ratio was more reli-
able and reproducible than the Blackburne-
Peel.
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Scuderi, Windsor and Insall
 
18
 
 showed differences in the
incidence of patella baja after high tibial osteotomy (89%
 
vs
 
 73%) depending on whether the Insall-Salvati or Black-
burne-Peel ratio was used. After TKA, Koshino et al
 
19
 
found a significant incidence of patella baja when measured
using the Insall-Salvati ratio. It has been proposed that nei-
ther the Blackburne-Peel nor Caton-Deschamps ratio
should be used to diagnose patella baja after TKA since
they are altered by the position of the joint line.
 
5
 
By using these four ratios, we have assessed the reliability
and interobserver variability in the measurement of the
patellar height for patients who have undergone TKA.
 
Patients and Methods
 
The lateral radiographs of the knee of 44 patients who had
undergone a Kinemax TKA (Stryker, Newbury, United
Kingdom) were evaluated. The operations had been per-
formed at our institution, with osteoarthritis or rheuma-
toid arthritis being the only indications. One patient had
undergone bilateral TKA and the radiographs from both
procedures, which were performed at different times, were
included. Patients who had undergone a high tibial osteot-
omy, or a revision procedure, were excluded from the
study.
Lateral radiographs were taken before and after the
operation with the knee in at least 20˚ of flexion. The patel-
lar height was measured manually by two of the authors
(BAR, PT-B) in an independent sequential manner, and
under identical conditions. Each examiner was blinded to
the patients’ outcome or the conclusions of the other exam-
iner.
Each ratio was derived from two measurements, one
below (measurement A) and one above the lower patella
(measurement B). Four main methods of measuring patellar
A
B
Pre-operative
A
B
Post-operative Pre-operative
B
A
Post-operative
B
A
Pre-operative
B
A
Post-operative
B
A
Pre-operative
B
A
Post-operative
B
A
Fig. 1a
Diagrams showing the four methods of measuring patellar height. Figure 1a – The Insall-Salvati ratio: A, the initial flare/notch of
the anterior proximal tibia to the inferior patellar pole; B, inferior pole to superior pole of patella. Figure 1b – The modified Insall-
Salvati ratio: A, the initial flare/notch of the anterior proximal tibia to the inferior aspect of the patellar articular surface; B, length
of the patellar articular surface. Figure 1c – The Blackburne-Peel ratio: A, the perpendicular height from the tibial articular surface
to the inferior aspect of the patellar articular surface; B, the length of the patellar articular surface. Figure 1d – The Caton-
Deschamps ratio: A, the anterior border of the tibial plateau to the inferior aspect of the patellar articular surface; B, the length of
the patellar articular surface.
Fig. 1c
Fig. 1b
Fig. 1d
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height were recorded for all the radiographs (Fig. 1), with a
total of 720 measurements (360 ratios) per examiner. Mea-
surement A was taken from the point of insertion of the
patellar tendon on the anterior aspect of the proximal tibia
to the lower pole of the patella for the Insall-Salvati ratio
and to the inferior aspect of the articular surface of the
patella for the modified Insall-Salvati ratio. In radiographs
in which the patellar tendon was not readily identifiable,
measurement A was taken from the position of the initial
flare or notch in the proximal part of the anterior aspect of
the tibia.
For the modified Insall-Salvati, Caton-Deschamps and
Blackburne-Peel measurements, measurement B was the
length of the articular surface of the patella excluding
osteophytes. For the Caton-Deschamps ratio, measurement
A was the distance from the inferior point of measurement
B to the most superior point of the anterior surface of the
tibia, whereas for the Blackburne-Peel ratio it was the per-
pendicular distance between the inferior point of measure-
ment B and a line drawn tangentially from the tibial surface
(Fig. 1). The post-operative measurement of A in both the
Caton-Deschamps and Blackburne-Peel ratios was from the
anterosuperior corner of the polyethylene insert (Fig. 1), a
point readily identifiable on lateral radiographs.
An adjustment of 7 mm was added to measurement A for
the post-operative Blackburne-Peel measurement ratio in
order to account for the mean depth (5.8 mm to 7.5 mm) of
the polyethylene insert, thus ensuring that this measure-
ment related to the joint line. This measurement was spe-
cific to the Kinemax insert and is likely to be different in
other types of TKA.
 
Statistical analysis. 
 
The data were collated on Excel
(Microsoft, Redmond, Washington) with comparisons sub-
sequently made between ratios for both pre- and post-oper-
ative radiographs, interobserver variability and reliability.
Intraclass correlation coefficient statistical analysis was
undertaken using SPSS version 12 (SPSS Inc., Chicago, Illi-
nois).
 
Results
 
The mean interobserver variation and intraclass correlation
co-efficient, with 95% confidence intervals (CI), before and
after TKA for measurements A and B, and the overall ratio
for each of the four methods, are shown in Table I. Pre-
operatively, there was less interobserver variation and
greater reliability with measurement B compared with mea-
surement A for all methods.
The post-operative intraclass correlation co-efficient for
measurement A improved relative to its pre-operative value
when using the Caton-Deschamps (0.67 to 0.85) and Black-
burne-Peel (0.54 to 0.87) ratios, but deteriorated using the
Insall-Salvati (0.61 to 0.52) and modified Insall-Salvati
(0.66 to 0.53) ratios. There was, therefore, poor reproduc-
ibility for measurement A post-operatively using the Insall-
Salvati and modified Insall-Salvati ratios. Apart from the
Blackburne-Peel ratio, there were small improvements
in the post-operative correlation of measurement B. The
resulting post-operative intraclass correlation coefficient
between ratios showed greater reproducibility using the
Caton-Deschamps and Blackburne-Peel methods (0.82 and
0.83) compared with that using the Insall-Salvati and mod-
ified Insall-Salvati ratios (0.52 and 0.48).
Overall, there was an improvement in the post-operative
ratio compared with pre-operatively when using the Caton-
Deschamps (0.53 to 0.82) and Blackburne-Peel (0.62 and
0.83) methods. There were small reductions in the post-
operative correlation for both the Insall-Salvati and modi-
fied Insall-Salvati ratios.
The results indicate that interobserver variation in the
post-operative measurement A is principally responsible for
the deterioration of reproducibility of the Insall-Salvati and
modified Insall-Salvati ratios. In both these ratios, measure-
ment A represented the length of the deep surface of the
patellar tendon. In the original measurements of Insall, he
stated that if the patellar tendon could not be adequately
visualised, its length could be gauged by using a “clearly
defined notch” on the anterior aspect of the proximal tibia
 
Table I. 
 
Individual and overall ratios for the four methods used, before and after total knee arthroplasty
 
Pre-operative
 
*
 
Post-operative
 
*
 
CD BP IS mod IS CD BP IS mod IS
 
Measurement A 
Interobserver difference 2.73 2.07 4.50 4.79 1.36 1.60 4.62 4.79
ICC
 
†
 
0.67 0.54 0.61 0.66 0.85 0.87 0.52 0.53
95% CI‡ 0.52 to 0.74 0.42 to 0.66 0.47 to 0.81 0.45 to 0.81 0.75 to 0.95 0.78 to 0.93 0.30 to 0.73 0.27 to 0.73
Measurement B
Interobserver difference 0.67 0.67 1.19 0.67 1.05 1.05 1.14 1.05
ICC 0.80 0.80 0.93 0.80 0.84 0.84 0.58 0.84
95% CI 0.65 to 0.88 0.65 to 0.88 0.87 to 0.96 0.65 to 0.88 0.56 to 0.86 0.56 to 0.86 0.45 to 0.65 0.56 to 0.86
Overall 
Interobserver difference 0.10 0.08 0.11 0.17 0.05 0.05 0.11 0.16
ICC 0.53 0.62 0.58 0.54 0.82 0.83 0.52 0.48
95% CI 0.45 to 0.63 0.49 to 0.67 0.44 to 0.65 0.47 to 0.59 0.69 to 0.95 0.71 to 0.90 0.49 to 0.60 0.36 to 0.56
* CD, Caton-Deschamps; BP, Blackburne-Peel; IS, Insall-Salvati; mod IS, modified Insall-Salvati
† ICC, intraclass correlation co-efficient
‡ 95% CI, 95% confidence interval
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as a point of reference.
 
3
 
 However, we had difficulty in iden-
tifying such a notch or flare in ready radiographs, with the
presence of multiple notches or a smooth convex proximal
tibial profile being common problems.
There are inaccuracies inherent in determining measure-
ment B with the Blackburne-Peel, Caton-Deschamps and
modified Insall-Salvati ratios, since it represents the length
of the articular surface of the patella. Before TKA, provided
that osteophytes were ignored, this was relatively uncom-
plicated. However, the articular surface of the patella may
not be fully visible after replacement arthroplasty since it
may be partially located within the trochlear groove of the
femur (Fig. 2) and its length must be estimated.
 
Discussion
 
The results from our study indicate that, for patients under-
going TKA, there are significant differences in reliability
and interobserver variability in the four main methods used
to measure patellar height. These methods rely on the posi-
tional relationship between the patella and proximal tibia,
while the insertion of the prosthesis alters the accuracy and
reproducibility. These differences also vary depending on
whether patellar height is measured before or after TKA.
The Blackburne-Peel and Caton-Deschamps ratios both
require the precise identification of the proximal joint sur-
face of the tibia for their evaluation. In joints with a signif-
icant amount of osteoarthritis or rheumatoid arthritis,
visualisation of this surface is difficult and may need to be
estimated. However, after TKA the tibial insert provides a
precise point of reference, thereby improving the inter-
observer variability for these methods (Fig. 1). Our study, in
order to give an accurate measurement to the new joint sur-
face, compensated for the dishing of the tibial insert in the
determination of measurement A for the Blackburne-Peel
ratio. A similar compensation is difficult to introduce into
the Caton-Deschamps measurement, since unlike the
Blackburne-Peel method, it is not made perpendicular to
the joint surface.
The application of a particular ratio to the measurement
of patellar height in TKA depends on the information
required by the clinician. The original description of patella
baja was defined before joint replacement surgery and was
related to shortening of the patellar tendon, distal position-
ing of the patella relative to the femoral trochlea and a
reduction of the distance between the patella and tibial sur-
face. After TKA, however, the patella may be positioned dis-
tal to the femoral condyles and closer to the joint surface of
the tibia while the patellar tendon remains a constant length.
This has been termed 
 
pseudo
 
-patella baja, a reduction in
patellar height relative to the joint surface
 
5
 
 and is related to
the thickness of the insert (Fig. 3). It can be due to ‘over-
stuffing’ of the knee, or as a necessary consequence of soft-
tissue release and occurs when the thickness of the tibial tray
plus insert is greater than the thickness of tibia removed.
True patella baja necessitates shortening of the patellar
tendon, so its measurement requires indices which relate to
Line B
Fig. 2
Radiograph showing line B which is the estimated length of the
articular surface of the patella.
H
T
PT
Fig. 3
Diagram showing the effect of the thickness of the tibial
insert on the position of the patella. As the thickness T of
the insert increases, the position of the tibia becomes more
distal. The inelastic patellar tendon (PT), attached to the
displaced tibia, pulls the patella distally thus reducing the
patellar height H.
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the tibial tuberosity and not to either the tibial plateau or
the tibial component of a TKA. The Insall-Salvati and mod-
ified Insall-Salvati ratios relate the length of the patella to
the length of the patellar tendon and are therefore indepen-
dent of the joint surface.
The biomechanics of the patellofemoral joint are related
to the position of the patella within the trochlear groove
and changes to this relationship have been shown to be det-
rimental. During weight-bearing, the position of the femo-
ral condyles, and hence the trochlear groove, is directly
related to the position of the joint line. It is therefore logical
to measure the height of the patella from the joint surface,
as changes in this height will indicate potential problems.
This is especially the case in TKA in which changes in the
position of the joint line will not be identified by measuring
the length of the patellar tendon.
Despite the theoretical advantages of using the Insall-Sal-
vati and modified Insall-Salvati methods for the assessment
of true patellar height, our study highlights their inferior
interobserver reproducibility after TKA, mainly related to
difficulties in identifying the patellar tendon and tibial land-
marks on post-operative radiographs. However, although
the Blackburne-Peel and Caton-Deschamps ratios show a
greater degree of correlation after TKA, they are affected by
the changes in the position of the joint line and do not accu-
rately correlate with 
 
true
 
 patellar height.
Thus, for the assessment of patellar height in patients
undergoing TKA, the clinician should tailor the ratio used
to the requirements. Measurement of the true patellar
height and identification of 
 
true
 
 patella baja or alta, neces-
sitate the use of the Insall-Salvati or modified Insall-Salvati
ratio. However, these ratios have inferior interobserver cor-
relation and reproducibility; measurements after operation
are misleading if the position of the joint line has been
altered. The Blackburne-Peel and Caton-Deschamps ratios
evaluate patellar height relative to the joint surface and will
identify 
 
pseudo
 
-patella baja. These methods have superior
reliability and interobserver correlation after TKA.
 
We wish to acknowledge the valuable help and comments of Dr A. Saifuddin
(Consultant Radiologist, Royal National Orthopaedic Hospital) in the prepara-
tion of this paper.
No other benefits have been received or will be received from a commercial
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The role of total hip arthroplasty (THA) for fracture in octogenarians remains unclear. Over a two-year period,
354 patients aged N 80 years were admitted with a displaced intracapsular hip fracture. Using deﬁned clinical
guidelines, 38 patients underwent THA with a median age of 84 years, mean follow-up of 20 months. Primary
outcomes were dislocation, 30-day and one-year mortality, revision surgery and periprosthetic fracture.
There were no dislocations or periprosthetic fractures and patient survival was 97% at 30 days and 87% at one
year. There was one revision for deep infection. This study demonstrates that THA for selected octogenarians
can be performed safely, allows the majority of patients to return to independent living and has a low
complication rate.
© 2014 Elsevier Inc. All rights reserved.
Total Hip Arthroplasty (THA) for displaced intracapsular hip
fracture has been shown to provide better function, lower re-
operation rates and greater cost-effectiveness when compared to
Hemiarthroplasty (HA) [1–3]. With an increasingly active and
independent elderly population the use of THA for managing hip
fracture is likely to increase. Recent UK guidance from the National
Institute for Health and Clinical Excellence (NICE) has recommended
total hip arthroplasty for this injury in patients who are able to walk
independently and have no cognitive impairment [4]. Concerns
remain about the suitability and safety proﬁle of THA for elderly
patients possibly due to the perceived greater risk of dislocation
associated with THA when compared to Hemiarthroplasty [2]. There
is debate regarding application of the available evidence which has
led to widespread variations in treatment; patients in England and
Wales are only one third as likely to receive a THA compared to
an equivalent population in Sweden [5].
The purpose of this study was to establish the safety proﬁle,
survival and short-term results for patients of 80 years and over who
received THA for fracture according to United Kingdom National
guidelines [4]. Functional outcome scores such as the Oxford/Harris
Hip Scores were not performed.
Patients & Methods
Study Design& Patient Selection
Database
This study was a retrospective analysis of data from our
Institution’s Hip Fracture database, incorporating data submitted to
the National Hip Fracture Database (NHFD). These data were used to
analyse outcomes in patients 80 years and older who sustained an
intracapsular hip fracture.
Patient Selection
All patients who sustained an intracapsular neck of femur between
November 2009 and November 2011 were identiﬁed and those who
were selected for THA were identiﬁed as a sub-group and their
outcomes studied (See Fig. 1). Active, independent patients with no
history of cognitive impairment were offered THA as recommended by
current UK Guidance (ie those who did not use any walking aids, were
admitted from their own home and had an abbreviated mental test
score (Hodkinson’s AMTS) of greater than 8 out of 10) [4]. Our unit uses
a scoring system to quantify this with a total of 15 or greater indicating
THA as the procedure of choice;
1) An AMTS of N8/10 then they score 5 points (2 if 8/10 or less),
2) Mobility using one stick or no aids scores 5 points (two sticks or
worse scores 2).
3) Admission from their own home scores 5 (residential accom-
modation or care scores 2),
4) Age b80 scores 5 points (80 years old or older scores 2),
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All patients requiring surgery had a score of 17.
Patients who had a stable fracture pattern such as a valgus-
impacted intracapsular fracture were treated with internal ﬁxation or
non-operatively.
Primary Outcomes
Primary outcomes monitored were; 30-day and 1-year mortality,
dislocation, revision or re-operation for all causes, peri-prosthetic
fracture, discharge destination and length of stay.
Hip Fracture Care
All patients were admitted under the joint care of a Consultant
Orthopaedic surgeon and Consultant Orthogeriatrician, undergoing
surgery on a dedicated Trauma list. The surgical approach used was
chosen by the senior surgeon and component selection for all patients
was a cemented Exeter femoral component and uncemented Trident
acetabular component with polyethylene liner (Stryker, Mahwah,
New Jersey, USA). A 36 mm diameter cobalt chrome head was used in
all but a single patient where a 28 mm diameter head was used due
to surgeon preference.
Results
Demographics
Three hundred and ﬁfty four patients 80 years and over were
admittedwith an intracapsular fracturedneck of femur over the twoyear
period (See Fig. 1). There were 38 patients from this cohort selected
for THA. Median age was 84 years, (Range 80–93). 14 patients were
male, 24 were female. The surgical approach chosen and grade of the
operating surgeon are shown in Table 1 whilst Table 2 shows ASA grade.
Mean follow-up was 20 months (Range 12–33 months). Follow-up
was by clinic appointments. The hemiarthroplasty cohort of the other
group was not followed-up with clinic appointments and complica-
tions were taken from hospital episode databases.
Of those not selected for THA; Median age was 88 years (Range
80–104). 69 were male, 227 were female. ASA grade is shown in
Table 2.
Survival
One patient had died at 30 days (2.6%) whilst three more died in
the year after surgery (10.5%). Of the deaths prior to one year, one
patient had an intra-operative cerebrovascular accident (CVA) and
died 5 days post-operatively. The remainder were at a mean of
165 days post-operatively and all from causes unrelated to their
operation (metastatic disease of unknown primary, traumatic
intracerebral haemorrhage and CVA followed by seizures). The
median length of stay was 5.9 days (range 3.8–9.6).
Discharge Destination
Five weeks after surgery 23 surviving patients (64%) had returned
home whilst ﬁve (17%) had started residential care (deﬁned as
requiring continuous help with activities of daily living). The
remaining eight patients (22%) were discharged to long-term
rehabilitation (deﬁned as a step-down medical facility for non-acute
care). Two patients died during rehabilitation. (See Fig. 2).
Of those not receiving a THA only 77 who survived to be
discharged from rehabilitation were able to return to their own
home within 5 weeks of surgery (29%). Of the patients who were
admitted from their own home and survived to discharge, only 40%
(71/175) were discharged back to their home.
Complications
There were no recorded dislocations or periprosthetic fractures.
One patient underwent staged revision surgery for deep infection
which developed one month after surgery.
Of the non-THA group 7 patients suffered dislocation of their HA
(2.3%) and 4 patients suffered periprosthetic fractures post-opera-
tively (1.3%). 5 patients had infective complications (1.6%), 2 of which
were resolved by debridement and washout, 3 of which necessitated
2 stage revision surgery. One further patient was revised to THA due
to pain putting the overall revision rate at 3.7%.
Discussion
The management of hip fracture in elderly patients is an
increasingly important aspect of Orthopaedic care worldwide. This
study shows that THA is a safe and efﬁcient use of resources when
performed in selected patients over 80 years old. This represents a
signiﬁcant caseload for Orthopaedic services within the United
Kingdom and is likely to increase in the future.
In the UK projections estimate that the incidence will rise from
70,000 patient events per year in the UK to 101,000 by 2020 [7]. The
Fig. 1. Caseload of fractured neck of femur patients by age and procedure performed
between November 2009 and November 2011. (‘Other’ includes Internal ﬁxation of all
types and those patients treated non-operatively).
Table 1
Grade of Primary Surgeon and Surgical Approach.
n %
Grade of Surgeon Consultant 15 40
Associate Specialist 6 15
Registrar 17 45
Surgical Approach Posterior 13 32
Anterolateral 25 68
Table 2
American Society of Anaesthesiologists Grade (ASA) [6].
ASA
Grade
THA Group Other Group
n % n %
I 4 3 1.0
II 22 57.9 82 26.1%
III 11 28.9 192 61.1%
IV 1 2.6 36 11.5%
V 0 0 1 0.3%
NB: 2 patients in the Other Group were not scored as they were not assessed for
suitability of anaesthesia.
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potential cost of treating all fragility fractures in this patient
population is £2.2 billion per year [8]. Several randomised studies
have supported the use of arthroplasty over internal ﬁxation of
displaced intracapsular fractures [9–11].Whether a patient undergoes
THA or hemiarthroplasty remains controversial although the use of
THA in independently mobile patients with displaced fractures has
been supported by three randomised controlled trials in their short
term results [1,12,13].
The beneﬁts of THA over Hemiarthroplasty are balanced by an
increased risk of dislocation, greater operative time and higher
implant cost [14]. The dislocation rate after THA ranges from 2% to
20% [1,13,15–21] following fracture although this may be reducing as
the use of larger head sizes becomes commonplace [22]. There were
no dislocations in the group of patients we studied. Although the
sample size was small, undoubtedly there was no evidence of a high
dislocation rate in this group. In fact the dislocation rate after HA in
our cohort was signiﬁcant and doubtless has morbidity and mortality
associated with it as evidenced by Blewitt et al [23] who suggested
that 6 months post dislocation the mortality is 65%.
All of the factors used to select patients for THA are also
independently associated with survival after hip fracture hence
this cohort would be expected to demonstrate high rates of survival
[24–26]. Indeed the survival is predictably high in this cohort (89.5%
at 1 year). The aim of THA is to afford better post-operative function
which we have shown by the high proportion of patients returning to
independent living.
Phillips et al [27] reported the results of elective THA in patients
over 90 years. 52% were able to return to their normal abode whilst
45% required prolonged rehabilitation. Encouragingly over 60% of our
patients returned to their pre-morbid level of independence after
hip fracture.
Patients selected for THA for fracture can have their procedure
delayed or postponed whilst a suitably skilled surgeon becomes
available in smaller centres which is frequently not the case for HA.
This model of hip fracture care requires sufﬁcient manpower to
perform THA which might not be possible in all centres. In addition as
the use of THA for fracture becomesmore commonplace this will have
implications for training and workforce planning which are yet to be
deﬁned. If the Australian model is to be followed where outcomes are
measured against caseload then patients may be best served by a
surgeon with signiﬁcant experience in hip arthroplasty performing
their surgery.
Delays to surgery impact on patient experience, mortality, length
of stay and recently the attainment of the best practice tariff for hip
fracture [28]. These factors may alter the cost–beneﬁt ratio of THA
compared with Hemiarthroplasty which was estimated at £3000 per
patient [29]. We did not attempt to delineate the impact delay to
surgery has on outcomes and survival.
Confounding factors in this study relate to the selection bias for
THA versus HA. Whilst in our unit we try to quantify this with a
scoring system, in many places it is down to surgeon discretion alone
as to what implant a patient receives. These confounding factors are
the basis for selection and those judged to be ‘less ﬁt’ pre-morbidly are
arguably more likely to have worse outcomes and prognoses.
Hemiarthroplasty is not associated with lesser risk however as
evidence exists regarding complications with one showing a
6 month mortality after dislocated hemiarthroplasty for fractured
neck of femur as 65% [23] and another showing that of those
patients who suffer a periprosthetic fracture 24% die prior to fracture
union [30].
Future studies in this area
Hip fracture studies aiming to demonstrate long-term functional
outcome must be very large as high rates of mortality leave only a
small group of survivors for assessment. Bannister et al [31] had an
overall mortality of 42% at a mean follow-up of 9 years and only a 4%
loss to follow-up. Large multi-centred RCTs have similar difﬁculties
[12,17,32] in maintaining large patient cohorts. One systematic
review [2] was unable to conclude deﬁnitively that THA affords
superior functional outcomes and lower re-operation rates when
compared to HA. This ambiguity results from the distinct heteroge-
neity in the population in question. Matching patients for example
comparison with a hemiarthroplasty group is very difﬁcult as
selection bias is the discriminator used to determine which patients
are suitable for THA. Our cohort demonstrates this well as those
patients who are often less ﬁt and less likely to survive longer term
to beneﬁt from a THA are by default selected for HA, confounding
their trend towards worse results.
Conclusions
Our ﬁndings, demonstrate that THA in suitably selected octoge-
narians can produce excellent short term results without a high risk
of complication. However evidence regarding the long-term cost-
effectiveness and patient related outcomes of these patients will
require a much larger patient cohort.
An increasingly active elderly population now expects optimal
functional capability following a fracture of the femoral neck. This
study demonstrates that total hip arthroplasty for selected octoge-
narians affords a low complication rate with the majority of patients
returning to independent living.
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T he transparency of surgical outcomes data and the drive for quality has been highlighted since the public inquiry, 
led by Professor Ian Kennedy, into chil-
dren’s heart surgery at the Bristol Royal 
Infirmary. This was formalized in Lord 
Darzi’s 2008 report High Quality Care for 
All, that proposed the NHS should: ‘sys-
tematically measure and publish informa-
tion about the quality of care’. Subsequently 
the NHS White paper, Equity and 
Excellence: Liberating the NHS  (Department 
of Health, 2010), set out the ambitions 
and aims of the NHS and in particular that 
it should provide: ‘...a service that offers 
care that is safe and of the highest quality.’ 
Patient-reported outcome measures are 
standardized, validated questionnaires that 
are completed by patients to measure their 
own functional status and general health. 
They were originally designed for use in 
clinical trials (Fitzpatrick et al, 1998). Since 
2009, wider use of patient-reported out-
come measures within the NHS has been 
proposed to augment mortality data from 
Hospital Episode Statistics, which are con-
sidered an insufficient measure of quality.
However, controversies exist regarding 
the widespread implementation, data col-
lection and interpretation of patient-report-
ed outcome measures within the UK and 
internationally (Dawson et al, 2010). This 
editorial considers some of the relevant 
issues inherent in collecting and analysing 
patient-reported outcome measures data.
Introduction of patient-reported 
outcome measures
Many scoring systems and questionnaires 
have been designed both to assess treat-
ment effectiveness in the context of 
research and to quantify patient perspec-
tives of care outcomes. The validity of this 
later use remains somewhat controversial 
(Judge et al, 2011). The outcomes-based 
definition of patient-reported outcome 
measures distinguishes them from ques-
tionnaires used to measure patients’ expe-
rience of the care process.
To date, patient-reported outcome 
measures data have been used in clinical 
trials, national audits (Williams et al, 
2002) and registers for joint replacement 
(Malchau et al, 2005). However, since 
April 2009, it has been mandatory for 
NHS hospitals to collect patient-reported 
outcome measures data for four separate 
surgical procedures in the first instance: 
inguinal hernia repair, varicose vein sur-
gery, hip and knee replacements. The aim 
is to achieve a quantifiable and transparent 
improvement in quality.
With the use in the context of audit and 
‘registers’ to inform individual care and 
manage the performance of health-care 
providers, patient-reported outcome meas-
ures data are now becoming increasingly 
widespread at a local level as well as 
national level (Greenhalgh et al, 2005; 
Marshall et al, 2006).
Components of patient-reported 
outcome measures data
There are two principal components of 
patient-reported outcome measures data:
1. A measure of a patient’s perception of 
his/her general health (‘generic’ health 
status) 
2. The patient’s perceptions of his/her 
health in relation to pathology (‘specif-
ic’ health status). 
Patients complete patient-reported out-
come measure questionnaires by rating 
their current health status in response to 
individual questions. Commonly used 
generic questionnaires include Short form 
36, EQ5D, ASCOT and Perceived Impact 
of Problem Profile. Commonly used spe-
cific questionnaires include the Parkinson’s 
disease questionnaire, visual function 
questionnaire and Oxford hip and knee 
scores. The individual ratings are com-
bined, usually one generic and one specif-
ic, to produce an overall score to represent 
an underlying phenomenon or ‘construct’, 
such as ‘perceived level of pain’ or ‘anxiety’. 
The analysis of patient-reported out-
come measures tends to focus on the 
amount of change that has occurred in the 
patient’s condition or his/her general 
health-related quality of life, as represented 
by a change in patient-reported outcome 
measure score following an intervention.
The collection of patient-reported out-
come measures data outside the remit of 
clinical research risks a lack of clarity and 
focus, which may in turn result in sub-
optimal data interpretation. Therefore cli-
nicians and managers should be aware that 
the quality of both processes and out-
comes can be audited (Table 1).
Collection of patient-reported 
outcome measures data
It is essential that there is a cogent reason 
for data collection and a defined duration 
of follow-up when no clear hypothesis or 
research question exists. Clearly stated 
inclusion and exclusion criteria will aid the 
standardization of data collection and 
interpretation. In addition, the data points 
Using patient-reported outcome 
measures to assess health-care quality
Processes  Communication: improved communication between patient and health-care provider
 Concordance: agreement between patient and health-care provider about problems and solutions
 Provider behaviours: changes in health-care providers’ diagnosis and treatment of patient conditions
 Patient behaviours: patient self-efficacy, adherence and behavioural change
Outcomes  Patient satisfaction: patient-reported satisfaction with the consultation, treatment or care overall
 Health status: patients’ health and wellbeing as indicated by clinical measures or patient reports
 Resource use: patients’ subsequent use of health and other services
Table 1. Specific examples of the processes and outcomes that may be 
quantified with patient-reported outcome measures data
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need to be clearly specified, e.g. are the data 
patient-specific or pathology-specific (i.e. 
one patient may have two arthritic knees).
The logistics of data collection should be 
clarified before the widespread implemen-
tation of patient-reported outcome meas-
ures, preferably with the use of a pilot 
study. In essence who, how, when and 
where is the data to be collected? In par-
ticular, has informed consent been 
obtained, is a written protocol available 
and is all the relevant documentation avail-
able in a variety of languages? 
In order to minimize bias, mechanisms 
need to be in place to ensure that only the 
patients are responding. Further, the means 
of patient recruitment needs to be consid-
ered, e.g. including only patients attending 
the outpatients department risks selection 
bias, as there is likely to be a greater propor-
tion of patients with problems attending. A 
mechanism is needed to reduce non-
responders, incomplete or duplicated data. 
Finally, as with all confidential patient infor-
mation, data storage must be secure, while 
remaining easily retrievable for analysis. 
Potential benefits of patient-
reported outcome measures data
The appropriate implementation and inter-
pretation of patient-reported outcome 
measures data collection has several poten-
tial benefits. It can have a diverse role in 
altering how health problems are perceived 
and managed by patients and health-care 
providers. Patients are stimulated to present 
problems that concern them in addition to 
symptoms elicited in traditional consulta-
tions. Health professionals are encouraged 
to think beyond the conventional limita-
tions in identifying problems and selecting 
solutions jointly with patients. There is also 
improved identification of goals and priori-
ties over time between health professional 
and patients faced with complex, evolving 
and multifaceted problems. However, to 
date few academic studies have validated 
the role of the questionnaires currently used 
for patient-reported outcome measures data 
against these potential benefits. 
Potential problems with patient-
reported outcome measures data
The interpretation of patient-reported out-
come measures data has an inconsistent 
impact on health status depending on the 
actual questionnaire used. For any single 
The widespread introduction and inter-
pretation of patient-reported outcome 
measures data is not straightforward and 
will require auditing at local and national 
level since the definite advantages remain 
unclear. BJHM
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condition, the choice of patient-reported 
outcome measure questionnaire used will 
influence the study results. To increase pro-
vider understanding of patient needs, pri-
orities and/or preferences, the most appro-
priate patient-reported outcome measures 
should be applied to accurately reflect these 
issues. However, the most commonly used 
patient-reported outcome measures cur-
rently only capture a single facet of patient 
health or were created without the involve-
ment of patients. Therefore, they may not 
actually accurately reflect patients’ needs, 
priorities and preferences (Higginson and 
Carr, 2001). For example, questions relat-
ing to sports activity are not relevant to 
most elderly patients. While numerous 
measures are available (see www.proqolid.
org), care is needed to ensure the most 
appropriate choice of data capture is used.
Constraints on the number and focus of 
questions imposed by standardization may 
prevent patient-reported outcome measures 
data from addressing the issues that are 
most important to patients. Furthermore, 
patient-reported outcome measures data 
should be evaluated against potential 
impacts beyond provider actions and 
patient health status, e.g. is there an impact 
on patient–clinician communication?
Conclusions
Clinicians should question what goals are 
achievable with the routine use of patient-
reported outcome measures data for a spe-
cific patient population and whether all the 
potential benefits (processes and outcomes) 
are being used. More multidimensional and 
individualized measures, although more 
difficult to interpret, may help patient-
reported outcome measures to optimize 
patient-centred care (Marshall et al, 2006). 
Careful and thorough evaluation of patient-
reported outcome measures will be required 
to ensure these tools enhance patient 
involvement (Greenhalgh et al, 2005). 
KEY POINTS 
n Patient-reported outcome measures are standardized questionnaires that allow patients to measure 
their functional status and general health.
n Patient-reported outcome measures are being used throughout the NHS to evaluate health-care quality.
n Processes and outcomes may both be audited with patient-reported outcome measures.
n To afford valid information, the choice of questionnaire and the methods used to collect and interpret 
the data are critical.
n The definite advantages of patient-reported outcome measures remain unclear.
British Journal of Hospital Medicine. Downloaded from magonlinelibrary.com by 188.039.068.002 on November 27, 2015. For personal use only. No other uses without permission. . All rights reserved.
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In this study we evaluated whether pre-operative Western Ontario and McMaster 
Universities (WOMAC) osteoarthritis scores can predict satisfaction following total hip 
arthroplasty (THA). Prospective data for a cohort of patients undergoing THA from two large 
academic centres were collected, and pre-operative and one-year post-operative WOMAC 
scores and a 25-point satisfaction questionnaire were obtained for 446 patients. Satisfaction 
scores were dichotomised into either improvement or deterioration. Scatter plots and 
Spearman’s rank correlation coefficient were used to describe the association between pre-
operative WOMAC and one-year post-operative WOMAC scores and patient satisfaction. 
Satisfaction was compared using receiver operating characteristic (ROC) analysis against 
pre-operative, post-operative and δ WOMAC scores. 
We found no relationship between pre-operative WOMAC scores and one-year post-
operative WOMAC or satisfaction scores, with Spearman’s rank correlation coefficients of 
0.16 and –0.05, respectively. The ROC analysis showed areas under the curve (AUC) of 0.54 
(pre-operative WOMAC), 0.67 (post-operative WOMAC) and 0.43 (δ WOMAC), respectively, 
for an improvement in satisfaction. 
We conclude that the pre-operative WOMAC score does not predict the post-operative 
WOMAC score or patient satisfaction after THA, and that WOMAC scores can therefore not 
be used to prioritise patient care.
Cite this article: Bone Joint J 2015;97-B:150–3.
Total hip arthroplasty (THA) is one of the
most commonly performed and consistently
successful orthopaedic procedures, but pre-
dicting which patients will benefit most from
surgery remains difficult and controversial.1
The routine collection of patient-reported
outcome measures (PROMs) has been intro-
duced in several countries, not only to quan-
tify success but also as a possible means of
defining a threshold for surgery.1,2 The focus
has shifted from the technical aspects of sur-
gery in isolation, such as implant survival, to
PROMs, including the Oxford scores1,3-6 and
Western Ontario and McMaster Universities
(WOMAC) osteoarthritis index.7,8 These
scores were introduced to compare outcomes
in clinical trials and have subsequently been
shown to be reliable and valid in that set-
ting.9-12 The WOMAC osteoarthritis index
assesses pain, stiffness and physical function
in patients with osteoarthritis (OA) of the hip
and knee.12 It consists of 24 items divided
into three subscales and the total score ranges
from 0 to 100, with 0 being the best
possible score and 100 being the worst possi-
ble score.
Expanding the use of PROMs to prioritise
patients for surgery is controversial and cur-
rently lacks a substantial base of evidence.1 A
recent study based in the United Kingdom
which prospectively analysed a cohort of 1523
total knee arthroplasties (TKAs) and 1784
THAs demonstrated that the pre-operative
Oxford hip and knee scores did not predict
post-operative patient satisfaction and should
not be used to prioritise care.1 
Similar work comparing other ways of
assessing outcome, such as the WOMAC
score, has not been undertaken. In addition,
the relationship between PROMs, satisfaction
and objective activity scores remains unclear.
The aim of this study was to assess to what
extent the pre-operative WOMAC score can be
used to predict WOMAC scores and satisfac-
tion one year following THA.
Patients and Methods
We reviewed prospectively collected data from
the SafeT (Safe Activities Following Elective
THA) study (funded by the Canadian Institu-
tion of Health Research, grant number
MOP84316), performed at two large academic
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centres between 2007 and 2010. This prospective multi-
centre cohort study evaluates patient activities following
THA.
We analysed the data for 446 patients who underwent
THA and who were available for review one year post-
operatively. A total of 217 patients (49%) were men. The
average age of the patients at the time of surgery was 63
years (25 to 80) and their average body mass index (BMI)
was 30 kg/m2 (19 to 38). An uncemented THA was used in
394 patients (88%), a hybrid construct in 48 (11%) and a
cemented THA in four (1%). The bearing surfaces were
metal-on-polyethylene (374 patients, 84%), ceramic-on-
polyethylene (35 patients, 8%), metal-on-metal (35
patients, 8%), ceramic-on-ceramic (one patient 0.2%) and
metal-on-ceramic (one patient, 0.2%). 
Fellowship-trained surgeons performed all operations.
All patients were aged < 80 years and underwent primary
THA with similar post-operative rehabilitation regimes.
Overall, 438 underwent surgery for OA. The WOMAC
scores were completed pre- and one year post-operatively
for all patients, who also completed a 25-point satisfaction
questionnaire at these times. Data collection was done by
trained research assistants independently of the clinicians. 
All patients who had fully completed WOMAC and sat-
isfaction scores at both times were included. Demographic
data (age and gender), comorbidities, diagnosis and the
indication for surgery were also recorded. Satisfaction
scores were dichotomised into either improvement or dete-
rioration, using a previously described method.1 
Statistical analysis. Spearman’s rank correlation coefficient
and scatter plots were used to evaluate the correlation
between the pre-operative WOMAC scores and the
WOMAC scores and patient satisfaction one year post-
operatively. Receiver operating characteristic (ROC) analy-
sis was used to compare satisfaction scores against three
polynomial variables, the pre-operative, post-operative and
δ WOMAC scores. δ WOMAC was defined as the change
between the pre- and one-year post-operative WOMAC
scores. ROC analysis was also used to identify thresholds
associated with patient satisfaction.
The area under the ROC curve (AUC) was interpreted as
the possibility of correctly identifying whether or not
patients were satisfied one year post-operatively, based on
their pre-operative scores. This area ranges in value
between 0.5 (useless test with no accuracy) and 1.0 (perfect
accuracy).1
Results
Data were collected for 446 patients who had completed
both pre-operative and one-year post-operative WOMAC
and satisfaction scores; 12 patients had been previously
excluded because of incomplete data. The average pre- and
post-operative and δ WOMAC and satisfaction scores are
shown in Table I. A scatter plot analysis showed no rela-
tionship between the pre-operative WOMAC score and
post-operative satisfaction (Fig. 1), or between the pre-and
post-operative WOMAC scores (Fig. 2). Spearman’s rank
correlation coefficient was –0.05 (95% confidence interval
(CI) –0.08 to 0.18) between the pre-operative WOMAC
score and the one-year post-operative satisfaction and 0.16
(95% CI -0.12 to 0.19) between the pre- and one-year post-
operative WOMAC scores.
The ROC curve analysis showed that for an improve-
ment in satisfaction, the AUC for the pre-operative
WOMAC (Fig. 3), the post-operative WOMAC (Fig. 4) and
the δ WOMAC scores (Fig. 5) was 0.54 (95% CI 0.48 to
Table I. The mean, standard deviation (SD) and range of the pre-operative,
post-operative and δ Western Ontario and McMaster Universities osteo-
arthritis index (WOMAC) and satisfaction scores for all patients
WOMAC score Satisfaction
Pre-operative
Mean (SD) (range) 51 (17) (2 to 94) 22 (3) (6 to 25)
Post-operative
Mean (SD) (range) 13 (15) (0 to 72) 21 (4) (5 to 25)
δ
Mean (SD) (range) 38 (3) (2 to 22) 1 (1) (0 to 1)
R² = 0.0065
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Fig. 1
Scatter plot of the pre-operative Western Ontario and McMaster Uni-
versities osteoarthritis index (WOMAC) scores against patient satisfac-
tion one year after surgery.
152 B. A. ROGERS, B. ALOLABI, A. D. CARROTHERS, H. J. KREDER, R. J. JENKINSON
THE BONE & JOINT JOURNAL
0.62), 0.67 (95% CI 0.59 to 0.73) and 0.43 (95% CI 0.38
to 0.43), respectively. 
Discussion
This study shows that the pre-operative WOMAC score
does not predict post-operative WOMAC scores or patient
satisfaction with THA one year after surgery. 
The goals of hip replacement surgery include pain relief,
functional improvement and satisfaction.13 PROMs have
been introduced as a means to quantify the success or oth-
erwise of medical or surgical interventions, and also as a
possible method of defining a threshold for intervention.1,2
However, the WOMAC score was initiated as a research
tool to assess post-operative outcomes following hip and
knee arthroplasty surgery. These PROMs are now com-
monly used to prioritise patients’ access to care, despite
insufficient evidence for this purpose or a demonstrable
correlation with patient outcomes or satisfaction.1,9-12
Furthermore, many studies have shown that pre-operative
pain and function are not associated with satisfaction
following surgery.14,15 In particular, Judge et al1 recently
demonstrated that pre-operative Oxford hip and knee
scores do not predict satisfaction, and concluded that these
scores should not be used to prioritise patients for hip and
knee arthroplasty surgery. Our findings are similar with
regard to the use of the WOMAC scores in predicting out-
come following THA.
The analysis of the ROC curves illustrates no threshold
in the pre-operative, post-operative or WOMAC scores
that predicts satisfaction. Even though the AUC of the post-
operative WOMAC was higher than the pre-operative or δ
WOMAC scores, it relates to a sensitivity of 64% and a
specificity of 66%, both of which are poor. Also, the post-
operative WOMAC score is a measure only available after
surgery, and as such it can be of no use in stratifying
patients before operation.
Quantifying satisfaction one year following surgery is
appropriate, as previous studies have shown that satisfac-
tion remains high beyond six months after both THA and
TKA.16-18 
Although most patients are satisfied following THA, a
small proportion are not,14,19,20 and predicting such
R² = 0.0041
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Fig. 2
Scatter plot of the pre-operative Western Ontario and McMaster Uni-
versities osteoarthritis index (WOMAC) scores against the WOMAC
score one year after surgery.
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Fig. 3
Receiver operating characteristic (ROC) curve comparing sat-
isfaction with pre-operative Western Ontario and McMaster
Universities osteoarthritis index score. The area under the
curve = 0.54.
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Fig. 4
Receiver operating characteristic (ROC) curve comparing
satisfaction with pre-operative Western Ontario and
McMaster Universities osteoarthritis index score. The area
under the curve = 0.67.
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Fig. 5
Receiver operating characteristic (ROC) curve comparing
satisfaction with pre-operative Western Ontario and
McMaster Universities osteoarthritis index score. The area
under the curve = 0.43.
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patients is difficult. It has been reported that patients with
inferior pre-operative mental health status and/or depres-
sion are more likely to be dissatisfied.14,21 Age, gender and
comorbidities do not seem to be associated with patient sat-
isfaction,14-16,21,22, but a single study22 has shown increased
age to be associated with dissatisfaction after THA,
whereas poorer results in younger patients have been
reported after TKA.23
Designing a dimensional assessment tool that includes
patient-reported outcomes, pain, function, quality of life
and satisfaction and provides a predictive capacity for out-
come and satisfaction would be highly beneficial. The abil-
ity to identify key factors associated with patient
dissatisfaction or inferior outcomes is clearly important,
and would allow pre-operative intervention in modifiable
risk factors.1 The evidence from this and previous studies
shows that WOMAC and Oxford hip and knee scores are
unsuitable for predicting outcomes and satisfaction, and
therefore should not be used to prioritise patient care. 
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